[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US20040009555A1 - Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins - Google Patents

Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins Download PDF

Info

Publication number
US20040009555A1
US20040009555A1 US10/437,708 US43770803A US2004009555A1 US 20040009555 A1 US20040009555 A1 US 20040009555A1 US 43770803 A US43770803 A US 43770803A US 2004009555 A1 US2004009555 A1 US 2004009555A1
Authority
US
United States
Prior art keywords
hyp
ser
seq
thr
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/437,708
Inventor
Marcia Kieliszewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio University
Original Assignee
Ohio University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/897,556 external-priority patent/US6570062B1/en
Priority claimed from US09/119,507 external-priority patent/US6548642B1/en
Application filed by Ohio University filed Critical Ohio University
Priority to US10/437,708 priority Critical patent/US20040009555A1/en
Assigned to OHIO UNIVERSITY, TECHNOLOGY TRANSFER OFFICE, TECHNOLOGY AND ENTERPRISE BUILDING reassignment OHIO UNIVERSITY, TECHNOLOGY TRANSFER OFFICE, TECHNOLOGY AND ENTERPRISE BUILDING ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KIELISZEWSKI, MARCIA J.
Publication of US20040009555A1 publication Critical patent/US20040009555A1/en
Priority to US12/781,490 priority patent/US20110003340A1/en
Priority to US13/149,016 priority patent/US8871468B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates generally to the field of plant gums and other hydroxyproline-rich glycoproteins, and in particular, to the expression of synthetic genes designed from repetitive peptide sequences.
  • Gummosis is a common wound response that results in the exudation of a gum sealant at the site of cracks in bark.
  • A. M. Stephen et al. “Exudate Gums”, Methods Plant Biochem . (1990).
  • the exudate is a composite of polysaccharides and glycoproteins structurally related to cell wall components such as galactans [G. O.
  • Gum arabic is probably the best characterized of these exudates (although it has been largely refractory to chemical analysis). It is a natural plant exudate secreted by various species of Acacia trees. Acacia senegal accounts for approximately 80% of the production of gum arabic with Acacia seyal, Acacia laeta, Acacia camplylacantha , and Acacia drepanolobium supplying the remaining 20%. The gum is gathered by hand in Africa. It is a tedious process involving piercing and stripping the bark of the trees, then returning later to gather the dried tear drop shaped, spherical balls that form in response to mechanical wounding.
  • whey proteins can be used to increase the functionality of gum arabic.
  • A. Prakash et al. “The effects of added proteins on the functionality of gum arabic in soft drink emulsion systems,” Food Hydrocolloids 4:177 (1990).
  • this approach has limitations. Only low concentrations of such additives can be used without producing off-flavors in the final food product.
  • the present invention involves a new approach in the field of plant gums and presents a new solution to the production of hydroxyproline(Hyp)-rich glycoproteins (HRGPs), repetitive proline-rich proteins (RPRPs) and arabinogalactan-proteins (AGPs).
  • HRGPs hydroxyproline(Hyp)-rich glycoproteins
  • RPRPs repetitive proline-rich proteins
  • AGPs arabinogalactan-proteins
  • the present invention contemplates the expression of synthetic genes designed from repetitive peptide sequences of such glycoproteins, including the peptide sequences of gum arabic glycoprotein (GAGP).
  • the present invention contemplates a substantially purified polypeptide comprising at least a portion of the amino acid sequence Ser-Hyp-Hyp-Hyp-[Hyp/Thr]-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His (SEQ ID NO:1 and SEQ ID NO:2) or variants thereof.
  • variants it is meant that the sequence need not comprise the exact sequence; up to five (5) amino acid substitutions are contemplated.
  • a Leu or Hyp may be substituted for the Gly; Leu may also be substituted for Ser and one or more Hyp.
  • variants it is also meant that the sequence need not be the entire nineteen (19) amino acids. Illustrative variants are shown in Table 3. In one preferred embodiment, variants contain one or more of the following three motifs: Ser-Hyp 4 , Ser-Hyp 3 -Thr, and Xaa-Hyp-Xaa-Hyp, where Xaa is any amino acid other than hydroxyproline.
  • the present invention be limited by the precise length of the purified polypeptide.
  • the peptide comprises more than twelve (12) amino acids from the nineteen (19) amino acids of the sequence.
  • a portion of the nineteen (19) amino acids is utilized as a repetitive sequence.
  • all nineteen (19) amino acids are utilized as a repetitive sequence.
  • the sequence (i.e. SEQ ID NO:1 and SEQ ID NO:2) or variants thereof may be used as a repeating sequence between one (1) and up to fifty (50) times, more preferably between ten (10) and up to thirty (30) times, and most preferably approximately twenty (20) times.
  • the sequence (i.e. SEQ ID NO:1 and SEQ ID NO:2) or variants thereof may be used as contiguous repeats or may be used as non-contiguous repeats (with other amino acids, or amino acid analogues, placed between the repeating sequences).
  • the present invention specifically contemplates fusion proteins comprising a non-gum arabic protein or glycoprotein sequence and a portion of the gum arabic glycoprotein sequence (SEQ ID NO:1 and SEQ ID NO:2). It is not intended that the present invention be limited by the nature of the non-gum arabic glycoprotein sequence.
  • the non-gum arabic glycoprotein sequence is a green fluorescent protein.
  • the present invention contemplates synthetic genes encoding such peptides.
  • synthetic genes it is meant that the nucleic acid sequence is derived using the peptide sequence of interest (in contrast to using the nucleic acid sequence from cDNA).
  • the present invention contemplates an isolated polynucleotide sequence encoding a polypeptide comprising at least a portion of the polypeptide of SEQ ID NO:1 and SEQ ID NO:2 or variants thereof.
  • the present invention specifically contemplates a polynucleotide sequence comprising a nucleotide sequence encoding a polypeptide comprising one or more repeats of SEQ ID NO:1 and SEQ ID NO:2 or variants thereof.
  • the present invention contemplates synthetic genes encoding portions of HRGPs, wherein the encoded peptides contain one or more of the highly conserved Ser-Hyp 4 (SEQ ID NO:3) motif(s).
  • the present invention also contemplates synthetic genes encoding portions of RPRPs, wherein the encoded peptides contain one or more of the pentapeptide motif: Pro-Hyp-Val-Tyr-Lys (SEQ ID NO:4) and variants of this sequence such as X-Hyp-Val-Tyr-Lys (SEQ ID NO:5) and Pro-Hyp-Val-X-Lys (SEQ ID NO:6) and Pro-Pro-X-Tyr-Lys and Pro-Pro-X-Tyr-X (SEQ ID NO:8), where “X” can be Thr, Glu, Hyp, Pro, His and Ile.
  • the present invention also contemplates synthetic genes encoding portions of AGPs, wherein the encoded peptides contain one or more Xaa-Hyp-Xaa-Hyp (SEQ ID NO:9) repeats.
  • Such peptides can be expressed in a variety of forms, including but not limited to fusion proteins.
  • the present invention contemplates a polynucleotide sequence comprising the sequence: 5′-CCA CCA CCT TCA CCT CCA CCC CCA TCT CCA-3′ (SEQ ID NO:10).
  • motifs for AGPs contemplates a polynucleotide sequence comprising the sequence: 5′-TCA CCA TCA CCA TCT CCT TCG CCA TCA CCC-3′ (SEQ ID NO:11).
  • SEQ ID NO:11 amino acid sequence
  • the present invention specifically contemplates sequences that are not identical but are nonetheless homologous to the sequences of SEQ ID NOS: 10 and 11.
  • the present invention also contemplates sequences that are complementary (including sequences that are only partially complementary) sequences to the sequences of SEQ ID NOS: 10 and 11.
  • Such complementary sequences include sequences that will hybridize to the sequences of SEQ ID NOS: 10 and 11 under low stringency conditions as well as high stringency conditions (see Definitions below).
  • the present invention also contemplates the mixing of motifs (i.e. modules) which are not found in wild-type sequences. For example, one might add GAGP modules to extensin and RPRP crosslinking modules to AGP-like molecules.
  • the present invention contemplates using the polynucleotides of the present invention for expression of the polypeptides in vitro and in vivo. Therefore, the present invention contemplates polynucleotide sequences encoding two or more repeats of the sequence of SEQ ID NO:1 and SEQ ID NO:2 or variants thereof, wherein said polynucleotide sequence is contained on a recombinant expression vector. It is also contemplated that such vectors will be introduced into a variety of host cells, both eukaryotic and prokaryotic (e.g. bacteria such as E. coli ).
  • eukaryotic and prokaryotic e.g. bacteria such as E. coli
  • the vector further comprises a promoter. It is not intended that the present invention be limited to a particular promoter. Any promoter sequence which is capable of directing expression of an operably linked nucleic acid sequence encoding a portion of a plant gum polypeptide (or other hydroxyproline-rich polypeptide of interest as described above) is contemplated to be within the scope of the invention. Promoters include, but are not limited to, promoter sequences of bacterial, viral and plant origins. Promoters of bacterial origin include, but are not limited to, the octopine synthase promoter, the nopaline synthase promoter and other promoters derived from native Ti plasmids.
  • Viral promoters include, but are not limited to, the 35S and 19S RNA promoters of cauliflower mosaic virus (CaMV), and T-DNA promoters from Agrobacterium.
  • Plant promoters include, but are not limited to, the ribulose-1,3-bisphosphate carboxylase small subunit promoter, maize ubiquitin promoters, the phaseolin promoter, the E8 promoter, and the Tob7 promoter.
  • the invention is not limited to the number of promoters used to control expression of a nucleic acid sequence of interest. Any number of promoters may be used so long as expression of the nucleic acid sequence of interest is controlled in a desired manner. Furthermore, the selection of a promoter may be governed by the desirability that expression be over the whole plant, or localized to selected tissues of the plant, e.g., root, leaves, fruit, etc. For example, promoters active in flowers are known (Benfy et al. (1990) Plant Cell 2:849-856).
  • the promoter activity of any nucleic acid sequence in host cells may be determined (i.e., measured or assessed) using methods well known in the art and exemplified herein.
  • a candidate promoter sequence may be tested by ligating it in-frame to a reporter gene sequence to generate a reporter construct, introducing the reporter construct into host cells (e.g. tomato or potato cells) using methods described herein, and detecting the expression of the reporter gene (e.g., detecting the presence of encoded mRNA or encoded protein, or the activity of a protein encoded by the reporter gene).
  • the reporter gene may confer antibiotic or herbicide resistance.
  • reporter genes include, but are not limited to, dhfr which confers resistance to methotrexate [Wigler M et al., (1980) Proc Natl Acad Sci 77:3567-70]; npt, which confers resistance to the aminoglycosides neomycin and G-418 [Colbere-Garapin F et al., (1981) J. Mol. Biol. 150:1-14] and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyl transferase, respectively.
  • the expression construct preferably contains a transcription termination sequence downstream of the nucleic acid sequence of interest to provide for efficient termination.
  • the termination sequence is the nopaline synthase (NOS) sequence.
  • the termination region comprises different fragments of sugarcane ribulose-1,5-biphosphate carboxylase/oxygenase (rubisco) small subunit (scrbcs) gene.
  • the termination sequences of the expression constructs are not critical to the invention. The termination sequence may be obtained from the same gene as the promoter sequence or may be obtained form different genes.
  • polyadenylation sequences are also commonly added to the expression construct.
  • the polyadenylation sequences include, but are not limited to, the Agrobacteriuni octopine synthase signal, or the nopaline synthase signal.
  • the invention is not limited to constructs which express a single nucleic acid sequence of interest. Constructs which contain a plurality of (i.e., two or more) nucleic acid sequences under the transcriptional control of the same promoter sequence are expressly contemplated to be within the scope of the invention. Also included within the scope of this invention are constructs which contain the same or different nucleic acid sequences under the transcriptional control of different promoters. Such constructs may be desirable to, for example, target expression of the same or different nucleic acid sequences of interest to selected plant tissues.
  • the present invention contemplates using the polynucleotides of the present invention for expression of a portion of plant gum polypeptides in vitro and in vivo. Where expression takes place in vivo, the present invention contemplates transgenic plants.
  • the transgenic plants of the invention are not limited to plants in which each and every cell expresses the nucleic acid sequence of interest. Included within the scope of this invention is any plant (e.g. tobacco, tomato, maize, algae, etc.) which contains at least one cell which expresses the nucleic acid sequence of interest. It is preferred, though not necessary, that the transgenic plant express the nucleic acid sequence of interest in more than one cell, and more preferably in one or more tissue. It is particularly preferred that expression be followed by proper glycosylation of the plant gum polypeptide fragment or variant thereof, such that the host cell produces functional (e.g. in terms of use in the food or cosmetic industry) plant gum polypeptide.
  • transformation of plant cells has taken place with the nucleic acid sequence of interest may be determined using any number of methods known in the art. Such methods include, but are not limited to, restriction mapping of genomic DNA, PCR analysis, DNA-DNA hybridization, DNA-RNA hybridization, and DNA sequence analysis.
  • Expressed polypeptides can be immobilized (covalently or non-covalently) on solid supports or resins for use in isolating HRGP-binding molecules from a variety of sources (e.g. algae, plants, animals, microorganisms). Such polypeptides can also be used to make antibodies.
  • sources e.g. algae, plants, animals, microorganisms.
  • the invention further provides a substantially purified polypeptide comprising at least a portion of the gum arabic consensus sequence.
  • the invention provides a substantially purified polypeptide comprising at least a portion of amino acid sequence A-Hyp-B-C-D-E-F-Hyp-G-H-I-Hyp-J-Hyp-Hyp-K-L-Pro-M (SEQ ID NO:136), wherein A is selected from Ser, Thr, and Ala; B is selected from Hyp, Pro, Leu, and Ile; C is selected from Pro and Hyp; D is selected from Hyp, Pro, Ser, Thr, and Ala; E is selected from Leu and Ile; F is selected from Ser, Thr, and Ala; G is selected from Ser, Leu, Hyp, Thr, Ala, and Ile; H is selected from Hyp, Pro, Leu, and Ile; I is selected from Thr, Ala, and Ser; J is selected from Thr, Ser, and Ala
  • the portion occurs in the polypeptide as a repeating sequence.
  • the repeating sequence repeats from 1 to 64 times.
  • A is Ser; B is selected from Hyp, and Leu; D is selected from Hyp, Ser, and Thr; E is Leu; F is Ser; G is selected from Ser, Leu, and Hyp; H is selected from Hyp, Pro, and Leu; I is selected from Thr and Ala; J is Thr; K is selected from Thr, Leu, and Hyp; L is selected from Gly and Leu; and M is selected from His and Pro.
  • amino acid sequence is selected from Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His (SEQ ID NO:143), Ser-Hyp-Hyp-Thr-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Hyp-Hyp-Gly-Pro-His (SEQ ID NO:144), Ser-Hyp-Hyp-Hyp-Ser-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Thr-Gly-Pro-His (SEQ ID NO:145), Ser-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Thr
  • the portion comprises a motif selected from (Xaa-Hyp) x (SEQ ID NO:182) and Xaa-Hyp-Xaa-Xaa-Hyp-Xaa (SEQ ID NO:183), wherein Xaa is any amino acid other than hydroxyproline, and wherein x is from 2 to 1000.
  • the portion comprises the sequence Xaa-Hyp-Xaa-Hyp (SEQ ID NO:9), and wherein Xaa is selected from Ser, Thr, and Ala.
  • the portion comprises a motif selected from Xaa-Hyp-Hyp n (SEQ ID NO:209) and Xaa-Pro-Hyp n (SEQ ID NO:210), wherein n is from 1 to 100, and wherein Xaa is any amino acid other than hydroxyproline.
  • the portion comprises a peptide sequence selected from Ser-Hyp 2 (SEQ ID NO:211), Ser-Hyp 3 (SEQ ID NO:212), Ser-Hyp 4 (SEQ ID NO:3), Thr-Hyp 2 (SEQ ID NO:213), and Thr-Hyp 3 (SEQ ID NO:214).
  • the portion comprises a peptide sequence selected from Ser-Hyp 2 -Pro (SEQ ID NO:215) and Ser-Hyp 2 -Pro-Hyp (SEQ ID NO:216).
  • the invention further provides a substantially purified polypeptide comprising a non-contiguous hydroxyproline motif
  • the invention provides a substantially purified polypeptide comprising a first motif selected from (Xaa-Hyp) x (SEQ ID NO:182) and Xaa-Hyp-Xaa-Xaa-Hyp-Xaa (SEQ ID NO:183), wherein Xaa is any amino acid other than hydroxyproline, and wherein x is from 2 to 1000.
  • the sequence is Xaa-Hyp-Xaa-Hyp (SEQ ID NO:9), wherein Xaa is selected from Ser, Thr, and Ala.
  • the polypeptide further comprises a contiguous hydroxyproline motif (i.e., a second motif) selected from Xaa-Hyp-Hyp n (SEQ ID NO:209) and Xaa-Pro-Hyp n (SEQ ID NO:210), wherein n is from 1 to 100, and wherein Xaa is any amino acid other than hydroxyproline.
  • a contiguous hydroxyproline motif i.e., a second motif
  • Xaa-Hyp-Hyp n SEQ ID NO:209
  • Xaa-Pro-Hyp n SEQ ID NO:210
  • the first and second motifs alternate in the polypeptide.
  • the alternating first and second motifs repeat from 1 to 500 times.
  • a substantially purified polypeptide comprising a motif selected from Xaa-Hyp-Hyp n (SEQ ID NO:209) and Xaa-Pro-Hyp n (SEQ ID NO:210), wherein n is from 1 to 100, and wherein Xaa is any amino acid other than hydroxyproline.
  • the portion comprises a peptide sequence selected from Ser-Hyp 2 (SEQ ID NO:211), Ser-Hyp 3 (SEQ ID NO:212), Ser-Hyp 4 (SEQ ID NO:3), Thr-Hyp 2 (SEQ ID NO:213), and Thr-Hyp 3 (SEQ ID NO:214).
  • the invention also provides a fusion protein comprising a first sequence selected from a non-gum arabic protein sequence and a non-gum arabic glycoprotein sequence operably linked to at least a portion of an amino acid sequence selected from (a) A-Hyp-B-C-D-E-F-Hyp-G-H-I-Hyp-J-Hyp-Hyp-K-L-Pro-M (SEQ ID NO:136), wherein A is selected from Ser, Thr, and Ala; B is selected from Hyp, Pro, Leu, and Ile; C is selected from Pro and Hyp; D is selected from Hyp, Pro, Ser, Thr, and Ala; E is selected from Leu and Ile; F is selected from Ser, Thr, and Ala; G is selected from Ser, Leu, Hyp, Thr, Ala, and Ile; H is selected from Hyp, Pro, Leu, and Ile; I is selected from Thr, Ala, and Ser; J is selected from Thr
  • an isolated polynucleotide sequence encoding at least a portion of an amino acid sequence selected from (a) A-Hyp-B-C-D-E-F-Hyp-G-H-I-Hyp-J-Hyp-Hyp-K-L-Pro-M (SEQ ID NO:136), wherein A is selected from Ser, Thr, and Ala; B is selected from Hyp, Pro, Leu, and Ile; C is selected from Pro and Hyp; D is selected from Hyp, Pro, Ser, Thr, and Ala; E is selected from Leu and Ile; F is selected from Ser, Thr, and Ala; G is selected from Ser, Leu, Hyp, Thr, Ala, and Ile; H is selected from Hyp, Pro, Leu, and Ile; I is selected from Thr, Ala, and Ser; J is selected from Thr, Ser, and Ala; K is selected from Thr, Leu, Hyp, Ser, Ala
  • the invention further provides a recombinant expression vector comprising a polynucleotide sequence encoding a portion of an amino acid sequence selected from (a) A-Hyp-B-C-D-E-F-Hyp-G-H-I-Hyp-J-Hyp-Hyp-K-L-Pro-M (SEQ ID NO:136), wherein A is selected from Ser, Thr, and Ala; B is selected from Hyp, Pro, Leu, and Ile; C is selected from Pro and Hyp; D is selected from Hyp, Pro, Ser, Thr, and Ala; E is selected from Leu and Ile; F is selected from Ser, Thr, and Ala; G is selected from Ser, Leu, Hyp, Thr, Ala, and Ile; H is selected from Hyp, Pro, Leu, and Ile; I is selected from Thr, Ala, and Ser; J is selected from Thr, Ser, and Ala; K is selected from Thr, Leu,
  • the expression vector further comprises a promoter operably linked to the polynucleotide sequence.
  • the promoter is a viral promoter.
  • the viral promoter is selected from the group consisting of the 35S and 19S RNA promoters of cauliflower mosaic virus.
  • the expression vector further comprises a signal sequence selected from extensin signal sequence (SEQ ID NO:14), and tomato arabinogalactan-protein signal sequence (SEQ ID NO:215).
  • the expression vector further comprises a reporter gene.
  • the reporter gene is the green fluorescence protein gene.
  • the vector is contained within a host cell.
  • the host cell is a plant cell.
  • the plant cell expresses a glycoprotein comprising the portion.
  • a method for producing at least a portion of a glycoprotein comprising: a) providing: i) a recombinant expression vector comprising a polynucleotide sequence encoding at least a portion of an amino acid sequence selected from (a) A-Hyp-B-C-D-E-F-Hyp-G-H-I-Hyp-J-Hyp-Hyp-K-L-Pro-M (SEQ ID NO:136), wherein A is selected from Ser, Thr, and Ala; B is selected from Hyp, Pro, Leu, and Ile; C is selected from Pro and Hyp; D is selected from Hyp, Pro, Ser, Thr, and Ala; E is selected from Leu and Ile; F is selected from Ser, Thr, and Ala; G is selected from Ser, Leu, Hyp, Thr, Ala, and Ile; H is selected from Hyp, Pro, Leu, and Ile; I is selected from Thr
  • the host cell is growing in culture. In a preferred embodiment, the method further comprises the step of c) recovering the portion from the host cell culture. In an alternative embodiment, the host cell is a plant cell. In a more preferred embodiment, the plant cell is derived from a plant selected from the family Leguminoseae.
  • FIG. 1 shows the nucleic acid sequence (SEQ ID NO:12) of one embodiment of a synthetic gene of the present invention.
  • FIG. 2 shows one embodiment of a synthetic gene in one embodiment of an expression vector.
  • FIG. 3 is a graph showing size-fractionation of expressed protein from transformed tobacco cells.
  • FIG. 4 is a graph showing the isolation of GA-EGFP by reverse phase chromatography.
  • FIG. 5 is the elution profile for dGAGP by reverse phase chromatography on a Hamilton PRP-1 column and fractionation by gradient elution.
  • FIG. 6 is the elution profile for dGAGP incomplete pronase digest by reverse phase chromatography.
  • An incomplete digest of dGAGP fractionated on the Hamilton PRP-1 reverse phase column yielded two major peptide fractions, designated P1 and P3.
  • FIG. 7 is the elution profile for a chymotryptic digest of dGAGP fractionated on a Polysulfoethyl aspartamide cation exchange column.
  • FIG. 8 is the elution profile of dGAGP chymotryptic peptides by reverse phase column chromatography of a) S1, and b)S2.
  • FIG. 9 shows a proposed model for an exemplary glycopeptide containing an exemplary consensus sequence.
  • FIG. 10 is the elution profile of the GAGP base hydrolysate by Sephadex G-50 gel permeation chromatography.
  • FIG. 11 shows the oligonucleotide sequence (SEQ ID NOs:112, 113, 115, 116, 118-121, 123 and 124) sets used to build the synthetic genes which encode the Ser-Pro internal repeat polypeptide (SEQ ID NO:114), the GAGP internal repeat polypeptide (SEQ ID NO:117), the 5′-linker (SEQ ID NO:122) and 3′-linker (SEQ ID NO:125).
  • FIG. 12 shows Superose-12 gel permeation chromatography with fluorescence detection of (A) culture medium containing (Ser-Hyp) 32 -EGFP, (B) (GAGP) 3 -EGFP medium concentrated four-fold, (C) Medium of EGFP targeted to the extracellular matrix (concentrated ten-fold), and (D) 10 mg standard EGFP from Clontech.
  • FIG. 13 shows PRP-1 reverse-phase fractionation of the Superose-12 peaks containing (A) (Ser-Hyp) 32 -EGFP, (B) (GAGP) 3 -EGFP, and (C) (Glyco)proteins in the medium of non-transformed tobacco cells.
  • FIG. 14 shows polypeptide sequences of (Ser-Hyp) 32 -EGFP and (GAGP) 3 -EGFP before and after deglycosylation.
  • A N-terminal amino acid sequence of the glycoprotein, (Ser-Hyp) 32 -EGFP, with partial sequence of both the glycoprotein (upper sequence) (SEQ ID NO:126) and its polypeptide after deglycosylation (lower sequence) (SEQ ID NO:127).
  • X denotes blank cycles which correspond to glycosylated Hyp; glycoamino acids tend to produce blank cycles during Edman degradation, an exception being arabinosyl Hyp.
  • FIG. 15 is a diagram of the cloning strategy for generating repeats of GAGP sequences.
  • FIG. 16 depicts the exemplary (A) nucleotide sequence (SEQ ID NO:130) and amino acid sequence (SEQ ID NO:131) of two GAGP repeats, and (B) nucleotide sequence (SEQ ID NO:132) and amino acid sequence (SEQ ID NO:133) of four GAGP repeats (SEQ ID NOs:133).
  • the term “gene” refers to a DNA sequence that comprises control and coding sequences necessary for the production of a polypeptide or its precursor.
  • the polypeptide can be encoded by a full length coding sequence or by any portion of the coding sequence.
  • nucleic acid sequence of interest refers to any nucleic acid sequence the manipulation of which may be deemed desirable for any reason by one of ordinary skill in the art (e.g., confer improved qualities).
  • wild-type when made in reference to a gene refers to a gene which has the characteristics of a gene isolated from a naturally occurring source.
  • wild-type when made in reference to a gene product refers to a gene product which has the characteristics of a gene product isolated from a naturally occurring source.
  • a wild-type gene is that which is most frequently observed in a population and is thus arbitrarily designated the “normal” or “wild-type” form of the gene.
  • modified or mutant when made in reference to a gene or to a gene product refers, respectively, to a gene or to a gene product which displays modifications in sequence and/or functional properties (i.e., altered characteristics) when compared to the wild-type gene or gene product. It is noted that naturally-occurring mutants can be isolated; these are identified by the fact that they have altered characteristics when compared to the wild-type gene or gene product.
  • the term “recombinant” when made in reference to a DNA molecule refers to a DNA molecule which is comprised of segments of DNA joined together by means of molecular biological techniques.
  • the term “recombinant” when made in reference to a protein or a polypeptide refers to a protein molecule which is expressed using a recombinant DNA molecule.
  • vector and “vehicle” are used interchangeably in reference to nucleic acid molecules that transfer DNA segment(s) from one cell to another.
  • expression vector or “expression cassette” as used herein refers to a recombinant DNA molecule containing a desired coding sequence and appropriate nucleic acid sequences necessary for the expression of the operably linked coding sequence in a particular host organism.
  • Nucleic acid sequences necessary for expression in prokaryotes usually include a promoter, an operator (optional), and a ribosome binding site, often along with other sequences.
  • Eukaryotic cells are known to utilize promoters, enhancers, and termination and polyadenylation signals.
  • targeting vector or “targeting construct” refer to oligonucleotide sequences comprising a gene of interest flanked on either side by a recognition sequence which is capable of homologous recombination of the DNA sequence located between the flanking recognition sequences.
  • operable combination refers to the linkage of nucleic acid sequences in such a manner that a nucleic acid molecule capable of directing the transcription of a given gene andfor the synthesis of a desired protein molecule is produced.
  • operable order refers to the linkage of amino acid sequences in such a manner so that a functional protein is produced.
  • transformation refers to the introduction of foreign DNA into cells. Transformation of a plant cell may be accomplished by a variety of means known in the art including particle mediated gene transfer (see, e.g., U.S. Pat. No. 5,584,807 hereby incorporated by reference); infection with an Agrobacterium strain containing the foreign DNA for random integration (U.S. Pat. No. 4,940,838 hereby incorporated by reference) or targeted integration (U.S. Pat. No. 5,501,967 hereby incorporated by reference) of the foreign DNA into the plant cell genome; electroinjection (Nan et al. (1995) In “Biotechnology in Agriculture and Forestry,” Ed. Y. P. S.
  • infectious and “infection” with a bacterium refer to co-incubation of a target biological sample, (e.g., cell, tissue, etc.) with the bacterium under conditions such that nucleic acid sequences contained within the bacterium are introduced into one or more cells of the target biological sample.
  • a target biological sample e.g., cell, tissue, etc.
  • Agrobacterium refers to a soil-borne, Gram-negative, rod-shaped phytopathogenic bacterium which causes crown gall.
  • Agrobacterium includes, but is not limited to, the strains Agrobacterium tumefaciens , (which typically causes crown gall in infected plants), and Agrobacterium rhizogens (which causes hairy root disease in infected host plants). Infection of a plant cell with Agrobacterium generally results in the production of opines (e.g., nopaline, agropine, octopine etc.) by the infected cell.
  • opines e.g., nopaline, agropine, octopine etc.
  • Agrobacterium strains which cause production of nopaline are referred to as “nopaline-type” Agrobacteria
  • Agrobacterium strains which cause production of octopine e.g., 'strain LBA4404, Ach5, B6
  • octopine-type e.g., 'strain LBA4404, Ach5, B6
  • octopine-type e.g., 'strain LBA4404, Ach5, B6
  • Agrobacterium strains which cause production of agropine e.g., strain EHA105, EHA101, A281
  • agropine-type agropine-type
  • biolistic bombardment refers to the process of accelerating particles towards a target biological sample (e.g., cell, tissue, etc.) to effect wounding of the cell membrane of a cell in the target biological sample and/or entry of the particles into the target biological sample.
  • a target biological sample e.g., cell, tissue, etc.
  • Methods for biolistic bombardment are known in the art (e.g., U.S. Pat. No. 5,584,807, the contents of which are herein incorporated by reference), and are commercially available (e.g., the helium gas-driven microprojectile accelerator (PDS-1000/He) (BioRad).
  • microwounding when made in reference to plant tissue refers to the introduction of microscopic wounds in that tissue. Microwounding may be achieved by, for example, particle or biolistic bombardment.
  • transgenic when used in reference to a plant cell refers to a plant cell which comprises a transgene, or whose genome has been altered by the introduction of a transgene.
  • transgenic when used in reference to a plant refers to a plant which comprises one or more cells which contain a transgene, or whose genome has been altered by the introduction of a transgene.
  • transgenic cells and transgenic plants may be produced by several methods including the introduction of a “transgene” comprising nucleic acid (usually DNA) into a target cell or integration into a chromosome of a target cell by way of human intervention, such as by the methods described herein.
  • transgene refers to any nucleic acid sequence which is introduced into the genome of a plant cell by experimental manipulations.
  • a transgene may be an “endogenous DNA sequence,” or a “heterologous DNA sequence” (i.e., “foreign DNA”).
  • endogenous DNA sequence refers to a nucleotide sequence which is naturally found in the cell into which it is introduced so long as it does not contain some modification (e.g., a point mutation, the presence of a selectable marker gene, etc.) relative to the naturally-occurring sequence.
  • heterologous DNA sequence refers to a nucleotide sequence which is ligated to, or is manipulated to become ligated to, a nucleic acid sequence to which it is not ligated in nature, or to which it is ligated at a different location in nature.
  • Heterologous DNA is not endogenous to the cell into which it is introduced, but has been obtained from another cell.
  • Heterologous DNA also includes an endogenous DNA sequence which contains some modification.
  • heterologous DNA encodes RNA and proteins that are not normally produced by the cell into which it is expressed.
  • heterologous DNA examples include mutated wild-type genes (i.e., wild-type genes that have been modified such that they are no longer wild-type genes), reporter genes, transcriptional and translational regulatory sequences, selectable marker proteins (e.g., proteins which confer drug resistance), etc.
  • the term “probe” when made in reference to an oligonucleotide refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, recombinantly or by PCR amplification, which is capable of hybridizing to another oligonucleotide of interest.
  • a probe may be single-stranded or double-stranded. Probes are useful in the detection, identification and isolation of particular gene sequences. Oligonucleotide probes may be labelled with a “reporter molecule,” so that the probe is detectable using a detection system. Detection systems include, but are not limited to, enzyme, fluorescent, radioactive, and luminescent systems.
  • selectable marker refers to a gene which encodes an enzyme having an activity that confers resistance to an antibiotic or drug upon the cell in which the selectable marker is expressed.
  • Selectable markers may be “positive” or “negative.” Examples of positive selectable markers include the neomycin phosphotrasferase (NPTII) gene which confers resistance to G418 and to kanamycin, and the bacterial hygromycin phosphotransferase gene (hyg), which confers resistance to the antibiotic hygromycin.
  • Negative selectable markers encode an enzymatic activity whose expression is cytotoxic to the cell when grown in an appropriate selective medium. For example, the HSV-tk gene is commonly used as a negative selectable marker.
  • HSV-tk gene expression of the HSV-tk gene in cells grown in the presence of gancyclovir or acyclovir is cytotoxic; thus, growth of cells in selective medium containing gancyclovir or acyclovir selects against cells capable of expressing a functional HSV TK enzyme.
  • promoter element refers to a DNA sequence that is located at the 5′ end (i.e. precedes) the protein coding region of a DNA polymer. The location of most promoters known in nature precedes the transcribed region. The promoter functions as a switch, activating the expression of a gene. If the gene is activated, it is said to be transcribed, or participating in transcription. Transcription involves the synthesis of mRNA from the gene. The promoter, therefore, serves as a transcriptional regulatory element and also provides a site for initiation of transcription of the gene into mRNA.
  • PCR polymerase chain reaction
  • This process for amplifying the target sequence consists of introducing a large excess of two oligonucleotide primers to the DNA mixture containing the desired target sequence, followed by a precise sequence of thermal cycling in the presence of a DNA polymerase.
  • the two primers are complementary to their respective strands of the double stranded target sequence.
  • the mixture is denatured and the primers then annealed to their complementary sequences within the target molecule.
  • the primers are extended with a polymerase so as to form a new pair of complementary strands.
  • the steps of denaturation, primer annealing and polymerase extension can be repeated many times (i.e., denaturation, annealing and extension constitute one “cycle”; there can be numerous “cycles”) to obtain a high concentration of an amplified segment of the desired target sequence.
  • the length of the amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter.
  • the method is referred to as the “polymerase chain reaction” (hereinafter “PCR”). Because the desired amplified segments of the target sequence become the predominant sequences (in terms of concentration) in the mixture, they are said to be “PCR amplified.”
  • any oligonucleotide sequence can be amplified with the appropriate set of primer molecules.
  • the amplified segments created by the PCR process itself are, themselves, efficient templates for subsequent PCR amplifications.
  • Amplified target sequences may be used to obtain segments of DNA (e.g., genes) for the construction of targeting vectors, transgenes, etc.
  • the present invention contemplates using amplification techniques such as PCR to obtain the cDNA (or portions thereof) of plant genes encoding plant gums and other hydroxyproline-rich polypeptides.
  • primers are designed using the synthetic gene sequences (e.g. containing sequences encoding particular motifs) described herein and PCR is carried out (using genomic DNA or other source of nucleic acid from any plant capable of producing a gurn exudate) under conditions of low stringency.
  • PCR is carried out under high stringency.
  • the amplified products can be run out on a gel and isolated from the gel.
  • hybridization refers to any process by which a strand of nucleic acid joins with a complementary strand through base pairing [Coombs J (1994) Dictionary of Biotechnology , Stockton Press, New York N.Y.]
  • the terms “complementary” or “complementarity” when used in reference to polynucleotides refer to polynucleotides which are related by the base-pairing rules. For example, for the sequence 5′-AGT-3′ is complementary to the sequence 5′-ACT-3′. Complementarity may be “partial,” in which only some of the nucleic acids' bases are matched according to the base pairing rules. Or, there may be “complete” or “total” complementarity between the nucleic acids. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, as well as detection methods which depend upon binding between nucleic acids.
  • the term “homology” when used in relation to nucleic acids refers to a degree of complementarity. There may be partial homology or complete homology (i.e., identity).
  • a partially complementary sequence is one that at least partially inhibits a completely complementary sequence from hybridizing to a target nucleic acid is referred to using the functional term “substantially homologous.”
  • the inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or Northern blot, solution hybridization and the like) under conditions of low stringency.
  • a substantially homologous sequence or probe will compete for and inhibit the binding (i.e., the hybridization) of a sequence which is completely homologous to a target under conditions of low stringency.
  • low stringency conditions are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction.
  • the absence of non-specific binding may be tested by the use of a second target which lacks even a partial degree of complementarity (e.g., less than about 30% identity); in the absence of non-specific binding the probe will not hybridize to the second non-complementary target.
  • Low stringency conditions when used in reference to nucleic acid hybridization comprise conditions equivalent to binding or hybridization at 68° C. in a solution consisting of 5 ⁇ SSPE (43.8 g/l NaCl, 6.9 g/l NaH 2 PO 4 ⁇ H 2 O and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 1% SDS, 5 ⁇ Denhardt's reagent [50 ⁇ Denhardt's contains the following per 500 ml: 5 g Ficoll (Type 400, Pharmacia), 5 g BSA (Fraction V; Sigma)] and 100 ⁇ g/ml denatured salmon sperm DNA followed by washing in a solution comprising 0.2 ⁇ SSPE, and 0.1% SDS at room temperature when a DNA probe of about 100 to about 1000 nucleotides in length is employed.
  • 5 ⁇ SSPE 43.8 g/l NaCl, 6.9 g/l NaH 2 PO 4 ⁇ H 2 O and 1.85 g/l EDTA, pH adjusted to
  • High stringency conditions when used in reference to nucleic acid hybridization comprise conditions equivalent to binding or hybridization at 68° C. in a solution consisting of 5 ⁇ SSPE, 1% SDS, 5 ⁇ Denhardt's reagent and 100 ⁇ g/ml denatured salmon sperm DNA followed by washing in a solution comprising 0.1 ⁇ SSPE, and 0.1% SDS at 68° C. when a probe of about 100 to about 1000 nucleotides in length is employed.
  • hybridization condition when made in reference to a hybridization condition as it relates to a hybridization condition of interest means that the hybridization condition and the hybridization condition of interest result in hybridization of nucleic acid sequences which have the same range of percent (%) homology.
  • a hybridization condition of interest results in hybridization of a first nucleic acid sequence with other nucleic acid sequences that have from 50% to 70% homology to the first nucleic acid sequence
  • another hybridization condition is said to be equivalent to the hybridization condition of interest if this other hybridization condition also results in hybridization of the first nucleic acid sequence with the other nucleic acid sequences that have from 50% to 70% homology to the first nucleic acid sequence.
  • nucleic acid hybridization When used in reference to nucleic acid hybridization the art knows well that numerous equivalent conditions may be employed to comprise either low or high stringency conditions; factors such as the length and nature (DNA, RNA, base composition) of the probe and nature of the target (DNA, RNA, base composition, present in solution or immobilized, etc.) and the concentration of the salts and other components (e.g., the presence or absence of formamide, dextran sulfate, polyethylene glycol) are considered and the hybridization solution may be varied to generate conditions of either low or high stringency hybridization different from, but equivalent to, the above listed conditions.
  • factors such as the length and nature (DNA, RNA, base composition) of the probe and nature of the target (DNA, RNA, base composition, present in solution or immobilized, etc.) and the concentration of the salts and other components (e.g., the presence or absence of formamide, dextran sulfate, polyethylene glycol) are considered and the hybridization solution may be varied to generate conditions of either low
  • “Stringency” when used in reference to nucleic acid hybridization typically occurs in a range from about T m -5° C. (5° C. below the T m of the probe) to about 20° C. to 25° C. below T m .
  • a stringent hybridization can be used to identify or detect identical polynucleotide sequences or to identify or detect similar or related polynucleotide sequences.
  • stringent conditions a nucleic acid sequence of interest will hybridize to its exact complement and closely related sequences.
  • fusion protein refers to a chimeric protein containing the protein of interest (i.e., GAGP and fragments thereof) joined to an exogenous protein fragment (the fusion partner which consists of a non-GAGP sequence).
  • the fusion partner may provide a detectable moiety, may provide an affinity tag to allow purification of the recombinant fusion protein from the host cell, or both.
  • the fusion protein may be removed from the protein of interest (i.e., GAGP protein or fragments thereof) by a variety of enzymatic or chemical means known to the art.
  • the fusion proteins of the invention may be used as substrates for plant glycosyl transfgerases.
  • the exemplary (Ser-Hyp) 32 -EGFP may be used as an acceptor for galactose addition, with UDP-galactose as co-substrate, catalyzed by galactosyl transferase.
  • the fusion partner EGFP allows facile isolation of the newly galactosyalted polypeptide. Fusion proteins containing sequences of the invention may be isolated using methods known in the art, such as gel filtration (Example 22), hydrophobic interaction chromatograph (HIC), reverse phase chromatography, and anion exchange chromatography.
  • non-gum arabic glycoprotein or “non-gum arabic glycoprotein sequence” refers to that portion of a fusion protein which comprises a protein or protein sequence which is not derived from a gum arabic glycoprotein.
  • protein of interest refers to the protein whose expression is desired within the fusion protein.
  • the protein of interest e.g., GAGP
  • another protein or protein domain e.g., GFP
  • the term “purified” or “to purify” refers to the removal of contaminants from a sample.
  • recombinant HRGP polypeptides, including HRGP-GFP fusion proteins are purified by the removal of host cell components such as nucleic acids, lipopolysaccharide (e.g., endotoxin).
  • host cell components such as nucleic acids, lipopolysaccharide (e.g., endotoxin).
  • “Substantially purified” molecules are at least 60% free, preferably at least 75% free, and more preferably at least 90% free from other components with which they are naturally associated.
  • recombinant DNA molecule refers to a DNA molecule which is comprised of segments of DNA joined together by means of molecular biological techniques.
  • recombinant protein or “recombinant polypeptide” as used herein refers to a protein molecule which is expressed ftom a recombinant DNA molecule.
  • portion when in reference to a protein (as in “a portion of a given protein”) refers to fragments of that protein.
  • the fragments may range in size from four (4) amino acid residues to the entire amino acid sequence minus one amino acid.
  • a portion of an amino acid sequence which is 30 nucleotides long refers to any fragment of that sequence which ranges in size from 4 to 29 contiguous amino acids of that sequence.
  • a polypeptide comprising “at least a portion of” an amino acid sequence comprises from four (4) contiguous amino acid residues of the amino acid sequence to the entire amino acid sequence.
  • portion means a fragment which ranges in size from twelve (12) nucleic acids to the entire nucleic acid sequence minus one nucleic acid.
  • a nucleic acid sequence comprising “at least a portion of” a nucleotide sequence comprises from twelve (12) contiguous nucleotide residues of the nucleotide sequence to the entire nucleotide sequence.
  • isolated when used in relation to a nucleic acid, as in “an isolated nucleic acid sequence” refers to a nucleic acid sequence that is identified and separated from at least one contaminant nucleic acid with which it is ordinarily associated in its natural source.
  • motif and “module” are equivalent terms when made in reference to an amino acid sequence, and refer to the particular type, number, and arrangement of amino acids in that sequence.
  • glycomodule refers to a glycopeptide in which the carbohydrate portion is covalently linked to an amino acid sequence motif.
  • repeating sequence when made in reference to a peptide sequence that is contained in a polypeptide sequence means that the peptide sequence is reiterated from 1 to 10 times, more preferably from 1 to 100 times, and most preferably from 1 to 1000 times, in the polypeptide sequence.
  • the repeats of the peptide sequence may be non-contiguous or contiguous.
  • non-contiguous repeat when made in reference to a repeating peptide sequence means that at least one amino acid (or amino acid analog) is placed between the repeating sequences.
  • contiguous repeat when made in reference to a repeating peptide sequence means that there are no intervening amino acids (or amino acid analogs) between the repeating sequences.
  • the present invention relates generally to the field of plant gums and other hydroxyproline-rich glycoproteins, and in particular, to the expression of synthetic genes designed from repetitive peptide sequences.
  • the hydroxyproline-rich glycoprotein (HRGP) superfamily is ubiquitous in the primary cell wall or extracellular matrix throughout the plant kingdom. Family members are diverse in structure and implicated in all aspects of plant growth and development. This includes plant responses to stress imposed by pathogenesis and mechanical wounding.
  • Plant HRGPs have no known animal homologs. Furthermore, hydroxyproline residues are O-glycosylated in plant glycoproteins but never in animals. At the molecular level the function of these unique plant glycoproteins remains largely unexplored.
  • HRGPS are, to a lesser or greater extent, extended, repetitive, modular proteins.
  • the modules are small (generally 4-6 amino acid residue motifs), usually glycosylated, with most HRGPs being made up of more than one type of repetitive module.
  • it is useful to view the glycosylated polypeptide modules not merely as peptides or oligosaccharides but as small functional motifs.
  • the description of the invention involves A) the design of the polypeptide of interest, B) the production of synthetic genes encoding the polypeptide of interest, C) the construction of the expression vectors, D) selection of the host cells, E) introduction of the expression construct into a particular cell (whether in vitro or in vivo), F) preferred consensus sequences and portions thereof, and G) O-glycosylation codes.
  • the present invention contemplates polypeptides that are fragments of hydroxyproline-rich glycoproteins (HRGPs), repetitive proline-rich proteins (RPRPs) and arabinogalactan-proteins (AGPs).
  • HRGPs hydroxyproline-rich glycoproteins
  • RPRPs repetitive proline-rich proteins
  • AGPs arabinogalactan-proteins
  • the present invention contemplates portions of HRGPs comprising one or more of the highly conserved Ser-Hyp 4 (SEQ ID NO:3) motif(s).
  • the present invention also contemplates portions of RPRPs comprising one or more of the pentapeptide motif: Pro-Hyp-Val-Tyr-Lys (SEQ ID NO:4).
  • AGPs comprising one or more Xaa-Hyp-Xaa-Hyp (SEQ ID NO:9) repeats.
  • Extensins occupy an intermediate position in the glycosylation continuum, containing about 50% carbohydrate which occurs mainly as Hyp-arabinosides (1-4 Ara residues), but not as Hyp-arabinogalactan polysaccharide.
  • Extensins contain the repetitive, highly arabinosylated, diagnostic Ser-Hyp 4 (SEQ ID NO:3) glycopeptide module. The precise function of this module is unknown, but earlier work indicates that these motifs of arabinosylated Hyp help stabilize the extended polyproline-II helix of the extensins. Monogalactose also occurs on the Ser residues.
  • the classical Ser-Hyp 4 (SEQ ID NO:3) glycopeptide module is of special interest.
  • a tetra-L-arabinofuranosyl oligosaccharide is attached to each Hyp residue in the motif.
  • Three uniquely b-linked arabinofuranosyl residues and an a-linked nonreducing terminus comprise the tetraarabinooligosaccharide. While an understanding of the natural mechanism of glycosylation is not required for the successful operation of the present invention, it is believed that the arabinosylated Hyp residues together with the single galactosyl-serine residue undoubtedly form a unique molecular surface topography which interacts with and is recognized by other wall components, possibly including itself. Shorter motifs of Hyp, namely Hyp 3 and Hyp 2 , lack the fourth (a-linked) arabinose residue, again suggesting that the fourth Ara unique to the Hyp 4 motif, has a special role and is presented for recognition or cleavage.
  • Tetra-arabinose and tri-arabinose are attached to known tetra-Hyp motifs.
  • Those Ser-Hyp 4 isolated from native extensins have every Hyp residue arabinosylated.
  • the Ser-Hyp 4 repeats fused to EGFP as disclosed herein showed that some Hyp residues were nonglycosylated, while some were mono- and di-arabinosylated.
  • the Hyp residues were tri-arabinosylated and tetra-arabinosylated.
  • Hyp-Ara 4 was 31% of total Hyp
  • Hyp-Ara 3 was 52% of total Hyp
  • Hyp-Ara 2 was 8% of total Hyp
  • Hyp-Ara was 2% of total Hyp.
  • 7% of the total Hyp was not glyscosylated.
  • Most of the serine residues in the invention's exemplary Ser-Hyp 4 repeats fused to EGFP were not galactosylated. This is in contrast to naturally occurring Ser-Hyp 4 in which Ser is often mono-galactosylated.
  • Hyp-polysaccharide were never detected by the inventors in the Ser-Hyp 4 repeats fused to EGFP.
  • the arabinogalactan-proteins (AGPs) and the related gum arabic glycoprotein (GAGP) are uniquely glycosylated with arabinogalactan polysaccharides.
  • GAGP and all AGPs so far characterized by Hyp-glycoside profiles contain Hyp-linked arabinosides assigned to contiguous Hyp residues by the Hyp contiguity hypothesis.
  • these glycoproteins also uniquely contain Xaa-Hyp-Xaa-Hyp (SEQ ID NO:9) repeats. These repeats are putative polysaccharide attachment sites.
  • the present invention contemplates in particular fragments of gum arabic glycoprotein (GAGP).
  • GAGP gum arabic glycoprotein
  • the largest peptide obtained and sequenced from gum arabic was a peptide of twelve (12) arino acids having the sequence Ser-Hyp-Ser-Hyp-Thr-HypThr-Hyp-Hyp-Hyp-Gly-Pro (SEQ ID NO:13).
  • SEQ ID NO:13 Ser-Hyp-Ser-Hyp-Thr-HypThr-Hyp-Hyp-Hyp-Gly-Pro
  • the present invention contemplates using this Delonnay sequence as well as (heretofore undescribed) larger peptide fragments of GAGP (and variants thereof) for the design of synthetic genes. In this manner, “designer plant gums” can be produced (“designer extensins” are also contemplated).
  • the present invention contemplates a substantially purified polypeptide comprising at least a portion of the amino acid consensus sequence Ser-Hyp-Hyp-Hyp-[Hyp/Thr]-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His (SEQ ID NO:1 and SEQ ID NO:2) or variants thereof.
  • this GAGP 19-amino acid consensus repeat (which contains both contiguous Hyp and non-contiguous Hyp repeats) is glycosylated in native GAGP with both Hyp-arabinosides and Hyp-polysaccharide in molar ratios. It is further believed that the high molecular weight protein component of gum arabic (i.e. GAGP) is responsible for the remarkable (and advantageous) emulsifying and stabilizing activity exploited by the food and soft drink industries.
  • sequences of the invention may be used to isolate hydroxyproline rich glycoprotein-binding molecules.
  • polypeptides encoded by the invention's polynucloetide sequences may be immobilized (covalently or non-covalently) on solid supports or resins for use in isolating HRGP-binding molecules from a variety of sources (e.g. algae, plants, animals, microorganisms).
  • sources e.g. algae, plants, animals, microorganisms.
  • Generic methods for immobilizing polypeptides are known in the art using commercially available kits.
  • the desired polypeptide sequence may be expressed as a fusion protein with heterologous protein A which allows immobilization of the fusion protein on immobilized immunoglobulin.
  • pGEX vectors may be used to express the desired polypeptides as a fusion protein with glutathione S-transferase (GST) which may be adsorbed to glutathione-agarose beads.
  • GST glutathione S-transferase
  • the invention's sequences may also be used to make polyclonal and monoclonal antibodies.
  • Generic methods for generating polyclonal and monoclonal antibodies are known in the art.
  • monoclonal antibodies may be generated using the methods of Kohler and Milstein (1976) Eur. J. Immunol. 6:511-519 (Exhibit B) and of J. Goding (1986) In “Monoclonal Antibodies: Principles and Practice,” Academic Press, pp 59-103.
  • the present invention contemplates the use of synthetic genes engineered for the expression of repetitive glycopeptide modules in cells, including but not limited to callus and suspension cultures. It is not intended that the present invention be limited by the precise number of repeats.
  • the present invention contemplates the nucleic acid sequences encoding the consensus sequence for GAGP (i.e. SEQ ID NO:1 and SEQ ID NO:2) or variants thereof may be used as a repeating sequence between two (2) and up to fifty (50) times, more preferably between ten (10) and up to thirty (30) times, and most preferably approximately twenty (20) times.
  • the nucleic acid sequence encoding the consensus sequence (i.e. SEQ ID NO:1 and SEQ ID NO:2) or variants thereof may be used as contiguous repeats or may be used as non-contiguous repeats.
  • [0114] 1) Minimization of the repetitive nature of the coding sequence while still taking into account the HRGP codon bias of the host plant e.g., when tomato is the host plant, the codon usage bias of the tomato which favors CCA and CCT [but not CCG] for Pro residues, and TCA and TCC for Ser residues is employed.
  • Zea mays such as corn
  • other graminaceous monocotyledons e.g. rice barley, wheat and all grasses
  • CCG and CCC for proline
  • GTC and CTT for valine
  • AAG for lysine.
  • Dicotyledons (including legumes) prefer CCA and CCT for proline and TCA and TCT for serine.
  • Non-palindromic ends are used for the monomers and end linkers to assure proper “head-to-tail” polymerization.
  • the constructs contain no internal restriction enzyme recognition sites for the restriction enzymes employed for the insertion of these sequences into expression vectors or during subsequent manipulations of such vectors.
  • the 5′ linker contains a XmaI site downstream of the BamHI site used for cloning into the cloning vector (e.g., pBluescript).
  • the XmaI site is used for insertion of the HRGP gene cassette into the expression vector (e.g., pBI121-Sig-EGFP).
  • the 3′ linker contains a AgeI site upstream of the EcoRI site used for cloning into the cloning vector (e.g., pBluescript).
  • the AgeI site is used for insertion of the HRGP gene cassette into the expression vector.
  • plasmid pBI121-Sig which does not contain GFP for the fusion protein—the same signal sequence (SS) is used, but the 3′ linkers contain an Sst I restriction site for insertion as an Xma I/Sst I fragment behind the signal sequence and before the NOS terminator].
  • the oligonucleotides used are high quality (e.g., from GibcoBRL, Operon) and have been purified away from unwanted products of the synthesis.
  • T M of correctly aligned oligomers is greater than the T M of possible dimers, hairpins or crossdimers.
  • hydroxyproline (Hyp) residues in the sequences of the invention are produced as the result of post-translational modification of proline (Pro) residues in the polypeptide which is encoded by the gene.
  • Pro proline
  • the corresponding codon would be selected to encode proline.
  • the Edman degradation may be used to identify which Pro residues had been hydroxylated to Hyp as described in Example 23, infra.
  • a variety of vectors are contemplated.
  • two plant transformation vectors are prepared, both derived from pBI121 (Clontech). Both contain an extensin signal sequence (SS) for transport of the constructs through the ER/Golgi for posttranslational modification.
  • SS extensin signal sequence
  • a first plasmid construct contained Green Fluorescent Protein (GFP) as a reporter protein instead of GUS.
  • GFP Green Fluorescent Protein
  • pBI121 is the Jefferson vector in which the BamHI and SstI sites can be used to insert foreign DNA between the 35S CaMV promoter and the termination/polyadenylation signal from the nopaline synthase gene (NOS-ter) of the Agrobacterium Ti plasmid); it also contains an RK2 origin of replication, a kanamycin resistance gene, and the GUS reporter gene.
  • GUS sequence is replaced (via BamHI/SstI) with a synthetic DNA sequence encoding a peptide signal sequence based on the extensin signal sequences of Nicotiana plumbaginifolia and N. tabacum
  • MGKMASLFATFLVVLVSLSLA QTTRVVPVASSAP (SEQ ID NO:14) The DNA sequence also contains 15 bp of the 5′ untranslated region, and restriction sites for Bam HI in its 5′ terminus and Sst I in its extreme 3′ terminus for insertion into pBI121 in place of GUS.
  • An XmaI restriction site occurs 16 bp upstream from the Sst I site to allow subsequent insertion of EGFP into the plasmid as a Xma I/Sst I fragment.
  • the sequence underlined above targets N. plumbaginifolia extensin fusion proteins through the ER and Golgi for post-translational modifications, and finally to the wall.
  • the signal sequence proposed also involves transport of extensins and extensin modules in the same plant family (Solanaceae). Alternatively, one can use the signal sequence from tomato P1 extensin itself.
  • the tomato arabinogalactan-protein (Le-AGP-1) signal sequence may be used.
  • This sequence has previously been cloned [Li (1996) “Isolation and characterization of genes and complementary DNAs encoding a tomato arabiogalactan protein, PhD. Dissertation, Ohio University, Athens, Ohio] and encodes the protein sequence MDRKFVFLVSILCIVVASVTG (SEQ ID NO:215).
  • This sequence has successfully been used by the inventors to target expression of the inventions's sequences to the extracellular medium of tobacco cell cultures and is being used to target (Ala-Pro) n -EGFP and (Thr-Pro) n -EGFP to the extracellular matrix of tobacco cell cultures.
  • the repetitive HRGP-modules can be expressed as GFP fusion products rather than GUS fusions, and can also be expressed as modules without GFP.
  • Fusion with a green fluorescent protein reporter gene appropriately red-shifted for plant use e.g. EGFP (an S65T variant recommended for plants by Clontech) or other suitable mutants (see Table 1 above) allows the detection of ⁇ 700 GFP molecules at the cell surface.
  • GFP requires aerobic conditions for oxidative formation of the fluorophore. It works well at the lower temperatures used for plant cell cultures and normally it does not adversely affect protein function although it may allow the regeneration of plants only when targeted to the ER.
  • Promoters As noted above, it is not intended that the present invention be limited by the nature of the promoter(s) used in the expression constructs.
  • the CaMV35S promoter is preferred, although it is not entirely constitutive and expression is “moderate”. In some embodiments, higher expression of the constructs is desired to enhance the yield of HRGP modules; in such cases a plasmid with “double” CaMV35S promoters is employed.
  • a variety of host cells are contemplated (both eukaryotic and prokaryotic). It is not intended that the present invention be limited by the host cells used for expression of the synthetic genes of the present invention. Plant host cells are preferred, including but not limited to legumes (e.g. soy beans) and solanaceous plants (e.g. tobacco, tomato, etc.). Other cells contemplated to be within the scope of this invention are green algae [e.g., Chlamydomonas, Volvox, and duckweed (Lernna)].
  • legumes e.g. soy beans
  • solanaceous plants e.g. tobacco, tomato, etc.
  • Other cells contemplated to be within the scope of this invention are green algae [e.g., Chlamydomonas, Volvox, and duckweed (Lernna)].
  • the present invention is not limited by the nature of the plant cells. All sources of plant tissue are contemplated.
  • the plant tissue which is selected as a target for transformation with vectors which are capable of expressing the invention's sequences are capable of regenerating a plant.
  • the term “regeneration” as used herein, means growing a whole plant from a plant cell, a group of plant cells, a plant part or a plant piece (e.g., from seed, a protoplast, callus, protocorm-like body, or tissue part).
  • Such tissues include but are not limited to seeds. Seeds of flowering plants consist of an embryo, a seed coat, and stored food.
  • the embryo When fully formed, the embryo consists basically of a hypocotyl-root axis bearing either one or two cotyledons and an apical meristem at the shoot apex and at the root apex.
  • the cotyledons of most dicotyledons are fleshy and contain the stored food of the seed. In other dicotyledons and most monocotyledonss, food is stored in the endosperm and the cotyledons function to absorb the simpler compounds resulting from the digestion of the food.
  • Species from the following examples of genera of plants may be regenerated from transformed protoplasts: Fragaria, Lotus, Medicago, Onobrychis, Trifolium, Trigonella, Vigna, Citrus, Linum, Geranium, Manihot, Daucus, Arabidopsis, Brassica, Raphanus, Sinapis, Atropa, Capsicum, Hyoscyamus, Lycopersicon, Nicotiana, Solanum, Petunia, Digitalis, Majorana, Ciohorium, Helianthus, Lactuca, Bromus, Asparagus, Antirrhinum, Hererocallis, Nemesia, Pelargonium, Panicum, Penimsetum, Ranunculus, Senecio, Salpiglossis, Cucumis, Browaalia, Glycine, Lolium, Zea, Triticum, Sorghum, and Datura.
  • transgenic plants For regeneration of transgenic plants from transgenic protoplasts, a suspension of transformed protoplasts or a petri plate containing transformed explants is first provided. Callus tissue is formed and shoots may be induced from callus and subsequently rooted. Alternatively, somatic embryo formation can be induced in the callus tissue. These somatic embryos germinate as natural embryos to form plants.
  • the culture media will generally contain various amino acids and plant hormones, such as auxin and cytokinins. It is also advantageous to add glutamic acid and proline to the medium, especially for such species as corn and alfalfa. Efficient regeneration will depend on the medium, on the genotype, and on the history of the culture. These three variables may be empirically controlled to result in reproducible regeneration.
  • Plants may also be regenerated from cultured cells or tissues.
  • Dicotyledonous plants which have been shown capable of regeneration from transformed individual cells to obtain transgenic whole plants include, for example, apple ( Malus pumila ), blackberry (Rubus), Blackberry/raspberry hybrid (Rubus), red raspberry (Rubus), carrot ( Daucus carota ), cauliflower ( Brassica oleracea ), celery ( Apium graveolens ), cucumber ( Cucumis sativus ), eggplant ( Solanum melongena ), lettuce ( Lactuca sativa ), potato ( Solanum tuberosum ), rape ( Brassica napus ), wild soybean ( Glycine canescens ), strawberry (Fragaria x ananassa), tomato ( Lycopersicon esculenturn ), walnut ( Juglans regia ), melon ( Cucumis melo ), grape ( Vitis vinifera ), and mango ( Mangifera indica ).
  • the regenerated plants are transferred to standard soil conditions and cultivated in a conventional manner. After the expression vector is stably incorporated into regenerated transgenic plants, it can be transferred to other plants by vegetative propagation or by sexual crossing.
  • vegetatively propagated crops the mature transgenic plants are propagated by the taking of cuttings or by tissue culture techniques to produce multiple identical plants.
  • the mature transgenic plants are self crossed to produce a homozygous inbred plant which is capable of passing the transgene to its progeny by Mendelian inheritance.
  • the inbred plant produces seed containing the nucleic acid sequence of interest. These seeds can be grown to produce plants that would produce the desired polypeptides.
  • the inbred plants can also be used to develop new hybrids by crossing the inbred plant with another inbred plant to produce a hybrid.
  • Monocotyledons include grasses, lilies, irises, orchids, cattails, palms, Zea mays (such as corn), rice barley, wheat and all grasses.
  • Dicotyledons include almost all the familiar trees and shrubs (other than confers) and many of the herbs (non-woody plants).
  • Tomato cultures are the ideal recipients for repetitive HRGP modules to be hydroxylated and glycosylated: Tomato is readily transformed.
  • the cultures produce cell surface HRGPs in high yields easily eluted from the cell surface of intact cells and they possess the required posttranslational enzymes unique to plants—HRGP prolyl hydroxylases, hydroxyproline O-glycosyltransferases and other specific glycosyltransferases for building complex polysaccharide side chains.
  • tomato genetics, and tomato leaf disc transformation/plantlet regeneration are well worked out.
  • Expression constructs of the present invention may be introduced into host cells (e.g. plant cells) using methods known in the art.
  • the expression constructs are introduced into plant cells by particle mediated gene transfer.
  • Particle mediated gene transfer methods are known in the art, are commercially available, and include, but are not limited to, the gas driven gene delivery instrument descried in McCabe, U.S. Pat. No. 5,584,807, the entire contents of which are herein incorporated by reference. This method involves coating the nucleic acid sequence of interest onto heavy metal particles, and accelerating the coated particles under the pressure of compressed gas for delivery to the target tissue.
  • Other particle bombardment methods are also available for the introduction of heterologous nucleic acid sequences into plant cells.
  • these methods involve depositing the nucleic acid sequence of interest upon the surface of small, dense particles of a material such as gold, platinum, or tungsten.
  • the coated particles are themselves then coated onto either a rigid surface, such as a metal plate, or onto a carrier sheet made of a fragile material such as mylar.
  • the coated sheet is then accelerated toward the target biological tissue.
  • the use of the flat sheet generates a uniform spread of accelerated particles which maximizes the number of cells receiving particles under uniform conditions, resulting in the introduction of the nucleic acid sample into the target tissue.
  • an expression construct may be inserted into the genome of plant cells by infecting them with a bacterium, including but not limited to an Agrobacterium strain previously transformed with the nucleic acid sequence of interest.
  • a bacterium including but not limited to an Agrobacterium strain previously transformed with the nucleic acid sequence of interest.
  • disarmed Agrobacterium cells are transformed with recombinant Ti plasmids of Agrobacterium tumefaciens or Ri plasmids of Agrobacterium rhizogenes (such as those described in U.S. Pat. No. 4,940,838, the entire contents of which are herein incorporated by reference) which are constructed to contain the nucleic acid sequence of interest using methods well known in the art (Sambrook, J. et al., (1989) supra),.
  • the nucleic acid sequence of interest is then stably integrated into the plant genome by infection with the transformed Agrobacterium strain.
  • heterologous nucleic acid sequences have been introduced into plant tissues using the natural DNA transfer system of Agrobacterium tumefaciens and Agrobacterium rhizogenes bacteria (for review, see Klee et al. (1987) Ann. Rev. Plant Phys. 38:467-486).
  • Agrobacterium may be enhanced by using a number of methods known in the art. For example, the inclusion of a natural wound response molecule such as acetosyringone (AS) to the Agrobacterium culture has been shown to enhance transformation efficiency with Agrobacterium tumefaciens [Shahla et al. (1987) Plant Molec. Biol. 8:291-298].
  • transformation efficiency may be enhanced by wounding the target tissue to be transformed. Wounding of plant tissue may be achieved, for example, by punching, maceration, bombardment with microprojectiles, etc. [see, e.g., Bidney et al. (1992) Plant Molec. Biol. 18:301-313].
  • nucleic acid sequence of interest it may be desirable to target the nucleic acid sequence of interest to a particular locus on the plant genome.
  • Site-directed integration of the nucleic acid sequence of interest into the plant cell genome may be achieved by, for example, homologous recombination using Agrobacterium-derived sequences.
  • plant cells are incubated with a strain of Agrobacterium which contains a targeting vector in which sequences that are homologous to a DNA sequence inside the target locus are flanked by Agrobacterium transfer-DNA (T-DNA) sequences, as previously described (Offringa et al., (1996), U.S. Pat. No. 5,501,967, the entire contents of which are herein incorporated by reference).
  • T-DNA Agrobacterium transfer-DNA
  • homologous recombination may be achieved using targeting vectors which contain sequences that are homologous to any part of the targeted plant gene, whether belonging to the regulatory elements of the gene, or the coding regions of the gene. Homologous recombination may be achieved at any region of a plant gene so long as the nucleic acid sequence of regions flanking the site to be targeted is known.
  • the targeting vector used may be of the replacement- or insertion-type (Offringa et al. (1996), supra).
  • Replacement-type vectors generally contain two regions which are homologous with the targeted genomic sequence and which flank a heterologous nucleic acid sequence, e.g., a selectable marker gene sequence.
  • Replacement type vectors result in the insertion of the selectable marker gene which thereby disrupts the targeted gene.
  • Insertion-type vectors contain a single region of homology with the targeted gene and result in the insertion of the entire targeting vector into the targeted gene.
  • the present invention contemplates introducing nucleic acid via the leaf disc transformation method.
  • carbenicillin 500 ⁇ g/ml
  • kanamycin 300 ⁇ g/
  • Cells and tissues which are transformed with a heterologous nucleic acid sequence of interest are readily detected using methods known in the art including, but not limited to, restriction mapping of the genomic DNA, PCR-analysis, DNA-DNA hybridization, DNA-RNA hybridization, DNA sequence analysis and the like.
  • selection of transformed cells may be accomplished using a selection marker gene. It is preferred, though not necessary, that a selection marker gene be used to select transformed plant cells.
  • a selection marker gene may confer positive or negative selection.
  • a positive selection marker gene may be used in constructs for random integration and site-directed integration.
  • Positive selection marker genes include antibiotic resistance genes, and herbicide resistance genes and the like.
  • the positive selection marker gene is the NPTII gene which confers resistance to geneticin (G418) or kanamycin.
  • the positive selection marker gene is the HPT gene which confers resistance to hygromycin.
  • the choice of the positive selection marker gene is not critical to the invention as long as it encodes a functional polypeptide product.
  • Positive selection genes known in the art include, but are not limited to, the ALS gene (chlorsulphuron resistance), and the DHFR-gene (methothrexate resistance).
  • a negative selection marker gene may also be included in the constructs.
  • the use of one or more negative selection marker genes in combination with a positive selection marker gene is preferred in constructs used for homologous recombination.
  • Negative selection marker genes are generally placed outside the regions involved in the homologous recombination event.
  • the negative selection marker gene serves to provide a disadvantage (preferably lethality) to cells that have integrated these genes into their genome in an expressible manner. Cells in which the targeting vectors for homologous recombination are randomly integrated in the genome will be harmed or killed due to the presence of the negative selection marker gene. Where a positive selection marker gene is included in the construct, only those cells having the positive selection marker gene integrated in their genome will survive.
  • the choice of the negative selection marker gene is not critical to the invention as long as it encodes a functional polypeptide in the transformed plant cell.
  • the negative selection gene may for instance be chosen from the aux-2 gene from the Ti-plasmid of Agrobacterium, the tk-gene from SV40, cytochrome P450 from Streptomyces griseolus , the Adh-gene from Maize or Arabidopsis, etc. Any gene encoding an enzyme capable of converting a substance which is otherwise harmless to plant cells into a substance which is harmful to plant cells may be used.
  • the host cells which are transformed with the invention's sequences or with expression constructs containing these sequences be limited to cells which display any particular phenotype. All that is necessary is that the transformed cells express a polypeptide encoded by the invention's sequences. Such host cells may be used to purify the expressed polypeptides for subsequent use, (e.g., in the food or cosmetic industry, for isolating HRGP-binding molecules, and for making antibodies).
  • the invention intended to be limited to transformed cells which express the invention's nucleotide sequences at a particular level, a particular time during the cell's life cycle, or a particular part of a transformed plant. Rather, the invention expressly contemplates cells which express relatively low and relatively high levels of expression of the desired proteins, regardless of whether such expression occurs in some or all parts of the transformed plant, and whether it changes or is unchanged in level during cell growth or plant development.
  • the present invention provides GAGP sequences, and in particular the consensus sequence of SEQ ID NO:134.
  • Gum arabic glycoprotein (GAGP) is a large molecular weight, hydroxyproline-rich arabinogalactan-protein (AGP) component of gum arabic.
  • GAGP has a simple, highly biased amino acid composition indicating a repetitive polypeptide backbone. It has been suggested that the repetitive polypeptide backbone contains repetitive small ( ⁇ 10 amino acid residues) repetitive peptide motifs each with three Hyp-arabinoside attachment sites and a single Hyp-arabinogalactan polysaccharide attachment site [Qi et al. (1991) supra].
  • the inventors have tested this hypothesis by generating and sequencing peptides of GAGP, and determining the glycosyl and linkage analysis of an isolated Hyp-polysaccharide.
  • the inventors discovered a 19-amino acid consensus sequence, which is roughly twice the size of that previously postulated by Qi et al. (1991).
  • the inventors also surprisingly discovered that the peptides in the invention's 19-amino acid consensus sequence lacked some of the amino acids present in Qi et al.'s the empirical formula [i.e., Hyp 4 Ser2 Thr Pro Gly Leu His (SEQ ID NO:135)] of the repeat motif suggested by Qi et.
  • the invention's 19-amino acid GAGP consensus motif contains approximately nine Hyp residues, with only a single polysaccharide attachment site. Judging from the Hyp-glycoside profile of GAGP, the invention's consensus motif contained six Hyp-arabinosides rather than Qi et al.'s three, and two Hyp-polysaccharides rather than Qi et al's one.
  • the invention provides the consensus sequence (SEQ ID NO:136): A-Hyp-B-C-D-E-F-Hyp-G-H-I-Hyp-J-Hyp-Hyp-K-L-Pro-M, wherein A is selected from Ser, Thr, and Ala; B is selected from Hyp, Pro, Leu, and Ile; C is selected from Pro and Hyp; D is selected from Hyp, Pro, Ser, Thr, and Ala; E is selected from Leu and Ile; F is selected from Ser, Thr, and Ala; G is selected from Ser, Leu, Hyp, Thr, Ala, and Ile; H is selected from Hyp, Pro, Leu, and Ile; I is selected from Thr, Ala, and Ser; J is selected from Thr, Ser, and Ala; K is selected from Thr, Leu, Hyp, Ser, Ala, and Ile; L is selected from Gly, Leu, Ala, and Ile; and M is selected
  • the invention's GAGP consensus sequence contains 19 amino acids, of which approximately nine are Hyp residues. Judging from the Hyp-glycoside profile of GAGP (Table 7) about one in every five Hyp residues is polysaccharide-substituted. Thus, in one preferred embodiment, there are approximately two Hyp-polysaccharide sites in the consensus sequence and portions thereof.
  • the inventors predicted arabinosylation of contiguous Hyp residues and arabinogalactan-polysaccharide addition to clustered non-contiguous Hyp residues, such as the X-Hyp-X-Hyp modules common in AGPs [Nothnagel (1997) International Review of Cytology 174:195].
  • the inventors are of the view that the inventions's 19-amino acid consensus motif preferably contains approximately two polysaccharide attachment sites in the clustered non-contiguous Hyp motif [F-Hyp-G-H-I-Hyp (SEQ ID NO:137), where F is selected from Ser, Thr, and Ala; G is selected from Ser, Leu, Hyp, Thr, Ala, and Ile; H is selected from Hyp, Pro, Leu, and Ile; and I is selected from Thr, Ala, and Ser] which is exemplified by Ser-Hyp-Ser-Hyp-Thr-Hyp (SEQ ID NO:138)], and which is flanked by arabinosylated contiguous Hyp residues such as A-Hyp-B-C-D-E (SEQ ID NO:139) where A is selected from Ser, Thr, and Ala; B is selected from Hyp, Leu, and Ile; C
  • the consensus sequence and portions thereof is selected from Ser-Hyp-Hyp-Hyp-A-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-B-Gly-Pro-His (SEQ ID NO:179), where A is selected from Hyp, Thr and Ser, and B is selected from Hyp and Leu (Table 6).
  • A is selected from Hyp, Thr and Ser
  • B is selected from Hyp and Leu
  • fifteen amino acid residues of this sequence are “quasi-palindromic,” i.e., the side chain sequence is almost the same whether read from the N-terminus or C-terminus.
  • the repeating glycopeptide symmetry of two central polysaccharides flanked by Hyp arabinosides may enhance gum arabic's remarkable properties which include: an anomalously low viscosity [Churms et al. (1983) Carbohydrate Research 123:267], the ability to act as a flavor emulsifier and stabilizer, and GAGP's biological role as a component of a plastic sealant.
  • the invention's sequences and portions thereof may be used as repeats.
  • the repeats preferably range from 1 to 500, more preferably from 1 to 100 and most preferably from 1 to 10.
  • Data disclosed herein demonstrates the production of 8, 16, 20, 32, and 64 repeats of gum arabic motifs (Example 19).
  • the repeats may be contiguous or noncontiguous. Contiguous repeats are those without intervening amino acids, or amino acid analogues, placed between the repeating sequences.
  • the repeats may contain two or more sequences which are described by the consensus sequence (SEQ ID NO:136) and portions thereof. The two or more sequences may be the same or different.
  • Another example of a single repeat in which the two 19-amino acid sequences are different are those of motif 7-motif 13 of Table 2, having the sequence (SEQ ID NO:180): Gly-Pro-Hyp- Ser-Hyp-Hyp-Hyp-Thr-Leu-Ser-Hyp-Hyp-Leu-Thr-Hyp-Thr-Hyp-Hyp-Leu-Leu-Pro-His -Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Leu-Thr-Hyp-Thr-Hyp-Hyp-Leu, in which motif 13 is underlined, and is flanked by motif 7.
  • the invention's sequences and portions thereof are used as noncontiguous repeats, i.e., with from 1 to 1000, more preferably from 1 to 100, and even more preferably from 1 to 10, intervening amino acids, or amino acid analogues, placed between the repeating sequences.
  • amino acid analog refers to an amino acid is a chemically modified amino acid. Illustrative of such modifications would be replacement of hydrogen by an alkyl, acyl, or amino group, or formation of covalent adducts with biotin or fluorescent groups.
  • Amino acids include biological amino acids as well as non-biological amino acids.
  • biological amino acid refers to any one of the known 20 coded amino acids that a cell is capable of introducing into a polypeptide translated from an MRNA.
  • non-biological amino acid refers to an amino acid that is not a biological amino acid. Non-biological amino acids are useful, for example, because of their stereochemistry or their chemical properties.
  • the non-biological amino acid norleucine for example, has a side chain similar in shape to that of methionine. However, because it lacks a side chain sulfur atom, norleucine is less susceptible to oxidation than methionine.
  • non-biological amino acids include aminobutyric acids, norvaline and allo-isoleucine, that contain hydrophobic side chains with different steric properties as compared to biological amino acids.
  • derivative when in reference to an amino acid sequence means that the amino acid sequence contains at least one amino acid analog.
  • the consensus sequence and portions thereof contains at least one noncontiguous hydroxyproline sequence and/or at least one contiguous hydroxyproline sequence. In a more preferred embodiment, the consensus sequence and portions thereof contains at least one noncontiguous hydroxyproline sequence and at least one contiguous hydroxyproline sequence.
  • noncontiguous hydroxyproline sequence refers to a sequence selected from (Xaa-Hyp) x and Xaa-Hyp-Xaa-Xaa-Hyp-Xaa, wherein Xaa is any amino acid other than hydroxyproline, and wherein x is from 2 to 1000, more preferably from 2 to 100, and most preferably from 2 to 50.
  • the noncontiguous hydroxyproline sequence is Xaa-Hyp-Xaa-Hyp (SEQ ID NO:9), wherein Xaa is selected from Ser, Thr, and Ala.
  • the term “contiguous hydroxyproline sequence” refers to a sequence selected from Xaa-Hyp-Hyp n (SEQ ID NO:209) and Xaa-Pro-Hyp n (SEQ ID NO:210), wherein n is from 1 to 100, and wherein Xaa is any amino acid other than hydroxyproline.
  • the contiguous hydroxyproline sequence is selected from Ser-Hyp 2 (SEQ ID NO:211), Ser-Hyp 3 (SEQ ID NO:212), Ser-Hyp 4 (SEQ D NO:3), Thr-Hyp 2 (SEQ ID NO:213), and Thr-Hyp 3 (SEQ ID NO:214).
  • noncontiguous hydroxyproline sequences [e.g., (Xaa-Hyp) x where x is preferably at least 2] are functional glycomodules which direct the exclusive addition of arabinogalactan polysaccharide to Hyp, while contiguous hydroxyproline sequences are functional glycomodules which direct arabinosylation (Example 23).
  • the term “functional” when made in reference to a noncontiguous hydroxyproline sequence or to sequences containing a noncontiguous hydroxyproline sequence means that the sequence directs exclusive addition of arabinogalactan polysaccharide to Hyp residues in that sequence.
  • arabinogalactan polysaccharide to Hyp residues may be determined using methods described herein (Example 23).
  • the term “functional” when made in reference to a contiguous hydroxyproline sequence or to sequences containing a contiguous hydroxyproline sequence a means that the sequence directs arabinosylation of Hyp residues in that sequence as determined by methods disclosed herein (Example 23).
  • the invention contemplates sequences that are complementary, and partially complementary to SEQ ID NO:136 and portions thereof, such as those which hybridize under low stringency conditions and high stringency conditions to these sequences.
  • sequences of the invention may be used to isolate hydroxyproline rich glycoprotein-binding molecules and to make polyclonal and monoclonal antibodies as described supra.
  • the invention's sequences may be used as emulsifying agents and/or to stabilize emulsions, both of which are properties which are highly valued by the food industry for GAGP.
  • the emulsifying and emulsion stabilizing activities of the invention's proteins, glycoproteins, and portions thereof may be determined using generic methods known in the art [Kevin & John (1978) J. Agric. Food Chem 26(3):716-723; James & Patel, “Development of a standard oil-in-water emulsification test for proteins,” Leatherhead Food RA Res. Rep. No. 631] which employ commercially available reagents.
  • the following assay may be employed using orange oil (Sigma) following essentially the manufacturer's instructions. Freeze-dried glycoproteins are dissolved in 0.05 M phosphate buffer (pH 6.5) at a concentration of 0.5% (m/v). The aqueous solutions are combined with orange oil in a 60:40 (v/v) ratio. A 1 ml emulsion is prepared in a glass tube at 0° C. with a Sonic Dismembrator (Fisher Scientific) equipped with a Microtip probe. The amplitude value is set at 4 and mixing time is set to 1 min.
  • the emulsion is diluted serially with a solution containing 0.1 M NaCl and 0.1% SDS to give a final dilution of ⁇ fraction (1/1500) ⁇ .
  • the optical density of the diluted emulsion is then determined in a 1-cm pathlenght cuvette at a wavelength of 50 nm and defined as EA.
  • the emulsion is stored vertically in a glass tube for 3 h at room temperature, then the optical density of 1:1500 dilution of the low phase of the stored sample is measured.
  • Emulsifying stability (ES) is defined as the percentage optical density remaining after 2 hour of storage.
  • BSA is used as a positive control. This assay has been used to determine the activity of sequences within the scope of the invention, as described in Example 24.
  • the invention further provides sequences which signal O-glycosylation.
  • the O-glycosylation sequences are the noncontiguous hydroxyproline sequences (Xaa-Hyp) x (SEQ ID NO:182) and Xaa-Hyp-Xaa-Xaa-Hyp-Xaa (SEQ ID NO:183), wherein Xaa is any amino acid other than hydroxyproline, and wherein x is a number from I to 1000, more preferably from 2 to 100, and yet more preferably from 2 to 50.
  • the sequence is Xaa-Hyp-Xaa-Hyp (SEQ ID NO:9), wherein Xaa is selected from Ser, Thr, and Ala.
  • Hyp galactosylation of clustered non-contiguous Hyp residues results in the addition of a galactan core with sidechairs of arabinose and other sugars to form characteristic Hyp-arabinogalactan polysaccharides.
  • the inventor's discovery of the O-glycosylation sequences relied on a new approach to HRGP glycosylation site mapping as disclosed herein.
  • the first synthetic gene dubbed Sig-(Ser-Pro) 32 -EGFP, encoded a signal sequence (Sig) at the N-terminus followed by a repetitive Ser-Hyp motif [i.e., (Ser-Pro) 32 ] which encoded only clustered non-contiguous Hyp residues, which the inventors predicted would code as polysaccharide addition sites.
  • the (Ser-Pro) 32 was followed by EGFP at the C-terminus (FIG. 11).
  • the inventors predicted that polysaccharide addition to noncontiguous Hyp should yield an expression product containing Hyp-polysaccharide exclusively.
  • the second synthetic gene dubbed Sig-(GAGP) 3 -EGFP, encoded three repeats of a slightly modified 19-amno acid residue GAGP consensus sequence (FIG. 14) and was used by the inventors to determine whether it yielded an expression product that contains Hyp arabinosides as well as Hyp-polysaccharide.
  • the third synthetic gene was a control construct (Sig-EGFP) that encoded only the signal sequence and EGFP.
  • the expression product was a control to test whether or not any Hyp glycosylation could be attributed to EGFP modification that encode putative AGP glycomodules.
  • Data presented herein shows that, when expressed and targeted for secretion, the two experimental sequence modules behaved as simple endogenous substrates for HRGP glycosyl transferases.
  • the first construct expressing noncontiguous Hyp showed exclusive polysaccharide addition with polysaccharide O-linked to all Hyp residues.
  • the second construct containing noncontiguous Hyp and additional contiguous Hyp showed both polysaccharide and arabinooligosaccharide. From this data, the inventors arrived at the invention's O-glycosylation sequences.
  • the invention's sequences find use as substrates for O-Hyp arabinosyl- and galactosyltransferases. These substrates may be used to isolate and unambiguously identify these enzymes as well as to determine the enzymes' substrate preferences.
  • glycoproteins which contain the O-glycosylation sequences of the invention may be used as emulsifying agents and/or to stabilize emulsions, as described supra as well as in Example 24.
  • DNA deoxyribonucleic acid
  • cDNA complementary DNA
  • RNA ribonucleic acid
  • mRNA messenger ribonucleic acid
  • X-gal 5-bromo-4-chloro-3-indolyl- ⁇ -D-galactopyranoside
  • LB Lia Broth
  • PAGE polyacrylamide gel electrophoresis
  • NAA ⁇ -naphtaleneacetic acid
  • BAP 6-benzyl aminopurine
  • Tris tris(hydroxymethyl)-aminomethane
  • PBS phosphate buffered saline
  • 2 ⁇ SSC 0.3 M NaCl, 0.03 M Na 3 citrate, pH 7.0
  • GAGP SEQ ID NO:15
  • chymotrypsin the deglycosylated polypeptide backbone
  • GAGP does not contain the usual chymotryptic cleavage sites, it does contain leucyl and histidyl residues which are occasionally cleaved. Chymotrypsin cleaved sufficient of these “occasionally cleaved” sites to produce a peptide map of closely related peptides.
  • Synthetic gene cassettes encoding contiguous and noncontiguous Hyp modules are constructed using partially overlapping sets consisting of oligonucleotide pairs, “internal repeat pairs” and “external 3′- and 5′-linker pairs” respectively, all with complementary “sticky” ends.
  • the design strategy for the repetitive HRGP modules combines proven approaches described earlier for the production in E. coli of novel repetitive polypeptide polymers (McGrath et al. [1990] Biotechnol. Prog. 6:188), of a repetitious synthetic analog of the bioadhesive precursor protein of the mussel Mytilus edulis, of a repetitive spider silk protein (Lewis et al. [1996] Protein Express.
  • a synthetic gene encoding the extensin-like Ser-Hyp 4 (SEQ ID NO:3) module is constructed using the following partially overlapping sets of oligonucleotide pairs.
  • 5′-Linker Amino Acid: A G S S T R A S P (P P P) (SEQ ID NO:29) 5′-GCT GGA TCC TCA ACC CGG GCC TCA CCA (SEQ ID NO:30) CGA CCT AGG AGT TGG GCC CCG AGT GGT GGT GGT GGA-5′ (SEQ ID NO:31)
  • 3′ Linker for pBI121-Sig-EGFP: Amino Acid: P P P S P V A R H S P P (SEQ ID NO:32) 5′-CCA CCA CCT TCA CCG GTC GCC CGG AAT TCA CCA CCC (SEQ ID NO:33) AGT GGC CAG CGG GCC TTA AGT GGT GGG-5′ (SEQ ID NO:34)
  • 3′ Linker (for pBI121-Sig): Amino Acid: 5′-CCA CCA CCT TAA TAG AGC TCC CCC (SEQ ID NO:35) ATT ATC TCG AGG GGG-5′ (SEQ ID NO:36)
  • [0196] Combine the 5′ external linker duplex with the internal repeat duplexes in an approximately 1:20 molar ratio and anneal by further cooling to yield long duplex DNA capped by the 5′ linker.
  • the 5′ linker is covalently joined to the internal repeat duplex by ligation using T4 DNA ligase. (Preferably up to 50, more preferably up to 30, repeats of the internal repeat duplex can be used).
  • a synthetic gene cassette encoding the GAGP consensus sequence is generated as described above using the following 5′ linker, internal repeat and 3′ linker duplexes.
  • 5′-Linker Amino Acid A A G S S T R A (S P S) (SEQ ID NO:40) 5′-GCT GCC GGA TCC TCA ACC CGG GCC-3′ (SEQ ID NO:41) 3′-CGA CGG CCT AGG AGT TGG CCC CGG AGT CCC ACT-5′(SEQ ID NO:42)
  • 3′-Linker for pBI121-Sig-EGFP
  • Amino Acid S P S P V A R N S P P (SEQ ID NO:43) 5′-TCA CCC TCA CCG QTC GCC CGG AAT TCA CCA CCC-3′ (SEQ ID NO:44) 3′GGC CAG CGG GCC TTA AGT GGT GGG-5′ (SEQ ID NO:45)
  • the above GAGP internal repeat is a consensus sequence
  • it is also desirable to have repeats that comprise a repeat sequence that varies from the consensus sequence see e.g. Table 3 above.
  • the variant sequences are likely to be glycosylated in a slightly different manner, which may confer different properties (e.g. more soluble etc.).
  • Other constructs are shown for other illustrative modules in Table 4.
  • P1 extensin signal sequence i.e., signal peptide
  • P1 extensin cDNA clones were isolated using oligonucleotides designed after the P1-unique protein sequence (SEQ ID NO:51): Val-Lys-Pro-Tyr-His-Pro-Thr-Hyp-Val-Tyr-Lys.
  • SEQ ID NO:51 P1-unique protein sequence
  • the P1 extensin signal sequence directs the nascent peptide chain to the ER.
  • pBI121 is an expression vector which permits the high level expression and secretion of inserted genes in plant cells (e.g., tomato, tobacco, members of the genus Solanaceac, members of the family Leguminoseae, non-graminaceous monocotyledons).
  • pBI121 contains the 35S CaMV promoter, the tobacco ( Nicotiana plumbaginifolia ) extensin signal sequence, a EGFP gene, the termination/polyadenylation signal from the nopaline synthetase gene (NOS-ter), a kanamycin-resistance gene (nptII) and the right and left borders of T-DNA to permit transfer into plants by Agrobacterium-mediated transformation.
  • the P3-Type Extensin Palindromic Module P3-Type Extensin Palindromic Internal Repeat Oligo's: (SEQ ID NQ:86) 5′-CCA CCA CCT TCA CCC TCT CCA CCT CCA CCA TCT CCG TCA CCA (SEQ ID NO:87) AGT GGG AGA GGT GGA GGT GGT AGA GGC AGT GGT GGT GGT GGA-5′ P3-Type Extensin Palindromic External Linker Oligo's: Use the [SPPP] n linkers (SEE ABOVE) e.
  • the Potato Lectin HRGP Palindromic Module Potato Lectin ERGP Palindromic External Linker Oligo's: (SEQ ID NO:88) 5′-CCA CCA CCT TCA CCC CCA TCT CCA CCT CCA CCA TCT CCA CCG TCA CCA (SEQ ID NO:89) AGT GGG GGT AGA GGT GGA GGT GGT AGA GGT GGC AGT GGT GGT GGT GGA-5′ Potato Lectin HRGP Palindromic External Linker Oligo's: Use the [SPPP] n linkers (SEE ABOVE) f.
  • Pi-Extensin-Like Modules i.
  • the SPPPPTPVYK Module SPPPPTPVYK Internal Repeat Oligo's: (SEQ ID NO:90) 5′-CCA CCA CCT ACT CCC GTT TAC AAA TCA CCA CCA CCT ACT CCC GTT TAC AAA TCA CCA (SEQ ID NO: 91) TGA GGG CAA ATG TTT AGT GGT GGT GGT GGA TCA GGG CAA ATG TTT AGT GGT GGT GGA-5′ SPPPPTPVYK External Linker Oligo's: Use the [SPPP] n linkers (SEE ABOVE) ii.
  • the SPPPPVKPYHPTPVFL Module SPPPPVKPYHPTPVFL Internal Repeat Oligo's: (SEQ ID NO:92) 5′-CCA CCA CCT GTC AAG CCT TAC CAC CCC ACT CCC GTT TTT CTT TCA CCA (SEQ ID NO:93) CAG TTC GGA ATG GTG GGG TGA GGG CAA AAA GAA AGT GGT GGT GGT GGA-5′ SPPPPVKPYHPTPVFL External Linker Oligo's: Use the [SPPP] n linkers (SEE ABOVE) iii.
  • SPPPPVLPFHPTPVYK Module SPPPPVLPFHPTPVYK Internal Repeat Oligo's: (SEQ ID NO:94) 5′-CCA CCA CCT GTC TTA CCT TTC CAC CCC ACT CCC GTT TAC AAA TCA CCA (SEQ ID NO:95) CAG AAT GGA AAG GTG GGG TGA GGG CAA ATG TTT AGT GGT GGT GGT GGA-5′ SPPPPVLPFEPTPVYK External Linker Oligo's: Use the [SPPP] n linkers (SEE ABOVE) EGFP 3′ Linker Olig9's needed to insert EGFP into pBI121-Sig-EGF (SEQ ID NO:96) 5′-GGC CGC GAG CTC CAG CAC GGG (SEQ ID NO:97) CG CTC GAG GTC GTG CCC-5′
  • the EGFP gene encodes a green fluorescent protein (GFP) appropriately red-shifted for plant use (the EGFP gene encodes a S65T variant optimized for use in plants and is available from Clontech). Other suitable mutants may be employed (see Table 1). These modified GFPs allow the detection of less than 700 GFP molecules at the cell surface.
  • the use of a GFP gene provides a reporter gene and permits the formation of fusion proteins comprising repetitive HRGP modules. GFPs require aerobic conditions for oxidative formation of the fluorophore. It is functional at the lower temperatures used for plant cell cultures, normally it does not adversely affect protein function.
  • Plasmids pBI121-Sig and pBI121-Sig-EGFP are constructed as follows.
  • the GUS gene present in pBI121 (Clontech) is deleted by digestion with BamHI and SstI and a pair of partially complementary oligonucleotides encoding the tobacco extensin signal sequence is annealed to the BamHI and SstI ends.
  • the oligonucleotides encoding the 21 amino acid extensin signal sequence have the following sequence: 5′-GA TCC GCA ATG GGA AAA ATG GCT TCT CTA TTT GCC ACA TTT TTA GTG GTT TTA GTG TCA CTT AGC TTA GCA CAA ACA ACC CGG GTA CCG GTC GCC ACC ATG GTG TAA AGC GGC CGC GAG CT-3′ (SEQ ID NO:98) and 5′-C GCG GCC GCT TTA CAC CAT GGT GGC GAC CGG TAC CCG GGT TGT TTG TGC TAA GCT AAG TGA CAC TAA AAC CAC TAA AAA TGT GGC AAA TAG AGA AGC CAT TTT TCC CAT TGC G-3′ (SEQ ID NO:99).
  • this pair of oligonucleotides when inserted into the digested pBI121 vector, provides a BamHI site (5′ end) and XmaI and SstI sites (3′ end). The XmaI and SstI sites allow the insertion of the GFP gene.
  • the modified pBI121 vector lacking the GUS gene and containing the synthetic extensin signal sequence is termed pBI121-Sig. Proper construction of pBI121 is confirmed by DNA sequencing.
  • the GFP gene (e.g., the EGFP gene) is inserted into pBI121-Sig to make pBI121-Sig-EGFP as follows.
  • the EGFP gene is excised from pEGFP (Clontech) as a 1.48 kb XmaI/NotI fragment (base pairs 270 to 1010 in pEGFP). This 1.48 kb XmaI/NotI fragment is then annealed and ligated to a synthetic 3′ linker (see above).
  • the EGFP-3′ linker is then digested with SstI to produce an XmaI/SstI EGFP fragment which in inserted into the XmaI/SstI site of pBI121-Sig to create pBI121-Sig-EGFP.
  • the AgeI discussed below
  • XmaI and SstI sites provide unique restriction enzyme sites. Proper construction of the plasmids is confirmed by DNA sequencing.
  • the EGFP sequences in pBI121-Sig-EGFP contain an AgeI site directly before the translation start codon (i.e., ATG) of EGFP.
  • Synthetic HRGP gene cassettes are inserted into the plasmid between the signal sequence and the EGFP gene sequences as XmaI/AgeI fragments; the HRGP gene cassettes are excised as XmaI/AgeI fragments from the pbluescript constructs described in Ex.2. Proper construction of HRGP-containing expression vectors is confirmed by DNA sequencing and/or restriction enzyme digestion.
  • Expression of the synthetic HRGP gene cassettes is not dependent upon the use of the pBI121-Sig and pBI121-Sig-EGFP gene cassette.
  • Analogous expression vectors containing other promoter elements functional in plant cells may be employed (e.g., the CaMV region IV promoter, ribulose-1,6-biphosphate (RUBP) carboxylase small subunit (ssu) promoter, the nopaline promoter, octopine promoter, mannopine promoter, the ⁇ -conglycinin promoter, the ADH promoter, heat shock promoters, tissue-specific promoters, e.g., promoters associated with fruit ripening, promoters regulated during seed ripening (e.g., promoters from the napin, phaseolin and glycinin genes).
  • promoter elements functional in plant cells may be employed (e.g., the CaMV region IV promoter, ribulose-1,6-biphosphate (RUBP) carboxylase small sub
  • expression vectors containing a promoter that directs high level expression of inserted gene sequences in the seeds of plants may be employed.
  • Expression may also be carried out in green algae.
  • reporter genes may be employed in place of the GFP gene.
  • Suitable reporter genes include ⁇ -glucuronidase (GUS), neomycin phosphotransferase II gene (nptII), alkaline phosphatase, luciferase, CAT (Chloramphenicol AcetylTransferase).
  • GUS ⁇ -glucuronidase
  • nptII neomycin phosphotransferase II gene
  • alkaline phosphatase luciferase
  • CAT Chloramphenicol AcetylTransferase
  • Preferred reporter genes lack Hyp residues.
  • the proteins encoded by the synthetic HRGP genes need not be expressed as fusion proteins. This is readily accomplished using the pBI121-Sig vector.
  • the present invention contemplates recombinant HRGPs encoded by expression vectors comprising synthetic HRGP gene modules are expressed in tomato cell suspension cultures.
  • the expression of recombinant HRGPs in tomato cell suspension cultures is illustrated by the discussion provided below for recombinant GAGP expression.
  • An expression vector containing the synthetic GAGP gene cassette (capable of being expressed as a fusion with GFP or without GFP sequences) is introduced into tomato cell suspension cultures.
  • a variety of means are known to the art for the transfer of DNA into tomato cell suspension cultures, including Agrobacterium-mediated transfer and biolistic transformation.
  • Agrobacterium-mediated transfonnation contemplates transforming both suspension cultured cells (Bonnie Best cultures) and tomato leaf discs by mobilizing the above-described plasmid constructions (and others) from E. coli into Agrobacterium tumefaciens strain LBA4404 via triparental mating. Positive colonies are used to infect tomato cultures or leaf discs (Lysopersicon esculentum). Transformed cells/plants are selected on MSO medium containing 500 mg/mL carbenicillin and 100 mg/mL kanamycin. Expression of GFP fusion products are conveniently monitored by fluorescence microscopy using a high Q FITC filter set (Chroma Technology Corp.).
  • FITC conjugates e.g. FITC-BSA
  • FITC-BSA purified recombinant GFP as controls for microscopy set-up.
  • Cultured tomato cells show only very weak autofluorescence.
  • Transgenic cells/plants can be examined for transgene copy number and construct fidelity genomic Southern blotting and for the HRGP construct mRNA by northern blotting, using the internal repeat oligonucleotides as probes.
  • Controls include tissue/plants which are untransformed, transformed with the pBI121 alone, pBI121 containing only GFP, and pBI121 having the signal sequence and GFP but no HRGP synthetic gene.
  • Microprojectile bombardment 1.6 M gold particles are coated with each appropriate plasmid construct DNA for use in a Biolistic particle delivery system to transform the tomato suspension cultures/callus or other tissue. Controls include: particles without DNA, particles which contain PBI121 only, and particles which contain PBI121 and GFP.
  • HRGPs include, but are not limited to, RPRps, extensins, AGPs and other plant gums (e.g. gum Karaya, gum Tragacanth, gum Ghatti, etc.).
  • HRGP chimeras include but are not limited to HRGP plant lectins, including the solanaceous lectins, plant chitinases, and proteins in which the HRGP portion serves as a spacer (such as in sunflower).
  • the present invention specifically contemplates using the HRGP modules (described above) as spacers to link non-HRGP proteins (e.g. enzymes) together.
  • Synthetic gene cassettes encoding contiguous and noncontiguous Hyp modules were constructed using partially overlapping sets consisting of oligonucleotide pairs, “internal repeat pairs” and “external 3′- and 5′-linker pairs” respectively, all with complementary “sticky” ends.
  • the following 5′-linker, internal repeat and 3′-linker duplexes were employed:
  • 5′-Linker A A G S S T R A (S P S) (SEQ ID NO:40) 5′-GCT GCC GGA TCC TCA ACC CGG GCC-3′ (SEQ ID NO:41) 3′-CGA CGG CCT AGG AGT TGG GCC CGG AGT GGG AGT-5′ (SEQ ID NO:42)
  • SEQ ID NO:106 The following synthetic gene (SEQ ID NO:106) was eventually expressed in tobacco and tomato cell cultures and tobacco plants using the above constructs: M G K M A S L F A T F L V V L V 5′-GGA TCC GCA ATG GGA AAA ATG GCT TCT GTA TTT GCG AGA TTT TTA GTC GTT TTA GTG 3′-CCT AGG CGT TAG CCT TTT TAC CGA AGA GAT AAA CGG TGT AAA AAT CAC CAA AAT CAC S L S L A Q T T T R D S P S P T P T A P TCA CTT AGC TTA GCA CAA ACA ACC CGG GAC TCA CCC TCA CCA ACT CCT ACC GCA CCA AGT GAA TCG AAT CGT GTT TGT TGG GCC CTG AGT GGG AGT GGT TGA GGA TGG CGT GGT P G P H S P P P T L S P S P T P T A P CCT GGT CCA CAC
  • Tube 1 5.5 ⁇ l GAGP internal repeat sense oligonucleotide (0.5 nmol/ ⁇ l), 5.5 ⁇ l GAGP internal repeat antisense oligonucleotide (0.5 nmol/ ⁇ l), 11 ⁇ l T4 ligase 10 ⁇ ligation buffer (New England Biolabs);
  • Tube 2 ⁇ l 5′-sense linker (0.05 nmol/ ⁇ l), 2 ⁇ l 5′-antisense linker (0.05 nmol/ ⁇ l), 1 ⁇ l H2O, 5 ⁇ l T4 ligase 10 ⁇ ligation buffer (New England Biolabs);
  • Tube 3 2 ⁇ l 3′-sense linker (1 mnol/ ⁇ l), 2 ⁇ l 3′-antisense liker (1 nmol/ ⁇ l), 1 ⁇ l water, 5 ⁇ l T4 ligase 10 ⁇ ligation buffer (New England Biolabs).
  • the 3′-end of the polymer was then capped by adding 50 ⁇ l of the ligated GAGP 5′-linker mixture from above to 5 ⁇ l of solution from Tube 3 (3′-linker), heating to 30° C., and incubating at 17° C. for 3 hours. 20 ⁇ l water and 2 ⁇ l T4 DNA ligase (New England Biolabs) was then added, and the solution incubated at 12-15° C. for 36 hr. Finally, the solution was heated at 65° C. for 10 minutes to denature the ligase.
  • SK plasmid vector (Strategene) was restricted with BamHI and EcoRI and restricted large plasmid fragments were isolated from agarose gel. To 2-3 ⁇ g restricted SK plasmid in 10 ⁇ l water was added 6 ⁇ l restricted GAGP gene construct from Step (E), 2 ⁇ l T4 DNA ligase buffer (New England Biolabs), and 1 ⁇ l T4 DNA ligase (New England Biolabs). The solution was then kept at 8° C. overnight for ligation. 100 ⁇ l competent XL1-Blue cells (Stratagene) were then transformed with 3 ⁇ l ligation mixture.
  • Clones were selected via Blue/White assay (Promega Corporation), as described by Promega Protocols and Applciations Guide, 2 ed. (1991), by hybridization with 32P-labeled antisense internal oligonucleotide, and by restriction mapping.
  • Synthetic gene cassettes encoding contiguous and noncontiguous Hyp modules. were constructed using partially overlapping sets consisting of oligonucleotide pairs, “internal repeat pairs” and “external 3′- and 5′-linker pairs” respectively, all with complementary “sticky” ends.
  • the following 5′-linker, internal repeat and 3′-linker duplexes were employed:
  • 5′-Linker A A G S S T R A (S P S) (SEQ ID NO:40) 5′-GCT GCC GGA TCC TCA ACC CGG GCC-3′ (SEQ ID NO:41) 3′-CGA CGG CCT AGG AGT TGG GCC CGG AGT GGG AGT-5′ (SEQ ID NO:42)
  • Tube 1 5.5 ⁇ l SP internal repeat sense oligonucleotide (0.5 nmol/ ⁇ l), 5.5 ⁇ l SP internal repeat antisense oligonucleotide (0.5 nmol/ ⁇ l), 11 ⁇ l T4 ligase 10 ⁇ ligation buffer (New England Biolabs);
  • Tube 2 ⁇ l 5′-sense linker (0.05 nmol/ ⁇ l), 2 ⁇ l 5′-antisense linker (0.05 nmol/ ⁇ l), 1 ⁇ l H2O, 5 ⁇ l T4 ligase 10 ⁇ ligation buffer (New England Biolabs);
  • Tube 3 2 ⁇ l 3′-sense linker (1 nmol/ ⁇ l), 2 ⁇ l 3′-antisense linker (1 nmol/ ⁇ l), 1 ⁇ l water, 5 ⁇ l T4 ligase 10 ⁇ ligation buffer (New England Biolabs).
  • the 3′ end of the polymer was then capped by adding 50 ⁇ l of the ligated SP-5′ linker mixture from above to 5 ⁇ l of solution from Tube 3 (3′ linker), heating to 30° C., and incubating at 17° C. for 3 hours. 20 ⁇ l water and 2 ⁇ l T4 DNA ligase (New England Biolabs) was then added, and the solution was incubated at 12-15° C. for 36 hr. Finally, the solution was heated at 65° C. for 10 minutes to denature the ligase.
  • SK plasmid vector (Strategene) was restricted with BamHI and EcoRI and restricted large plasmid fragments were isolated from agarose gel. To 2-3 ⁇ g restricted SK plasmid in 10 ⁇ l water was added 6 ⁇ l restricted SP gene construct from Step (E), 2 ⁇ l T4 DNA ligase buffer (New England Biolabs), and 1 ⁇ l l T4 DNA ligase (New England Biolabs). The solution was then kept at 8° C. overnight for ligation. 100 ⁇ l competent XL1-Blue cells (Stratagene) were then transformed with 3 ⁇ l ligation mixture.
  • Clones were selected via Blue/White assay (Promega Corporation), as described by Promega Protocols and Applications Guide, 2 ed. (1991), by hybridization with 32P-labeled antisense internal oligonucleotide, and by restriction mapping.
  • Plasmid and DNA fragments were isolated from gels using QIAEX II gel extraction kits (Qiagen).
  • the DNA ligase employed was 400 U T4 (New England Biolabs).
  • Vector:fragment ratios employed were 1:2-1:6, and ligation volumes were 20 ⁇ l.
  • Transformation of E. coli was done in 5-10 ⁇ l ligation reaction volumes with XL-Blue competent cells (Stratagene). Cells were plated on LB plates containing 50 ⁇ g/ml ampicillin or 30 ⁇ g/ml kanamycin.
  • Plasmid isolation was performed by growing transformed XL-Blue cells in 3 mL LB-ampicillin or LB-kanamycin medium. The plasmids were then isolated using a Wizard Plus Miniprep DNA Purification System (Promega).
  • This example involved: (A) Insertion of the synthetic gene into pEGFP; (B) Insertion of GAGP-EGFP or SP-EGFP fragment into pKS; (C) Construction of the Signal Sequence and cloning into pUC18; (D) Insertion of GAGP-EGFP or SP-EGFP construct into pUC18; (E) Insertion of SS-GAGP-EGFP or SS-SP-EGFP genes into pBI121.
  • This step was carried out to allow directional cloning of the gene at the 5′ end of EGFP.
  • the GAGP or SP gene was isolated from pSK [from Examples 6(F) and 7(F)] as a BamHI (New England Biolabs) and AgeI (New England Biolabs) fragment.
  • the pEGFP (Clontech) was then restricted with BamHI and AgeI.
  • the BamHI/AgeI-restricted gene was annealed with BamHI/AgeI-restricted pEGFP, and ligated to yield pEGFP containing the synthetic gene inserted at the 5′ end of the EGFP.
  • This step was carried out to obtain an Sst I site at the 3′ end of EGFP.
  • the GAGP-EGFP or SP-EGFP construct from (A) above was isolated from pEGFP as an XmaI/NotI fragment.
  • pKS Strategene
  • XmaI and NotI New England Biolabs.
  • the GAGP-EGFP or SP-EGFP construct was annealed with cut pKS and ligated to yield pKS containing GAGP-EGFP or SP-EGFP.
  • annealed oligonucleotides were then extended via primer extension.
  • the polymerase was then denatured by heating at 70° C. for 10 minutes
  • 8 ⁇ l Buffer 4 (New England Biolabs), 66 ⁇ l H 2 O, 2 ⁇ l BamHI 20 U/ ⁇ l (New England Biolabs), and 2 ⁇ l SstI 14 U/ ⁇ l (Sigma) was added and the mixture incubated at 37° C. overnight.
  • the restriction enzymes were then denatured by heating at 70° C. for 10 minutes.
  • This step was carried out to insert the GAGP-EGFP or SP-EGFP construct “behind” the signal sequence.
  • the GAGP-EGFP or SP-EGFP construct from (B) above was removed from pKS as an XmaI/SstI fragment.
  • pUC18 containing the signal sequence (SS-pUC18) was restricted with XmaI/Sst.
  • the GAGP-EGFP or SP-EGFP fragment was then annealed with cut SS-pUC18, and ligated.
  • the SS-GAGP-EGFP or SS-SP-EGFP gene sequence was then confirmed through DNA sequencing using the pUC18 17-residue sequencing primer (Stratagene).
  • Tobacco cells were grown for 5-7 days in NT-1 medium (pH 5.2, per liter: IL packet of MS Salts (Sigma #S5524), 30 g sucrose, 3 ml 6% KH 2 PO 4 , 100 mg Myo-Inositol, 1 mL Thiamine ⁇ HCl (1 mg/ml stock), 20 ⁇ l 2,4-D (10 mg/ml stock) ) containing 100 ⁇ g/ml kanamycin.
  • the cells were grown in 1L flasks containing 500 mL medium on a rotary shaker (94 rpm, 27° C.) to between 15-40% packed cell volume.
  • Agrobacterium cells transformed with pBI121-derived plasmid were grown overnight in Luria Broth containing 30 ⁇ g/ml kanamycin.
  • the Agrobacterium cell broth was pelletized for 1 minutes at 6000 rpm, and the pellet resuspended in 200 ⁇ l NT-1 medium.
  • Tomato cells were grown for 5-7 days in Schenk-Hildebrand medium (pH 5.8, per liter: IL packet of S-H basal salt (Sigma #S6765), 34 g sucrose, 1 g Schenck-Hildebrandt vitamin powder (Sigma #S3766), 100 ⁇ l Kinetin 1 mg/ml stock (Sigma #K32532), 44 ⁇ l 2,4-D 10 mg/ml stock, 2.1 ml p-chlorophenoxy acetic acid 1 mg/ml stock (Sigma) ) containing 200 ⁇ g/ml kanamycin.
  • Schenk-Hildebrand medium pH 5.8, per liter: IL packet of S-H basal salt (S6765), 34 g sucrose, 1 g Schenck-Hildebrandt vitamin powder (Sigma #S3766), 100 ⁇ l Kinetin 1 mg/ml stock (Sigma #K32532), 44 ⁇ l 2,4-D 10 mg/ml stock, 2.1
  • the cells were grown in 1L flasks containing 500 mL medium on a rotary shaker (94 rpm, 27° C.) to between 15-40% packed cell volume.
  • Agrobacterium cells transformed with pBII21-derived plasmid (Example 9) were grown overnight in Luria Broth containing 30 ⁇ g/ml kanamycin.
  • the Agrobacterium cell broth was pelletized for 1 minutes at 6000 rpm, and the pellet resuspended in 200 ⁇ l NT-1 medium.
  • the mixture was then washed 4 times with 20 ml NT-1 to remove the Agrobacterium cells, and then the plant cells were plate-washed on NT-1 plates containing 400 ⁇ g/ml timentin and 200 ⁇ g/ml kanamycin. Cells which grew on the antibiotics were selected and checked for green fluorescence through fluorescence microscopy, excitation wavelength 488 nm.
  • Transformed tobacco cells were grown on rotary shaker as described in Example 11 above.
  • the medium was separated from the cells by filtration on a glass sintered funnel (coarse grade), and the medium concentrated by freeze-drying.
  • the medium was then resuspended in water ( ⁇ 50 ml/500 mL original volume before lyophilization), and dialyzed against cold water for 48 hours (water changed 6 times).
  • the precipitated pectin contaminants were removed by centrifuge, the pellet discarded, and the supernatant freeze-dried.
  • the Superose peak containing GAGP-EGFP was dialyzed against cold water for 24 hours (4 water changes), and freeze-dried.
  • the dried GAGP-EGFP peak was then dissolved in 250 ⁇ l 0.1% aqueous TFA (Pierce) and loaded onto a PRP-1 column (Polymeric Reverse Phase, Hamilton) equilibrated in Buffer A (0.1% aqueous TFA).
  • UV absorbance was monitored at 220 nm, and GAGP-EGFP eluted at 63 minutes (see FIG. 4, Example 15 for method used to analyze peaks).
  • the TFA/acetonitrile was removed through N 2 (g) blowdown.
  • the sample was shown to contain hydroxyproline and sugar, accounting for 50% of the fusion product on a dry weight basis.
  • Galactose, arabinose, and rhamnose occur in 3:3:1 molar ratio similar to that of native GAGP's 3.5:4:1 molar ratio. This is consistent with the likely presence of both Hyp-arabinosides and Hyp-arabinogalactan polysaccharide in the expresssed construct.
  • the lower ratio of Ara in the GAGP-EGFP fusion glycoprotein is consistent with the Ala for Pro substitution (See Example 6), which removes one arabinosylation site in the peptide.
  • GAGP-EGFP and SP-EGFP products from tomato and tobacco cell medium and column peaks were detected by Enyzme-Linked Immunosorbant Assays (ELISA) using the method of Kieliszewski and Lamport, “Cross-reactivities of polyclonal antibodies against extension precursors determined via ELISA techniques,” Phytochemistry 25:673-677 (1986).
  • the GAGP-EGFP product was also assayed using anti-EGFP antibodies.
  • Anti-EGFP antibodies (Clontech) were the primary antibody, diluted 1000-fold as recommended by the manufacturer.
  • the secondary antibody was Peroxidase conjugated goat-anti-rabbit IGG diluted 5000-fold (Sigma).
  • Recombinant EGFP (Clontech) was used as a control. This assay was used to generate FIGS. 3 and 4 from Example 12 above.
  • This Example describes amino acid sequencing, glycosyl and linkage analysis of GAGP which yielded sequences (including preferred consensus sequences) within the scope of SEQ ID NO:136.
  • GAGP was isolated via preparative Superose-6 gel filtration using the method of Qi et al. [Qi et al. (1991) supra] as follows. Nodules of gum arabic (Kordofan province, Sudan) were a gift from Gary Wine of AEP Colloids (Ballston Spa, N.Y.). Nodules were ground to a fine flour (ca. 2 min.) in a Tekmar A-10 mill. Samples of gum arabic (100 mg/ml) were dissolved in water then diluted to 50 mg/ml in 0.2 M sodium phosphate buffer (pH 7).
  • chymotryptic peptide mapping GAGP was HF-deglycosylated as follows.
  • the Superose-6 fractionated GAGP (designated dGAGP) was deglycosylated in anhydrous hydrogen fluoride (HF) (20 mg powder/ml HF for 1 h at 4°) as described earlier [Qi et al. (1991) supra], repeating the procedure twice to ensure complete deglycosylation.
  • HF hydrous hydrogen fluoride
  • dGAGP chymotryptic peptides 400 mg/injection were fractionated on a PolySULFOETHYL ATM cation exchange column (9.4 mm i.d. ⁇ 200 mm; PolyLC, Ellicot City, Md.) equilibrated with Buffer A (5mM potassium phosphate/phosphoric acid buffer, pH 3, containing 25% v/v acetonitrile) and eluted with Buffer B (Buffer A containing 1 M KCl) using progranuned gradient elution. The elution gradient was 0-4% Buffer B in 45 min., 4-8% Buffer B from 45 to 50 min, and 8-30% Buffer B. from 50-65 min. The flow rate was 0.4 mL/min and the absorbance was monitored at 220 nm. The collected peaks were pooled, blown down with N 2 (g), redissolved in ddH 2 O, then freeze dried.
  • Buffer A 5mM potassium phosphate/phosphoric acid buffer, pH
  • dGAGP peptides were sequenced at the Michigan State University Macromolecular Facility on a 477A Applied Biosystems (Foster City, Calif.) gas phase sequencer.
  • Amino acid compositions were determined by precolumn derivatization of amino acids with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate followed by reverse-phase HPLC (Nova-PakTM C 18 column) using the Waters AccQ-Tag Chemistry Package and the gradient recommended by Waters for analyzing collagen hydrolysates [Crimmins and Cherian (1997) Analytical Biochemistry 244:407; van Wandelen and Cohen (1997) Journal of Chromatography A 763:11].
  • FIG. 5 is the elution profile for dGAGP by reverse phase chromatography on a Hamilton PRP-1 column and fractionation by gradient elution. The component at 35 min. was a Hyp-poor contaminant.
  • dGAGP was also digested with chymotrypsin, which slowly cleaved leucyl and histidyl bonds, followed by a two-stage HPLC fractionation scheme.
  • chymotrypsin which slowly cleaved leucyl and histidyl bonds
  • a two-stage HPLC fractionation scheme Initial separation of the chymotryptides on a PolySULFOETHYL ATM (PolyLC, Inc. Ellicott City, Md.) cation exchanger yielded two major fractions designated S1 and S2 (FIG. 7).
  • S1 and S2 The major chymotryptic fractions, S1 and S2 were collected for further fractionation by reverse phase column chromatography.
  • the exemplary 19-amino acid residue GAGP consensus sequence of Table 6 contains approximately nine Hyp residues and is roughly twice the size of that previously postulated to contain only a single polysaccharide attachment site [Qi et al. (1991) supra]. Judging from the Hyp-glycoside profile of GAGP (Table 7) [Qi et al. (1991) supra], about one in every five Hyp residues is polysaccharide-substituted.
  • Hyp-Ara 4 SEQ ID NO:200
  • Hyp-Ara 3 SEQ ID NO:201
  • Hyp-Ara 2 SEQ ID NO:202
  • Hyp-Ara SEQ ID NO:203
  • Hyp-polysaccharide sites there are approximately two Hyp-polysaccharide sites in the invention's exemplary consensus sequence.
  • the inventors predict arabinosylation of contiguous Hyp residues and arabinogalactan-polysaccharide addition to clustered non-contiguous Hyp residues, such as the X-Hyp-X-Hyp modules common in AGPs [Nothnagel (1997) International Review of Cytology 174:195].
  • FIG. 9 uses the standard single letter code for amino acids except for Hyp which is denoted by [Du et al. (1994) Plant Cell 6:1643], and the standard three letter code for sugars, except for glucuronic acid which is denoted as GlcA.
  • each small polysaccharide contains two pentasaccharide side chains (Gal, Ara 2 , GlcA, Rha) arranged along a ⁇ 7-residue (1-3) ⁇ -D-galactan backbone helix which also contains monosaccharide side chains of Ara and Gal.
  • Hyp-polysaccharide (Table 9) may be comprised of repeat units containing approximately 12 galactose residues/repeat.
  • the inventors estimate that as many as five side-chains ( ⁇ 40 sugars) occur in the larger arabinogalactan moieties which eluted in fractions 18-26 from the G-50 Sephadex column (FIG. 10). The inventors further believe that GAGP and other AGP sensitivity to alkaline degradation involves peptide bonds rather than glycosidic linkages.
  • This Example discloses construction of synthetic genes for the expression of gum arabic glycoprotein repeats based on the invention's consensus sequences.
  • the 64 contiguous units [i.e., (motif 1-motif 2) 32 ] were constructed using a modification of the previously described [Lewis et al. (1996) Protein Expression & Purification 7:400-406] strategy involving compatible but nonregenerable restriction sites, which allowed construction of very large inserts with precise control over the number of DNA repeat number.
  • Plasmid pUC18 has an endogenous BsrFI site in the Amp r gene. This site was eliminated by mutation to make the plasmid amenable to subcloning of the XmaI-BsrFI synthetic gene fragments, using the PCR core system I kit (Promega).
  • the PCR Primer 1: (upstream primer) had the sequence (SEQ ID NO:204) GATACCGCGAGACCCACGCTC ACC A GCTCC; this primer was designed from nucleotides 1756 to 1785 of pUC18 except for 1 substitution (A for G) at position 1780 (bolded and underlined).
  • PCR Primer 2 (downstream primer) had the sequence (SEQ ID NO:205) CTCGGTCGCCGCATACACTAT and was designed from nt 2220 to 2198 of pUC18.
  • the PCR reaction conditions were 2 min @ 95° C., 30 sec @ 95° C., 1 min @ 48° C., 1 min @ 72° C. (30 cycles), 5 min @ 72° C.
  • PCR products were separated on a 1.5% agarose gel.
  • the 464 bp PCR fragment was extracted from the gel using the QLAEX II gel extraction kit. The isolated fragment was restricted and subcloned into pUC18 as a ScaI-BpmI fragment.
  • the new plasmid was designated MpUC18 and has an active Amp r gene and no BsrFI site.
  • DNA encoding gum arabic glycoprotein contiguous units of motif 1 linked to motif was constructed using previously described methods [Current Protocols in Molecular Biology section 8.2.8-8.2.10].
  • a DNA fragment encoding the two GAGP motifs was synthesized by primer extension of two partially overlapping synthetic oligonucleotides: First oligonucleotide (SEQ ID NO:206): 5′-G GCA AGC TTC CGG AGT GCC GGC CCT CAT AGC CCA CCT CCA CCA TTA TCA CCA TCA CCT ACT CCA ACT CCT CCT TTG GGA CCA CAC AG -3′; second oligonucleotide (SEQ ID NO:207): 5′-GGT CCC GGG GGG TGG TGT TGG GGT TGG TGA AGG GGA AAG TGT AGG GGG TGG A CT GTG TGG TCC CAA AGG AGG -3′.
  • the oligonucleotides (0.05 nm of each) were heated for 5 min @ 95° C., annealed for 5 min @ 48° C., then extended by DNA polymerase I Klenow fragment (Promega) for 30 min @ 37° C. The reaction was stopped by heating 10 min at 75° C. and the buffer was exchanged via a Sephacryl S-200 column (Pharmacia MicrospinTM). The plasmid was then subcloned into MpUC18 as a Hind I-XmaI fragment. The plasmid was sequenced with the pUC/M13 forward primer (17-mer).
  • the resulting plasmid (MpUC gum-4) contained 4 GAGP internal repeats [i.e., (motif 1-motif 2) 2 ] (FIG. 16B). This strategy was successfully used to build plasmids containing 8, 16, 20, 32, and 64 internal repeats of GAGP.
  • the gum genes (gum-8, gum-20, and gum-32) were removed from MpUC18 plasmid as BspEI/SacI fragments and subcloned into pUC ss-EGFP plasmid behind the signal sequence. During this subcloning, EGFP was removed from pUC ss-EGFP as XmaI/SacI fragment. XmaI and BspEI restriction sites are compatible but nonregenerable.
  • pUC ss-EGFP plasmid was cut with XmaI and treated with Mung Bean endonuclease (New England Biolabs). The enzymes were inactivated by phenol/chloroform extraction followed by ethanol precipitation. Then plasmid was cut with SacI. The EGFP fragment isolated after restriction was subcloned into pUC ss-gum plasmids which was cut with SmaI/SacI restriction enzymes.
  • the signal sequence-synthetic gene-EGFP fragments were removed from MpUC18 plasmid as BamHI/SacI fragments and subcloned into pBI121, replacing the ⁇ -glucuronidase reporter gene.
  • the MpUC ss-gum 20 -EGFP and MpUC ss-gum 32 -EGFP plasmids were sequenced with pUC/M13 forward (17 mer) primer and with GFP primer GAAGATGGTGCGCTCCTGGACGT (SEQ ID NO:226) from nucleotide 566 to nucleotide 588 of pEGFP.
  • the expression vectors contained an extension signal sequence or a tomato signal sequence for transport of the constructs through the ER/Golgi for posttranslational modification, as well as Green Fluorescent Protein (GFP) as a reporter protein as described below.
  • GFP Green Fluorescent Protein
  • Transformation vectors were derived from pBI121 (Clontech). These vectors contained an extensin signal sequence (SS) as well as Green Fluorescent Protein (GFP) as a reporter protein. 8, 20, 32, and 64 internal repeats of GAGP were inserted between the signal sequence and GFP to yield plasmids SS-GAGP 8 -EGFP, SS-GAGP 20 -EGFP, SS-GAGP 32 -EGFP, and SS-GAGP 64 -EGFP, respectively.
  • SS extensin signal sequence
  • GFP Green Fluorescent Protein
  • the tomato LeAGP-1 signal sequence was used as an alternative to the extensin signal sequence. Cloning of the LeAGP-1 signal sequence was as follows using the sense primer 5′-CTC TTT TTC TCT G ⁇ GA TCC GGT CTA TAT TTT CTT TTA GC-3′ (SEQ ID NO:227) (Tm: 68° C.) with the arrow showing the BamHI restriction site, and the antisense primer 5′-CGG GTG CTG C ⁇ CC GGG TTG TCT GAC CCG TGA CAC TTG C-3′ (SEQ ID NO:228) (Tm: 80° C.) with the arrow showing the XmaI restriction site.
  • PCR was carried out using 52.8 pmol of sense primer and 47 pmol of antisense primer.
  • the LeAGP-1 signal sequence template (0.01 ⁇ g) was added together with the PCR mixture.
  • the reaction solution was covered with oil and the incubation was at 95° C. 5 min (circle one); 95° C. 45 sec, 58° C Imin, 74° C. 1 min (circle 2-30); 74° C. 5 min. 20 ⁇ l out of 50 ⁇ l total PCR solution was removed and purified using 2% agarose gel.
  • the PCR product was 127-bp in size and was isolated by using QIAEXII kit. This fragment was digested as follows at 37° C.
  • the digested samples were run on an agarose gel.
  • the vector and fragment were cut from the gel and were isolated with the QIAEXII kit.
  • the ligation reaction [pUC-SS Tob GFP(BX) 100 ng, PCR fragment(BX) 20 ng, Ligase Buffer (10 ⁇ ) 1 ⁇ l, Ligase 1 ⁇ l] was incubated at 10° C. overnight.
  • Transformation was carried out and 3 clones were cultured separately in LB media containing ampicillin overnight. Plasmids were isolated from the transformed cells and digested with BamH1 and Xmal to confirm that the fragments were 99 bp long. The plasmid containing the tomato signal sequence was named pUC-SS Tom -GFP.
  • the transformed Agrobacterium cells were used to transform tobacco cultured cells as described above (Example 10). Transformed cells were selected by detection of fluorescent cells which express GFP.
  • Transformed Agrobacterium cells will be used to transform tomato cultured cells and tobacco discs as described above (Examples 11 and 17, supra). Transformed cells will be selected by detection of fluorescent cells which express GFP. Successful expression of 8, 20, and 32, internal repeats of GAGP in tobacco cultured cells, tobacco leaf discs, and tomato cultured cells will be confirmed using the methods described in the above Examples.
  • SP Contiguous and Noncontiguous Hydroxyproline glycomodules
  • This Example describes construction of three plasmids, each encoding a tobacco signal sequence and EGFP, as well as subcloning of (SP) 32 , (GAGP) 3 , EGFP, (SPP) 24 , (SPPP) 16 , (SPPPP) 18 .
  • the signal sequence was used to direct the products through the ER and Golgi, then out to the extracellular matrix [Goodenough et al. (1986) J. Cell Biol. 103 , 403; Gardiner & Chrispeels (1975) Plant Physiol. 55, 536-541].
  • Two of the plasmids also contained a synthetic gene (SEQ ID NOs:112, 113, 115, 116) encoding either six (Ser-Pro) internal repeat units (SEQ ID NO:117) or three (GAGP) internal repeat units (SEQ ID NO:122) (FIG. 11) sandwiched between the signal sequence and gene-enhanced green fluorescent protein (EGFP).
  • SEQ ID NOs:112, 113, 115, 116 encoding either six (Ser-Pro) internal repeat units (SEQ ID NO:117) or three (GAGP) internal repeat units (SEQ ID NO:122) (FIG. 11) sandwiched between the signal sequence and gene-enhanced green fluorescent protein (EGFP).
  • FIG. 11 internal repeat oligonucleotide sets encoding Ser-Pro repeats or the GAGP sequence were polymerized head-to-tail in the presence of the 5′-linker set [SEQ ID NOs:120 and 121 which encode SEQ ID NO:122].
  • the 3′-linker [SEQ ID NOs:123 and 124 which encode SEQ ID NO:125] was added and the genes then restricted with BamHI and EcoRI and inserted into pBluescript II SK.
  • the signal sequence (SEQ ID NOs:118 and 119) was built by primer extension of the overlapping oligonucleotides featured here. The overlap is underlined.
  • the conserved (Ser-Hyp) n motif was chosen because it occurs both in green algae (Chlamydomonas) and in higher plant AGPs. This noncontiguous Hyp motif is of particular interest because it also occurs together with a contiguous Hyp motif in the consensus sequence of GAGP which contains both oligoarabinoside and polysaccharide addition sites.
  • the signal sequence (FIG. 11) was modeled after an extensin signal sequence from Nicotiana plumbaginifolia ; mutually priming oligonucleotides were extended by T7 DNA Polymerase and the duplex placed in pUC18 as a Bam HI-Sst I fragment. Construction of a given synthetic gene involved the polymerization of three sets of partially overlapping, complementary oligonucleotide pairs as described earlier (FIG. 11).
  • the signal sequence was assembled by using mutually priming oligonucleotides [Current Protocols in Molecular Biology,” (1995) pages 8.2.8-8.2.10]. Oligonucleotides (0.2 nmol, 0.2 nmol) were annealed (5 min at 70° C. followed by 5 min at 40° C.) and extended by DNA polymerase I (Klenow) large fragment (Promega) (30 min at 37° C.). The reaction was stopped by heating 10 min at 75° C. The resulting DNA fragment was cut with BamHI and SstI enzymes and was placed in pUC18 plasmid. The plasmid was sequenced with pUC/M13 forward (17 mer) primer.
  • Oligonucleotides were synthesized and SDS-PAGE purified by Gibco-BRL or Integrated DNA Technologies Inc. They were dissolved in water at appropriate concentrations.
  • the 5′-end linker-internal repeat polymers were capped with the 3′-end linker.
  • 5 ⁇ l of the 3′-end linker were added to 50 ⁇ l of ligation reaction from the step above.
  • the mixture was heated to 30° C. (to destroy unspecific hybridization), and incubated at 17° C. for 3 hours.
  • 20 ⁇ l of water and 2 ⁇ l T4 DNA ligase (4,000 U) were added and the ligation reaction was incubated at 12-15° C. for 36 hours. The reaction was stopped by heating at 65° C. for 10 min.
  • the constructs were ethanol precipitated, washed with 70% ethanol and air dried. The pellet was dissolved in 80 ⁇ l of water. 10 ⁇ l was used for restriction with EcoRI (10 Units) and BamHI (20 Units).
  • the Sephacryl S-400 column (Pharmacia MicrospinTM) was used to remove salts and small oligonucleotide fragments.
  • Qiaquick Nucleotide removal kit (Qiagen) was used to remove enzymes.
  • the resultant fragments were inserted in pBluescript II SK plasmid (Stratagene) The selection of clones was done by white-blue assay. The structure of synthetic genes was checked by sequencing with pUC/M13 forward (17 mer) primer.
  • the synthetic genes were first removed from pBluescript II SK (Strategene) as BamHI/AgeI fragments and subcloned in pEGFP (Clontech). (This step allowed directional cloning).
  • the synthetic gene—EGFP fragments were removed from pEGFP as XmaI/NotI fragments and subcloned in KS (Stratagene) (This step was done to obtain SstI site at the end of EGFP).
  • the synthetic gene—EGFP fragments were removed from KS as XmaI/SstI fragments and subcloned in pUC-signal sequence plasmid behind the signal sequence.
  • the structure of the synthetic genes was checked by sequencing with pUC/M13 forward (17 mer) primer.
  • the signal sequence-synthetic gene-EGFP fragments were removed from pUC18 plasmid as BamHI/SstI fragments and subcloned in pBI121 (Clontech).
  • the EGFP fragment was removed from pEGFP as XmaI/NotI fragments and subcloned in KS. (This step was done to obtain SstI site at the end of EGFP).
  • the EGFP fragment was removed from KS as XmaI/SstI fragments and subcloned in pUC-signal sequence plasmid behind the signal sequence.
  • the signal sequence-—EGFP fragment was removed from pUC18 plasmid as BamHI/SstI fragments and subcloned in pBI121.
  • the 5′-end linker-internal repeat polymers were capped with 3′-end linker. I added 15 ⁇ l of the 3′-end linker to 40 ⁇ l of ligation reaction from step above and 0.5 ⁇ l of T4 DNA ligase (1.5 U). The ligation reaction was incubated 3 hours at 20° C. The reaction was stopped by heating at 65° C. for 10 min. 3 ⁇ l of ligation mixture was used to check the extent of polymerization on 2% agarose gel. The Sephacryl S-200 column (Pharmacia Microspin)TM was used to remove salts. 4-6 ⁇ l of solution was used for restriction with EcoRI (10 Units) and BamHI (20 units). After restriction, 150-bp to 500-bp fragments were cut out of 2% agarose gel. QIAEX II gel extraction kit was used to isolate fragments from the gel.
  • the synthetic genes were removed from pUC18 as XmaI/NcoI fragments and subcloned behind the signal sequence and in front of EGFP in pUC-signal sequence-EGFP plasmid.
  • the signal sequence-synthetic gene-EGFP fragments were removed from pUC18 plasmid as BamHI/SstI fragments and subcloned in pBI121.
  • This Example describes transformation of suspension cultured tobacco cells with the expression vectors of Example 20 and selection of transformants which express green fluorescent protein.
  • Suspension cultured tobacco cells ( Nicotiana tabacum , BY2) were transformed with Agrobacterium tumifaciens strain LBA4404 containing the pBI121-derived plant transformation vector.
  • Transformed cell lines were selected on solid Murashige-Skoog medium (Sigma # 5524) containing 100 mg/mL kanamycin. Timentin was initially included at 400 mg/mL to kill Agrobacterium. Cells were later grown in 1 L flasks containing 560 mL Shenck-Hildebrand medium (Sigma # 6765) and 100 mg/mL kanamycin, rotated at 100 rpm on a gyrotary shaker.
  • This Example demonstrates that inclusion of the EGFP reporter protein facilitated the selection of transformed cells and subsequent detection of the expression products during isolation (FIGS. 13 & 14).
  • EGFP fluorescence in the growth medium was also a visual demonstration of Sig efficacy in directing secretion.
  • the absence of any obvious cell lysis in the cultures and excellent product yields of the glycosylated expression products confirmed that the green fluorescence represented bona fide secretory products.
  • EGFP without a glycomodule was secreted at very low levels, perhaps due to lower solubility.
  • This Example describes the isolation of sequences containing contiguous and noncontiguous Hyp residues from the growth medium of tobacco cells transformed with expression vectors which express these polypeptides.
  • the Superose-12 column was calibrated with molecular weight standards (BSA, insulin, catalase, and sodium azide). Fluorescent Superose-12 fractions were injected directly onto a Hamilton PRP-1 reverse phase column and gradient eluted at a flow rate of 0.5 mL/min. Start buffer consisted of 0.1% TFA (aq) and elution buffer was 0.1% TFA/80% acetonitrile (aq). The sample was repeatedly injected (0.5 mL/minute) onto the column over 35 min, then eluted with a gradient of elution buffer (0-70% /135 min). Native GAGP was isolated from gum arabic nodules as described by Qi et. al.
  • FIG. 13 shows PRP-1 reverse-phase fractionation of the Superose-12 peaks containing (A) (Ser-Hyp) 32 -EGFP, (B) (GAGP) 3 -EGFP, and (C) Glycoproteins in the medium of non-transformed tobacco cells. Endogenous tobacco AGPs eluted between 47 and 63 minutes; extensins eluted at 67 min.
  • Control medium collected from non-transformed tobacco cells was first fractionated on Superose-12 and the fractions eluting between 47 and 63 min collected for further separation on PRP-1 to determine if any endogenous AGPs/HRGPs co-chromatographed with (Ser-Hyp) 32 -EGFP or with (GAGP) 3 -EGFP, which they did not.
  • FIG. 12 shows Superose-12 gel permeation chromatography with fluorescence detection of (A) culture medium containing (Ser-Hyp) 32 -EGFP, (B) (GAGP) 3 -EGFP medium concentrated four-fold, (C) Medium of EGFP targeted to the extracellular matrix (concentrated ten-fold), and (D) 10 mg standard EGFP from Clontech. Not shown is the fractionation of medium from non-transformed tobacco cells, which gave no fluorescent peaks consistent with the results discussed above. Superose-12 fractionation of the two fusion glycoproteins (FIG.
  • SPP 24 -EGFP The recombinant (SPP) 24 -EGFP, (SPPP) 16 -EGFP, and (SPPPP) 18 -EGFP were isolated from transformed cells as described supra in this Example with respect to (SP) 32 -EGFP and (GAGP) 3 -EGFP.
  • glycoproteins isolated from transformed tobacco cells as described in Example 22 were characterized as follows, and were shown to be new arabinogalactan-proteins (AGPs).
  • (Ser-Hyp) 32 -EGFP, (GAGP) 3 -EGFP, tobacco AGPs, and native GAGP were co-precipitated with the Yariv reagent as described earlier. Both (Ser-Hyp) 32 -EGFP and (GAGP) 3 -EGFP precipitated with Yariv reagent (Table 10), which is a specific property of b-1,3-linked arabinogalactan-proteins.
  • Hyp-glycoside profiles were determined as described by Lamport and Miller. We hydrolyzed 5.8-12.2 mg (Ser-Hyp) 32 -EGFP or (GAGP) 3 -EGFP in 0.44 N NaOH and neutralized the hydrolysate with 0.3 M HCl before injection onto a C2 cation exchange colurnn.
  • Each Hyp residue in (Ser-Hyp) 32 -EGFP contained an arabinogalactan-polysaccharide substituent;
  • (GAGP) 3 -EGFP Hyp residues contained arabinooligosaccharide substituents in addition to arabinogalactan-polysaccharide (Table 11).
  • Hyp-glycoside profile of (Ser-Hyp) 32 -EGFP gave a single peak of Hyp corresponding to Hyp-polysaccharide. Significantly, peaks corresponding to Hyp-arabinosides and non-glycosylated Hyp were absent. Importantly, this indicates that all of the Hyp residues in the glycomodule were linked to a polysaccharide.
  • (GAGP) 3 -EGFP yielded peaks corresponding to Hyp-arabinosides, non-glycosylated Hyp, and Hyp-polysaccharide.
  • (GAGP) 3 -EGFP (FIGS. 11 & 15) was designed with fewer contiguous Hyp residues than the consensus sequence of native GAGP and yielded fewer Hyp arabinosides consistent with fewer contiguous Hyp arabinosylation sites [Kieliszewski & Lamport (1994) Plant J. 5, 157-172; Kieliszewski et al. (1992) Plant Physiol. 98, 919-926.; Kieliszewski et al. (1995) J. Biol.
  • the Ser-Pro-Pro gene expressed the protein sequence [Pro-Hyp-Ser-Hyp-Hyp-Ser-Hyp-Hyp-Ser-Hyp-Hyp-Ser] 6 (SEQ ID NO:231) which had the following Hyp-glycoside profile: Hyp (51% of total Hyp), Hyp-Ara (0% of total Hyp), Hyp-Ara 2 (0% of total Hyp), Hyp-Ara 3 (49% of total Hyp), Hyp-Ara 4 (0% of total Hyp), Hyp-Polysaccharide (0% of total Hyp).
  • the expressed the protein sequence had the following Hyp-glycoside profile: Hyp (0% of total Hyp), Hyp-Ara (0% of total Hyp), Hyp-Ara 2 (21% of total Hyp), Hyp-Ara 3 (39% of total Hyp), Hyp-Ara 4 (3% of total Hyp), Hyp-Polysaccharide (37% of total Hyp).
  • the [SPPPP] n module was expresed using the following sequence: GGA TCC TCA ACC CGG GCC TCA CCA [CCA CCA CCT TCA CCT CCA CCC CCA TCT (SEQ ID NO:234) G S S T R A S P [P P P S P P P P S (SEQ ID NO:235) CCA] 9 CCA CCA CCT TCC ATG GCA TTA TAG AGC TCG P ] 9 P P P S M A Stop Stop
  • the expressed the protein sequence had the following Hyp-glycoside profile: Hyp (7% of total Hyp), Hyp-Ara (2% of total Hyp), Hyp-Ara 2 (8% of total Hyp), Hyp-Ara 3 (52% of total Hyp), Hyp-Ara 4 (31% of total Hyp), Hyp-Polysacchride (0% of total Hyp).
  • Gal and Ara accounted for the bulk of the saccharides in both fusion proteins, with lesser amounts of Rha and GlcUA (Table 12); saccharide accounted for 58% (dw) of (Ser-Hyp) 32 -EGFP and 48% (dw) of (GAGP) 3 -EGFP.
  • Hyp glycoside profiles showed the molar ratio of Hyp-polysaccharide in each fusion glycoprotein (Table 11). This gives the number of (polysaccharide)-Hyp residues in each glycoprotein molecule. (e.g. Hyp-polysaccharide accounted for 100% of the Hyp glycosides in (Ser-Hyp) 32 i.e. 31-32 Hyp-polysaccharide). Glycoprotein size before and after deglycosylation gave an approximate size for the attached polysaccharide.
  • each fusion protein before and after deglycosylation was ⁇ 95-115 kDa and 34 kDa respectively for (Ser-Hyp) 32 -EGFP ( ⁇ 71 kDa carbohydrate), and ⁇ 70-100 kDa and 34 kDa respectively for (GAGP) 3 -EGFP ( ⁇ 51 kDa carbohydrate). Judging by the gene sequence (not shown) and FIG.
  • This Example analyzes the emulsifying activity (EA) and emulsion stabilizing activity (ES) of recombinant (GAGP) 3 -EGFP which was expressed in the medium of transformed tobacco cell cultures as described above (Example 23). These activities were compared with those for bovine serum albumin (BSA), crude gum arabic glycoprotein (crude GAGP) which was isolated from Acacia senegal , dialyzed gum arabic glycoprotein, and tobacco arabinogalactan-protein (AGP) which contains a mixture of at least four different arabinogalactan-proteins.
  • BSA bovine serum albumin
  • CAGP crude gum arabic glycoprotein
  • AGP tobacco arabinogalactan-protein
  • this Example describes the emulsifying activity and emulsion stabilizing activity of (GAGP) 3 -EGFP protein fractions which were fractionated on Superose-6 and reverse-phase columns (Example 23), as well as the effect of size and glycosylation of (GAGP) 3 -EGFP on emulsifying activity and emulsion stabilizing activity. All GAGP emulsions used in Tables 14-17, infra, were prepared at a concentration of 0.5% (w/v).
  • the emulsifying activity and emulsion stabilizing activity were determined using orange oil (Sigma) following essentially the manufacturer's instructions. Freeze-dried glycoproteins were dissolved in 0.05 M phosphate buffer (pH 6.5) at a concentration of 0.5% (m/v). The aqueous solutions were combined with orange oil in a 60:40 (v/v) ratio. A 1 ml emulsion was prepared in a glass tube at 0° C. with a Sonic Dismembrator (Fisher Scientific) equipped with a Microtip probe. The amplitude value was set at 4 and mixing time was set to 1 min.
  • EA emulsifying ability
  • the emulsion was diluted serially with a solution containing 0.1 M NaCl and 0.1% SDS to give a final dilution of ⁇ fraction (1/1500) ⁇ .
  • the optical density of the diluted emulsion was then determined in a 1-cm pathlength cuvette at a wavelength of 50 nm and defined as the emulsifying activity (EA).
  • BSA was used as a positive control.
  • Test samples which showed an emulsifying activity which was at least 10%, more preferably at least 50%, and most preferably at least 75% of the emulsifying activity of a BSA control are said to be “characterized by having emulsifying activity.”
  • Emulsifying stability For emulsifying stability, the emulsion was stored vertically in a glass tube for 3 h at room temperature, then the optical density of 1:1500 dilution of the low phase of the stored sample was measured. Emulsifying stability (ES) was defined as the percentage optical density remaining after 2 hour of storage. BSA was used as a positive control. Test samples which showed an emulsion stabilizing activity which was at least 10%, more preferably at least 50%, and most preferably at least 75% of the emulsion stabilizing activity of a BSA control are said to be “characterized by having emulsion stabilizing activity.”
  • the F-2 fraction was further separated on Hydrophobic Interaction column (HIC).
  • HIC Hydrophobic Interaction column
  • the F-2 fraction was dissolved in 4.2 M NaCl and injected onto the HIC column.
  • the column was eluted, starting by 4.2 M NaCl, followed by 3.0 M NaCl, 2.0 M NaCl, 1.0 M NaCl, and distilled water.
  • the resulting fractions were tested and the results are shown in Table 15, which demonstrates that F-2 contains GAGP which is characterized by having emulsifying activity and emulsion stabilizing activity.
  • Table 15 also demonstrates that F-2 separates into four components which differ in hydrophobicity, with the 2.0M and 1.0M NaCl hydrolysates being good emulsifiers TABLE 15 Emulsion Properties of F-2 Fractions Separated by Hydrophobic Interaction Column 4.2 M NaCl 3.0 M 2.0 M 1.0 M Distilled Fractions 1 2 NaCl NaCl NaCl water EA 0.076 0.284 0.475 0.710 0.670 0.04 ES 28% 60.5% 78.5% 93.5% 94.6% 21.0%
  • the F-2 fraction containing native GAGP was incubated in 0.2 N NaOH at 50° C. for 0.5 hr, 1.0 hr, 2.0 hr, 4.0 hr, and 8.0 hr and the emulsifying properties of each sampl e were determined as shown in Table 16.
  • the F-2 fraction was partially deglycosylated by anhydrous hydrogen fluoride (HF) as described above, and the emulsifying properties of the deglycosylated sample were determined.
  • Deglycosylated F-2 fraction had an EA of 0.269, and an ES of 46.5%.
  • the present invention provides a new approach and solution to the problem of producing plant gums.
  • the approach is not dependent on environmental factors and greatly simplifies production of a variety of naturally-occurring gums, as well as designer gums.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A new approach in the field of plant gums is described which presents a new solution to the production of hydroxyproline(Hyp)-rich glycoproteins (HRGPs), repetitive proline-rich proteins (RPRPs) and arabinogalactan-proteins (AGPs). The expression of synthetic genes designed from repetitive peptide sequences of such glycoproteins, including the peptide sequences of gum arabic glycoprotein (GAGP), is taught in host cells, including plant host cells.

Description

    FIELD OF THE INVENTION
  • The present invention relates generally to the field of plant gums and other hydroxyproline-rich glycoproteins, and in particular, to the expression of synthetic genes designed from repetitive peptide sequences. [0001]
    • BACKGROUND
  • Gummosis is a common wound response that results in the exudation of a gum sealant at the site of cracks in bark. A. M. Stephen et al., “Exudate Gums”, [0002] Methods Plant Biochem. (1990). Generally the exudate is a composite of polysaccharides and glycoproteins structurally related to cell wall components such as galactans [G. O. Aspinall, “Plant Gums”, The Carbohydrates 2B:522536 (1970)] and hydroxyproline-rich glycoproteins [Anderson and McDougall, “The chemical characterization of the gum exudates from eight Australian Acacia species of the series Phyllodineae.” Food Hydrocolloids, 2: 329 (1988)].
  • Gum arabic is probably the best characterized of these exudates (although it has been largely refractory to chemical analysis). It is a natural plant exudate secreted by various species of Acacia trees. [0003] Acacia senegal accounts for approximately 80% of the production of gum arabic with Acacia seyal, Acacia laeta, Acacia camplylacantha, and Acacia drepanolobium supplying the remaining 20%. The gum is gathered by hand in Africa. It is a tedious process involving piercing and stripping the bark of the trees, then returning later to gather the dried tear drop shaped, spherical balls that form in response to mechanical wounding.
  • The exact chemical nature of gum arabic has not been elucidated. It is believed to consist of two major components, a microheterogeneous glucurono-arabinorhamnogalactan polysaccharide and a higher molecular weight hydroxyproline-rich glycoprotein. Osman et al., “Characterization of Gum Arabic Fractions Obtained By Anion-Exchange Chromatography” Phytochemistry 38:409 (1984) and Qi et al., “Gum Arabic Glycoprotein Is A Twisted Hairy Rope” Plant Physiol. 96:848 (1991). While the amino composition of the protein portion has been examined, little is known with regard to the precise amino acid sequence. [0004]
  • While the precise chemical nature of gum arabic is elusive, the gum is nonetheless particularly useful due to its high solubility and low viscosity compared to other gums. The FDA declared the gum to be a GRAS food additive. Consequently, it is widely used in the food industry as a thickener, emulsifier, stabilizer, surfactant, protective colloid, and flavor fixative or preservative. J. Dziezak, “A Focus on Gums” [0005] Food Technology (March 1991). It is also used extensively in the cosmetics industry.
  • Normally, the world production of gum arabic is over 100,000 tons per year. However, this production depends on the environmental and political stability of the region producing the gum. In the early 1970s, for example, a severe drought reduced gum production to 30,00 tons. Again in 1985, drought brought about shortages of the gum, resulting in a 600% price increase. [0006]
  • Three approaches have been used to deal with the somewhat precarious supply problem of gum arabic. First, other gums have been sought out in other regions of the world. Second, additives have been investigated to supplement inferior gum arabic. Third, production has been investigated in cultured cells. [0007]
  • The effort to find other gums in other regions of the world has met with some limited success. However, the solubility of gum arabic from Acacia is superior to other gums because it dissolves well in either hot or cold water. Moreover, while other exudates are limited to a 5% solution because of their excessive viscosity, gum arabic can be dissolved readily to make 55% solutions. [0008]
  • Some additives have been identified to supplement gum arabic. For example, whey proteins can be used to increase the functionality of gum arabic. A. Prakash et al., “The effects of added proteins on the functionality of gum arabic in soft drink emulsion systems,” [0009] Food Hydrocolloids 4:177 (1990). However, this approach has limitations. Only low concentrations of such additives can be used without producing off-flavors in the final food product.
  • Attempts to produce gum arabic in cultured Acacia Senegal cells has been explored. Unfortunately, conditions have not been found which lead to the expression of gum arabic in culture. A. Mollard and J -P. Joseleau, “[0010] Acacia senegal cells cultured in suspension secrete a hydroxyproline-deficient arabinogalactan-protein” Plant Physiol. Biochem. 32:703 (1994).
  • Clearly, new approaches to improve gum arabic production are needed. Such approaches should not be dependent on environmental or political factors. Ideally, such approaches should simplify production and be relatively inexpensive. [0011]
    • SUMMARY OF THE INVENTION
  • The present invention involves a new approach in the field of plant gums and presents a new solution to the production of hydroxyproline(Hyp)-rich glycoproteins (HRGPs), repetitive proline-rich proteins (RPRPs) and arabinogalactan-proteins (AGPs). The present invention contemplates the expression of synthetic genes designed from repetitive peptide sequences of such glycoproteins, including the peptide sequences of gum arabic glycoprotein (GAGP). [0012]
  • With respect to GAGP, the present invention contemplates a substantially purified polypeptide comprising at least a portion of the amino acid sequence Ser-Hyp-Hyp-Hyp-[Hyp/Thr]-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His (SEQ ID NO:1 and SEQ ID NO:2) or variants thereof. By “variants” it is meant that the sequence need not comprise the exact sequence; up to five (5) amino acid substitutions are contemplated. For example, a Leu or Hyp may be substituted for the Gly; Leu may also be substituted for Ser and one or more Hyp. By “variants” it is also meant that the sequence need not be the entire nineteen (19) amino acids. Illustrative variants are shown in Table 3. In one preferred embodiment, variants contain one or more of the following three motifs: Ser-Hyp[0013] 4, Ser-Hyp3-Thr, and Xaa-Hyp-Xaa-Hyp, where Xaa is any amino acid other than hydroxyproline.
  • Indeed, it is not intended that the present invention be limited by the precise length of the purified polypeptide. In one embodiment, the peptide comprises more than twelve (12) amino acids from the nineteen (19) amino acids of the sequence. In another embodiment, a portion of the nineteen (19) amino acids (see SEQ ID NO:1 and SEQ ID NO:2) is utilized as a repetitive sequence. In yet another embodiment, all nineteen (19) amino acids (see SEQ ID NO:1 and SEQ ID NO:2) with or without amino acid substitutions) are utilized as a repetitive sequence. [0014]
  • It is not intended that the present invention be limited by the precise number of repeats. The sequence (i.e. SEQ ID NO:1 and SEQ ID NO:2) or variants thereof may be used as a repeating sequence between one (1) and up to fifty (50) times, more preferably between ten (10) and up to thirty (30) times, and most preferably approximately twenty (20) times. The sequence (i.e. SEQ ID NO:1 and SEQ ID NO:2) or variants thereof may be used as contiguous repeats or may be used as non-contiguous repeats (with other amino acids, or amino acid analogues, placed between the repeating sequences). [0015]
  • The present invention specifically contemplates fusion proteins comprising a non-gum arabic protein or glycoprotein sequence and a portion of the gum arabic glycoprotein sequence (SEQ ID NO:1 and SEQ ID NO:2). It is not intended that the present invention be limited by the nature of the non-gum arabic glycoprotein sequence. In one embodiment, the non-gum arabic glycoprotein sequence is a green fluorescent protein. [0016]
  • As noted above, the present invention contemplates synthetic genes encoding such peptides. By “synthetic genes” it is meant that the nucleic acid sequence is derived using the peptide sequence of interest (in contrast to using the nucleic acid sequence from cDNA). In one embodiment, the present invention contemplates an isolated polynucleotide sequence encoding a polypeptide comprising at least a portion of the polypeptide of SEQ ID NO:1 and SEQ ID NO:2 or variants thereof. The present invention specifically contemplates a polynucleotide sequence comprising a nucleotide sequence encoding a polypeptide comprising one or more repeats of SEQ ID NO:1 and SEQ ID NO:2 or variants thereof. Importantly, it is not intended that the present invention be limited to the precise nucleic acid sequence encoding the polypeptide of interest. [0017]
  • The present invention contemplates synthetic genes encoding portions of HRGPs, wherein the encoded peptides contain one or more of the highly conserved Ser-Hyp[0018] 4 (SEQ ID NO:3) motif(s). The present invention also contemplates synthetic genes encoding portions of RPRPs, wherein the encoded peptides contain one or more of the pentapeptide motif: Pro-Hyp-Val-Tyr-Lys (SEQ ID NO:4) and variants of this sequence such as X-Hyp-Val-Tyr-Lys (SEQ ID NO:5) and Pro-Hyp-Val-X-Lys (SEQ ID NO:6) and Pro-Pro-X-Tyr-Lys and Pro-Pro-X-Tyr-X (SEQ ID NO:8), where “X” can be Thr, Glu, Hyp, Pro, His and Ile. The present invention also contemplates synthetic genes encoding portions of AGPs, wherein the encoded peptides contain one or more Xaa-Hyp-Xaa-Hyp (SEQ ID NO:9) repeats. Such peptides can be expressed in a variety of forms, including but not limited to fusion proteins.
  • With regard to motifs for HRGPs, the present invention contemplates a polynucleotide sequence comprising the sequence: 5′-CCA CCA CCT TCA CCT CCA CCC CCA TCT CCA-3′ (SEQ ID NO:10). With regard to motifs for AGPs, the present invention contemplates a polynucleotide sequence comprising the sequence: 5′-TCA CCA TCA CCA TCT CCT TCG CCA TCA CCC-3′ (SEQ ID NO:11). Of course, it is not intended that the present invention be limited by the particular sequence. Indeed, the present invention specifically contemplates sequences that are not identical but are nonetheless homologous to the sequences of SEQ ID NOS: 10 and 11. The present invention also contemplates sequences that are complementary (including sequences that are only partially complementary) sequences to the sequences of SEQ ID NOS: 10 and 11. Such complementary sequences include sequences that will hybridize to the sequences of SEQ ID NOS: 10 and 11 under low stringency conditions as well as high stringency conditions (see Definitions below). [0019]
  • The present invention also contemplates the mixing of motifs (i.e. modules) which are not found in wild-type sequences. For example, one might add GAGP modules to extensin and RPRP crosslinking modules to AGP-like molecules. [0020]
  • The present invention contemplates using the polynucleotides of the present invention for expression of the polypeptides in vitro and in vivo. Therefore, the present invention contemplates polynucleotide sequences encoding two or more repeats of the sequence of SEQ ID NO:1 and SEQ ID NO:2 or variants thereof, wherein said polynucleotide sequence is contained on a recombinant expression vector. It is also contemplated that such vectors will be introduced into a variety of host cells, both eukaryotic and prokaryotic (e.g. bacteria such as [0021] E. coli).
  • In one embodiment, the vector further comprises a promoter. It is not intended that the present invention be limited to a particular promoter. Any promoter sequence which is capable of directing expression of an operably linked nucleic acid sequence encoding a portion of a plant gum polypeptide (or other hydroxyproline-rich polypeptide of interest as described above) is contemplated to be within the scope of the invention. Promoters include, but are not limited to, promoter sequences of bacterial, viral and plant origins. Promoters of bacterial origin include, but are not limited to, the octopine synthase promoter, the nopaline synthase promoter and other promoters derived from native Ti plasmids. Viral promoters include, but are not limited to, the 35S and 19S RNA promoters of cauliflower mosaic virus (CaMV), and T-DNA promoters from Agrobacterium. Plant promoters include, but are not limited to, the ribulose-1,3-bisphosphate carboxylase small subunit promoter, maize ubiquitin promoters, the phaseolin promoter, the E8 promoter, and the Tob7 promoter. [0022]
  • The invention is not limited to the number of promoters used to control expression of a nucleic acid sequence of interest. Any number of promoters may be used so long as expression of the nucleic acid sequence of interest is controlled in a desired manner. Furthermore, the selection of a promoter may be governed by the desirability that expression be over the whole plant, or localized to selected tissues of the plant, e.g., root, leaves, fruit, etc. For example, promoters active in flowers are known (Benfy et al. (1990) Plant Cell 2:849-856). [0023]
  • The promoter activity of any nucleic acid sequence in host cells may be determined (i.e., measured or assessed) using methods well known in the art and exemplified herein. For example, a candidate promoter sequence may be tested by ligating it in-frame to a reporter gene sequence to generate a reporter construct, introducing the reporter construct into host cells (e.g. tomato or potato cells) using methods described herein, and detecting the expression of the reporter gene (e.g., detecting the presence of encoded mRNA or encoded protein, or the activity of a protein encoded by the reporter gene). The reporter gene may confer antibiotic or herbicide resistance. Examples of reporter genes include, but are not limited to, dhfr which confers resistance to methotrexate [Wigler M et al., (1980) [0024] Proc Natl Acad Sci 77:3567-70]; npt, which confers resistance to the aminoglycosides neomycin and G-418 [Colbere-Garapin F et al., (1981) J. Mol. Biol. 150:1-14] and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyl transferase, respectively. Recently, the use of a reporter gene system which expresses visible markers has gained popularity with such markers as β-glucuronidase and its substrate (X-Gluc), luciferase and its substrate (luciferin), and β-galactosidase and its substrate (X-Gal) being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system [Rhodes C A et al. (1995) Methods Mol Biol 55:121-131].
  • In addition to a promoter sequence, the expression construct preferably contains a transcription termination sequence downstream of the nucleic acid sequence of interest to provide for efficient termination. In one embodiment, the termination sequence is the nopaline synthase (NOS) sequence. In another embodiment the termination region comprises different fragments of sugarcane ribulose-1,5-biphosphate carboxylase/oxygenase (rubisco) small subunit (scrbcs) gene. The termination sequences of the expression constructs are not critical to the invention. The termination sequence may be obtained from the same gene as the promoter sequence or may be obtained form different genes. [0025]
  • If the mRNA encoded by the nucleic acid sequence of interest is to be efficiently translated, polyadenylation sequences are also commonly added to the expression construct. Examples of the polyadenylation sequences include, but are not limited to, the Agrobacteriuni octopine synthase signal, or the nopaline synthase signal. [0026]
  • The invention is not limited to constructs which express a single nucleic acid sequence of interest. Constructs which contain a plurality of (i.e., two or more) nucleic acid sequences under the transcriptional control of the same promoter sequence are expressly contemplated to be within the scope of the invention. Also included within the scope of this invention are constructs which contain the same or different nucleic acid sequences under the transcriptional control of different promoters. Such constructs may be desirable to, for example, target expression of the same or different nucleic acid sequences of interest to selected plant tissues. [0027]
  • As noted above, the present invention contemplates using the polynucleotides of the present invention for expression of a portion of plant gum polypeptides in vitro and in vivo. Where expression takes place in vivo, the present invention contemplates transgenic plants. The transgenic plants of the invention are not limited to plants in which each and every cell expresses the nucleic acid sequence of interest. Included within the scope of this invention is any plant (e.g. tobacco, tomato, maize, algae, etc.) which contains at least one cell which expresses the nucleic acid sequence of interest. It is preferred, though not necessary, that the transgenic plant express the nucleic acid sequence of interest in more than one cell, and more preferably in one or more tissue. It is particularly preferred that expression be followed by proper glycosylation of the plant gum polypeptide fragment or variant thereof, such that the host cell produces functional (e.g. in terms of use in the food or cosmetic industry) plant gum polypeptide. [0028]
  • The fact that transformation of plant cells has taken place with the nucleic acid sequence of interest may be determined using any number of methods known in the art. Such methods include, but are not limited to, restriction mapping of genomic DNA, PCR analysis, DNA-DNA hybridization, DNA-RNA hybridization, and DNA sequence analysis. [0029]
  • Expressed polypeptides (or fragments thereof) can be immobilized (covalently or non-covalently) on solid supports or resins for use in isolating HRGP-binding molecules from a variety of sources (e.g. algae, plants, animals, microorganisms). Such polypeptides can also be used to make antibodies. [0030]
  • The invention further provides a substantially purified polypeptide comprising at least a portion of the gum arabic consensus sequence. In particular, the invention provides a substantially purified polypeptide comprising at least a portion of amino acid sequence A-Hyp-B-C-D-E-F-Hyp-G-H-I-Hyp-J-Hyp-Hyp-K-L-Pro-M (SEQ ID NO:136), wherein A is selected from Ser, Thr, and Ala; B is selected from Hyp, Pro, Leu, and Ile; C is selected from Pro and Hyp; D is selected from Hyp, Pro, Ser, Thr, and Ala; E is selected from Leu and Ile; F is selected from Ser, Thr, and Ala; G is selected from Ser, Leu, Hyp, Thr, Ala, and Ile; H is selected from Hyp, Pro, Leu, and Ile; I is selected from Thr, Ala, and Ser; J is selected from Thr, Ser, and Ala; K is selected from Thr, Leu, Hyp, Ser, Ala, and Ile; L is selected from Gly, Leu, Ala, and Ile; and M is selected from His and Pro; and wherein the portion is greater than twelve contiguous amino acids of the amino acid sequence. In a preferred embodiment, the portion occurs in the polypeptide as a repeating sequence. In a more preferred embodiment, the repeating sequence repeats from 1 to 64 times. In an alternative preferred embodiment, A is Ser; B is selected from Hyp, and Leu; D is selected from Hyp, Ser, and Thr; E is Leu; F is Ser; G is selected from Ser, Leu, and Hyp; H is selected from Hyp, Pro, and Leu; I is selected from Thr and Ala; J is Thr; K is selected from Thr, Leu, and Hyp; L is selected from Gly and Leu; and M is selected from His and Pro. In another alternative embodiment, the amino acid sequence is selected from Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His (SEQ ID NO:143), Ser-Hyp-Hyp-Hyp-Thr-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His (SEQ ID NO:144), Ser-Hyp-Hyp-Hyp-Ser-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Thr-Gly-Pro-His (SEQ ID NO:145), Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-Hyp (SEQ ID NO:146), Ser-Hyp-Leu-Pro-Thr-Leu-Ser-Hyp-Leu-Pro-Thr-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His (SEQ ID NO:147), Ser-Hyp-Leu-Pro-Thr-Leu-Ser-Hyp-Leu-Pro-Ala-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His (SEQ ID NO:148), Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Leu-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-Hyp (SEQ ID NO:149), Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His (SEQ ID NO: 150), Ser-Hyp-Hyp-Hyp-Thr-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His (SEQ ID NO:151), Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Hyp-Ala-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His (SEQ ID NO:152), Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Leu-Pro-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His (SEQ ID NO:153), Ser-Hyp-Hyp-Hyp-Ser-Leu-Ser-Hyp-Leu-Pro-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His (SEQ ID NO:154), Ser-Hyp-Hyp-Hyp-Thr-Leu-Ser-Hyp-Hyp-Leu-Thr-Hyp-Thr-Hyp-Hyp-Leu-Leu-Pro-His (SEQ ID NO:155), Hyp-Hyp-Thr-Leu-Ser-Hyp-Hyp-Leu-Thr-Hyp-Thr-Hyp-Hyp-Leu-Leu-Pro (SEQ ID NO:156), Ser-Hyp-Hyp-Hyp-Ser-Leu-Ser-Hyp-Leu-Pro-Thr-Hyp-Thr-Hyp-Hyp-Leu (SEQ ID NO:157), Hyp-Hyp-Leu-Ser-Hyp-Leu-Pro-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His (SEQ ID NO:158), Ser-Hyp-Hyp-Hyp-Thr-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp (SEQ ID NO:159), Leu-Ser-Hyp-Ser-Leu-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-Hyp (SEQ ID NO:160), Hyp-Thr-Leu-Ser-Hyp-Leu-Pro-Ala-Hyp-Thr-Hyp-Hyp-Hyp-Gly (SEQ ID NO:161), Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp (SEQ ID NO:162), Ser-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Thr (SEQ ID NO:163), Hyp-Hyp-Thr-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp (SEQ ID NO:164), Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His (SEQ ID NO:165), Hyp-Hyp-Thr-Leu-Ser-Hyp-Hyp-Leu-Thr-Hyp (SEQ ID NO:166), Ser-Hyp-Hyp-Hyp-Ser-Leu-Ser-Hyp-Leu-Pro (SEQ ID NO: 167), Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His (SEQ ID NO:168), Hyp-Leu-Ser-Hyp-Ser-Hyp-Ala-Hyp (SEQ ID NO:169), Hyp-Hyp-Hyp-Thr-Leu-Ser-Hyp-Ser (SEQ ID NO:170), Thr-Hyp-Hyp-Hyp-Gly-Pro (SEQ ID NO:171), Hyp-Hyp-Leu-Ser-Hyp-Ser (SEQ ID NO:172), Ser-Hyp-Leu-Pro-Ala-Hyp (SEQ ID NO:173), Leu-Pro-Thr-Leu-Ser-Hyp (SEQ ID NO:174), Ser-Hyp-Ser-Hyp (SEQ ID NO:175), Ser-Hyp-Thr-Hyp (SEQ ID NO:176), Thr-Hyp-Thr-Hyp (SEQ ID NO:177), Thr-Hyp-Hyp-Hyp (SEQ ID NO:178), Ser-Hyp-Pro-Pro-Pro-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His (SEQ ID NO:217), Ser-Hyp-Hyp-Pro-Pro-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His (SEQ ID NO:218), Ser-Hyp-Pro-Hyp-Pro-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His (SEQ ID NO:219), Ser-Hyp-Pro-Pro-Hyp-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His (SEQ ID NO:220), Ser-Hyp-Hyp-Hyp-Pro-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His (SEQ ID NO:221), Ser-Hyp-Hyp-Pro-Hyp-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His (SEQ ID NO:222), Ser-Hyp-Pro-Hyp-Hyp-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His (SEQ ID NO:223), Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Pro-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His (SEQ ID NO:224), Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Leu-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His (SEQ ID NO:225), Ser-Hyp-Hyp-Hyp-Thr-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His-Ser-Hyp-Hyp-Hyp-(Hyp) (SEQ ID NO:18), Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His (SEQ ID NO:23), Ser-Hyp-Hyp-Hyp-A-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-B-Gly-Pro-His (SEQ ID NO:179), where A is selected from Hyp, Thr, and Ser, and B is selected from Hyp and Lys, SEQ ID NO:131, and SEQ ID NO:133. In yet another alternative embodiment, the portion comprises a motif selected from (Xaa-Hyp)[0031] x (SEQ ID NO:182) and Xaa-Hyp-Xaa-Xaa-Hyp-Xaa (SEQ ID NO:183), wherein Xaa is any amino acid other than hydroxyproline, and wherein x is from 2 to 1000. In a preferred embodiment, the portion comprises the sequence Xaa-Hyp-Xaa-Hyp (SEQ ID NO:9), and wherein Xaa is selected from Ser, Thr, and Ala. In a further alternative embodiment, the portion comprises a motif selected from Xaa-Hyp-Hypn (SEQ ID NO:209) and Xaa-Pro-Hypn (SEQ ID NO:210), wherein n is from 1 to 100, and wherein Xaa is any amino acid other than hydroxyproline. In a preferred embodiment, the portion comprises a peptide sequence selected from Ser-Hyp2 (SEQ ID NO:211), Ser-Hyp3 (SEQ ID NO:212), Ser-Hyp4 (SEQ ID NO:3), Thr-Hyp2 (SEQ ID NO:213), and Thr-Hyp3 (SEQ ID NO:214). In an additional alternative embodiment, the portion comprises a peptide sequence selected from Ser-Hyp2-Pro (SEQ ID NO:215) and Ser-Hyp2-Pro-Hyp (SEQ ID NO:216).
  • The invention further provides a substantially purified polypeptide comprising a non-contiguous hydroxyproline motif In particular, the invention provides a substantially purified polypeptide comprising a first motif selected from (Xaa-Hyp)[0032] x (SEQ ID NO:182) and Xaa-Hyp-Xaa-Xaa-Hyp-Xaa (SEQ ID NO:183), wherein Xaa is any amino acid other than hydroxyproline, and wherein x is from 2 to 1000. In one embodiment, the sequence is Xaa-Hyp-Xaa-Hyp (SEQ ID NO:9), wherein Xaa is selected from Ser, Thr, and Ala. In an alternative embodiment, the polypeptide further comprises a contiguous hydroxyproline motif (i.e., a second motif) selected from Xaa-Hyp-Hypn (SEQ ID NO:209) and Xaa-Pro-Hypn (SEQ ID NO:210), wherein n is from 1 to 100, and wherein Xaa is any amino acid other than hydroxyproline. In a preferred embodiment, the first and second motifs alternate in the polypeptide. In a more preferred embodiment, the alternating first and second motifs repeat from 1 to 500 times.
  • Also provided herein is a substantially purified polypeptide comprising a motif selected from Xaa-Hyp-Hyp[0033] n (SEQ ID NO:209) and Xaa-Pro-Hypn (SEQ ID NO:210), wherein n is from 1 to 100, and wherein Xaa is any amino acid other than hydroxyproline. In one embodiment, the portion comprises a peptide sequence selected from Ser-Hyp2 (SEQ ID NO:211), Ser-Hyp3 (SEQ ID NO:212), Ser-Hyp4 (SEQ ID NO:3), Thr-Hyp2 (SEQ ID NO:213), and Thr-Hyp3 (SEQ ID NO:214).
  • The invention also provides a fusion protein comprising a first sequence selected from a non-gum arabic protein sequence and a non-gum arabic glycoprotein sequence operably linked to at least a portion of an amino acid sequence selected from (a) A-Hyp-B-C-D-E-F-Hyp-G-H-I-Hyp-J-Hyp-Hyp-K-L-Pro-M (SEQ ID NO:136), wherein A is selected from Ser, Thr, and Ala; B is selected from Hyp, Pro, Leu, and Ile; C is selected from Pro and Hyp; D is selected from Hyp, Pro, Ser, Thr, and Ala; E is selected from Leu and Ile; F is selected from Ser, Thr, and Ala; G is selected from Ser, Leu, Hyp, Thr, Ala, and Ile; H is selected from Hyp, Pro, Leu, and Ile; I is selected from Thr, Ala, and Ser; J is selected from Thr, Ser, and Ala; K is selected from Thr, Leu, Hyp, Ser, Ala, and Ile; L is selected from Gly, Leu, Ala, and Ile; and M is selected from His and Pro; and wherein the portion is greater than twelve contiguous amino acids of the amino acid sequence, (b) a polypeptide comprising a first motif selected from (Xaa-Hyp)[0034] x (SEQ ID NO:182) and Xaa-Hyp-Xaa-Xaa-Hyp-Xaa (SEQ ID NO:183), wherein x is from 2 to 1000, (c) a polypeptide comprising a second motif selected from Xaa-Hyp-Hypn (SEQ ID NO:209) and Xaa-Pro-Hypn (SEQ ID NO:210), wherein n is from 1 to 500, and (d) a polypeptide comprising the first motif and the second motif, wherein Xaa is any amino acid other than hydroxyproline. In one embodiment, the first sequence is a green fluorescent protein amino acid sequence.
  • Also provided by the invention is an isolated polynucleotide sequence encoding at least a portion of an amino acid sequence selected from (a) A-Hyp-B-C-D-E-F-Hyp-G-H-I-Hyp-J-Hyp-Hyp-K-L-Pro-M (SEQ ID NO:136), wherein A is selected from Ser, Thr, and Ala; B is selected from Hyp, Pro, Leu, and Ile; C is selected from Pro and Hyp; D is selected from Hyp, Pro, Ser, Thr, and Ala; E is selected from Leu and Ile; F is selected from Ser, Thr, and Ala; G is selected from Ser, Leu, Hyp, Thr, Ala, and Ile; H is selected from Hyp, Pro, Leu, and Ile; I is selected from Thr, Ala, and Ser; J is selected from Thr, Ser, and Ala; K is selected from Thr, Leu, Hyp, Ser, Ala, and Ile; L is selected from Gly, Leu, Ala, and Ile; and M is selected from His and Pro; and wherein the portion is greater than twelve contiguous amino acids of the amino acid sequence, (b) a polypeptide comprising a first motif selected from (Xaa-Hyp)[0035] x (SEQ ID NO:182) and Xaa-Hyp-Xaa-Xaa-Hyp-Xaa (SEQ ID NO:183), wherein x is from 2 to 1000, (c) a polypeptide comprising a second motif selected from Xaa-Hyp-Hypn (SEQ ID NO:209) and Xaa-Pro-Hypn (SEQ ID NO:210), wherein n is from 1 to 500, and (d) a polypeptide comprising the first motif and the second motif, wherein Xaa is any amino acid other than hydroxyproline.
  • The invention further provides a recombinant expression vector comprising a polynucleotide sequence encoding a portion of an amino acid sequence selected from (a) A-Hyp-B-C-D-E-F-Hyp-G-H-I-Hyp-J-Hyp-Hyp-K-L-Pro-M (SEQ ID NO:136), wherein A is selected from Ser, Thr, and Ala; B is selected from Hyp, Pro, Leu, and Ile; C is selected from Pro and Hyp; D is selected from Hyp, Pro, Ser, Thr, and Ala; E is selected from Leu and Ile; F is selected from Ser, Thr, and Ala; G is selected from Ser, Leu, Hyp, Thr, Ala, and Ile; H is selected from Hyp, Pro, Leu, and Ile; I is selected from Thr, Ala, and Ser; J is selected from Thr, Ser, and Ala; K is selected from Thr, Leu, Hyp, Ser, Ala, and Ile; L is selected from Gly, Leu, Ala, and Ile; and M is selected from His and Pro; and wherein the portion is greater than twelve contiguous amino acids of the amino acid sequence, (b) a polypeptide comprising a first motif selected from (Xaa-Hyp)[0036] x (SEQ ID NO:182) and Xaa-Hyp-Xaa-Xaa-Hyp-Xaa (SEQ ID NO:183), wherein x is from 2 to 1000, (c) a polypeptide comprising a second motif selected from Xaa-Hyp-Hypn (SEQ ID NO:209) and Xaa-Pro-Hypn (SEQ ID NO:210), wherein n is from 1 to 500, and (d) a polypeptide comprising the first motif and the second motif, wherein Xaa is any amino acid other than hydroxyproline. In one embodiment, the expression vector further comprises a promoter operably linked to the polynucleotide sequence. In a preferred embodiment, the promoter is a viral promoter. In a more preferred embodiment, the viral promoter is selected from the group consisting of the 35S and 19S RNA promoters of cauliflower mosaic virus. In an alternative preferred embodiment, the expression vector further comprises a signal sequence selected from extensin signal sequence (SEQ ID NO:14), and tomato arabinogalactan-protein signal sequence (SEQ ID NO:215). In a more preferred embodiment, the expression vector further comprises a reporter gene. In a yet more preferred embodiment, the reporter gene is the green fluorescence protein gene. In another embodiment, the vector is contained within a host cell. In a preferred embodiment, the host cell is a plant cell. In a more preferred embodiment, the plant cell expresses a glycoprotein comprising the portion.
  • Also provided herein is a method for producing at least a portion of a glycoprotein, comprising: a) providing: i) a recombinant expression vector comprising a polynucleotide sequence encoding at least a portion of an amino acid sequence selected from (a) A-Hyp-B-C-D-E-F-Hyp-G-H-I-Hyp-J-Hyp-Hyp-K-L-Pro-M (SEQ ID NO:136), wherein A is selected from Ser, Thr, and Ala; B is selected from Hyp, Pro, Leu, and Ile; C is selected from Pro and Hyp; D is selected from Hyp, Pro, Ser, Thr, and Ala; E is selected from Leu and Ile; F is selected from Ser, Thr, and Ala; G is selected from Ser, Leu, Hyp, Thr, Ala, and Ile; H is selected from Hyp, Pro, Leu, and Ile; I is selected from Thr, Ala, and Ser; J is selected from Thr, Ser, and Ala; K is selected from Thr, Leu, Hyp, Ser, Ala, and Ile; L is selected from Gly, Leu, Ala, and Ile; and M is selected from His and Pro; and wherein the portion is greater than twelve contiguous amino acids of the amino acid sequence, (b) a polypeptide comprising a first motif selected from (Xaa-Hyp)[0037] x (SEQ ID NO:182) and Xaa-Hyp-Xaa-Xaa-Hyp-Xaa (SEQ ID NO:183), wherein x is from 2 to 1000, (c) a polypeptide comprising a second motif selected from Xaa-Hyp-Hypn (SEQ ID NO:209) and Xaa-Pro-Hypn (SEQ ID NO:210), wherein n is from 1 to 500, and (d) a polypeptide comprising the first motif and the second motif, wherein Xaa is any amino acid other than hydroxyproline; and ii) a host cell; and b) introducing the vector into the host cell under conditions such that the portion is expressed. In one embodiment, the host cell is growing in culture. In a preferred embodiment, the method further comprises the step of c) recovering the portion from the host cell culture. In an alternative embodiment, the host cell is a plant cell. In a more preferred embodiment, the plant cell is derived from a plant selected from the family Leguminoseae.
    •  DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows the nucleic acid sequence (SEQ ID NO:12) of one embodiment of a synthetic gene of the present invention. [0038]
  • FIG. 2 shows one embodiment of a synthetic gene in one embodiment of an expression vector. [0039]
  • FIG. 3 is a graph showing size-fractionation of expressed protein from transformed tobacco cells. [0040]
  • FIG. 4 is a graph showing the isolation of GA-EGFP by reverse phase chromatography. [0041]
  • FIG. 5 is the elution profile for dGAGP by reverse phase chromatography on a Hamilton PRP-1 column and fractionation by gradient elution. [0042]
  • FIG. 6 is the elution profile for dGAGP incomplete pronase digest by reverse phase chromatography. An incomplete digest of dGAGP fractionated on the Hamilton PRP-1 reverse phase column yielded two major peptide fractions, designated P1 and P3. [0043]
  • FIG. 7 is the elution profile for a chymotryptic digest of dGAGP fractionated on a Polysulfoethyl aspartamide cation exchange column. [0044]
  • FIG. 8 is the elution profile of dGAGP chymotryptic peptides by reverse phase column chromatography of a) S1, and b)S2. [0045]
  • FIG. 9 shows a proposed model for an exemplary glycopeptide containing an exemplary consensus sequence. [0046]
  • FIG. 10 is the elution profile of the GAGP base hydrolysate by Sephadex G-50 gel permeation chromatography. [0047]
  • FIG. 11 shows the oligonucleotide sequence (SEQ ID NOs:112, 113, 115, 116, 118-121, 123 and 124) sets used to build the synthetic genes which encode the Ser-Pro internal repeat polypeptide (SEQ ID NO:114), the GAGP internal repeat polypeptide (SEQ ID NO:117), the 5′-linker (SEQ ID NO:122) and 3′-linker (SEQ ID NO:125). [0048]
  • FIG. 12 shows Superose-12 gel permeation chromatography with fluorescence detection of (A) culture medium containing (Ser-Hyp)[0049] 32-EGFP, (B) (GAGP)3-EGFP medium concentrated four-fold, (C) Medium of EGFP targeted to the extracellular matrix (concentrated ten-fold), and (D) 10 mg standard EGFP from Clontech.
  • FIG. 13 shows PRP-1 reverse-phase fractionation of the Superose-12 peaks containing (A) (Ser-Hyp)[0050] 32-EGFP, (B) (GAGP)3-EGFP, and (C) (Glyco)proteins in the medium of non-transformed tobacco cells.
  • FIG. 14 shows polypeptide sequences of (Ser-Hyp)[0051] 32-EGFP and (GAGP)3-EGFP before and after deglycosylation. (A) N-terminal amino acid sequence of the glycoprotein, (Ser-Hyp)32-EGFP, with partial sequence of both the glycoprotein (upper sequence) (SEQ ID NO:126) and its polypeptide after deglycosylation (lower sequence) (SEQ ID NO:127). X denotes blank cycles which correspond to glycosylated Hyp; glycoamino acids tend to produce blank cycles during Edman degradation, an exception being arabinosyl Hyp. (B) Polypeptide sequence of glycosylated (GAGP)3-EGFP (upper sequence) (SEQ ID NO:128) and deglycosylated (GAGP)3-EGFP (lower sequence) (SEQ ID NO:129). Residues marked with an asterisk (*) denote low molar yields of Hyp and likely sites of arabinogalactan polysaccharide attachment in glycosylated (GAGP)3-EGFP. For example, yields were 480 pM Asp in the first cycle, 331 pM Ser in the second, 194 pM Hyp in the third, and 508 pM Ser in the fourth cycle.
  • FIG. 15 is a diagram of the cloning strategy for generating repeats of GAGP sequences. [0052]
  • FIG. 16 depicts the exemplary (A) nucleotide sequence (SEQ ID NO:130) and amino acid sequence (SEQ ID NO:131) of two GAGP repeats, and (B) nucleotide sequence (SEQ ID NO:132) and amino acid sequence (SEQ ID NO:133) of four GAGP repeats (SEQ ID NOs:133).[0053]
    • DEFINITIONS
  • The term “gene” refers to a DNA sequence that comprises control and coding sequences necessary for the production of a polypeptide or its precursor. The polypeptide can be encoded by a full length coding sequence or by any portion of the coding sequence. [0054]
  • The term “nucleic acid sequence of interest” refers to any nucleic acid sequence the manipulation of which may be deemed desirable for any reason by one of ordinary skill in the art (e.g., confer improved qualities). [0055]
  • The term “wild-type” when made in reference to a gene refers to a gene which has the characteristics of a gene isolated from a naturally occurring source. The term “wild-type” when made in reference to a gene product refers to a gene product which has the characteristics of a gene product isolated from a naturally occurring source. A wild-type gene is that which is most frequently observed in a population and is thus arbitrarily designated the “normal” or “wild-type” form of the gene. In contrast, the term “modified” or “mutant” when made in reference to a gene or to a gene product refers, respectively, to a gene or to a gene product which displays modifications in sequence and/or functional properties (i.e., altered characteristics) when compared to the wild-type gene or gene product. It is noted that naturally-occurring mutants can be isolated; these are identified by the fact that they have altered characteristics when compared to the wild-type gene or gene product. [0056]
  • The term “recombinant” when made in reference to a DNA molecule refers to a DNA molecule which is comprised of segments of DNA joined together by means of molecular biological techniques. The term “recombinant” when made in reference to a protein or a polypeptide refers to a protein molecule which is expressed using a recombinant DNA molecule. [0057]
  • As used herein, the terms “vector” and “vehicle” are used interchangeably in reference to nucleic acid molecules that transfer DNA segment(s) from one cell to another. [0058]
  • The term “expression vector” or “expression cassette” as used herein refers to a recombinant DNA molecule containing a desired coding sequence and appropriate nucleic acid sequences necessary for the expression of the operably linked coding sequence in a particular host organism. Nucleic acid sequences necessary for expression in prokaryotes usually include a promoter, an operator (optional), and a ribosome binding site, often along with other sequences. Eukaryotic cells are known to utilize promoters, enhancers, and termination and polyadenylation signals. [0059]
  • The terms “targeting vector” or “targeting construct” refer to oligonucleotide sequences comprising a gene of interest flanked on either side by a recognition sequence which is capable of homologous recombination of the DNA sequence located between the flanking recognition sequences. [0060]
  • The terms “in operable combination”, “in operable order” and “operably linked” as used herein refer to the linkage of nucleic acid sequences in such a manner that a nucleic acid molecule capable of directing the transcription of a given gene andfor the synthesis of a desired protein molecule is produced. The term also refers to the linkage of amino acid sequences in such a manner so that a functional protein is produced. [0061]
  • The term “transformation” as used herein refers to the introduction of foreign DNA into cells. Transformation of a plant cell may be accomplished by a variety of means known in the art including particle mediated gene transfer (see, e.g., U.S. Pat. No. 5,584,807 hereby incorporated by reference); infection with an Agrobacterium strain containing the foreign DNA for random integration (U.S. Pat. No. 4,940,838 hereby incorporated by reference) or targeted integration (U.S. Pat. No. 5,501,967 hereby incorporated by reference) of the foreign DNA into the plant cell genome; electroinjection (Nan et al. (1995) In “Biotechnology in Agriculture and Forestry,” Ed. Y. P. S. Bajaj, Springer-Verlag Berlin Heidelberg, Vol 34:145-155; Griesbach (1992) HortScience 27:620); fusion with liposomes, lysosomes, cells, minicells or other fusible lipid-surfaced bodies (Fraley et al. (1982) [0062] Proc. Natl. Acad. Sci. USA 79:1859-1863; polyethylene glycol (Krens et al. (1982) Nature 296:72-74); chemicals that increase free DNA uptake; transformation using virus, and the like.
  • The terms “infecting” and “infection” with a bacterium refer to co-incubation of a target biological sample, (e.g., cell, tissue, etc.) with the bacterium under conditions such that nucleic acid sequences contained within the bacterium are introduced into one or more cells of the target biological sample. [0063]
  • The term “Agrobacterium” refers to a soil-borne, Gram-negative, rod-shaped phytopathogenic bacterium which causes crown gall. The term “Agrobacterium” includes, but is not limited to, the strains [0064] Agrobacterium tumefaciens, (which typically causes crown gall in infected plants), and Agrobacterium rhizogens (which causes hairy root disease in infected host plants). Infection of a plant cell with Agrobacterium generally results in the production of opines (e.g., nopaline, agropine, octopine etc.) by the infected cell. Thus, Agrobacterium strains which cause production of nopaline (e.g., strain LBA4301, C58, A208) are referred to as “nopaline-type” Agrobacteria; Agrobacterium strains which cause production of octopine (e.g., 'strain LBA4404, Ach5, B6) are referred to as “octopine-type” Agrobacteria; and Agrobacterium strains which cause production of agropine (e.g., strain EHA105, EHA101, A281) are referred to as “agropine-type” Agrobacteria.
  • The terms “bombarding, “bombardment,” and “biolistic bombardment” refer to the process of accelerating particles towards a target biological sample (e.g., cell, tissue, etc.) to effect wounding of the cell membrane of a cell in the target biological sample and/or entry of the particles into the target biological sample. Methods for biolistic bombardment are known in the art (e.g., U.S. Pat. No. 5,584,807, the contents of which are herein incorporated by reference), and are commercially available (e.g., the helium gas-driven microprojectile accelerator (PDS-1000/He) (BioRad). [0065]
  • The term “microwounding” when made in reference to plant tissue refers to the introduction of microscopic wounds in that tissue. Microwounding may be achieved by, for example, particle or biolistic bombardment. [0066]
  • The term “transgenic” when used in reference to a plant cell refers to a plant cell which comprises a transgene, or whose genome has been altered by the introduction of a transgene. The term “transgenic” when used in reference to a plant refers to a plant which comprises one or more cells which contain a transgene, or whose genome has been altered by the introduction of a transgene. These transgenic cells and transgenic plants may be produced by several methods including the introduction of a “transgene” comprising nucleic acid (usually DNA) into a target cell or integration into a chromosome of a target cell by way of human intervention, such as by the methods described herein. [0067]
  • The term “transgene” as used herein refers to any nucleic acid sequence which is introduced into the genome of a plant cell by experimental manipulations. A transgene may be an “endogenous DNA sequence,” or a “heterologous DNA sequence” (i.e., “foreign DNA”). The term “endogenous DNA sequence” refers to a nucleotide sequence which is naturally found in the cell into which it is introduced so long as it does not contain some modification (e.g., a point mutation, the presence of a selectable marker gene, etc.) relative to the naturally-occurring sequence. The term “heterologous DNA sequence” refers to a nucleotide sequence which is ligated to, or is manipulated to become ligated to, a nucleic acid sequence to which it is not ligated in nature, or to which it is ligated at a different location in nature. Heterologous DNA is not endogenous to the cell into which it is introduced, but has been obtained from another cell. Heterologous DNA also includes an endogenous DNA sequence which contains some modification. Generally, although not necessarily, heterologous DNA encodes RNA and proteins that are not normally produced by the cell into which it is expressed. Examples of heterologous DNA include mutated wild-type genes (i.e., wild-type genes that have been modified such that they are no longer wild-type genes), reporter genes, transcriptional and translational regulatory sequences, selectable marker proteins (e.g., proteins which confer drug resistance), etc. [0068]
  • As used herein, the term “probe” when made in reference to an oligonucleotide (i.e., a sequence of nucleotides) refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, recombinantly or by PCR amplification, which is capable of hybridizing to another oligonucleotide of interest. A probe may be single-stranded or double-stranded. Probes are useful in the detection, identification and isolation of particular gene sequences. Oligonucleotide probes may be labelled with a “reporter molecule,” so that the probe is detectable using a detection system. Detection systems include, but are not limited to, enzyme, fluorescent, radioactive, and luminescent systems. [0069]
  • The term “selectable marker” as used herein, refer to a gene which encodes an enzyme having an activity that confers resistance to an antibiotic or drug upon the cell in which the selectable marker is expressed. Selectable markers may be “positive” or “negative.” Examples of positive selectable markers include the neomycin phosphotrasferase (NPTII) gene which confers resistance to G418 and to kanamycin, and the bacterial hygromycin phosphotransferase gene (hyg), which confers resistance to the antibiotic hygromycin. Negative selectable markers encode an enzymatic activity whose expression is cytotoxic to the cell when grown in an appropriate selective medium. For example, the HSV-tk gene is commonly used as a negative selectable marker. Expression of the HSV-tk gene in cells grown in the presence of gancyclovir or acyclovir is cytotoxic; thus, growth of cells in selective medium containing gancyclovir or acyclovir selects against cells capable of expressing a functional HSV TK enzyme. [0070]
  • The terms “promoter element,” “promoter,” or “promoter sequence” as used herein, refer to a DNA sequence that is located at the 5′ end (i.e. precedes) the protein coding region of a DNA polymer. The location of most promoters known in nature precedes the transcribed region. The promoter functions as a switch, activating the expression of a gene. If the gene is activated, it is said to be transcribed, or participating in transcription. Transcription involves the synthesis of mRNA from the gene. The promoter, therefore, serves as a transcriptional regulatory element and also provides a site for initiation of transcription of the gene into mRNA. [0071]
  • The term “amplification” is defined as the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction technologies well known in the art [Dieffenbach C W and G S Dveksler (1995) [0072] PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview N.Y.] As used herein, the term “polymerase chain reaction” (“PCR”) refers to the method disclosed in U.S. Pat. Nos. 4,683,195, 4,683,202 and 4,965,188, all of which are hereby incorporated by reference, which describe a method for increasing the concentration of a segment of a target sequence in a mixture of genomic DNA without cloning or purification. This process for amplifying the target sequence consists of introducing a large excess of two oligonucleotide primers to the DNA mixture containing the desired target sequence, followed by a precise sequence of thermal cycling in the presence of a DNA polymerase. The two primers are complementary to their respective strands of the double stranded target sequence. To effect amplification, the mixture is denatured and the primers then annealed to their complementary sequences within the target molecule. Following annealing, the primers are extended with a polymerase so as to form a new pair of complementary strands. The steps of denaturation, primer annealing and polymerase extension can be repeated many times (i.e., denaturation, annealing and extension constitute one “cycle”; there can be numerous “cycles”) to obtain a high concentration of an amplified segment of the desired target sequence. The length of the amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter. By virtue of the repeating aspect of the process, the method is referred to as the “polymerase chain reaction” (hereinafter “PCR”). Because the desired amplified segments of the target sequence become the predominant sequences (in terms of concentration) in the mixture, they are said to be “PCR amplified.”
  • With modern methods of PCR, it is possible to amplify a single copy of a specific target sequence in genomic DNA to a level detectable by several different methodologies (e.g., hybridization with a labeled probe; incorporation of biotinylated primers followed by avidin-enzyme conjugate detection; and/or incorporation of [0073] 32P-labeled deoxyribonucleotide triphosphates, such as dCTP or dATP, into the amplified segment). In addition to genomic DNA, any oligonucleotide sequence can be amplified with the appropriate set of primer molecules. In particular, the amplified segments created by the PCR process itself are, themselves, efficient templates for subsequent PCR amplifications. Amplified target sequences may be used to obtain segments of DNA (e.g., genes) for the construction of targeting vectors, transgenes, etc.
  • The present invention contemplates using amplification techniques such as PCR to obtain the cDNA (or portions thereof) of plant genes encoding plant gums and other hydroxyproline-rich polypeptides. In one embodiment, primers are designed using the synthetic gene sequences (e.g. containing sequences encoding particular motifs) described herein and PCR is carried out (using genomic DNA or other source of nucleic acid from any plant capable of producing a gurn exudate) under conditions of low stringency. In another embodiment, PCR is carried out under high stringency. The amplified products can be run out on a gel and isolated from the gel. [0074]
  • The term “hybridization” as used herein refers to any process by which a strand of nucleic acid joins with a complementary strand through base pairing [Coombs J (1994) [0075] Dictionary of Biotechnology, Stockton Press, New York N.Y.]
  • As used herein, the terms “complementary” or “complementarity” when used in reference to polynucleotides refer to polynucleotides which are related by the base-pairing rules. For example, for the [0076] sequence 5′-AGT-3′ is complementary to the sequence 5′-ACT-3′. Complementarity may be “partial,” in which only some of the nucleic acids' bases are matched according to the base pairing rules. Or, there may be “complete” or “total” complementarity between the nucleic acids. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, as well as detection methods which depend upon binding between nucleic acids.
  • The term “homology” when used in relation to nucleic acids refers to a degree of complementarity. There may be partial homology or complete homology (i.e., identity). A partially complementary sequence is one that at least partially inhibits a completely complementary sequence from hybridizing to a target nucleic acid is referred to using the functional term “substantially homologous.” The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or Northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or probe will compete for and inhibit the binding (i.e., the hybridization) of a sequence which is completely homologous to a target under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction. The absence of non-specific binding may be tested by the use of a second target which lacks even a partial degree of complementarity (e.g., less than about 30% identity); in the absence of non-specific binding the probe will not hybridize to the second non-complementary target. [0077]
  • Low stringency conditions when used in reference to nucleic acid hybridization comprise conditions equivalent to binding or hybridization at 68° C. in a solution consisting of 5× SSPE (43.8 g/l NaCl, 6.9 g/l NaH[0078] 2PO4·H2O and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 1% SDS, 5× Denhardt's reagent [50× Denhardt's contains the following per 500 ml: 5 g Ficoll (Type 400, Pharmacia), 5 g BSA (Fraction V; Sigma)] and 100 μg/ml denatured salmon sperm DNA followed by washing in a solution comprising 0.2× SSPE, and 0.1% SDS at room temperature when a DNA probe of about 100 to about 1000 nucleotides in length is employed.
  • High stringency conditions when used in reference to nucleic acid hybridization comprise conditions equivalent to binding or hybridization at 68° C. in a solution consisting of 5× SSPE, 1% SDS, 5× Denhardt's reagent and 100 μg/ml denatured salmon sperm DNA followed by washing in a solution comprising 0.1× SSPE, and 0.1% SDS at 68° C. when a probe of about 100 to about 1000 nucleotides in length is employed. [0079]
  • The term “equivalent” when made in reference to a hybridization condition as it relates to a hybridization condition of interest means that the hybridization condition and the hybridization condition of interest result in hybridization of nucleic acid sequences which have the same range of percent (%) homology. For example, if a hybridization condition of interest results in hybridization of a first nucleic acid sequence with other nucleic acid sequences that have from 50% to 70% homology to the first nucleic acid sequence, then another hybridization condition is said to be equivalent to the hybridization condition of interest if this other hybridization condition also results in hybridization of the first nucleic acid sequence with the other nucleic acid sequences that have from 50% to 70% homology to the first nucleic acid sequence. [0080]
  • When used in reference to nucleic acid hybridization the art knows well that numerous equivalent conditions may be employed to comprise either low or high stringency conditions; factors such as the length and nature (DNA, RNA, base composition) of the probe and nature of the target (DNA, RNA, base composition, present in solution or immobilized, etc.) and the concentration of the salts and other components (e.g., the presence or absence of formamide, dextran sulfate, polyethylene glycol) are considered and the hybridization solution may be varied to generate conditions of either low or high stringency hybridization different from, but equivalent to, the above listed conditions. [0081]
  • “Stringency” when used in reference to nucleic acid hybridization typically occurs in a range from about T[0082] m-5° C. (5° C. below the Tm of the probe) to about 20° C. to 25° C. below Tm. As will be understood by those of skill in the art, a stringent hybridization can be used to identify or detect identical polynucleotide sequences or to identify or detect similar or related polynucleotide sequences. Under “stringent conditions” a nucleic acid sequence of interest will hybridize to its exact complement and closely related sequences.
  • As used herein, the term “fusion protein” refers to a chimeric protein containing the protein of interest (i.e., GAGP and fragments thereof) joined to an exogenous protein fragment (the fusion partner which consists of a non-GAGP sequence). The fusion partner may provide a detectable moiety, may provide an affinity tag to allow purification of the recombinant fusion protein from the host cell, or both. If desired, the fusion protein may be removed from the protein of interest (i.e., GAGP protein or fragments thereof) by a variety of enzymatic or chemical means known to the art. In an alternative embodiment, the fusion proteins of the invention may be used as substrates for plant glycosyl transfgerases. For example after deglycosylation, the exemplary (Ser-Hyp)[0083] 32-EGFP (see Example 23) may be used as an acceptor for galactose addition, with UDP-galactose as co-substrate, catalyzed by galactosyl transferase. The fusion partner EGFP allows facile isolation of the newly galactosyalted polypeptide. Fusion proteins containing sequences of the invention may be isolated using methods known in the art, such as gel filtration (Example 22), hydrophobic interaction chromatograph (HIC), reverse phase chromatography, and anion exchange chromatography.
  • As used herein the term “non-gum arabic glycoprotein” or “non-gum arabic glycoprotein sequence” refers to that portion of a fusion protein which comprises a protein or protein sequence which is not derived from a gum arabic glycoprotein. [0084]
  • The term “protein of interest” as used herein refers to the protein whose expression is desired within the fusion protein. In a fusion protein the protein of interest (e.g., GAGP) will be joined or fused with another protein or protein domain (e.g., GFP), the fusion partner, to allow for enhanced stability of the protein of interest and/or ease of purification of the fusion protein. [0085]
  • As used herein, the term “purified” or “to purify” refers to the removal of contaminants from a sample. For example, recombinant HRGP polypeptides, including HRGP-GFP fusion proteins are purified by the removal of host cell components such as nucleic acids, lipopolysaccharide (e.g., endotoxin). “Substantially purified” molecules are at least 60% free, preferably at least 75% free, and more preferably at least 90% free from other components with which they are naturally associated. [0086]
  • The term “recombinant DNA molecule” as used herein refers to a DNA molecule which is comprised of segments of DNA joined together by means of molecular biological techniques. [0087]
  • The term “recombinant protein” or “recombinant polypeptide” as used herein refers to a protein molecule which is expressed ftom a recombinant DNA molecule. [0088]
  • As used herein the term “portion” when in reference to a protein (as in “a portion of a given protein”) refers to fragments of that protein. The fragments may range in size from four (4) amino acid residues to the entire amino acid sequence minus one amino acid. Thus, a portion of an amino acid sequence which is 30 nucleotides long refers to any fragment of that sequence which ranges in size from 4 to 29 contiguous amino acids of that sequence. A polypeptide comprising “at least a portion of” an amino acid sequence comprises from four (4) contiguous amino acid residues of the amino acid sequence to the entire amino acid sequence. When made in reference to a nucleic acid sequence, the term “portion” means a fragment which ranges in size from twelve (12) nucleic acids to the entire nucleic acid sequence minus one nucleic acid. Thus, a nucleic acid sequence comprising “at least a portion of” a nucleotide sequence comprises from twelve (12) contiguous nucleotide residues of the nucleotide sequence to the entire nucleotide sequence. [0089]
  • The term “isolated” when used in relation to a nucleic acid, as in “an isolated nucleic acid sequence” refers to a nucleic acid sequence that is identified and separated from at least one contaminant nucleic acid with which it is ordinarily associated in its natural source. [0090]
  • The terms “motif” and “module” are equivalent terms when made in reference to an amino acid sequence, and refer to the particular type, number, and arrangement of amino acids in that sequence. [0091]
  • The term “glycomodule” refers to a glycopeptide in which the carbohydrate portion is covalently linked to an amino acid sequence motif. [0092]
  • The term “repeating sequence” when made in reference to a peptide sequence that is contained in a polypeptide sequence means that the peptide sequence is reiterated from 1 to 10 times, more preferably from 1 to 100 times, and most preferably from 1 to 1000 times, in the polypeptide sequence. The repeats of the peptide sequence may be non-contiguous or contiguous. The term “non-contiguous repeat” when made in reference to a repeating peptide sequence means that at least one amino acid (or amino acid analog) is placed between the repeating sequences. The term “contiguous repeat” when made in reference to a repeating peptide sequence means that there are no intervening amino acids (or amino acid analogs) between the repeating sequences. [0093]
    • GENERAL DESCRIPTION OF THE INVENTION
  • The present invention relates generally to the field of plant gums and other hydroxyproline-rich glycoproteins, and in particular, to the expression of synthetic genes designed from repetitive peptide sequences. The hydroxyproline-rich glycoprotein (HRGP) superfamily is ubiquitous in the primary cell wall or extracellular matrix throughout the plant kingdom. Family members are diverse in structure and implicated in all aspects of plant growth and development. This includes plant responses to stress imposed by pathogenesis and mechanical wounding. [0094]
  • Plant HRGPs have no known animal homologs. Furthermore, hydroxyproline residues are O-glycosylated in plant glycoproteins but never in animals. At the molecular level the function of these unique plant glycoproteins remains largely unexplored. [0095]
  • HRGPS are, to a lesser or greater extent, extended, repetitive, modular proteins. The modules are small (generally 4-6 amino acid residue motifs), usually glycosylated, with most HRGPs being made up of more than one type of repetitive module. For purposes of constructing the synthetic genes of the present invention, it is useful to view the glycosylated polypeptide modules not merely as peptides or oligosaccharides but as small functional motifs. [0096]
  • The description of the invention involves A) the design of the polypeptide of interest, B) the production of synthetic genes encoding the polypeptide of interest, C) the construction of the expression vectors, D) selection of the host cells, E) introduction of the expression construct into a particular cell (whether in vitro or in vivo), F) preferred consensus sequences and portions thereof, and G) O-glycosylation codes. [0097]
  • A. Design Of The Polypeptide Of Interest [0098]
  • The present invention contemplates polypeptides that are fragments of hydroxyproline-rich glycoproteins (HRGPs), repetitive proline-rich proteins (RPRPs) and arabinogalactan-proteins (AGPs). The present invention contemplates portions of HRGPs comprising one or more of the highly conserved Ser-Hyp[0099] 4 (SEQ ID NO:3) motif(s). The present invention also contemplates portions of RPRPs comprising one or more of the pentapeptide motif: Pro-Hyp-Val-Tyr-Lys (SEQ ID NO:4). The present invention also contemplates portions of AGPs comprising one or more Xaa-Hyp-Xaa-Hyp (SEQ ID NO:9) repeats.
  • While an understanding of the natural mechanism of glycosylation is not required for the successful operation of the present invention, it is believed that in GAGP and other HRGPs, repetitive Xaa-Hyp motifs constitute a Hyp-glycosylation code where Hyp occurring in contiguous motifs (Xaa-Hyp-Hyp) and Hyp occurring in non-contiguous Hyp repeats is recognized by different enzymes: arabinosyltransferases and galactosyltransferases, respectively. [0100]
  • The RPRPs (and some nodulins) consist of short repetitive motifs (e.g. Soybean RPRP1: [POVYK][0101] n where O=Hyp) containing the least amount of contiguous Hyp. They also exemplify the low end of the glycosylation range with relatively few Hyp residues arabinosylated and no arabinogalactan polysaccharide. For example, in soybean RPRP1, L-arabinofuranose is attached to perhaps only a single Hyp residue in the molecule.
  • The Extensins occupy an intermediate position in the glycosylation continuum, containing about 50% carbohydrate which occurs mainly as Hyp-arabinosides (1-4 Ara residues), but not as Hyp-arabinogalactan polysaccharide. Extensins contain the repetitive, highly arabinosylated, diagnostic Ser-Hyp[0102] 4 (SEQ ID NO:3) glycopeptide module. The precise function of this module is unknown, but earlier work indicates that these motifs of arabinosylated Hyp help stabilize the extended polyproline-II helix of the extensins. Monogalactose also occurs on the Ser residues.
  • The classical Ser-Hyp[0103] 4 (SEQ ID NO:3) glycopeptide module is of special interest. A tetra-L-arabinofuranosyl oligosaccharide is attached to each Hyp residue in the motif. Three uniquely b-linked arabinofuranosyl residues and an a-linked nonreducing terminus comprise the tetraarabinooligosaccharide. While an understanding of the natural mechanism of glycosylation is not required for the successful operation of the present invention, it is believed that the arabinosylated Hyp residues together with the single galactosyl-serine residue undoubtedly form a unique molecular surface topography which interacts with and is recognized by other wall components, possibly including itself. Shorter motifs of Hyp, namely Hyp3 and Hyp2, lack the fourth (a-linked) arabinose residue, again suggesting that the fourth Ara unique to the Hyp4 motif, has a special role and is presented for recognition or cleavage.
  • Tetra-arabinose and tri-arabinose are attached to known tetra-Hyp motifs. Those Ser-Hyp[0104] 4 isolated from native extensins have every Hyp residue arabinosylated. However, the Ser-Hyp4 repeats fused to EGFP as disclosed herein showed that some Hyp residues were nonglycosylated, while some were mono- and di-arabinosylated. Mainly, the Hyp residues were tri-arabinosylated and tetra-arabinosylated. For example, Hyp-Ara4 was 31% of total Hyp, Hyp-Ara3 was 52% of total Hyp, Hyp-Ara2 was 8% of total Hyp, and Hyp-Ara was 2% of total Hyp. 7% of the total Hyp was not glyscosylated. Most of the serine residues in the invention's exemplary Ser-Hyp4 repeats fused to EGFP were not galactosylated. This is in contrast to naturally occurring Ser-Hyp4 in which Ser is often mono-galactosylated. Importantly, Hyp-polysaccharide were never detected by the inventors in the Ser-Hyp4 repeats fused to EGFP.
  • At the high end of the glycosylation range (˜90% sugar), the arabinogalactan-proteins (AGPs) and the related gum arabic glycoprotein (GAGP) are uniquely glycosylated with arabinogalactan polysaccharides. GAGP and all AGPs so far characterized by Hyp-glycoside profiles contain Hyp-linked arabinosides assigned to contiguous Hyp residues by the Hyp contiguity hypothesis. However these glycoproteins also uniquely contain Xaa-Hyp-Xaa-Hyp (SEQ ID NO:9) repeats. These repeats are putative polysaccharide attachment sites. [0105]
  • The present invention contemplates in particular fragments of gum arabic glycoprotein (GAGP). As noted above, GAGP has been largely refractory to chemical analysis. Prior to the inventors' discovery of the sequences disclosed herein, the largest peptide obtained and sequenced from gum arabic was a peptide of twelve (12) arino acids having the sequence Ser-Hyp-Ser-Hyp-Thr-HypThr-Hyp-Hyp-Hyp-Gly-Pro (SEQ ID NO:13). C. L. Delonnay, “Determination of the Protein Constituent Of Gum Arabic” Master of Science Thesis (1993). The present invention contemplates using this Delonnay sequence as well as (heretofore undescribed) larger peptide fragments of GAGP (and variants thereof) for the design of synthetic genes. In this manner, “designer plant gums” can be produced (“designer extensins” are also contemplated). [0106]
  • In one embodiment, the present invention contemplates a substantially purified polypeptide comprising at least a portion of the amino acid consensus sequence Ser-Hyp-Hyp-Hyp-[Hyp/Thr]-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His (SEQ ID NO:1 and SEQ ID NO:2) or variants thereof. While an understanding of the natural mechanism of glycosylation is not required for the successful operation of the present invention, it is believed that this GAGP 19-amino acid consensus repeat (which contains both contiguous Hyp and non-contiguous Hyp repeats) is glycosylated in native GAGP with both Hyp-arabinosides and Hyp-polysaccharide in molar ratios. It is further believed that the high molecular weight protein component of gum arabic (i.e. GAGP) is responsible for the remarkable (and advantageous) emulsifying and stabilizing activity exploited by the food and soft drink industries. [0107]
  • The sequences of the invention may be used to isolate hydroxyproline rich glycoprotein-binding molecules. For example, polypeptides encoded by the invention's polynucloetide sequences may be immobilized (covalently or non-covalently) on solid supports or resins for use in isolating HRGP-binding molecules from a variety of sources (e.g. algae, plants, animals, microorganisms). Generic methods for immobilizing polypeptides are known in the art using commercially available kits. For example, the desired polypeptide sequence may be expressed as a fusion protein with heterologous protein A which allows immobilization of the fusion protein on immobilized immunoglobulin. Additionally, pGEX vectors (Promega, Madison Wis.) may be used to express the desired polypeptides as a fusion protein with glutathione S-transferase (GST) which may be adsorbed to glutathione-agarose beads. [0108]
  • The invention's sequences may also be used to make polyclonal and monoclonal antibodies. Generic methods for generating polyclonal and monoclonal antibodies are known in the art. For example, monoclonal antibodies may be generated using the methods of Kohler and Milstein (1976) Eur. J. Immunol. 6:511-519 (Exhibit B) and of J. Goding (1986) In “Monoclonal Antibodies: Principles and Practice,” Academic Press, pp 59-103. [0109]
  • B. Production of Synthetic Genes [0110]
  • The present invention contemplates the use of synthetic genes engineered for the expression of repetitive glycopeptide modules in cells, including but not limited to callus and suspension cultures. It is not intended that the present invention be limited by the precise number of repeats. [0111]
  • In one embodiment, the present invention contemplates the nucleic acid sequences encoding the consensus sequence for GAGP (i.e. SEQ ID NO:1 and SEQ ID NO:2) or variants thereof may be used as a repeating sequence between two (2) and up to fifty (50) times, more preferably between ten (10) and up to thirty (30) times, and most preferably approximately twenty (20) times. The nucleic acid sequence encoding the consensus sequence (i.e. SEQ ID NO:1 and SEQ ID NO:2) or variants thereof may be used as contiguous repeats or may be used as non-contiguous repeats. [0112]
  • In designing any HRGP gene cassette the following guidelines are employed: [0113]
  • 1) Minimization of the repetitive nature of the coding sequence while still taking into account the HRGP codon bias of the host plant (e.g., when tomato is the host plant, the codon usage bias of the tomato which favors CCA and CCT [but not CCG] for Pro residues, and TCA and TCC for Ser residues is employed). Zea mays (such as corn) and perhaps other graminaceous monocotyledons (e.g. rice barley, wheat and all grasses) prefer CCG and CCC for proline; GTC and CTT for valine; and AAG for lysine. Dicotyledons (including legumes) prefer CCA and CCT for proline and TCA and TCT for serine. [0114]
  • 2) Minimization of strict sequence periodicity. [0115]
  • 3) Non-palindromic ends are used for the monomers and end linkers to assure proper “head-to-tail” polymerization. [0116]
  • 4) The constructs contain no internal restriction enzyme recognition sites for the restriction enzymes employed for the insertion of these sequences into expression vectors or during subsequent manipulations of such vectors. Typically, the 5′ linker contains a XmaI site downstream of the BamHI site used for cloning into the cloning vector (e.g., pBluescript). The XmaI site is used for insertion of the HRGP gene cassette into the expression vector (e.g., pBI121-Sig-EGFP). Typically, the 3′ linker contains a AgeI site upstream of the EcoRI site used for cloning into the cloning vector (e.g., pBluescript). The AgeI site is used for insertion of the HRGP gene cassette into the expression vector. [For plasmid pBI121-Sig—which does not contain GFP for the fusion protein—the same signal sequence (SS) is used, but the 3′ linkers contain an Sst I restriction site for insertion as an Xma I/Sst I fragment behind the signal sequence and before the NOS terminator]. [0117]
  • 5) The oligonucleotides used are high quality (e.g., from GibcoBRL, Operon) and have been purified away from unwanted products of the synthesis. [0118]
  • 6) The T[0119] M of correctly aligned oligomers is greater than the TM of possible dimers, hairpins or crossdimers.
  • One of skill in the art appreciates that the hydroxyproline (Hyp) residues in the sequences of the invention are produced as the result of post-translational modification of proline (Pro) residues in the polypeptide which is encoded by the gene. Thus, where a hydroxyproline residue is desired to be present in the sequences of the invention, the corresponding codon would be selected to encode proline. The Edman degradation may be used to identify which Pro residues had been hydroxylated to Hyp as described in Example 23, infra. [0120]
  • C. Construction of Expression Vectors [0121]
  • It is not intended that the present invention be limited by the nature of the expression vector. A variety of vectors are contemplated. In one embodiment, two plant transformation vectors are prepared, both derived from pBI121 (Clontech). Both contain an extensin signal sequence (SS) for transport of the constructs through the ER/Golgi for posttranslational modification. A first plasmid construct contained Green Fluorescent Protein (GFP) as a reporter protein instead of GUS. A second plasmid does not contain GFP. [0122]
  • pBI121 is the Jefferson vector in which the BamHI and SstI sites can be used to insert foreign DNA between the 35S CaMV promoter and the termination/polyadenylation signal from the nopaline synthase gene (NOS-ter) of the Agrobacterium Ti plasmid); it also contains an RK2 origin of replication, a kanamycin resistance gene, and the GUS reporter gene. [0123]
  • Signal Sequences. As noted above, the GUS sequence is replaced (via BamHI/SstI) with a synthetic DNA sequence encoding a peptide signal sequence based on the extensin signal sequences of [0124] Nicotiana plumbaginifolia and N. tabacum
  • [0125] MGKMASLFATFLVVLVSLSLAQTTRVVPVASSAP (SEQ ID NO:14) The DNA sequence also contains 15 bp of the 5′ untranslated region, and restriction sites for Bam HI in its 5′ terminus and Sst I in its extreme 3′ terminus for insertion into pBI121 in place of GUS. An XmaI restriction site occurs 16 bp upstream from the Sst I site to allow subsequent insertion of EGFP into the plasmid as a Xma I/Sst I fragment.
  • The sequence underlined above targets [0126] N. plumbaginifolia extensin fusion proteins through the ER and Golgi for post-translational modifications, and finally to the wall. The signal sequence proposed also involves transport of extensins and extensin modules in the same plant family (Solanaceae). Alternatively, one can use the signal sequence from tomato P1 extensin itself.
    TABLE 1
    GFP MUTANTs
    WAVELENGTH (nm)
    MUTANT Excitation Emitting
    mGFPX10; F99S, M153T, Excites at 395
    V163A
    mGFPX10-5 Excites at 489 Emits at 508
    GFPA2; I167T Excites at 471
    GFPB7; Y66H Excites at 382 Emits at 440
    (blue
    fluorescence)
    GFPX10-C7; F99S, M153T, Excites at 395 and 473
    V163A, I167T, S175G
    GFPX10-D3; F99S, M153T, Excites at 382 Emits at 440
    V163A, Y66H
  • In yet another alternative, the tomato arabinogalactan-protein (Le-AGP-1) signal sequence may be used. This sequence has previously been cloned [Li (1996) “Isolation and characterization of genes and complementary DNAs encoding a tomato arabiogalactan protein, PhD. Dissertation, Ohio University, Athens, Ohio] and encodes the protein sequence MDRKFVFLVSILCIVVASVTG (SEQ ID NO:215). This sequence has successfully been used by the inventors to target expression of the inventions's sequences to the extracellular medium of tobacco cell cultures and is being used to target (Ala-Pro)[0127] n-EGFP and (Thr-Pro)n-EGFP to the extracellular matrix of tobacco cell cultures.
  • Addition of GFP. The repetitive HRGP-modules can be expressed as GFP fusion products rather than GUS fusions, and can also be expressed as modules without GFP. Fusion with a green fluorescent protein reporter gene appropriately red-shifted for plant use, e.g. EGFP (an S65T variant recommended for plants by Clontech) or other suitable mutants (see Table 1 above) allows the detection of <700 GFP molecules at the cell surface. GFP requires aerobic conditions for oxidative formation of the fluorophore. It works well at the lower temperatures used for plant cell cultures and normally it does not adversely affect protein function although it may allow the regeneration of plants only when targeted to the ER. [0128]
  • Promoters. As noted above, it is not intended that the present invention be limited by the nature of the promoter(s) used in the expression constructs. The CaMV35S promoter is preferred, although it is not entirely constitutive and expression is “moderate”. In some embodiments, higher expression of the constructs is desired to enhance the yield of HRGP modules; in such cases a plasmid with “double” CaMV35S promoters is employed. [0129]
  • D. Selection Of Host Cells [0130]
  • A variety of host cells are contemplated (both eukaryotic and prokaryotic). It is not intended that the present invention be limited by the host cells used for expression of the synthetic genes of the present invention. Plant host cells are preferred, including but not limited to legumes (e.g. soy beans) and solanaceous plants (e.g. tobacco, tomato, etc.). Other cells contemplated to be within the scope of this invention are green algae [e.g., Chlamydomonas, Volvox, and duckweed (Lernna)]. [0131]
  • The present invention is not limited by the nature of the plant cells. All sources of plant tissue are contemplated. In one embodiment, the plant tissue which is selected as a target for transformation with vectors which are capable of expressing the invention's sequences are capable of regenerating a plant. The term “regeneration” as used herein, means growing a whole plant from a plant cell, a group of plant cells, a plant part or a plant piece (e.g., from seed, a protoplast, callus, protocorm-like body, or tissue part). Such tissues include but are not limited to seeds. Seeds of flowering plants consist of an embryo, a seed coat, and stored food. When fully formed, the embryo consists basically of a hypocotyl-root axis bearing either one or two cotyledons and an apical meristem at the shoot apex and at the root apex. The cotyledons of most dicotyledons are fleshy and contain the stored food of the seed. In other dicotyledons and most monocotyledonss, food is stored in the endosperm and the cotyledons function to absorb the simpler compounds resulting from the digestion of the food. [0132]
  • Species from the following examples of genera of plants may be regenerated from transformed protoplasts: Fragaria, Lotus, Medicago, Onobrychis, Trifolium, Trigonella, Vigna, Citrus, Linum, Geranium, Manihot, Daucus, Arabidopsis, Brassica, Raphanus, Sinapis, Atropa, Capsicum, Hyoscyamus, Lycopersicon, Nicotiana, Solanum, Petunia, Digitalis, Majorana, Ciohorium, Helianthus, Lactuca, Bromus, Asparagus, Antirrhinum, Hererocallis, Nemesia, Pelargonium, Panicum, Penimsetum, Ranunculus, Senecio, Salpiglossis, Cucumis, Browaalia, Glycine, Lolium, Zea, Triticum, Sorghum, and Datura. [0133]
  • For regeneration of transgenic plants from transgenic protoplasts, a suspension of transformed protoplasts or a petri plate containing transformed explants is first provided. Callus tissue is formed and shoots may be induced from callus and subsequently rooted. Alternatively, somatic embryo formation can be induced in the callus tissue. These somatic embryos germinate as natural embryos to form plants. The culture media will generally contain various amino acids and plant hormones, such as auxin and cytokinins. It is also advantageous to add glutamic acid and proline to the medium, especially for such species as corn and alfalfa. Efficient regeneration will depend on the medium, on the genotype, and on the history of the culture. These three variables may be empirically controlled to result in reproducible regeneration. [0134]
  • Plants may also be regenerated from cultured cells or tissues. Dicotyledonous plants which have been shown capable of regeneration from transformed individual cells to obtain transgenic whole plants include, for example, apple ([0135] Malus pumila), blackberry (Rubus), Blackberry/raspberry hybrid (Rubus), red raspberry (Rubus), carrot (Daucus carota), cauliflower (Brassica oleracea), celery (Apium graveolens), cucumber (Cucumis sativus), eggplant (Solanum melongena), lettuce (Lactuca sativa), potato (Solanum tuberosum), rape (Brassica napus), wild soybean (Glycine canescens), strawberry (Fragaria x ananassa), tomato (Lycopersicon esculenturn), walnut (Juglans regia), melon (Cucumis melo), grape (Vitis vinifera), and mango (Mangifera indica). Monocotyledonous plants which have been shown capable of regeneration from transformed individual cells to obtain transgenic whole plants include, for example, rice (Oryza sativa), rye (Secale cereale), and maize.
  • In addition, regeneration of whole plants from cells (not necessarily transformed) has also been observed in: apricot ([0136] Prunus armeniaca), asparagus (Asparagus officinalis), banana (hybrid Musa), bean (Phaseolus vulgaris), cherry (hybrid Prunus), grape (Vitis vinifera), mango (Mangifera indica), melon (Cucumis melo), ochra (Abelmoschus esculentus), onion (hybrid Allium), orange (Citrus sinensis), papaya (Carrica papaya), peach (Prunus persica), plum (Prunus domestica), pear (Pyrus communis), pineapple (Ananas comosus), watermelon (Citrullus vulgaris), and wheat (Triticum aestivum).
  • The regenerated plants are transferred to standard soil conditions and cultivated in a conventional manner. After the expression vector is stably incorporated into regenerated transgenic plants, it can be transferred to other plants by vegetative propagation or by sexual crossing. For example, in vegetatively propagated crops, the mature transgenic plants are propagated by the taking of cuttings or by tissue culture techniques to produce multiple identical plants. In seed propagated crops, the mature transgenic plants are self crossed to produce a homozygous inbred plant which is capable of passing the transgene to its progeny by Mendelian inheritance. The inbred plant produces seed containing the nucleic acid sequence of interest. These seeds can be grown to produce plants that would produce the desired polypeptides. The inbred plants can also be used to develop new hybrids by crossing the inbred plant with another inbred plant to produce a hybrid. [0137]
  • It is not intended that the present invention be limited to only certain types of plants. Both monocotyledons and dicotyledons are contemplated. Monocotyledons include grasses, lilies, irises, orchids, cattails, palms, Zea mays (such as corn), rice barley, wheat and all grasses. Dicotyledons include almost all the familiar trees and shrubs (other than confers) and many of the herbs (non-woody plants). [0138]
  • Tomato cultures are the ideal recipients for repetitive HRGP modules to be hydroxylated and glycosylated: Tomato is readily transformed. The cultures produce cell surface HRGPs in high yields easily eluted from the cell surface of intact cells and they possess the required posttranslational enzymes unique to plants—HRGP prolyl hydroxylases, hydroxyproline O-glycosyltransferases and other specific glycosyltransferases for building complex polysaccharide side chains. Furthermore, tomato genetics, and tomato leaf disc transformation/plantlet regeneration are well worked out. [0139]
  • Other preferred recipients for the invention's sequences include tobacco cultured cells and plants. [0140]
  • E. Introduction of Nucleic Acid [0141]
  • Expression constructs of the present invention may be introduced into host cells (e.g. plant cells) using methods known in the art. In one embodiment, the expression constructs are introduced into plant cells by particle mediated gene transfer. Particle mediated gene transfer methods are known in the art, are commercially available, and include, but are not limited to, the gas driven gene delivery instrument descried in McCabe, U.S. Pat. No. 5,584,807, the entire contents of which are herein incorporated by reference. This method involves coating the nucleic acid sequence of interest onto heavy metal particles, and accelerating the coated particles under the pressure of compressed gas for delivery to the target tissue. [0142]
  • Other particle bombardment methods are also available for the introduction of heterologous nucleic acid sequences into plant cells. Generally, these methods involve depositing the nucleic acid sequence of interest upon the surface of small, dense particles of a material such as gold, platinum, or tungsten. The coated particles are themselves then coated onto either a rigid surface, such as a metal plate, or onto a carrier sheet made of a fragile material such as mylar. The coated sheet is then accelerated toward the target biological tissue. The use of the flat sheet generates a uniform spread of accelerated particles which maximizes the number of cells receiving particles under uniform conditions, resulting in the introduction of the nucleic acid sample into the target tissue. [0143]
  • Alternatively, an expression construct may be inserted into the genome of plant cells by infecting them with a bacterium, including but not limited to an Agrobacterium strain previously transformed with the nucleic acid sequence of interest. Generally, disarmed Agrobacterium cells are transformed with recombinant Ti plasmids of [0144] Agrobacterium tumefaciens or Ri plasmids of Agrobacterium rhizogenes (such as those described in U.S. Pat. No. 4,940,838, the entire contents of which are herein incorporated by reference) which are constructed to contain the nucleic acid sequence of interest using methods well known in the art (Sambrook, J. et al., (1989) supra),. The nucleic acid sequence of interest is then stably integrated into the plant genome by infection with the transformed Agrobacterium strain. For example, heterologous nucleic acid sequences have been introduced into plant tissues using the natural DNA transfer system of Agrobacterium tumefaciens and Agrobacterium rhizogenes bacteria (for review, see Klee et al. (1987) Ann. Rev. Plant Phys. 38:467-486).
  • One of skill in the art knows that the efficiency of transformation by Agrobacterium may be enhanced by using a number of methods known in the art. For example, the inclusion of a natural wound response molecule such as acetosyringone (AS) to the Agrobacterium culture has been shown to enhance transformation efficiency with [0145] Agrobacterium tumefaciens [Shahla et al. (1987) Plant Molec. Biol. 8:291-298]. Alternatively, transformation efficiency may be enhanced by wounding the target tissue to be transformed. Wounding of plant tissue may be achieved, for example, by punching, maceration, bombardment with microprojectiles, etc. [see, e.g., Bidney et al. (1992) Plant Molec. Biol. 18:301-313].
  • It may be desirable to target the nucleic acid sequence of interest to a particular locus on the plant genome. Site-directed integration of the nucleic acid sequence of interest into the plant cell genome may be achieved by, for example, homologous recombination using Agrobacterium-derived sequences. Generally, plant cells are incubated with a strain of Agrobacterium which contains a targeting vector in which sequences that are homologous to a DNA sequence inside the target locus are flanked by Agrobacterium transfer-DNA (T-DNA) sequences, as previously described (Offringa et al., (1996), U.S. Pat. No. 5,501,967, the entire contents of which are herein incorporated by reference). One of skill in the art knows that homologous recombination may be achieved using targeting vectors which contain sequences that are homologous to any part of the targeted plant gene, whether belonging to the regulatory elements of the gene, or the coding regions of the gene. Homologous recombination may be achieved at any region of a plant gene so long as the nucleic acid sequence of regions flanking the site to be targeted is known. [0146]
  • Where homologous recombination is desired, the targeting vector used may be of the replacement- or insertion-type (Offringa et al. (1996), supra). Replacement-type vectors generally contain two regions which are homologous with the targeted genomic sequence and which flank a heterologous nucleic acid sequence, e.g., a selectable marker gene sequence. Replacement type vectors result in the insertion of the selectable marker gene which thereby disrupts the targeted gene. Insertion-type vectors contain a single region of homology with the targeted gene and result in the insertion of the entire targeting vector into the targeted gene. [0147]
  • Other methods are also available for the introduction of expression constructs into plant tissue, e.g., electroinjection (Nan et al. (1995) In “Biotechnology in Agriculture and Forestry,” Ed. Y. P. S. Bajaj, Springer-Verlag Berlin Heidelberg, Vol 34:145-155; Griesbach (1992) HortScience 27:620); fusion with liposomes, lysosomes, cells, minicells or other fusible lipid-surfaced bodies (Fraley et al. (1982) [0148] Proc. Natl. Acad. Sci. USA 79:1859-1863; polyethylene glycol (Krens et al. (1982) Nature 296:72-74); chemicals that increase free DNA uptake; transformation using virus, and the like.
  • In one embodiment, the present invention contemplates introducing nucleic acid via the leaf disc transformation method. Horsch et al. [0149] Science 227:1229-1231 (1985). Briefly, disks are punched from the surface of sterilized leaves and submerged with gentle shaking into a culture of A. tumefaciens that had been grown overnight in Luria Broth (LB) at 28° C. The disks are then blotted dry and placed upside-down onto nurse culture plates to induce the regeneration of shoots. Following 2-3 days, the leaf disks are transferred to petri plates containing the same media without feeder cells or filter papers, but in the presence of carbenicillin (500 μg/ml) and kanamycin (300 μg/ml) to select for antibiotic resistance. 2-4 weeks later, the shoots that developed are removed from calli and placed into root-inducing media with the appropriate antibiotic. These shoots were then further transplanted into soil following the presence of root formation.
  • Cells and tissues which are transformed with a heterologous nucleic acid sequence of interest are readily detected using methods known in the art including, but not limited to, restriction mapping of the genomic DNA, PCR-analysis, DNA-DNA hybridization, DNA-RNA hybridization, DNA sequence analysis and the like. [0150]
  • Additionally, selection of transformed cells may be accomplished using a selection marker gene. It is preferred, though not necessary, that a selection marker gene be used to select transformed plant cells. A selection marker gene may confer positive or negative selection. [0151]
  • A positive selection marker gene may be used in constructs for random integration and site-directed integration. Positive selection marker genes include antibiotic resistance genes, and herbicide resistance genes and the like. In one embodiment, the positive selection marker gene is the NPTII gene which confers resistance to geneticin (G418) or kanamycin. In another embodiment the positive selection marker gene is the HPT gene which confers resistance to hygromycin. The choice of the positive selection marker gene is not critical to the invention as long as it encodes a functional polypeptide product. Positive selection genes known in the art include, but are not limited to, the ALS gene (chlorsulphuron resistance), and the DHFR-gene (methothrexate resistance). [0152]
  • A negative selection marker gene may also be included in the constructs. The use of one or more negative selection marker genes in combination with a positive selection marker gene is preferred in constructs used for homologous recombination. Negative selection marker genes are generally placed outside the regions involved in the homologous recombination event. The negative selection marker gene serves to provide a disadvantage (preferably lethality) to cells that have integrated these genes into their genome in an expressible manner. Cells in which the targeting vectors for homologous recombination are randomly integrated in the genome will be harmed or killed due to the presence of the negative selection marker gene. Where a positive selection marker gene is included in the construct, only those cells having the positive selection marker gene integrated in their genome will survive. [0153]
  • The choice of the negative selection marker gene is not critical to the invention as long as it encodes a functional polypeptide in the transformed plant cell. The negative selection gene may for instance be chosen from the aux-2 gene from the Ti-plasmid of Agrobacterium, the tk-gene from SV40, cytochrome P450 from [0154] Streptomyces griseolus, the Adh-gene from Maize or Arabidopsis, etc. Any gene encoding an enzyme capable of converting a substance which is otherwise harmless to plant cells into a substance which is harmful to plant cells may be used.
  • It is not intended that the host cells which are transformed with the invention's sequences or with expression constructs containing these sequences be limited to cells which display any particular phenotype. All that is necessary is that the transformed cells express a polypeptide encoded by the invention's sequences. Such host cells may be used to purify the expressed polypeptides for subsequent use, (e.g., in the food or cosmetic industry, for isolating HRGP-binding molecules, and for making antibodies). [0155]
  • Nor is the invention intended to be limited to transformed cells which express the invention's nucleotide sequences at a particular level, a particular time during the cell's life cycle, or a particular part of a transformed plant. Rather, the invention expressly contemplates cells which express relatively low and relatively high levels of expression of the desired proteins, regardless of whether such expression occurs in some or all parts of the transformed plant, and whether it changes or is unchanged in level during cell growth or plant development. [0156]
  • F. Preferred Consensus Sequences and Portions Thereof [0157]
  • The present invention provides GAGP sequences, and in particular the consensus sequence of SEQ ID NO:134. Gum arabic glycoprotein (GAGP) is a large molecular weight, hydroxyproline-rich arabinogalactan-protein (AGP) component of gum arabic. GAGP has a simple, highly biased amino acid composition indicating a repetitive polypeptide backbone. It has been suggested that the repetitive polypeptide backbone contains repetitive small (˜10 amino acid residues) repetitive peptide motifs each with three Hyp-arabinoside attachment sites and a single Hyp-arabinogalactan polysaccharide attachment site [Qi et al. (1991) supra]. The inventors have tested this hypothesis by generating and sequencing peptides of GAGP, and determining the glycosyl and linkage analysis of an isolated Hyp-polysaccharide. Surprisingly, the inventors discovered a 19-amino acid consensus sequence, which is roughly twice the size of that previously postulated by Qi et al. (1991). In addition to the difference in size of the repeating motif, the inventors also surprisingly discovered that the peptides in the invention's 19-amino acid consensus sequence lacked some of the amino acids present in Qi et al.'s the empirical formula [i.e., Hyp[0158] 4 Ser2 Thr Pro Gly Leu His (SEQ ID NO:135)] of the repeat motif suggested by Qi et. al.[Qi et al. (1991) supra], most notably His (Table 6, peptide PH3G2.) The inventors also surprisingly discovered that the invention's 19-amino acid GAGP consensus motif contains approximately nine Hyp residues, with only a single polysaccharide attachment site. Judging from the Hyp-glycoside profile of GAGP, the invention's consensus motif contained six Hyp-arabinosides rather than Qi et al.'s three, and two Hyp-polysaccharides rather than Qi et al's one.
  • The invention provides the consensus sequence (SEQ ID NO:136): A-Hyp-B-C-D-E-F-Hyp-G-H-I-Hyp-J-Hyp-Hyp-K-L-Pro-M, wherein A is selected from Ser, Thr, and Ala; B is selected from Hyp, Pro, Leu, and Ile; C is selected from Pro and Hyp; D is selected from Hyp, Pro, Ser, Thr, and Ala; E is selected from Leu and Ile; F is selected from Ser, Thr, and Ala; G is selected from Ser, Leu, Hyp, Thr, Ala, and Ile; H is selected from Hyp, Pro, Leu, and Ile; I is selected from Thr, Ala, and Ser; J is selected from Thr, Ser, and Ala; K is selected from Thr, Leu, Hyp, Ser, Ala, and Ile; L is selected from Gly, Leu, Ala, and Ile; and M is selected from His, and Pro (Example 18, e.g., Tables 3 and 6). Also included within the scope of the invention are portions of the consensus sequence, having from 4 to 19 contiguous amino acid residues of the consensus sequence. [0159]
  • In a preferred embodiment, the invention's GAGP consensus sequence contains 19 amino acids, of which approximately nine are Hyp residues. Judging from the Hyp-glycoside profile of GAGP (Table 7) about one in every five Hyp residues is polysaccharide-substituted. Thus, in one preferred embodiment, there are approximately two Hyp-polysaccharide sites in the consensus sequence and portions thereof. Without limiting the invention to any particular mechanism, the inventors predicted arabinosylation of contiguous Hyp residues and arabinogalactan-polysaccharide addition to clustered non-contiguous Hyp residues, such as the X-Hyp-X-Hyp modules common in AGPs [Nothnagel (1997) International Review of Cytology 174:195]. Also without limiting the invention to a particular theory, the inventors are of the view that the inventions's 19-amino acid consensus motif preferably contains approximately two polysaccharide attachment sites in the clustered non-contiguous Hyp motif [F-Hyp-G-H-I-Hyp (SEQ ID NO:137), where F is selected from Ser, Thr, and Ala; G is selected from Ser, Leu, Hyp, Thr, Ala, and Ile; H is selected from Hyp, Pro, Leu, and Ile; and I is selected from Thr, Ala, and Ser] which is exemplified by Ser-Hyp-Ser-Hyp-Thr-Hyp (SEQ ID NO:138)], and which is flanked by arabinosylated contiguous Hyp residues such as A-Hyp-B-C-D-E (SEQ ID NO:139) where A is selected from Ser, Thr, and Ala; B is selected from Hyp, Leu, and Ile; C is selected from Pro and Hyp; D is selected from Hyp, Ser, Thr, and Ala; E is selected from Leu and Ile; and more preferably Ser-Hyp-Hyp-Hyp-(Hyp/Thr/Ser)-Leu (SEQ ID NO:140), and such as J-Hyp-Hyp-K-L-Pro-M (SEQ ID NO:141) where J is selected from Thr, Ser, and Ala; K is selected from Thr, Leu, Hyp, Ser, Ala, and Ile; L is selected from Gly, Leu, Ala, and Ile; and M is selected from His, and Pro; and more preferably Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-(Hyp/Leu)-Gly-Pro-His (SEQ ID NOs:142) (FIG. 9). The following Table 2 shows 45 illustrative sequences which have from 4 to 19 amino acids and which are encompassed by the inventions' SEQ ID NO:136. [0160]
    TABLE 2
    Exemplary Sequences*
    Motif
    Number Motif Sequence
    1 Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His
    (SEQ ID NO: 143)
    2 Ser-Hyp-Hyp-Hyp-Thr-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His
    (SEQ ID NO: 144)
    3 Ser-Hyp-Hyp-Hyp-Ser-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Thr-Gly-Pro-His
    (SEQ ID NO: 145)
    4 Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-Hyp
    (SEQ ID NO: 146)
    5 Ser-Hyp-Leu-Pro-Thr-Leu-Ser-Hyp-Leu-Pro-Thr-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His
    (SEQ ID NO: 147)
    6 Ser-Hyp-Leu-Pro-Thr-Leu-Ser-Hyp-Leu-Pro-Ala-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His
    (SEQ ID NO: 148)
    7 Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Leu-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-Hyp
    (SEQ ID NO: 149)
    8 Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His
    (SEQ ID NO: 150)
    9 Ser-Hyp-Hyp-Hyp-Thr-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His
    (SEQ ID NO: 151)
    10 Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Hyp-Ala-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His
    (SEQ ID NO: 152)
    11 Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Leu-Pro-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His
    (SEQ ID NO: 153)
    12 Ser-Hyp-Hyp-Hyp-Ser-Leu-Ser-Hyp-Leu-Pro-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His
    (SEQ ID NO: 154)
    13 Ser-Hyp-Hyp-Hyp-Thr-Leu-Ser-Hyp-Hyp-Leu-Thr-Hyp-Thr-Hyp-Hyp-Leu-Leu-Pro-His
    (SEQ ID NO: 155)
    14 Hyp-Hyp-Thr-Leu-Ser-Hyp-Hyp-Leu-Thr-Hyp-Thr-Hyp-Hyp-Leu-Leu-Pro
    (SEQ ID NO: 156)
    15 Ser-Hyp-Hyp-Hyp-Ser-Leu-Ser-Hyp-Leu-Pro-Thr-Hyp-Thr-Hyp-Hyp-Leu
    (SEQ ID NO: 157)
    16 Hyp-Hyp-Leu-Ser-Hyp-Leu-Pro-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His
    (SEQ ID NO: 158)
    17 Ser-Hyp-Hyp-Hyp-Thr-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp (SEQ ID NO: 159)
    18 Leu-Ser-Hyp-Ser-Leu-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-Hyp (SEQ ID NO: 160)
    19 Hyp-Thr-Leu-Ser-Hyp-Leu-Pro-Ala-Hyp-Thr-Hyp-Hyp-Hyp-Gly (SEQ ID NO: 161)
    20 Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp (SEQ ID NO: 162)
    21 Ser-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Thr (SEQ ID NO: 163)
    22 Hyp-Hyp-Thr-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp (SEQ ID NO: 164)
    23 Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His (SEQ ID NO: 165)
    24 Hyp-Hyp-Thr-Leu-Ser-Hyp-Hyp-Leu-Thr-Hyp (SEQ ID NO: 166)
    25 Ser-Hyp-Hyp-Hyp-Ser-Leu-Ser-Hyp-Leu-Pro (SEQ ID NO: 167)
    26 Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His (SEQ ID NO: 168)
    27 Hyp-Leu-Ser-Hyp-Ser-Hyp-Ala-Hyp (SEQ ID NO: 169)
    28 Hyp-Hyp-Hyp-Thr-Leu-Ser-Hyp-Ser (SEQ ID NO: 170)
    29 Thr-Hyp-Hyp-Hyp-Gly-Pro (SEQ ID NO: 171)
    30 Hyp-Hyp-Leu-Ser-Hyp-Ser (SEQ ID NO: 172)
    31 Ser-Hyp-Leu-Pro-Ala-Hyp (SEQ ID NO: 173)
    32 Leu-Pro-Thr-Leu-Ser-Hyp (SEQ ID NO: 174)
    33 Ser-Hyp-Ser-Hyp (SEQ ID NO: 175)
    34 Ser-Hyp-Thr-Hyp (SEQ ID NO: 176)
    35 Thr-Hyp-Thr-Hyp (SEQ ID NO: 177)
    36 Thr-Hyp-Hyp-Hyp (SEQ ID NO: 178)
    37 Ser-Hyp-Pro-Pro-Pro-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His
    (SEQ ID NO: 217)
    38 Ser-Hyp-Hyp-Pro-Pro-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His
    (SEQ ID NO: 218)
    39 Ser-Hyp-Pro-Hyp-Pro-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His
    (SEQ ID NO: 219)
    40 Ser-Hyp-Pro-Pro-Hyp-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His
    (SEQ ID NO: 220)
    41 Ser-Hyp-Hyp-Hyp-Pro-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His
    (SEQ ID NO: 221)
    42 Ser-Hyp-Hyp-Pro-Hyp-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His
    (SEQ ID NO: 222)
    43 Ser-Hyp-Pro-Hyp-Hyp-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His
    (SEQ ID NO: 223)
    44 Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Pro-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His
    (SEQ ID NO: 224)
    45 Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Leu-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His
    (SEQ ID NO: 225)
  • In one preferred embodiment, the consensus sequence and portions thereof is selected from Ser-Hyp-Hyp-Hyp-A-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-B-Gly-Pro-His (SEQ ID NO:179), where A is selected from Hyp, Thr and Ser, and B is selected from Hyp and Leu (Table 6). Remarkably, fifteen amino acid residues of this sequence are “quasi-palindromic,” i.e., the side chain sequence is almost the same whether read from the N-terminus or C-terminus. Without limiting the invention to a particular theory or mechanism, it is the inventors' consideration that such peptide symmetry, which occurs frequently in extensins and AGPs, may enhance molecular packing, recognition, and self-assembly. Indeed, palindromic symmetry rigidified by contiguous Hyp motifs in the motifs: Ser-Hyp-Hyp-Hyp-(Hyp) and Thr-Hyp-Hyp-(Hyp), may impart self-ordering properties in GAGP and other HRGPs. Thus, it is the inventor's consideration that GAGP properties are related to the polysaccharide substituents. In particular, the repeating glycopeptide symmetry of two central polysaccharides flanked by Hyp arabinosides may enhance gum arabic's remarkable properties which include: an anomalously low viscosity [Churms et al. (1983) Carbohydrate Research 123:267], the ability to act as a flavor emulsifier and stabilizer, and GAGP's biological role as a component of a plastic sealant. [0161]
  • In one embodiment, the invention's sequences and portions thereof may be used as repeats. The repeats preferably range from 1 to 500, more preferably from 1 to 100 and most preferably from 1 to 10. Data disclosed herein demonstrates the production of 8, 16, 20, 32, and 64 repeats of gum arabic motifs (Example 19). [0162]
  • The repeats may be contiguous or noncontiguous. Contiguous repeats are those without intervening amino acids, or amino acid analogues, placed between the repeating sequences. The repeats may contain two or more sequences which are described by the consensus sequence (SEQ ID NO:136) and portions thereof. The two or more sequences may be the same or different. Examples of a single repeat in which the two 19-amino acid sequences are different are those of motif 1-motif 2 [motif 1 (SEQ ID NO: 143)=Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His; motif 2 (SEQ ID NO: 144)=Ser-Hyp-Hyp-Hyp-Thr-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His], described below in Example 19. Another example of a single repeat in which the two 19-amino acid sequences are different are those of motif 7-motif 13 of Table 2, having the sequence (SEQ ID NO:180): Gly-Pro-Hyp-[0163] Ser-Hyp-Hyp-Hyp-Thr-Leu-Ser-Hyp-Hyp-Leu-Thr-Hyp-Thr-Hyp-Hyp-Leu-Leu-Pro-His-Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Leu-Thr-Hyp-Thr-Hyp-Hyp-Leu, in which motif 13 is underlined, and is flanked by motif 7. Yet another example of a single repeat in which the two 19-amino acid sequences are different are those of Table 2's motif 10motif 12 having the sequence (SEQ ID NO:181): Gly-Pro-His-Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Hyp-Ala-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His-Ser-Hyp-Hyp-Hyp-Ser-Leu-Ser-Hyp-Leu-Pro-Thr-Hyp-Thr-Hyp-Hyp-Leu, in which motif 10 is underlined and is flanked by motif 12. Examples of a single repeat in which the two 19-amino acid sequences are the same are those of (motif 1-motif 1), (motif 2-motif 2), (motif 3-motif 3), etc.
  • In an alternative embodiment, the invention's sequences and portions thereof are used as noncontiguous repeats, i.e., with from 1 to 1000, more preferably from 1 to 100, and even more preferably from 1 to 10, intervening amino acids, or amino acid analogues, placed between the repeating sequences. The term “amino acid analog” refers to an amino acid is a chemically modified amino acid. Illustrative of such modifications would be replacement of hydrogen by an alkyl, acyl, or amino group, or formation of covalent adducts with biotin or fluorescent groups. Amino acids include biological amino acids as well as non-biological amino acids. The term “biological amino acid” refers to any one of the known 20 coded amino acids that a cell is capable of introducing into a polypeptide translated from an MRNA. The term “non-biological amino acid” refers to an amino acid that is not a biological amino acid. Non-biological amino acids are useful, for example, because of their stereochemistry or their chemical properties. The non-biological amino acid norleucine, for example, has a side chain similar in shape to that of methionine. However, because it lacks a side chain sulfur atom, norleucine is less susceptible to oxidation than methionine. Other examples of non-biological amino acids include aminobutyric acids, norvaline and allo-isoleucine, that contain hydrophobic side chains with different steric properties as compared to biological amino acids. The term “derivative” when in reference to an amino acid sequence means that the amino acid sequence contains at least one amino acid analog. [0164]
  • The production of repeating sequences may be achieved using methods known in the art [for example, Lewis et al. (1996) Protein Expression & Purification 7:400-406] and the methods described herein (Example 19). [0165]
  • In a preferred embodiment, the consensus sequence and portions thereof contains at least one noncontiguous hydroxyproline sequence and/or at least one contiguous hydroxyproline sequence. In a more preferred embodiment, the consensus sequence and portions thereof contains at least one noncontiguous hydroxyproline sequence and at least one contiguous hydroxyproline sequence. [0166]
  • The term “noncontiguous hydroxyproline sequence” refers to a sequence selected from (Xaa-Hyp)[0167] x and Xaa-Hyp-Xaa-Xaa-Hyp-Xaa, wherein Xaa is any amino acid other than hydroxyproline, and wherein x is from 2 to 1000, more preferably from 2 to 100, and most preferably from 2 to 50. In a preferred embodiment, the noncontiguous hydroxyproline sequence is Xaa-Hyp-Xaa-Hyp (SEQ ID NO:9), wherein Xaa is selected from Ser, Thr, and Ala.
  • The term “contiguous hydroxyproline sequence” refers to a sequence selected from Xaa-Hyp-Hyp[0168] n (SEQ ID NO:209) and Xaa-Pro-Hypn (SEQ ID NO:210), wherein n is from 1 to 100, and wherein Xaa is any amino acid other than hydroxyproline. In a preferred embodiment, the contiguous hydroxyproline sequence is selected from Ser-Hyp2 (SEQ ID NO:211), Ser-Hyp3 (SEQ ID NO:212), Ser-Hyp4 (SEQ D NO:3), Thr-Hyp2 (SEQ ID NO:213), and Thr-Hyp3 (SEQ ID NO:214).
  • Data presented herein demonstrates that noncontiguous hydroxyproline sequences [e.g., (Xaa-Hyp)[0169] x where x is preferably at least 2] are functional glycomodules which direct the exclusive addition of arabinogalactan polysaccharide to Hyp, while contiguous hydroxyproline sequences are functional glycomodules which direct arabinosylation (Example 23). The term “functional” when made in reference to a noncontiguous hydroxyproline sequence or to sequences containing a noncontiguous hydroxyproline sequence means that the sequence directs exclusive addition of arabinogalactan polysaccharide to Hyp residues in that sequence. The addition of arabinogalactan polysaccharide to Hyp residues may be determined using methods described herein (Example 23). The term “functional” when made in reference to a contiguous hydroxyproline sequence or to sequences containing a contiguous hydroxyproline sequence a means that the sequence directs arabinosylation of Hyp residues in that sequence as determined by methods disclosed herein (Example 23).
  • The invention contemplates sequences that are complementary, and partially complementary to SEQ ID NO:136 and portions thereof, such as those which hybridize under low stringency conditions and high stringency conditions to these sequences. [0170]
  • The sequences of the invention may be used to isolate hydroxyproline rich glycoprotein-binding molecules and to make polyclonal and monoclonal antibodies as described supra. In addition, the invention's sequences may be used as emulsifying agents and/or to stabilize emulsions, both of which are properties which are highly valued by the food industry for GAGP. The emulsifying and emulsion stabilizing activities of the invention's proteins, glycoproteins, and portions thereof may be determined using generic methods known in the art [Kevin & John (1978) J. Agric. Food Chem 26(3):716-723; James & Patel, “Development of a standard oil-in-water emulsification test for proteins,” Leatherhead Food RA Res. Rep. No. 631] which employ commercially available reagents. [0171]
  • For example, the following assay may be employed using orange oil (Sigma) following essentially the manufacturer's instructions. Freeze-dried glycoproteins are dissolved in 0.05 M phosphate buffer (pH 6.5) at a concentration of 0.5% (m/v). The aqueous solutions are combined with orange oil in a 60:40 (v/v) ratio. A 1 ml emulsion is prepared in a glass tube at 0° C. with a Sonic Dismembrator (Fisher Scientific) equipped with a Microtip probe. The amplitude value is set at 4 and mixing time is set to 1 min. For the determination of emulsifying ability (EA), the emulsion is diluted serially with a solution containing 0.1 M NaCl and 0.1% SDS to give a final dilution of {fraction (1/1500)}. The optical density of the diluted emulsion is then determined in a 1-cm pathlenght cuvette at a wavelength of 50 nm and defined as EA. The emulsion is stored vertically in a glass tube for 3 h at room temperature, then the optical density of 1:1500 dilution of the low phase of the stored sample is measured. Emulsifying stability (ES) is defined as the percentage optical density remaining after 2 hour of storage. BSA is used as a positive control. This assay has been used to determine the activity of sequences within the scope of the invention, as described in Example 24. [0172]
  • G. O-Glycosylation Codes [0173]
  • The invention further provides sequences which signal O-glycosylation. The O-glycosylation sequences are the noncontiguous hydroxyproline sequences (Xaa-Hyp)[0174] x (SEQ ID NO:182) and Xaa-Hyp-Xaa-Xaa-Hyp-Xaa (SEQ ID NO:183), wherein Xaa is any amino acid other than hydroxyproline, and wherein x is a number from I to 1000, more preferably from 2 to 100, and yet more preferably from 2 to 50. In a more preferred embodiment, the sequence is Xaa-Hyp-Xaa-Hyp (SEQ ID NO:9), wherein Xaa is selected from Ser, Thr, and Ala.
  • The inventors' discovery of these sequences was based on their hypothesis that clustered, non-contiguous Hyp residues are sites for arabinogalactan polysaccharide attachment. In particular, the inventors predicted that Hyp galactosylation of clustered non-contiguous Hyp residues, such as the Xaa-Hyp-Xaa-Hyp repeats of AGPs, results in the addition of a galactan core with sidechairs of arabinose and other sugars to form characteristic Hyp-arabinogalactan polysaccharides. Hitherto, these sites of arabinogalactan polysaccharide attachment have been poorly defined because AGPs resist proteases, and because degradation by partial alkaline hydrolysis yields arabinogalactan-glycopeptides that are difficult to purify. [0175]
  • The inventor's discovery of the O-glycosylation sequences relied on a new approach to HRGP glycosylation site mapping as disclosed herein. To test their hypothesis that non-contiguous Hyp residues are sites for arabinogalactan polysaccharide attachment, the inventors designed three synthetic genes: The first synthetic gene, dubbed Sig-(Ser-Pro)[0176] 32-EGFP, encoded a signal sequence (Sig) at the N-terminus followed by a repetitive Ser-Hyp motif [i.e., (Ser-Pro)32] which encoded only clustered non-contiguous Hyp residues, which the inventors predicted would code as polysaccharide addition sites. The (Ser-Pro)32 was followed by EGFP at the C-terminus (FIG. 11). The inventors predicted that polysaccharide addition to noncontiguous Hyp should yield an expression product containing Hyp-polysaccharide exclusively. The second synthetic gene, dubbed Sig-(GAGP)3-EGFP, encoded three repeats of a slightly modified 19-amno acid residue GAGP consensus sequence (FIG. 14) and was used by the inventors to determine whether it yielded an expression product that contains Hyp arabinosides as well as Hyp-polysaccharide. The third synthetic gene was a control construct (Sig-EGFP) that encoded only the signal sequence and EGFP. The expression product was a control to test whether or not any Hyp glycosylation could be attributed to EGFP modification that encode putative AGP glycomodules. Data presented herein shows that, when expressed and targeted for secretion, the two experimental sequence modules behaved as simple endogenous substrates for HRGP glycosyl transferases. The first construct expressing noncontiguous Hyp showed exclusive polysaccharide addition with polysaccharide O-linked to all Hyp residues. In contrast, the second construct containing noncontiguous Hyp and additional contiguous Hyp showed both polysaccharide and arabinooligosaccharide. From this data, the inventors arrived at the invention's O-glycosylation sequences.
  • The invention's sequences find use as substrates for O-Hyp arabinosyl- and galactosyltransferases. These substrates may be used to isolate and unambiguously identify these enzymes as well as to determine the enzymes' substrate preferences. [0177]
  • Yet another use for the inventions' sequences is in the identification of potential sites of oligoarabinoside addition in HRGPs, which may be inferred from their genomic sequences. Furthermore, these sequences would permit the transfer of useful products like exudate gum glycoproteins [Breton et al. (1998) [0178] J. Biochem. (Tokyo) 123, 1000-1009; Islam et al. (1997) Food Hydrocolloids 11, 493-505] such as GAGP from thorny desert scrub like Acacia to other desirable crop plants.
  • A further use for the invention's sequences is that they facilitate the de novo design of new HRGPs and their manipulation to enhance desirable properties. For example, glycoproteins which contain the O-glycosylation sequences of the invention may be used as emulsifying agents and/or to stabilize emulsions, as described supra as well as in Example 24. [0179]
    • EXPERIMENTAL
  • The following examples serve to illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof. [0180]
  • In the experimental disclosure which follows, the following abbreviations apply: g (gram); mg (milligrams); μg (microgram); M (molar); mM (milliMolar); μM (microMolar); nm (nanometers); L (liter); ml (milliliter); μl (microliters); ° C. (degrees Centigrade); m (meter); sec. (second); DNA (deoxyribonucleic acid); cDNA (complementary DNA); RNA (ribonucleic acid); mRNA (messenger ribonucleic acid); X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside); LB (Luria Broth), PAGE (polyacrylamide gel electrophoresis); NAA (α-naphtaleneacetic acid); BAP (6-benzyl aminopurine); Tris (tris(hydroxymethyl)-aminomethane); PBS (phosphate buffered saline); 2× SSC (0.3 M NaCl, 0.03 M Na[0181] 3citrate, pH 7.0); Agri-Bio Inc. (North Miami, Fla.); Analytical Scientific Instruments (Alameda, Calif.); BioRad (Richmond, Calif.); Clontech (Palo Alto Calif.); Delmonte Fresh Produce (Kunia, Hi.); Difco Laboratories (Detroit, Mich.); Dole Fresh Fruit (Wahiawa, Hi.); Dynatech Laboratory Inc. (Chantilly Va.); Gibco BRL (Gaithersburg, Md.); Gold Bio Technology, Inc. (St. Louis, Mo.); GTE Corp. (Danvers, Mass.); MSI Corp. (Micron Separations, Inc., Westboro, Mass.); Operon (Operon Technolies, Alameda, Calif.); Pioneer Hi-Bred International, Inc. (Johnston, Iowa); 5 Prime 3 Prime (Boulder, Colo.); Sigma (St. Louis, Mo.); Promega (Promega Corp., Madison, Wis.); Stratagene (Stratagene Cloning Systems, La Jolla, Calif.); USB (U.S. Biochemical, Cleveland, Ohio).
    • EXAMPLE 1 Determination of the Peptide Sequence of Acacia Gum Arabic Glycoproteins
  • In this example, GAGP (SEQ ID NO:15) was isolated and (by using chymotrypsin) the deglycosylated polypeptide backbone was prepared. Although GAGP does not contain the usual chymotryptic cleavage sites, it does contain leucyl and histidyl residues which are occasionally cleaved. Chymotrypsin cleaved sufficient of these “occasionally cleaved” sites to produce a peptide map of closely related peptides. [0182]
  • Purification and Deglycosylation of GAGP (SEQ ID NO:15). GAGP was isolated via preparative Superose-6 gel filtration. Anhydrous hydrogen fluoride deglycosylated it (20 mg powder/mL HF at 4° C., repeating the procedure twice to ensure complete deglycosylation), yielding dGAGP which gave a single symmetrical peak (data not shown) after re-chromatography on Superose-6. Further purification of dGAGP by reverse phase chromatography also gave a single major peak, showing a highly biased but constant amino acid composition in fractions sampled across the peak. These data indicated that dGAGP was a single polypeptide component sufficiently pure for sequence analysis. [0183]
  • Sequence Analysis. An incomplete pronase digest gave a large peptide PRP3 which yielded a partial sequence (Table 3) containing all the amino acids present in the suggested dGAGP repeat motif. In view of the limitations of pronase, for further peptide mapping and to obtain more definitive sequence information, dGAGP was digested with chymotrypsin, followed by a two-stage BPLC fractionation scheme. Initial separation of the chymotryptides on a PolySULFOETHYL A™ (designated PSA, PolyLC, Inc. Ellicott City, Md.) cation exchanger yielded three major fractions:. S1 and S2 increased with digestion time while S3 showed a concomitant decrease. Further chromatography on PRP-1 resolved PSA fractions S1 and S2 into several peptides. [0184]
    TABLE 3
    AMINO ACID SEQUENCES OF THE GUM ARABIC GLYCOPROTEIN POLYPEPTIDE BACKBONE
    Peptide Sequence
    S1P5 Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Leu-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-(Pro)
    (SEQ ID NO:16)
    S1P3 Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-(Pro)
    (SEQ ID NO:17)
    S3 Ser-Hyp-Hyp-Hyp-Thr-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Hyp-Gly-pro-His-Ser-Hyp-Hyp-
    Hyp-(Hyp)
    (SEQ ID NO:18)
    S1P2 Ser-Hyp-Hyp-Hyp-Ser-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Thr-Gly-Pro-His
    (SEQ ID NO:19)
    S2P1 Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His
    (SEQ ID NO:20)
    S2P2a Ser-Hyp-Ser-Hyp-Ala-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His
    (SEQ ID NO:21)
    S2P2b Ser-Hyp-Leu-Pro-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His
    (SEQ ID NO:22)
    S2P3a Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His
    (SEQ ID NO:23)
    S2P4 Ser-Hyp-Hyp-Leu-Thr-Hyp-Thr-Hyp-Hyp-Leu-Leu-Pro-His
    (SEQ ID NO:24)
    S1P4 Ser-Hyp-Leu-Pro-Thr-Leu-Ser--Hyp-Leu-Pro-Ala/Thr-Hyp-Thr-Hyp-Hyp -Hyp-Gly-Pro-His
    (SEQ ID NOS:25 and 26)
    Consensus: (SEQ ID NOS:27 and 28)
    Ser-Hyp-Hyp-Hyp-Thr/Hyp-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His
             ↑   ↑    ↑                 ↑   ↑   ↑                   ↑           ↑
          (Leu) (Pro) (Ser)          (Leu) (Leu) (Ala)             (Hyp)       (Pro)
                                           (Pro)
  • Edman degradation showed that these chymotryptides were closely related to each other, to the partial sequence of the large pronase peptide (Table 3), and to the major pronase peptide of GAGP isolated earlier by Delonnay (see above). Indeed, all can be related to a single 19-amino acid residue consensus sequence with minor variation in some positions (Table 3). These peptides also reflect the overall amino acid composition and are therefore evidence of a highly repetitive polypeptide backbone with minor variations in the repetitive motif; these include occasional substitution of Leu for Hyp and Ser. Remarkably, fifteen residues of the consensus sequence are “quasi-palindromic” i.e. the side chain sequence is almost the same whether read from the N-terminus or C-terminus. [0185]
    • EXAMPLE 2 Construction of Synthetic HRGP Gene Cassettes
  • Synthetic gene cassettes encoding contiguous and noncontiguous Hyp modules are constructed using partially overlapping sets consisting of oligonucleotide pairs, “internal repeat pairs” and “external 3′- and 5′-linker pairs” respectively, all with complementary “sticky” ends. The design strategy for the repetitive HRGP modules combines proven approaches described earlier for the production in [0186] E. coli of novel repetitive polypeptide polymers (McGrath et al. [1990] Biotechnol. Prog. 6:188), of a repetitious synthetic analog of the bioadhesive precursor protein of the mussel Mytilus edulis, of a repetitive spider silk protein (Lewis et al. [1996] Protein Express. Purif. 7:400), and of a highly repetitive elastin-like polymer in tobacco [Zhang, X., Urry, D. W., and Daniell, H. “Expression of an environmentally friendly synthetic protein-based polymer gene in transgenic tobacco plants,” Plant Cell Reports, 16: 174 (1996)].
  • The basic design strategy for synthetic HRGP gene cassettes is illustrated by the following illustrative constructs. [0187]
  • a) Ser-Hyp[0188] 4 (SEQ ID NO:3) Gene Cassette
  • A synthetic gene encoding the extensin-like Ser-Hyp[0189] 4 (SEQ ID NO:3) module is constructed using the following partially overlapping sets of oligonucleotide pairs.
  • 5′-Linker: [0190]
    Amino Acid:
        A   G   S   S   T   R   A   S   P   (P   P   P) (SEQ ID NO:29)
    5′-GCT GGA TCC TCA ACC CGG GCC TCA CCA (SEQ ID NO:30)
       CGA CCT AGG AGT TGG GCC CCG AGT GGT GGT GGT GGA-5′ (SEQ ID NO:31)
  • 3′ Linker (for pBI121-Sig-EGFP): [0191]
    Amino Acid:
        P   P   P   S   P   V   A   R   H   S   P   P (SEQ ID NO:32)
    5′-CCA CCA CCT TCA CCG GTC GCC CGG AAT TCA CCA CCC (SEQ ID NO:33)
       AGT GGC CAG CGG GCC TTA AGT GGT GGG-5′ (SEQ ID NO:34)
  • 3′ Linker (for pBI121-Sig): [0192]
    Amino Acid: 5′-CCA CCA CCT TAA TAG AGC TCC CCC (SEQ ID NO:35)
                   ATT ATC TCG AGG GGG-5′ (SEQ ID NO:36)
  • Internal Repeat [0193]
    Amino Acid:
        P   P   P   S   P   P   P   P   S   P
    5′-CCA CCA CCT TCA CCT CCA CCC CCA TCT CCA (SEQ ID NO:38)
                   AGT GGA GGT GGG GOT AGA GOT GOT GOT GGA-5′ (SEQ ID NO:39)
  • Conversion of the “internal” and 5′ & 3′ “external” gene cassettes to long duplex DNA is complished using the following steps: [0194]
  • 1. Heat each pair of complementary oligonucleotides to 90° and then anneal by cooling slowly to 60° thereby forming short duplex internal and external DNAs. [0195]
  • 2. Combine the 5′ external linker duplex with the internal repeat duplexes in an approximately 1:20 molar ratio and anneal by further cooling to yield long duplex DNA capped by the 5′ linker. The 5′ linker is covalently joined to the internal repeat duplex by ligation using T4 DNA ligase. (Preferably up to 50, more preferably up to 30, repeats of the internal repeat duplex can be used). [0196]
  • 3. In molar excess, combine the 3′ external linker duplex with the above 5′ linker-internal repeat duplex, anneal and ligate as described above. [0197]
  • 4. Digest the 5′ linker-internal repeat-3′ linker duplex with BamHI (cuts within the 5′-linker) and EcoRI (cuts within the 3′-linker). [0198]
  • 5. Size fractionate the reaction products using Sephacryl gel permeation chromatography to select constructs greater than 90 bp. [0199]
  • 6. Insert the sized, digested synthetic gene cassette into a plasmid having a polylinker containing BamHI and EcoRI sites (e.g., pBluescript SK[0200] + or KS+ [Stratagene]).
  • 7. Transform [0201] E. coli cells (e.g., by electroporation or the use of competent cells) with the plasmid into which the synthetic gene construct has been ligated.
  • 8. Following [0202] E. coli transformation, the internal repeat oligonucleotides are used to screen and identify Ampicillin-resistant colonies carrying. the synthetic gene construct.
  • 9. The insert contained on the plasmids within the Ampicillin-resistant colonies are sequenced to confirm the fidelity of the synthetic gene construct. [0203]
  • b) GAGP (SEQ ID NO:15) Consensus Sequence Cassette [0204]
  • A synthetic gene cassette encoding the GAGP consensus sequence is generated as described above using the following 5′ linker, internal repeat and 3′ linker duplexes. [0205]
  • 5′-Linker [0206]
    Amino Acid:     A   A   G   S   S   T   R   A   (S   P   S) (SEQ ID NO:40)
    5′-GCT GCC GGA TCC TCA ACC CGG GCC-3′ (SEQ ID NO:41)
    3′-CGA CGG CCT AGG AGT TGG CCC CGG AGT CCC ACT-5′(SEQ ID NO:42)
  • 3′-Linker (for pBI121-Sig-EGFP) [0207]
    Amino Acid:     S   P   S   P   V   A   R   N   S   P   P (SEQ ID NO:43)
    5′-TCA CCC TCA CCG QTC GCC CGG AAT TCA CCA CCC-3′ (SEQ ID NO:44)
                   3′GGC CAG CGG GCC TTA AGT GGT GGG-5′ (SEQ ID NO:45)
  • Internal Repeat [0208]
    Amino Acid:
        S   P   S   P   T   P   T   P   P   P   G   P   H   S   P   P   P   T   L (SEQ ID NO:48)
    5′-TCA CCC TCA CCA ACT CCT ACC CCA CCA CCT GGT CCA CAC TCA CCA CCA CCA ACA TTG-3′ (SEQ ID NO:49)
                   3′-GGT TGA GGA TGG GGT GGT GGA CCA GGT GTG AGT GGT GGT GOT TGT AAC AGT 000 AGT-5′ (SEQ ID NO:50)
  • Conversion of the “internal” AGP-like motif and 5′ & 3′ “external” gene cassettes to long duplex DNA is accomplished using the steps described in section a) above. Up to fifty (50) repeats of the internal repeat duplex are desirable (more preferably up to thirty (30) repeats, and more preferably approximately twenty (20) repeats) (i.e., the wild-type protein contains 20 of these repeats). [0209]
  • Since the above GAGP internal repeat is a consensus sequence, it is also desirable to have repeats that comprise a repeat sequence that varies from the consensus sequence (see e.g. Table 3 above). In this regard, the variant sequences are likely to be glycosylated in a slightly different manner, which may confer different properties (e.g. more soluble etc.). Other constructs are shown for other illustrative modules in Table 4. [0210]
    • EXAMPLE 3 Isolation of Tomato P1 Extensin cDNA Clones
  • In order to obtain the tomato P1 extensin signal sequence (i.e., signal peptide), P1 extensin cDNA clones were isolated using oligonucleotides designed after the P1-unique protein sequence (SEQ ID NO:51): Val-Lys-Pro-Tyr-His-Pro-Thr-Hyp-Val-Tyr-Lys. When present at the N-terminus of a protein sequence, the P1 extensin signal sequence directs the nascent peptide chain to the ER. [0211]
    • EXAMPLE 4 Construction of One Embodiment Of An Expression Vector
  • pBI121 is an expression vector which permits the high level expression and secretion of inserted genes in plant cells (e.g., tomato, tobacco, members of the genus Solanaceac, members of the family Leguminoseae, non-graminaceous monocotyledons). pBI121 contains the 35S CaMV promoter, the tobacco ([0212] Nicotiana plumbaginifolia) extensin signal sequence, a EGFP gene, the termination/polyadenylation signal from the nopaline synthetase gene (NOS-ter), a kanamycin-resistance gene (nptII) and the right and left borders of T-DNA to permit transfer into plants by Agrobacterium-mediated transformation.
    TABLE 4
    ILLUSTRATIVE HRGP SYNTHETIC GENE MODULES
    1. MODULES FOR AGP-LIKE SEQUENCES
    a. The [SP]n Module
    [SP]n Internal Repeat Oligo's:
    (SEQ ID NO:52)
    5′-TCA CCC TCA CCA TCT CCT TCG CCA TCA CCC
    (SEQ ID NO:53)
                   GGT AGA GGA AGC GGT AGT GGG AGT GGG AGT-5′
    The [SP]n 3′ & 5′ External Linkers for both plasmids are the same as for the GAGP module.
    b. The [AP]n Module
    [AP]n Internal Repeat Oligo's:
    (SEQ ID NO:54)
    5′-GCT CCA GCA CCT GCC CCA GCC CCT GCA CCA -3′
    (SEQ ID NO:55)
                   GGA CGG GGT CGG GGA CGT GGT -5′
    [AP]n External Linker Oligo's for plasmid pBI121-Sig-EGFP
    (SEQ ID NO:5G)
    5′-Linker: 5′-GCT GCC GGA TCC TCA ACC CGG
    (SEQ ID NO:57)
    3′-CGA CGG CCT AGG AGT TGG GCC CGA GGT CGT-5′
    (SEQ ID NO:58)
    3′-Linker: 5′-GCT CCA GCA CCG GTC GCC CGG AAT TCA CCA CCC-3′
    (SEQ ID NO:59)
    3′-            GGC CAG CGG GCC TTA AGT GGT GGG-5′
    [AP]n External 3′ Linker Oligos for plasmid pBI121-Sig
    (SEQ ID NO:60)
    5′-GCT CCA GCA TAA TAG AGC TCC CCC
    (SEQ ID NO:61)
            ATT ATC TCG AGG GGG-5′
    c. The [TP]n Module
    [TP]n Internal Repeat Oligo's:
    (SEQ ID NO:62)
    5′-ACA CCA ACC CCT ACT CCC ACG CCA ACA CCT ACA CCC ACT CCA
    (SEQ ID NO:63)
                   GGA TGA GGG TGC GGT TGT GGA TCT GGG TGA GGT TGT GGT TGG-5′
    [TP]n External Linker Oligo's for pBI121-Sig-EGFP:
    (SEQ ID NO:64)
    5′Linker: 5′-GCT GCC GGA TCC TCA ACC CGG
    (SEQ ID NO:65)
    3′-CGA CGG CCT AGG AGT TGG GCC TGT GGT TGG-5′
    (SEQ ID NO:66)
    3′Linker: 5′-ACA CCA ACC CCG GTC GCC CGG AAT TCA CCA CCC-3′
    (SEQ ID NO:67)
                   GGC CAG CGG GCC TTA AGT GGT GGG-5′
    [TP]n External 3′ Linker Oligos for pBI121-Sig
    (SEQ ID NO:68) +TL,64
    5′-ACA CCA ACC TAA TAG AGC TCC CCC
    (SEQ ID NO:69)
                   ATT ATC TCG AGG GGG-5′
    2. MODULES FOR EXTENSIN-LIKE SEQUENCES
    a. The [SPP]n Module
    [SPP]n Internal Repeat Oligo's:
    (SEQ ID NO:70)
    5′-CCA CCA TCA CCA CCC TCT CCT CCA TCA CCC CCA TCC CCA CCA TCA
    (SEQ ID NO:71)
                   GGT GGG AGA GGA GGT AGT 000 GGT AGG GGT GGT AGT GGT GGT AGT-5′
    [SPP]n External Linkers for pBE121-Sig-EGFP:
    (SEQ ID NO:72)
    5′Linker: 5′-GCT GCC GGA TCC TCA ACC CGG GCC
    (SEQ ID NO:73)
    3′-CGA CGG CCT AGG AGT TGG GCC CGG GGT GGT AGT-5′
    (SEQ ID NO:74)
    3′Linker: 5′-CCACCA TCA CCG GTC GCC CGG AAT TCA CCA CCC-3′
    (SEQ ID NO:75)
                   GGC CAG CGG GCC TTA AGT GGT GGG-5′
    [SPP]n External 3′ Linker for pBE121-Sig:
    (SEQ ID NO:76)
    5′-CCA CCA TCA TAA TAG AGC TCC CCC
    (SEQ ID NO:77)
                   ATT ATC TCG AGG 000-5′
    b. The [SPPP]n, Module
    [SPPP]n Internal Repeat Oligo's:
    (SEQ ID NO:78)
    5′-CCA CCA CCT TCA CCA CCT CCA TCT CCC CCA CCT TCC CCT CCA CCA TCA
    (SEQ ID NO:79)
                   AGT GGT GGA GGT AGA GGG GGT GGA AGG GGA GGT GGT AGT GGT GGT GGA-5′
    [SPPP]n, External Linker Oligo's for pBI121-Sig-EGFP:
    (SEQ ID NO:80)
    5′-Linker: 5′-GCT GGA TCC TCA ACC CGG GCC TCA
    (SEQ ID NO:81)
    3′-CGA CCT AGG AGT TGG GCC CGG AGT GGT GGT GGA-5′
    (SEQ ID NO:82)
    3′-Linker: 5′-CCA CCA CCT TCA CCG GTC GCC CGG AAT TCA CCA CCC-3′
    (SEQ ID NO:83)
                   AGT GGC CAG CGG GGC TTA AGT GGT GGG-5′
    [SPPP]4 External 3′Linker Oligos for pBI121-Sig:
    (SEQ ID NO:84)
    5′-CCA CCA CCT TAA TAG AGC TCC CCC
    (SEQ ID NO:85)
                   ATT ATC TCG AGG GGG-5′
    d. The P3-Type Extensin Palindromic Module:
    P3-Type Extensin Palindromic Internal Repeat Oligo's:
    (SEQ ID NQ:86)
    5′-CCA CCA CCT TCA CCC TCT CCA CCT CCA CCA TCT CCG TCA CCA
    (SEQ ID NO:87)
                   AGT GGG AGA GGT GGA GGT GGT AGA GGC AGT GGT GGT GGT GGA-5′
    P3-Type Extensin Palindromic External Linker Oligo's: Use the [SPPP]n linkers (SEE ABOVE)
    e. The Potato Lectin HRGP Palindromic Module:
    Potato Lectin ERGP Palindromic External Linker Oligo's:
    (SEQ ID NO:88)
    5′-CCA CCA CCT TCA CCC CCA TCT CCA CCT CCA CCA TCT CCA CCG TCA CCA
    (SEQ ID NO:89)
                   AGT GGG GGT AGA GGT GGA GGT GGT AGA GGT GGC AGT GGT GGT GGT GGA-5′
    Potato Lectin HRGP Palindromic External Linker Oligo's: Use the [SPPP]n linkers (SEE ABOVE)
    f. Pi-Extensin-Like Modules:
    i. The SPPPPTPVYK Module:
    SPPPPTPVYK Internal Repeat Oligo's:
    (SEQ ID NO:90)
    5′-CCA CCA CCT ACT CCC GTT TAC AAA TCA CCA CCA CCA CCT ACT CCC GTT TAC AAA TCA CCA
    (SEQ ID NO: 91)
                   TGA GGG CAA ATG TTT AGT GGT GGT GGT GGA TCA GGG CAA ATG TTT AGT GGT GGT GGT GGA-5′
    SPPPPTPVYK External Linker Oligo's: Use the [SPPP]n linkers (SEE ABOVE)
    ii. The SPPPPVKPYHPTPVFL Module:
    SPPPPVKPYHPTPVFL Internal Repeat Oligo's:
    (SEQ ID NO:92)
    5′-CCA CCA CCT GTC AAG CCT TAC CAC CCC ACT CCC GTT TTT CTT TCA CCA
    (SEQ ID NO:93)
                   CAG TTC GGA ATG GTG GGG TGA GGG CAA AAA GAA AGT GGT GGT GGT GGA-5′
    SPPPPVKPYHPTPVFL External Linker Oligo's: Use the [SPPP]n linkers (SEE ABOVE)
    iii. The SPPPPVLPFHPTPVYK Module:
    SPPPPVLPFHPTPVYK Internal Repeat Oligo's:
    (SEQ ID NO:94)
    5′-CCA CCA CCT GTC TTA CCT TTC CAC CCC ACT CCC GTT TAC AAA TCA CCA
    (SEQ ID NO:95)
                   CAG AAT GGA AAG GTG GGG TGA GGG CAA ATG TTT AGT GGT GGT GGT GGA-5′
    SPPPPVLPFEPTPVYK External Linker Oligo's: Use the [SPPP]n linkers (SEE ABOVE)
    EGFP 3′ Linker Olig9's needed to insert EGFP into pBI121-Sig-EGF
    (SEQ ID NO:96)
    5′-GGC CGC GAG CTC CAG CAC GGG
    (SEQ ID NO:97)
           CG CTC GAG GTC GTG CCC-5′
  • The presence of the extensin signal sequence at the N-terminus of proteins encoded by genes inserted into the pBI121 expression vector (e.g., HRGPs encoded by synthetic gene constructs). The tobacco signal sequence was demonstrated to target extensin fusion proteins through the ER and Golgi for posttranslational modifications, and finally to the wall. The targeted expression of recombinant HRGPs is not dependent upon the use of the tobacco extensin signal sequence. Signal sequences involved in the transport of extensins and extensin modules in the same plant family (Solanaceae) as tobacco may be employed; alternatively, the signal sequence from tomato P1 extensin may be employed. [0213]
  • The EGFP gene encodes a green fluorescent protein (GFP) appropriately red-shifted for plant use (the EGFP gene encodes a S65T variant optimized for use in plants and is available from Clontech). Other suitable mutants may be employed (see Table 1). These modified GFPs allow the detection of less than 700 GFP molecules at the cell surface. The use of a GFP gene provides a reporter gene and permits the formation of fusion proteins comprising repetitive HRGP modules. GFPs require aerobic conditions for oxidative formation of the fluorophore. It is functional at the lower temperatures used for plant cell cultures, normally it does not adversely affect protein function. [0214]
  • Plasmids pBI121-Sig and pBI121-Sig-EGFP are constructed as follows. For both plasmids, the GUS gene present in pBI121 (Clontech) is deleted by digestion with BamHI and SstI and a pair of partially complementary oligonucleotides encoding the tobacco extensin signal sequence is annealed to the BamHI and SstI ends. The oligonucleotides encoding the 21 amino acid extensin signal sequence have the following sequence: 5′-GA TCC GCA ATG GGA AAA ATG GCT TCT CTA TTT GCC ACA TTT TTA GTG GTT TTA GTG TCA CTT AGC TTA GCA CAA ACA ACC CGG GTA CCG GTC GCC ACC ATG GTG TAA AGC GGC CGC GAG CT-3′ (SEQ ID NO:98) and 5′-C GCG GCC GCT TTA CAC CAT GGT GGC GAC CGG TAC CCG GGT TGT TTG TGC TAA GCT AAG TGA CAC TAA AAC CAC TAA AAA TGT GGC AAA TAG AGA AGC CAT TTT TCC CAT TGC G-3′ (SEQ ID NO:99). In addition to encoding the extensin signal sequence, this pair of oligonucleotides, when inserted into the digested pBI121 vector, provides a BamHI site (5′ end) and XmaI and SstI sites (3′ end). The XmaI and SstI sites allow the insertion of the GFP gene. The modified pBI121 vector lacking the GUS gene and containing the synthetic extensin signal sequence is termed pBI121-Sig. Proper construction of pBI121 is confirmed by DNA sequencing. [0215]
  • The GFP gene (e.g., the EGFP gene) is inserted into pBI121-Sig to make pBI121-Sig-EGFP as follows. The EGFP gene is excised from pEGFP (Clontech) as a 1.48 kb XmaI/NotI fragment (base pairs 270 to 1010 in pEGFP). This 1.48 kb XmaI/NotI fragment is then annealed and ligated to a synthetic 3′ linker (see above). The EGFP-3′ linker is then digested with SstI to produce an XmaI/SstI EGFP fragment which in inserted into the XmaI/SstI site of pBI121-Sig to create pBI121-Sig-EGFP. The AgeI (discussed below), XmaI and SstI sites provide unique restriction enzyme sites. Proper construction of the plasmids is confirmed by DNA sequencing. [0216]
  • The EGFP sequences in pBI121-Sig-EGFP contain an AgeI site directly before the translation start codon (i.e., ATG) of EGFP. Synthetic HRGP gene cassettes are inserted into the plasmid between the signal sequence and the EGFP gene sequences as XmaI/AgeI fragments; the HRGP gene cassettes are excised as XmaI/AgeI fragments from the pbluescript constructs described in Ex.2. Proper construction of HRGP-containing expression vectors is confirmed by DNA sequencing and/or restriction enzyme digestion. [0217]
  • Expression of the synthetic HRGP gene cassettes is not dependent upon the use of the pBI121-Sig and pBI121-Sig-EGFP gene cassette. Analogous expression vectors containing other promoter elements functional in plant cells may be employed (e.g., the CaMV region IV promoter, ribulose-1,6-biphosphate (RUBP) carboxylase small subunit (ssu) promoter, the nopaline promoter, octopine promoter, mannopine promoter, the β-conglycinin promoter, the ADH promoter, heat shock promoters, tissue-specific promoters, e.g., promoters associated with fruit ripening, promoters regulated during seed ripening (e.g., promoters from the napin, phaseolin and glycinin genes). For example, expression vectors containing a promoter that directs high level expression of inserted gene sequences in the seeds of plants (e.g., fruits, legumes and cereals, including but not limited to corn, wheat, rice, tomato, potato, yarn, pepper, squash cucumbers, beans, peas, apple, cherry, peach, black locust, pine and maple trees) may be employed. Expression may also be carried out in green algae. [0218]
  • In addition, alternative reporter genes may be employed in place of the GFP gene. Suitable reporter genes include β-glucuronidase (GUS), neomycin phosphotransferase II gene (nptII), alkaline phosphatase, luciferase, CAT (Chloramphenicol AcetylTransferase). Preferred reporter genes lack Hyp residues. Further, the proteins encoded by the synthetic HRGP genes need not be expressed as fusion proteins. This is readily accomplished using the pBI121-Sig vector. [0219]
    • EXAMPLE5 Expression of Recombinant HRGPs In Tomato Cell Suspension Cultures
  • The present invention contemplates recombinant HRGPs encoded by expression vectors comprising synthetic HRGP gene modules are expressed in tomato cell suspension cultures. The expression of recombinant HRGPs in tomato cell suspension cultures is illustrated by the discussion provided below for recombinant GAGP expression. [0220]
  • a) Expression of Recombinant GAGP [0221]
  • An expression vector containing the synthetic GAGP gene cassette (capable of being expressed as a fusion with GFP or without GFP sequences) is introduced into tomato cell suspension cultures. A variety of means are known to the art for the transfer of DNA into tomato cell suspension cultures, including Agrobacterium-mediated transfer and biolistic transformation. [0222]
  • Agrobacterium-mediated transfonnation: The present invention contemplates transforming both suspension cultured cells (Bonnie Best cultures) and tomato leaf discs by mobilizing the above-described plasmid constructions (and others) from [0223] E. coli into Agrobacterium tumefaciens strain LBA4404 via triparental mating. Positive colonies are used to infect tomato cultures or leaf discs (Lysopersicon esculentum). Transformed cells/plants are selected on MSO medium containing 500 mg/mL carbenicillin and 100 mg/mL kanamycin. Expression of GFP fusion products are conveniently monitored by fluorescence microscopy using a high Q FITC filter set (Chroma Technology Corp.). FITC conjugates (e.g. FITC-BSA) can be used along with purified recombinant GFP as controls for microscopy set-up. Cultured tomato cells show only very weak autofluorescence. Thus, one can readily verify the spatiotemporal expression of GFP-Hyp module fusion products.
  • Transgenic cells/plants can be examined for transgene copy number and construct fidelity genomic Southern blotting and for the HRGP construct mRNA by northern blotting, using the internal repeat oligonucleotides as probes. Controls include tissue/plants which are untransformed, transformed with the pBI121 alone, pBI121 containing only GFP, and pBI121 having the signal sequence and GFP but no HRGP synthetic gene. [0224]
  • Microprojectile bombardment: 1.6 M gold particles are coated with each appropriate plasmid construct DNA for use in a Biolistic particle delivery system to transform the tomato suspension cultures/callus or other tissue. Controls include: particles without DNA, particles which contain PBI121 only, and particles which contain PBI121 and GFP. [0225]
  • b) Expression of Other HRGPs Of Interest [0226]
  • As noted above, the present invention contemplates expressing a variety of HRGPs, fragments and variants. Such HRGPs include, but are not limited to, RPRps, extensins, AGPs and other plant gums (e.g. gum Karaya, gum Tragacanth, gum Ghatti, etc.). HRGP chimeras include but are not limited to HRGP plant lectins, including the solanaceous lectins, plant chitinases, and proteins in which the HRGP portion serves as a spacer (such as in sunflower). The present invention specifically contemplates using the HRGP modules (described above) as spacers to link non-HRGP proteins (e.g. enzymes) together. [0227]
    • EXAMPLE 6 Construction Of A Synthetic HRGP Gene Cassette Incorporating A GAGP Construct
  • Synthetic gene cassettes encoding contiguous and noncontiguous Hyp modules were constructed using partially overlapping sets consisting of oligonucleotide pairs, “internal repeat pairs” and “external 3′- and 5′-linker pairs” respectively, all with complementary “sticky” ends. The following 5′-linker, internal repeat and 3′-linker duplexes were employed: [0228]
  • 5′-Linker [0229]
        A   A   G   S   S   T   R   A  (S   P   S) (SEQ ID NO:40)
    5′-GCT GCC GGA TCC TCA ACC CGG GCC-3′ (SEQ ID NO:41)
    3′-CGA CGG CCT AGG AGT TGG GCC CGG AGT GGG AGT-5′ (SEQ ID NO:42)
  • 3′-Linker [0230]
        S   P   S   P   V   A   R   N   S   P   P (SEQ ID NO:43)
    5′-TCA CCC TCA CCG GTC GCC CGG AAT TCA CCA CCC-3′ (SEQ ID NO:44)
                ′-GGC CAG CGG GCC TTA AGT GGT GGG-5′ (SEQ ID NO:45)
  • Internal Repeat [0231]
         S   P   S   P   T   P   T   A   P   P   G   P   H   S   P   P   P   T   L (SEQ ID NO:100)
    [5′-TCA CCC TCA CCA ACT CCT ACC GCA CCA CCT GGT CCA CAC TCT CCA CCA CCA ACA TTG-3′ (SEQ ID NO:101)]
    [3′-AGT GGG AGT GGT TGA GGA TGG CGT GGT GGA CCA GGT GTG AGA GGT GGT GGT TGT AAC-5′ (SEQ ID NO:102)]2
    then:
         S   P   S   P   T   P   T   A   P   P   G   P   H   S   P   P   P   S    L (SEQ ID NO:103)
    5′-TCA CCC TCA CCA ACT CCT ACC GCA CCA CCT GGT CCA CAC TCT CCA CCA CCA TCA TTG-3′ (SEQ ID NO:104)
    3′-AGT GGG AGT GGT TGA GGA TGG CGT GGT GGA CCA GGT GTG AGA GGT GGT GGT AGT AAC-5′ (SEQ ID NO:105)
  • The following synthetic gene (SEQ ID NO:106) was eventually expressed in tobacco and tomato cell cultures and tobacco plants using the above constructs: [0232]
                    M   G   K   M   A   S   L   F   A   T   F   L   V   V   L   V
    5′-GGA TCC GCA ATG GGA AAA ATG GCT TCT GTA TTT GCG AGA TTT TTA GTC GTT TTA GTG
    3′-CCT AGG CGT TAG CCT TTT TAC CGA AGA GAT AAA CGG TGT AAA AAT CAC CAA AAT CAC
     S   L   S   L   A   Q   T   T   R   D   S   P   S   P   T   P   T    A    P
    TCA CTT AGC TTA GCA CAA ACA ACC CGG GAC TCA CCC TCA CCA ACT CCT ACC GCA  CCA
    AGT GAA TCG AAT CGT GTT TGT TGG GCC CTG AGT GGG AGT GGT TGA GGA TGG CGT  GGT
     P   G   P   H   S   P   P   P   T   L   S   P   S   P   T   P   T    A    P
    CCT GGT CCA CAC TCT CCA CCA CCA ACA TTG TCA GGG TCA CCA ACT CCT ACC GCA  CCA
    GGA CCA GGT GTG AGA GGT GGT GGT TGT AAC AGT GGG AGT GGT TGA GGA TGG CGT  GGT
     P   G   P   H   S   P   P   P   T   L   S   P   S   P   T   P   T    A    P
    CCT GGT CCA CAC TCA CCA CCA CCA ACA TTG TCA CCC TCA CCA ACT CCT ACC GCA  CCA
    GGA CCA GGT GTG AGT GGT GGT GGT TGT AAC AGT GGG AGT GGT TGA GGA TGG CGT  GGT
     P   G   P   H   S   P   P   P   S   L   S   P   S   P   V
    CCT GGT CCA CAC TCA CCA CCA CCA TCA TTG TCA CCC TCA CCG GTC GCC ACC-gfp-3′
    GGA CCA GGT GTG AGT GGT GGT GGT AGT AAC AGT GGG AGT GGC CAG GGG TGG-gfp-5′
  • This example involved: (A) Oligonucleotide pair preparation; (B) Oligonucleotide polymerization; (C) Construct precipitation; (D) Restriction of [0233] gene 3′-linker and 5′-linker capped ends; (E) Size-fractionation and removal of enzyme contaminants; (F) Gene insertion into SK plasmid vector. All SDS-PAGE purified oligonucleotides were synthesized by Gibco-BRL.
  • (A) Oligonucleotide Pair Preparation [0234]
  • In separate Eppendorf tubes were combined: [0235]
  • Tube 1) 5.5 μl GAGP internal repeat sense oligonucleotide (0.5 nmol/μl), 5.5 μl GAGP internal repeat antisense oligonucleotide (0.5 nmol/μl), 11 μl T4 ligase 10× ligation buffer (New England Biolabs); [0236]
  • Tube 2) 2 [0237] μl 5′-sense linker (0.05 nmol/μl), 2 μl 5′-antisense linker (0.05 nmol/μl), 1 μl H2O, 5 μl T4 ligase 10× ligation buffer (New England Biolabs);
  • Tube 3) 2 [0238] μl 3′-sense linker (1 mnol/μl), 2 μl 3′-antisense liker (1 nmol/μl), 1 μl water, 5 μl T4 ligase 10× ligation buffer (New England Biolabs).
  • All tubes were heated to 90-95° C. for 5 minutes, then slowly cooled over the next 3 hours to 45° C. The tubes were then incubated at 45° C. for 2 hours. [0239]
  • (B) Oligonucleotide Polymerization [0240]
  • 10 μl of solution from Tube I (internal repeat pair) was combined with 10 μl of solution from Tube 2 (5′ linker pair), and incubated at 17° C. for 3 hours. To this mixture was added 80 μl water and 2 μl (4000 U) T4 DNA ligase (New England Biolabs), and again incubated at 12-15° C. for 36 hours. The degree of polymerization was verified on 2.2% agarose gel (Fisher). [0241]
  • The 3′-end of the polymer was then capped by adding 50 μl of the ligated [0242] GAGP 5′-linker mixture from above to 5 μl of solution from Tube 3 (3′-linker), heating to 30° C., and incubating at 17° C. for 3 hours. 20 μl water and 2 μl T4 DNA ligase (New England Biolabs) was then added, and the solution incubated at 12-15° C. for 36 hr. Finally, the solution was heated at 65° C. for 10 minutes to denature the ligase.
  • (C) Construct Precipitation [0243]
  • 10 μl GAGP construct from (B) above was combined with 25 μl water and 5 μl 3 M NaAcetate. 150 μl EtOH was then added and the solution incubated at 4° C. for 30 minutes The solution was then centrifuged at 10,000 rpm for 30 minutes The resultant pellet was washed with 70% EtOH and dried. [0244]
  • (D) Restriction Of [0245] Gene 3′-Linker And 5′-Linker Capped Ends
  • The pellet from (C) above was dissolved in 14 μl water. 2 [0246] μl 10× EcoRi restriction buffer (New England Biolabs), 2 μl EcoRI 10 U/μl (New England Biolabs), and 2 μl BamHI 20 U/μl (New England Biolabs) was then added and the mixture incubated at 37° C. overnight.
  • (E) Size-Fractionation And Removal Of Enzyme Contaminants [0247]
  • 10 μl water was added to 20 μl of the restricted genes from Step (D) above. This mixture was then loaded onto a Sephacryl S-400 (Pharmacia Microspin™) minicolumn and spun to remove small (<90 bp) oligonucleotide fragments. The first effluent from the column (i.e. the large MW material) was collected. Finally, the enzymes were removed using a Qiaquick Nucleotide removal kit (Qiagen). The final volume of mixture was approximately 50 μl. [0248]
  • (F) Gene Insertion Into SK Plasmid Vector [0249]
  • SK plasmid vector (Strategene) was restricted with BamHI and EcoRI and restricted large plasmid fragments were isolated from agarose gel. To 2-3 μg restricted SK plasmid in 10 μl water was added 6 μl restricted GAGP gene construct from Step (E), 2 μl T4 DNA ligase buffer (New England Biolabs), and 1 μl T4 DNA ligase (New England Biolabs). The solution was then kept at 8° C. overnight for ligation. 100 μl competent XL1-Blue cells (Stratagene) were then transformed with 3 μl ligation mixture. Clones were selected via Blue/White assay (Promega Corporation), as described by Promega Protocols and Applciations Guide, 2 ed. (1991), by hybridization with 32P-labeled antisense internal oligonucleotide, and by restriction mapping. [0250]
    • EXAMPLE 7 Construction Of A Synthetic HRGP Gene Cassette Incorporating An SP Construct
  • Synthetic gene cassettes encoding contiguous and noncontiguous Hyp modules. were constructed using partially overlapping sets consisting of oligonucleotide pairs, “internal repeat pairs” and “external 3′- and 5′-linker pairs” respectively, all with complementary “sticky” ends. The following 5′-linker, internal repeat and 3′-linker duplexes were employed: [0251]
  • 5′-Linker [0252]
        A   A   G   S   S   T   R   A  (S   P   S) (SEQ ID NO:40)
    5′-GCT GCC GGA TCC TCA ACC CGG GCC-3′ (SEQ ID NO:41)
    3′-CGA CGG CCT AGG AGT TGG GCC CGG AGT GGG AGT-5′ (SEQ ID NO:42)
  • 3′-Linker [0253]
        S   P   S   P   V   A   R   N   S   P   P (SEQ ID NO:43)
    5′-TCA CCC TCA CCG GTC GCC CGG AAT TCA CCA CCC-3′ (SEQ ID NO:44)
                3′-GGC CAG CGG GCC TTA AGT GGT GGG-5′ (SEQ ID NO:45)
  • Internal Repeat [0254]
        S   P   S   P   S   P   S   P   S   P   (S   P   S) (SEQ ID NO:107)
    5′-TCA CCC TCA CCA TCT CCT TCG CCA TCA CCC (SEQ ID NO:108)
                3′-GGT AGA GGA AGC GGT AGT GGG AGT GGG AGT-5′ (SEQ ID NO: 109)
  • The following synthetic gene (SEQ ID NO:110) was eventually expressed in tobacco and tomato cell cultures and tobacco plants using the above constructs: [0255]
        G   S   A   M   G   K   M   A   S   L   F   A   T   F   L   V   V   L   V
    5′-GGA TCC GCA ATG GGA AAA ATG GCT TCT CTA TTT GCC ACA TTT TTA GTG GTT TTA GTG
    3′-CCT AGG CGT TAG CCT TTT TAC CGA AGA GAT AAA CGG TGT AAA AAT CAC CAA AAT CAC
     S   L   S   L   A   Q   T   T   R   A  [ S   P   S   P   S   P   S   P   S
    TCA CTT AGC TTA GCA CAA ACA ACC CGG GCC [TCA CCC TCA CCA TCT CCT TCG CCA TCA
    AGT GAA TCG AAT CGT GTT TGT TGG GCC CGG [AGT GGG AGT GGT AGA GGA AGC GGT AGT
     P ]    S   P   S   P   V   A   T
    CCC] 6 TCA CCC TCA CCG GTC GCC ACC-gfp-3′
    GGG] 6 AGT GGG AGT GGC CAG CGG TGG-gfp-5′
  • This example involved: (A) Oligonucleotide pair preparation; (B) Oligonucleotide polymerization; (C) Construct precipitation; (D) Restriction of [0256] gene 3′-linker and 5′-linker capped ends; (E) Size-fractionation and removal of enzyme contaminants; (F) Gene insertion into SK plasmid vector. All SDS-PAGE purified oligonucleotides were synthesized by Gibco-BRL.
  • (A) Oligonucleotide Pair Preparation [0257]
  • In separate Eppendorf tubes were combined: [0258]
  • Tube 1) 5.5 μl SP internal repeat sense oligonucleotide (0.5 nmol/μl), 5.5 μl SP internal repeat antisense oligonucleotide (0.5 nmol/μl), 11 μl T4 ligase 10× ligation buffer (New England Biolabs); [0259]
  • Tube 2) 2 [0260] μl 5′-sense linker (0.05 nmol/μl), 2 μl 5′-antisense linker (0.05 nmol/μl), 1 μl H2O, 5 μl T4 ligase 10× ligation buffer (New England Biolabs);
  • Tube 3) 2 [0261] μl 3′-sense linker (1 nmol/μl), 2 μl 3′-antisense linker (1 nmol/μl), 1 μl water, 5 μl T4 ligase 10× ligation buffer (New England Biolabs).
  • All tubes were heated to 90-95° C. for 5 minutes, then slowly cooled over the next 3 hours to 45° C. The tubes were then incubated at 45° C. for 2 hours. [0262]
  • (B) Oligonucleotide Polymerization [0263]
  • 10 μl of solution from Tube 1 (internal repeat pair) was combined with 10 μl of solution from Tube 2 (5′ linker pair), and incubated at 17° C. for 3 hours. To this mixture was added 80 μl water and 2 μl (4000 U) T4 DNA ligase (New England Biolabs), and again incubated at 12-15° C. for 36 hours. The degree of polymerization was verified on 2.2% agarose gel (Fisher). [0264]
  • The 3′ end of the polymer was then capped by adding 50 μl of the ligated SP-5′ linker mixture from above to 5 μl of solution from Tube 3 (3′ linker), heating to 30° C., and incubating at 17° C. for 3 hours. 20 μl water and 2 μl T4 DNA ligase (New England Biolabs) was then added, and the solution was incubated at 12-15° C. for 36 hr. Finally, the solution was heated at 65° C. for 10 minutes to denature the ligase. [0265]
  • (C) Construct Precipitation [0266]
  • 10 μl SP construct from (B) above was combined with 25 μl water and 5 μl 3 M NaAcetate. 150 μl EtOH was then added and the solution incubated at 4° C. for 30 minutes The solution was then centrifuged at 10,000 rpm for 30 minutes The resultant pellet was washed with 70% EtOH and dried. [0267]
  • (D) Restriction Of [0268] Gene 3′-Linker And 5′-Linker Capped Ends
  • The pellet from (C) above was dissolved in 14 μl water. 2 [0269] μl 10× EcoRI restriction buffer (New England Biolabs), 2 μl EcoRI 10 U/μl (New England Biolabs), and 2 μl BamHI 20 U/μl (New England Biolabs) was then added and the mixture incubated at 37° C. overnight.
  • (E) Size-Fractionation And Removal Of Enzyme Contaminants [0270]
  • 10 μl water was added to 20 μl of the restricted genes from Step (D) above. This mixture was then loaded onto a Sephacryl S-400 (Pharmacia Microspin™) minicolumn and spun to remove small (<90 bp) oligonucleotide fragments. The first effluent from the column (i.e. the high molecular weight material) was collected. Finally, the enzymes were removed using a Qiaquick Nucleotide removal kit (Qiagen). The final volume of mixture was approximately 50 μl. [0271]
  • (F) Gene Insertion Into SK Plasmid Vector [0272]
  • SK plasmid vector (Strategene) was restricted with BamHI and EcoRI and restricted large plasmid fragments were isolated from agarose gel. To 2-3 μg restricted SK plasmid in 10 μl water was added 6 μl restricted SP gene construct from Step (E), 2 μl T4 DNA ligase buffer (New England Biolabs), and 1 μl l T4 DNA ligase (New England Biolabs). The solution was then kept at 8° C. overnight for ligation. 100 μl competent XL1-Blue cells (Stratagene) were then transformed with 3 μl ligation mixture. Clones were selected via Blue/White assay (Promega Corporation), as described by Promega Protocols and Applications Guide, 2 ed. (1991), by hybridization with 32P-labeled antisense internal oligonucleotide, and by restriction mapping. [0273]
    • EXAMPLE 8 Gene Subcloning Into pEGP, pKS, pUC18 and pBI121 and Signal Sequence Synthesis
  • The methods of the following example were used to incorporate the synthetic genes of Examples 6 and 7 into the pBI121 plasmid. Restriction digests, ligations, subclonings, and [0274] E. Coli transformations were performed generally according to F. M. Ausubel, ed., “Current Protocols in Molecular Biology,” (1995), Chapter 3: Enzymatic Manipulation of DNA and DNA Restriction Mapping,; Subcloning of DNA Fragments. The restriction digests used were 1-2 μg of plasmid DNA, 5-10 U of restriction enzyme, and 1× recommended restriction buffer (starting with the 10× buffer provided by the company). Samples were run on 1-2.2% agarose gels in TBE buffers. Plasmid and DNA fragments were isolated from gels using QIAEX II gel extraction kits (Qiagen). The DNA ligase employed was 400 U T4 (New England Biolabs). Vector:fragment ratios employed were 1:2-1:6, and ligation volumes were 20 μl.
  • Transformation of [0275] E. coli was done in 5-10 μl ligation reaction volumes with XL-Blue competent cells (Stratagene). Cells were plated on LB plates containing 50 μg/ml ampicillin or 30 μg/ml kanamycin.
  • Plasmid isolation was performed by growing transformed XL-Blue cells in 3 mL LB-ampicillin or LB-kanamycin medium. The plasmids were then isolated using a Wizard Plus Miniprep DNA Purification System (Promega). [0276]
  • This example involved: (A) Insertion of the synthetic gene into pEGFP; (B) Insertion of GAGP-EGFP or SP-EGFP fragment into pKS; (C) Construction of the Signal Sequence and cloning into pUC18; (D) Insertion of GAGP-EGFP or SP-EGFP construct into pUC18; (E) Insertion of SS-GAGP-EGFP or SS-SP-EGFP genes into pBI121. [0277]
  • (A) Insert Synthetic Gene For GAGP Or SP Into pEGFP [0278]
  • This step was carried out to allow directional cloning of the gene at the 5′ end of EGFP. First, the GAGP or SP gene was isolated from pSK [from Examples 6(F) and 7(F)] as a BamHI (New England Biolabs) and AgeI (New England Biolabs) fragment. The pEGFP (Clontech) was then restricted with BamHI and AgeI. Finally, the BamHI/AgeI-restricted gene was annealed with BamHI/AgeI-restricted pEGFP, and ligated to yield pEGFP containing the synthetic gene inserted at the 5′ end of the EGFP. [0279]
  • (B) Insert GAGP-EGFP Or SP-EGFP Fragment Into pKS [0280]
  • This step was carried out to obtain an Sst I site at the 3′ end of EGFP. The GAGP-EGFP or SP-EGFP construct from (A) above was isolated from pEGFP as an XmaI/NotI fragment. pKS (Strategene) was then restricted with XmaI and NotI (New England Biolabs). Finally, the GAGP-EGFP or SP-EGFP construct was annealed with cut pKS and ligated to yield pKS containing GAGP-EGFP or SP-EGFP. [0281]
  • (C) Construct Of The Signal Sequence And Cloning Into pUC18 [0282]
  • In order to anneal the partially overlapping sense and antisense oligonucleotides encoding the extensin signal sequence, 2 μl signal sequence sense oligonucleotide (0.1 nmol/μl), 2 μl signal sequence antisense oligonucleotide (0.1 nmol/μl), 2 [0283] μl 10× DNA Polymerase Buffer (New England Biolabs), and 14 μl H2O was combined and heated to 85° C. for 5 minutes The mixture was then slowly cooled to 40° C. over 1 hour.
  • The annealed oligonucleotides were then extended via primer extension. To the above mixture was added 2 μl dNTP 2.5 mM (New England Biolabs) and 1 μl DNA Polymerase 5 U/μl (New England Biolabs), and the resultant mixture incubated at 37° C. for 10 minutes The polymerase was then denatured by heating at 70° C. for 10 minutes Then 8 μl Buffer 4 (New England Biolabs), 66 μl H[0284] 2O, 2 μl BamHI 20 U/μl (New England Biolabs), and 2 μl SstI 14 U/μl (Sigma) was added and the mixture incubated at 37° C. overnight. The restriction enzymes were then denatured by heating at 70° C. for 10 minutes.
  • The mixture was then precipitated with EtOH/NaAcetate (6 μl NaAcetate/300 μl EtOH), and pelletized in a centrifuge. The pellet was washed with 70% EtOH and dried. The pellet was then dissolved in 20 μl H[0285] 2O and 4 μl was used for ligation into 2 μg pSK (Stratagene) as a BamHI/SstI fragment. Finally, the signal sequence was subcloned into pUC18 as a BamHI/SstI fragment.
  • (D) Insertion Of GAGP-EGFP Or SP-EGFP Construct Into pUC18 [0286]
  • This step was carried out to insert the GAGP-EGFP or SP-EGFP construct “behind” the signal sequence. The GAGP-EGFP or SP-EGFP construct from (B) above was removed from pKS as an XmaI/SstI fragment. pUC18 containing the signal sequence (SS-pUC18) was restricted with XmaI/Sst. The GAGP-EGFP or SP-EGFP fragment was then annealed with cut SS-pUC18, and ligated. The SS-GAGP-EGFP or SS-SP-EGFP gene sequence was then confirmed through DNA sequencing using the pUC18 17-residue sequencing primer (Stratagene). [0287]
  • (E) Insertion Of SS-GAGP-EGFP Or SS-SP-EGFP Genes Into pBI121 [0288]
  • The SS-GAGP-EGFP or SS-SP-EGFP gene from (D) above was removed from pUC18 as BamHI/SstI fragments. pBI121 (Clontech) was restricted with BamHI and SstI and the larger plasmid fragments recovered. The smaller fragments, containing the GUS reporter gene, were discarded. The SS-GAGP-EGFP or SS-SP-EGFP fragment was annealed with the restricted pBI121 fragment and ligated. [0289]
    • EXAMPLE 9 Agrobacterium Transformation With pBI121-Derived Plasmids
  • 2 μg of the pBI121 containing SS-GAGP-EGFP or SS-SP-EGFP from Example 8 above was used to transform [0290] Agrobacterium tumefaciens (Strain LB4404, from Dr. Ron Sederoff, North Carolina State University) according to An et al., Plant Molecular Biology Manual A3:1-19 (1988).
    • EXAMPLE 10 Transformation Of Tobacco Cultured Cells With pBI121-Derived Plasmids
  • All steps were carried out under sterile conditions. Tobacco cells were grown for 5-7 days in NT-1 medium (pH 5.2, per liter: IL packet of MS Salts (Sigma #S5524), 30 g sucrose, 3 [0291] ml 6% KH2PO4, 100 mg Myo-Inositol, 1 mL Thiamine·HCl (1 mg/ml stock), 20 μl 2,4-D (10 mg/ml stock) ) containing 100 μg/ml kanamycin. The cells were grown in 1L flasks containing 500 mL medium on a rotary shaker (94 rpm, 27° C.) to between 15-40% packed cell volume. Agrobacterium cells transformed with pBI121-derived plasmid (Example 9) were grown overnight in Luria Broth containing 30 μg/ml kanamycin. The Agrobacterium cell broth was pelletized for 1 minutes at 6000 rpm, and the pellet resuspended in 200 μl NT-1 medium.
  • Excess medium was removed from the tobacco cell broth until the broth had a consistency approximate to applesauce. The tobacco cells were placed in petri dish, and 200 μl of the Agrobacterium preparation was added. The mixture was then incubated at room temperature, no light, for 48 hours. [0292]
  • The mixture was then washed 4 times with 20 ml NT-1 to remove the Agrobacterium cells, and the plant cells were plate-washed on NT-1 plates containing 400 μg/ml timentin and 100 μg/ml kanamycin. Cells which grew on the antibiotics were selected and checked for green fluorescence through fluorescence microscopy, excitation wavelength 488 nm (see Example 16). [0293]
    • EXAMPLE 11 Transformation Of Tomato Cultured Cells With pBI121-Derived Plasmids
  • All steps were carried out under sterile conditions. Tomato cells were grown for 5-7 days in Schenk-Hildebrand medium (pH 5.8, per liter: IL packet of S-H basal salt (Sigma #S6765), 34 g sucrose, 1 g Schenck-Hildebrandt vitamin powder (Sigma #S3766), 100 [0294] μl Kinetin 1 mg/ml stock (Sigma #K32532), 44 μl 2,4-D 10 mg/ml stock, 2.1 ml p-chlorophenoxy acetic acid 1 mg/ml stock (Sigma) ) containing 200 μg/ml kanamycin. The cells were grown in 1L flasks containing 500 mL medium on a rotary shaker (94 rpm, 27° C.) to between 15-40% packed cell volume. Agrobacterium cells transformed with pBII21-derived plasmid (Example 9) were grown overnight in Luria Broth containing 30 μg/ml kanamycin. The Agrobacterium cell broth was pelletized for 1 minutes at 6000 rpm, and the pellet resuspended in 200 μl NT-1 medium.
  • Excess medium was removed from the tomato cell broth until the broth had a consistency approximate to applesauce. The tomato cells were placed in petri dish, and 200 μl of the Agrobacterium preparation was added. The mixture was then incubated at room temperature, no light, for 48 hours. [0295]
  • The mixture was then washed 4 times with 20 ml NT-1 to remove the Agrobacterium cells, and then the plant cells were plate-washed on NT-1 plates containing 400 μg/ml timentin and 200 μg/ml kanamycin. Cells which grew on the antibiotics were selected and checked for green fluorescence through fluorescence microscopy, excitation wavelength 488 nm. [0296]
    • EXAMPLE 12 Isolation Of GAGP-EGFP From Tobacco Cell Suspension Culture Medium
  • Transformed tobacco cells were grown on rotary shaker as described in Example 11 above. The medium was separated from the cells by filtration on a glass sintered funnel (coarse grade), and the medium concentrated by freeze-drying. The medium was then resuspended in water (˜50 ml/500 mL original volume before lyophilization), and dialyzed against cold water for 48 hours (water changed 6 times). The precipitated pectin contaminants were removed by centrifuge, the pellet discarded, and the supernatant freeze-dried. The dried supernatant was then dissolved in [0297] Superose Buffer 20 mg/ml (200 mM sodium phosphate buffer, pH 7, containing 0.05% sodium azide), and spun in a centrifuge to pelletize insolubles. 1.5 ml of this preparation (18-30 mg) was then injected into a semi-preparative Superose-12 gel filtration column (Pharmacia), equilibrated in Superose Buffer and eluted at 1 ml/minutes The UV absorbance was monitored at 220 nm. 2 ml fractions were collected throughout, with GAGP-EGFP expected to elute between 59 and 70 minutes (˜2.5 Vo). GAGP-EGFP actually eluted at 65 minutes (see FIG. 3, Example 15 for method used to analyze peaks).
  • The Superose peak containing GAGP-EGFP was dialyzed against cold water for 24 hours (4 water changes), and freeze-dried. The dried GAGP-EGFP peak was then dissolved in 250 μl 0.1% aqueous TFA (Pierce) and loaded onto a PRP-1 column (Polymeric Reverse Phase, Hamilton) equilibrated in Buffer A (0.1% aqueous TFA). The column was then eluted with Buffer B (0.1% TFA/80% acetonitrile in water; gradient=0-70% B/100 min) at a rate of 0.5 mL/minutes UV absorbance was monitored at 220 nm, and GAGP-EGFP eluted at 63 minutes (see FIG. 4, Example 15 for method used to analyze peaks). Finally, the TFA/acetonitrile was removed through N[0298] 2 (g) blowdown.
    • EXAMPLE 13 Characterization Of GAGP-EGFP By Neutral Sugar Analysis
  • 100 μg of GAGP-EGFP isolated from tobacco cells was aliquoted into a 1 ml glass microvial and dried under N[0299] 2 (g). 200 μl 2N TFA was added and the vial capped. The vial was heated at 121° C. for 1 hour, then blown down under N2 at 50° C. to rid the sample of acid. 25 μl of sodium borohydride solution (20 mg/ml in 3 M ammonium hydroxide) was added and the mixture kept at room temperature for 1 hour. 1-3 drops of concentrated acetic acid were added until fizzing stops, and the mixture blown down under N2 at 40° C. 100 μl MeOH was added, the mixture vortexed, and blown down under N2 at 40° C., then this step was repeated. A mixture of 100 μl MeOH and 100 μl H2O was added, vortexed, and blown down under N2 at 40° C., then the procedure of adding 100 μl MeOH, vortexing, and N2 treatment was repeated 3 times. The resultant mixture was then dried under vacuum. overnight. 50 μl reagent grade acetic anhydride was added and the mixture heated at 121° C. for 0.5 hour. The sample was then analyzed by gas chromatography as described in Kieliszewski et al., Plant Physiol. 98:919 (1992). The sample was shown to contain hydroxyproline and sugar, accounting for 50% of the fusion product on a dry weight basis. Galactose, arabinose, and rhamnose occur in 3:3:1 molar ratio similar to that of native GAGP's 3.5:4:1 molar ratio. This is consistent with the likely presence of both Hyp-arabinosides and Hyp-arabinogalactan polysaccharide in the expresssed construct. The lower ratio of Ara in the GAGP-EGFP fusion glycoprotein is consistent with the Ala for Pro substitution (See Example 6), which removes one arabinosylation site in the peptide.
    • EXAMPLE 14 Characterization Of GAGP-EGFP By Hydroxyproline Assay
  • 100 μg purified GAGP-EGFP was hydrolyzed with 6N HCl (Pierce) at 110° C. for 18 hours. The excess acid was then removed by blowing down under N[0300] 2. Hydroxyproline was then determined following Kivirikko and Liesma, Scand. J. Clin. Lab. Invest. 11:128 (1959).
    • EXAMPLE 15 Characterization of Tobacco and Tomato Expression Products By Enyzme-Linked Immunosorbant Assay
  • GAGP-EGFP and SP-EGFP products from tomato and tobacco cell medium and column peaks (see Example 12) were detected by Enyzme-Linked Immunosorbant Assays (ELISA) using the method of Kieliszewski and Lamport, “Cross-reactivities of polyclonal antibodies against extension precursors determined via ELISA techniques,” [0301] Phytochemistry 25:673-677 (1986). The GAGP-EGFP product was also assayed using anti-EGFP antibodies. Anti-EGFP antibodies (Clontech) were the primary antibody, diluted 1000-fold as recommended by the manufacturer. The secondary antibody was Peroxidase conjugated goat-anti-rabbit IGG diluted 5000-fold (Sigma). Recombinant EGFP (Clontech) was used as a control. This assay was used to generate FIGS. 3 and 4 from Example 12 above.
    • EXAMPLE 16 Characterization of Tobacco and Tomato Expression Products By Fluorescence
  • Culture medium from both tobacco and tomato cells transformed with the GAGP-EGFP and the SP-EGFP genes was collected. The EGFP tag fluoresces when exposed to UV light; the excitation wavelength used here was 488 mn. These media were compared with media which included EGFP expressed behind the signal sequence and secreted into the medium, cells transformed with unaltered pBI121 and medium from untransformed cells. The unmistakable bright green fluorescence (data not shown) allowed visualization of the targeted products during their transit through the ER/Golgi membrane system. As Agrobacterium lacks the posttranslational machinery to make HRGPs, the fluorescing proteins must be of plant origin. [0302]
    • EXAMPLE 17 Tobacco Leaf Disc Transformation
  • Sterile tobacco leaves were cut into small pieces and wounded with a needle. 4 ml NT-1 medium without hormones (NT-1 medium of Example 10, omitting 2-4 D) and 150 ul concentrated overnight culture of Agrobacterium (see Example 9) was added to the leaves, and the leaf discs incubated for 48 hours, no light. The leaf discs were then washed with NT-1 medium, no hormones. The discs were then put on NT-1 solid medium plates (NT-1 medium of Example 10 plus 7.5 g Bactoagar (Difco Laboratories) ), 400 ul/ml timentin, and 100 ug/ml kanamycin. [0303]
  • After 3 weeks, shoots were transferred from NT-B solid medium without hormones [NT-1 Medium of Example 10, omitting 2-4 D, and adding 300 ul/L benzyl adenine, made from a 2 mg/ml stock made up in DMSO (N-benzyl-9-(tetrahydropyranyl) adenine (Sigma)] to root. Transformed plants have expressed SP-EGFP and GAGP-EGFP in leaf and root cells, as determined by the fluorescence assay of Example 16 (data not shown) [0304]
    • EXAMPLE 18 Sequence Analysis of GAGP and Determination of A Consensus Sequence
  • This Example describes amino acid sequencing, glycosyl and linkage analysis of GAGP which yielded sequences (including preferred consensus sequences) within the scope of SEQ ID NO:136. [0305]
  • 1. Experimental [0306]
  • The following experimental protocols were used to arrive at preferred embodiments of the invention's sequences. [0307]
  • A. Size Fractionation [0308]
  • GAGP was isolated via preparative Superose-6 gel filtration using the method of Qi et al. [Qi et al. (1991) supra] as follows. Nodules of gum arabic (Kordofan Province, Sudan) were a gift from Gary Wine of AEP Colloids (Ballston Spa, N.Y.). Nodules were ground to a fine flour (ca. 2 min.) in a Tekmar A-10 mill. Samples of gum arabic (100 mg/ml) were dissolved in water then diluted to 50 mg/ml in 0.2 M sodium phosphate buffer (pH 7). Samples were spun to pellet insoluble material and 1 ml aliquots were injected onto a semi-preparative Superose-6 gel filtration column (1.6 cm i.d.×50 cm, Pharmacia), eluted isocratically as described previously [Qi et al. (1991) supra]. The protein peaks corresponding to GAGP were dialyzed against water to remove salt and then freeze-dried. [0309]
  • B. HF-Deglycosylation [0310]
  • For chymotryptic peptide mapping GAGP was HF-deglycosylated as follows. The Superose-6 fractionated GAGP (designated dGAGP) was deglycosylated in anhydrous hydrogen fluoride (HF) (20 mg powder/ml HF for 1 h at 4°) as described earlier [Qi et al. (1991) supra], repeating the procedure twice to ensure complete deglycosylation. [0311]
  • C. Purification of size-fractionated GAGP and dGAGP by reverse phase HPLC [0312]
  • Superose-fractionated GAGP was purified for glycoside analyses, or dGAGP samples were used for peptide mapping on a Hamilton PRP-1 semi-preparative column (10 mm, 250×4.1 mm) by equilibrating with Buffer A (0.1% TFA, aqueous) and eluting with Buffer B (0.1% TFA, 80% acetonitrile, aqueous) by gradient elution (0-100% B/80 min.; 0.5 mL/min flow rate). The eluate was monitored at 220 nm. The collected peaks were blown down to dryness with N[0313] 2(g), redissolved in ddH2O, then freeze-dried.
  • D. Proteolysis of deglycosylated GAGP with chymotrypsin or pronase [0314]
  • 2-9 mg samples of dGAGP were digested with pronase or chymotrypsin as detailed earlier [Kieliszewski et al. (1992) Plant Physiology 99:538]. The digests were then freeze-dried. [0315]
  • E. Fractionation of dGAGP chymotryptic peptides by cation exchange HPLC [0316]
  • dGAGP chymotryptic peptides (400 mg/injection) were fractionated on a PolySULFOETHYL A™ cation exchange column (9.4 mm i.d.×200 mm; PolyLC, Ellicot City, Md.) equilibrated with Buffer A (5mM potassium phosphate/phosphoric acid buffer, [0317] pH 3, containing 25% v/v acetonitrile) and eluted with Buffer B (Buffer A containing 1 M KCl) using progranuned gradient elution. The elution gradient was 0-4% Buffer B in 45 min., 4-8% Buffer B from 45 to 50 min, and 8-30% Buffer B. from 50-65 min. The flow rate was 0.4 mL/min and the absorbance was monitored at 220 nm. The collected peaks were pooled, blown down with N2 (g), redissolved in ddH2O, then freeze dried.
  • F. Peptide isolation via reverse phase HPLC [0318]
  • The partial pronase digest of dGAGP and major peaks S1 and S2 PolySULFOETHYL Aspartamide column were dissolved in Buffer A (0.1% TFA, aqueous) and injected onto a Hamilton PRP-1 analytical reverse phase column (4.1 mm i.d.×150 mm) which was eluted at 0.5 mL/min with a Buffer B (0.1% TFA and 80% v/v acetonitrile) gradient of 0-50% in 100 min. The effluent was monitored at 220 nm and collected peaks were blown down with N[0319] 2(g), re-dissolved in ddH2O, and then freeze dried prior to sequencing. For increased resolution of pronase peptide P3 (FIG. 6), P3 was run through the PRP-1 column a second time, eluting with a 0-30% Buffer B gradient.
  • G. Automated Edman Degradation of dGAGP chymotryptic peptides [0320]
  • dGAGP peptides were sequenced at the Michigan State University Macromolecular Facility on a 477A Applied Biosystems (Foster City, Calif.) gas phase sequencer. [0321]
  • H. Amino Acid Analysis [0322]
  • Amino acid compositions were determined by precolumn derivatization of amino acids with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate followed by reverse-phase HPLC (Nova-Pak™ C[0323] 18 column) using the Waters AccQ-Tag Chemistry Package and the gradient recommended by Waters for analyzing collagen hydrolysates [Crimmins and Cherian (1997) Analytical Biochemistry 244:407; van Wandelen and Cohen (1997) Journal of Chromatography A 763:11].
  • Hydroxyproline Glycoside Profile. The distribution of GAGP hydroxyproline glycosides was determined after alkaline hydrolysis (105, 18 h, 0.22 N Ba(OH)[0324] 2) and neutralization followed by chromatography on a 75×0.6 cm Technicon Chromobeads C2 cation exchange resin as described earlier [Lamport and Miller (1971) Plant Physiology 48:454].
  • I. Isolation of the Hyp-polysaccharide [0325]
  • Alkaline hydrolysates (see above) of Superose-6 and PRP-1 purified GAGP were loaded onto a G-50 Sephadex gel permeation column eluted isocratically with 100 mM ammonium acetate buffer, pH 6.8, at a flow rate of 0.3 ml/min. One ml fractions were collected and 40 ml aliquots of each fraction were assayed for Hyp as described earlier [Kivirikko and Liesmaa (1959) Scandinavian Journal of Clinical Laboratories 11:128; Kieliszewski et al. (1990) Plant Physiology 92:316]. The fractions were freeze-dried, then weighed, and the amounts of Hyp and sugar in the fractions were calculated from the recovered weights, Hyp assays, and monosaccharide composition analyses. [0326]
  • J. Partial alkaline hydrolysis of GAGP [0327]
  • Superose-fractionated GAGP (10 mg/ml) was dissolved in 0.2 N NaOH/NaBH[0328] 4 and heated it at 50° C. as described earlier [Akiyama and Kato (1984) Agricultural and Biological Chemistry 48:235]. A 200 ml aliquot was removed immediately (time zero control) and hourly for 6 h, cooled in ice, then 20 ml glacial acetic acid was added (final pH=5.8). Each sample was assayed for Hyp as described earlier [Kivirikko and Liesmaa (1959) Scandinavian Journal of Clinical Laboratories 11:128; Kieliszewski et al. (1990) Plant Physiology 92:316].
  • K. Saccharide composition and linkage analysis [0329]
  • Monosaccharide compositions and linkage analyses were determined at the Complex Carbohydrate Research Center, University of Georgia following the methods of York et al [York et al. (1985) Methods in Enzymology 118:3] and Merkle and Poppe [Merkle and Poppe (1994) Methods Enzymology 230:1]. [0330]
  • 2. Determination Of An Exemplary Consensus Sequence [0331]
  • Using the method of Qi et al. [Qi et al. (1991) supra] the inventors isolated GAGP via preparative Superose-6 gel filtration. For chymotryptic peptide mapping HF-deglycosylated GAGP was used. This gave a major symmetrical peak (designated dGAGP) when further fractionated by reverse phase chromatography as shown in FIG. 5. FIG. 5 is the elution profile for dGAGP by reverse phase chromatography on a Hamilton PRP-1 column and fractionation by gradient elution. The component at 35 min. was a Hyp-poor contaminant. [0332]
  • Amino acid analysis showed dGAGP had a highly biased but constant amino acid composition in fractions sampled across the peak (Table 5), indicating that dGAGP was a single polypeptide component sufficiently pure for sequence analysis. [0333]
    TABLE 5
    Amino acid compositions of glycosylated GAGP (GAGP) and
    deglycosylated GAGP (dGAGP) fractions obtained by reverse phase
    HPLC compared to dGAGP isolated by Qi et. al. [Qi et al. (1991)
    Plant Physiology 96:848]
    GAGP
    [Qi et
    dGAGP Peak Fractions* al. (1991)
    Amino Acid+ GAGP Ascending Center Descending supra]
    Hyp 40.0 38.4 36.7 36.3 36.9
    Asx 0.0 0.0 0.0 0.0 1.6
    Ser 22.2 21.6 21.6 22.5 19.4
    Glx 0.0 0.0 0.0 0.0 1.9
    Gly 4.5 4.8 4.4 4.3 6.4
    His 6.6 8.7 8.2 8.4 7.1
    Arg 0.0 0.0 0.0 0.0 0.0
    Thr 10.2 10.6 12.2 11.4 8.8
    Ala 1.2 0.7 0.8 1.0 1.3
    Pro 8.0 7.6 8.3 8.1 6.8
    Tyr 0.0 0.0 0.0 0.0 0.3
    Val 0.0 0.0 0.0 0.0 0.8
    Met n.d.++ n.d.++ n.d.++ n.d.++ n.d.++
    Lys 0.0 0.0 0.0 0.0 1.0
    Ile 0.2 0.0 0.0 0.0 0.4
    Leu 6.4 7.6 7.8 8.1 6.4
    Phe 0.5 0.0 0.0 0.0 0.9
    Trp n.d.++ n.d.++ n.d.++ n.d.++ n.d.++
    Cys 0.0 0.0 0.0 0.0 0.0
  • This was confirmed by the isolation of peptides (Table 6) similar in composition to one other and to the parent GAGP (Table 5). [0334]
    TABLE 6
    Pronase and chymotryptic peptide sequences from
    the dGAGP Polypeptide Backbone
    Sequence
    Pronase Peptide
    P1 (SEQ ID NOs:184, SOOTLSOSOTOTOOOGPHSOOO(O)-
    185)
    P3 (SEQ ID NOs:186, SOOO(T/S)LSOSOTOTXOO-
    187)
    PH3G2+ (SEQ ID NO:         SOSOTOTOOOGP
    188)
    Chymotryptic Pep-
    tide
    S1P2 (SEQ ID NO: SOOOSLSOSOTOTOOTGPH
    189)
    S1P3 (SEQ ID NO: SOOOOLSOSOTOTOOOGP-
    190)
    S1P4 (SEQ ID NOs: SOLPTLSOLP(A/T)OTOOOGPH
    191, 192)
    S1P5 (SEQ ID NO: SOOOOLSOSLTOTOOLGP-
    193)
    S2P1 (SEQ ID NO:         SOSOTOTOOOGPH
    194)
    S2P2a (SEQ ID NO:         SOSOAOTOOLGPH
    195)
    S2P2b (SEQ ID NO:         SOLPTOTOOLGPHS
    196)
    S2P3 (SEQ ID NO:         SOSOTOTOOLGPH
    197)
    S2P4 (SEQ ID NO:         SOOLTOTOOLLPH
    198)
    Consensus++ (SEQ ID SOOO(O/T/S)LSOSOTOTOO(O/L)GPH
    NO:179)
  • Although native GAGP resists pronase digestion [Akiyama and Kato (1984) Agricultural and Biological Chemistry 48:235; Chikamai et al. (1996) Food Hydrocolloids 10:309], which only generates large fragments of ˜200 kDa [Connolly et al. (1988) Carbohydrate Polymers 8:23], preliminary work in Lamport's laboratory showed that exhaustive digestion with pronase effectively cleaved dGAGP to small peptides [Delonnay (1993) Masters Thesis, Michigan State University, Mich.] However, the peptides lacked some of the amino acids present in Qi et al.'s empirical formula: Hyp[0335] 4 Ser2 Thr Pro Gly Leu His (SEQ ID NO:199) of the repeat motif suggested by Qi et. al. [Qi et al. (1991) supra], most notably His (Table 6, peptide PH3G2.) Therefore, a partial pronase digestion of dGAGP was performed. This gave two large major peptides P1 and P3, as shown in FIG. 6, with partial sequences (Table 6) containing all of the amino acids in the empirical formula.
  • dGAGP was also digested with chymotrypsin, which slowly cleaved leucyl and histidyl bonds, followed by a two-stage HPLC fractionation scheme. Initial separation of the chymotryptides on a PolySULFOETHYL A™ (PolyLC, Inc. Ellicott City, Md.) cation exchanger yielded two major fractions designated S1 and S2 (FIG. 7). The major chymotryptic fractions, S1 and S2, were collected for further fractionation by reverse phase column chromatography. Further chromatography on a Hamilton PRP-1 reverse phase column resolved fraction S1 into five major peptides labeled S1P1-S1IP5, while fractionation of S2 resolved four major peptides, designated S2P1-S2P4, which were sequenced (FIGS. 8[0336] a & b). Edman degradation showed that these chymotryptides were closely related to each other and to the pronase peptides (Table 6). These peptides reflect the overall amino acid composition of GAGP and can be related to the 19-amino acid residue consensus sequence (SEQ ID NO:179) shown in Table 6.
  • From the above data, the inventors concluded that GAGP possesses a highly repetitive polypeptide, albeit with minor variations in the sequence. Based on a linear GAGP molecule of 150 nm [Qi et al. (1991) supra], and presuming the extended polyproline II helix present in both extensins and AGPs [Kieliszewski and Lamport (1994) Plant Journal 5:157; Nothnagel (1997) International Review of Cytology 174:195], the inventors estimate that GAGP contains about 20 peptide repeats with occasional partial repeats. Partial repeats of the consensus sequence may account for the somewhat higher serine content in native GAGP compared to that in the consensus sequence. [0337]
  • The exemplary 19-amino acid residue GAGP consensus sequence of Table 6 contains approximately nine Hyp residues and is roughly twice the size of that previously postulated to contain only a single polysaccharide attachment site [Qi et al. (1991) supra]. Judging from the Hyp-glycoside profile of GAGP (Table 7) [Qi et al. (1991) supra], about one in every five Hyp residues is polysaccharide-substituted. [0338]
    TABLE 7
    GAGP Hydroxyproline glycoside profile
    Percent of total hydroxy-
    Hydroxyproline glycoside proline
    Hyp-polysaccharide 20
    Hyp-Ara4 (SEQ ID NO:200) 5
    Hyp-Ara3 (SEQ ID NO:201) 27
    Hyp-Ara2 (SEQ ID NO:202) 27
    Hyp-Ara (SEQ ID NO:203) 10
    Nonglycosylated Hyp 11
  • Thus, there are approximately two Hyp-polysaccharide sites in the invention's exemplary consensus sequence. In order to determine which Hyp residues are involved in polysaccharide attachment, without limiting the invention to any particular mechanism, the inventors predict arabinosylation of contiguous Hyp residues and arabinogalactan-polysaccharide addition to clustered non-contiguous Hyp residues, such as the X-Hyp-X-Hyp modules common in AGPs [Nothnagel (1997) International Review of Cytology 174:195]. Based on this prediction, it is the inventor's view that the exemplary consensus sequence of Table 6 contains approximately two polysaccharide attachment sites in the clustered non-contiguous Hyp motif: Ser-Hyp-Ser-Hyp-Thr-Hyp which is flanked by arabinosylated contiguous Hyp residues as depicted in FIG. 9. FIG. 9 uses the standard single letter code for amino acids except for Hyp which is denoted by [Du et al. (1994) Plant Cell 6:1643], and the standard three letter code for sugars, except for glucuronic acid which is denoted as GlcA. This model depicts a symmetrical distribution of arabinosides and polysaccharide substituents which is directed by the palindrome-like arrangement of the Hyp residues in the peptide backbone; Ser-0 is the palindromic center. However degenerate variations occur (Table 6). The inventors base this structure on compositional and linkage analyses of the isolated Hyp-polysaccharide fraction (Tables 7 & 8) [Qi et al. (1991) supra] and on the pentasaccharide side-chain structure elucidated for crude gum arabic by Defaye and Wong [Defaye and Wong (1986) Carbohydrate Research 150:221] (corresponding to Rha[0339] t, Arat, 3-Ara, 4-GlcA, and 2,3,6-Gal in Table 9).
  • Hydroxyproline-O-glycosidic linkages are stable in base [Lamport (1967) Nature 216:1322; Miller et al. (1972) Science 176:918; Pope (1977) Plant Physiology 59:894], in contrast to other O-glycosylated hydroxyamino acids such as serine and threonine, which undergo β-elimination [Lamport et al. (1973) Biochemical Journal 133:125]. Therefore, alkaline hydrolysis was used to isolate and characterize Hyp-arabinogalactan polysaccharides from GAGP as demonstrated earlier [Qi et al. (1991) supra]. [0340]
  • Compositional analysis of the small Hyp-polysaccharides isolated from GAGP after fractionation of the alkaline hydrolysate on Sephadex G-50 (FIG. 10; Table 8) indicated a content of 5158 nM sugar. [0341]
    TABLE 8
    Glycosyl compositions of intact GAGP and a GAGP
    Hyp-polysaccharide isolated from GAGP base hydrolysates
    GAGP[Qi et al. (1991)
    supra] GAGP Hyp-polysaccharide
    Glycosyl Residue Mol%
    Ara 36 38
    Gal 46 34
    Rha 10 13
    GlcUA 9 15
  • In FIG. 10, assay of Hyp across the recovered fractions indicated a broad size range for the Hyp-polysaccharide (fractions 17-32). Fractions 27-30 were collected for linkage and composition analyses. Hyp arabinosides and non-glycosylated Hyp eluted in fractions 33-42. Corresponding quantitative Hyp assays showed a total of 220 nm Hyp in the peak isolated and analyzed (FIG. 10). The molar ratio of 220 nm Hyp: 5156 nm sugar indicated a ˜23-residue rhamnoglucuronoarabinogalactan Hyp-polysaccharide substituent in this fraction. Methylation analysis of the polysaccharide (Table 9) showed linkages consistent with the model featured in FIG. 9, but containing 21-22 sugar residues rather than the 23 featured in FIG. 9. [0342]
    TABLE 9
    Glycosyl linkages of Intact GAGP and a GAGP
    Hyp-polysaccharide isolated from the GAGP base hydrolysate
    GAGP GAGP Hyp-Polysaccharide
    Glycosyl Linkage Mol %
    t-Rha 6.7 10.4 (2)*
    2,3,4-Rha 3.3 0.0
    t-Ara (f) 13.3 16.2 (4)
    t-Ara (p) 1.7 2.3 (0-1)
    2-Ara (f) 2.5 0.0
    3-Ara (f) 8.3 11.0 (2-3)
    4-Ara (p) or 5-Ara (f) 1.7 0.0
    2,4-Ara or 2,5-Ara (f) 0.8 0.0
    2,3,4-Ara or 2,3,5-Ara (f) 2.5 0.0
    t-Gal 5.8 11.8 (3)
    2-Gal 0.8 0.0
    3-Gal 2.7 4.5 (1)
    4-Gal 0.8 0.5
    6-Gal 2.5 2.4 (0-1)
    3,4-Gal 2.5 7.7 (2)
    3,6-Gal 11.7 12.7 (3)
    3,4,6-Gal 10.0 9.4 (2)
    2,3,6-Gal 3.3 0.0
    2,3,4,6-Gal 5.8 0.0
    t-GlcUA 1.7 0.9
    4-GlcUA 7.5 10.2 (2)
    3,4-GlcUA 1.7 0.0
    2,4-GlcUA 0.8 0.0
    2,3,4-GlcUA 0.8 0.0
    4-Glc 0.8 0.0
  • Based on the above data, the inventors conclude that each small polysaccharide contains two pentasaccharide side chains (Gal, Ara[0343] 2, GlcA, Rha) arranged along a ˜7-residue (1-3)β-D-galactan backbone helix which also contains monosaccharide side chains of Ara and Gal.
  • Data presented herein demonstrates that the linkage analyses of both Hyp-polysaccharide and GAGP (Table 9) are similar, thus providing evidence of similarity between GAGP and gum arabic polysaccharides. These results suggest that the larger Hyp-polysaccharides (FIG. 10) may be comprised of repeat units containing approximately 12 galactose residues/repeat. Hence, without limiting the invention to any particular theory or mechanism, the inventors estimate that as many as five side-chains (˜40 sugars) occur in the larger arabinogalactan moieties which eluted in fractions 18-26 from the G-50 Sephadex column (FIG. 10). The inventors further believe that GAGP and other AGP sensitivity to alkaline degradation involves peptide bonds rather than glycosidic linkages. [0344]
    • EXAMPLE 19 Construction of 8, 16, 20, 32, and 64 Repeats of Gum Arabic Motifs and Expression in Plant Cells
  • This Example discloses construction of synthetic genes for the expression of gum arabic glycoprotein repeats based on the invention's consensus sequences. The genes had 8, 20, 32, or 64 contiguous units of two motifs [motif 1 (SEQ ID NO:143)=Ser-Hyp-Hyp-Hyp-Hyp-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Leu-Gly-Pro-His; motif 2 (SEQ ID NO:144)=Ser-Hyp-Hyp-Hyp-Thr-Leu-Ser-Hyp-Ser-Hyp-Thr-Hyp-Thr-Hyp-Hyp-Hyp-Gly-Pro-His], each of which is encompassed by the invention's consensus sequence. The 64 contiguous units [i.e., (motif 1-motif 2)[0345] 32] were constructed using a modification of the previously described [Lewis et al. (1996) Protein Expression & Purification 7:400-406] strategy involving compatible but nonregenerable restriction sites, which allowed construction of very large inserts with precise control over the number of DNA repeat number.
  • 1. Site-directed Mutagenesis of pUC18 to Eliminate BsrFI Restriction Site From the Amp[0346] r Gene
  • Plasmid pUC18 has an endogenous BsrFI site in the Amp[0347] r gene. This site was eliminated by mutation to make the plasmid amenable to subcloning of the XmaI-BsrFI synthetic gene fragments, using the PCR core system I kit (Promega). The PCR Primer 1: (upstream primer) had the sequence (SEQ ID NO:204) GATACCGCGAGACCCACGCTC ACCAGCTCC; this primer was designed from nucleotides 1756 to 1785 of pUC18 except for 1 substitution (A for G) at position 1780 (bolded and underlined). This changes one Ala codon (GCC) for another (GCT), retaining the Ampr amino acid sequence while mutating the BsrFI site. PCR Primer 2: (downstream primer) had the sequence (SEQ ID NO:205) CTCGGTCGCCGCATACACTAT and was designed from nt 2220 to 2198 of pUC18. The PCR reaction conditions were 2 min @ 95° C., 30 sec @ 95° C., 1 min @ 48° C., 1 min @ 72° C. (30 cycles), 5 min @ 72° C. PCR products were separated on a 1.5% agarose gel. The 464 bp PCR fragment was extracted from the gel using the QLAEX II gel extraction kit. The isolated fragment was restricted and subcloned into pUC18 as a ScaI-BpmI fragment. The new plasmid was designated MpUC18 and has an active Ampr gene and no BsrFI site.
  • 2. Synthesis of Gum Arabic Glycoproteins (GAGP) Repeats Using Mutually Priming Oligonucleotides [0348]
  • DNA encoding gum arabic glycoprotein contiguous units of [0349] motif 1 linked to motif was constructed using previously described methods [Current Protocols in Molecular Biology section 8.2.8-8.2.10]. A DNA fragment encoding the two GAGP motifs was synthesized by primer extension of two partially overlapping synthetic oligonucleotides: First oligonucleotide (SEQ ID NO:206): 5′-G GCA AGC TTC CGG AGT GCC GGC CCT CAT AGC CCA CCT CCA CCA TTA TCA CCA TCA CCT ACT CCA ACT CCT CCT TTG GGA CCA CAC AG-3′; second oligonucleotide (SEQ ID NO:207): 5′-GGT CCC GGG GGG TGG TGT TGG GGT TGG TGA AGG GGA AAG TGT AGG GGG TGG ACT GTG TGG TCC CAA AGG AGG-3′. The oligonucleotides (0.05 nm of each) were heated for 5 min @ 95° C., annealed for 5 min @ 48° C., then extended by DNA polymerase I Klenow fragment (Promega) for 30 min @ 37° C. The reaction was stopped by heating 10 min at 75° C. and the buffer was exchanged via a Sephacryl S-200 column (Pharmacia Microspin™). The plasmid was then subcloned into MpUC18 as a Hind I-XmaI fragment. The plasmid was sequenced with the pUC/M13 forward primer (17-mer).
  • 3. Multiplication of GAGP Internal Repeat Using Nonregenerable Restriction Sites [0350]
  • Synthetic genes containing controlled numbers of GAGP repeats were synthesized as follows, and as illustrated in FIG. 15. MpUC18 containing the PCR product described above (two GAGP motifs as shown in FIG. 16A) (designated MpUC gum-2) was divided between two tubes. MpUC gum-2 in tube I was restricted with ScaI and BsrFI; MpUC gum-2 in [0351] tube 2 was restricted with ScaI and XmaI. The digests were separated on a 1% agarose gel. The 1884 kb band from tube 1 (ScaI/BsrFI digest) and the 1044 kb band from the tube 2 (ScaI/XmaI digest) were excised from the gel, combined and ligated together. The resulting plasmid (MpUC gum-4) contained 4 GAGP internal repeats [i.e., (motif 1-motif 2)2] (FIG. 16B). This strategy was successfully used to build plasmids containing 8, 16, 20, 32, and 64 internal repeats of GAGP.
  • 4. Subcloning of Synthetic Gum Repeats Into pUC ss-EGFP Plasmid [0352]
  • The gum genes (gum-8, gum-20, and gum-32) were removed from MpUC18 plasmid as BspEI/SacI fragments and subcloned into pUC ss-EGFP plasmid behind the signal sequence. During this subcloning, EGFP was removed from pUC ss-EGFP as XmaI/SacI fragment. XmaI and BspEI restriction sites are compatible but nonregenerable. [0353]
  • The next subcloning was done to put the EGFP gene in frame behind the gum sequences. pUC ss-EGFP plasmid was cut with XmaI and treated with Mung Bean endonuclease (New England Biolabs). The enzymes were inactivated by phenol/chloroform extraction followed by ethanol precipitation. Then plasmid was cut with SacI. The EGFP fragment isolated after restriction was subcloned into pUC ss-gum plasmids which was cut with SmaI/SacI restriction enzymes. The signal sequence-synthetic gene-EGFP fragments were removed from MpUC18 plasmid as BamHI/SacI fragments and subcloned into pBI121, replacing the β-glucuronidase reporter gene. The MpUC ss-gum[0354] 20-EGFP and MpUC ss-gum32-EGFP plasmids were sequenced with pUC/M13 forward (17 mer) primer and with GFP primer GAAGATGGTGCGCTCCTGGACGT (SEQ ID NO:226) from nucleotide 566 to nucleotide 588 of pEGFP.
  • 5. Transformation of Tobacco Cultured Cells, Tobacco Leaf Discs, and Tomato Cultured Cells, and Expression of Multiple GAGP Internal Repeats [0355]
  • The expression vectors contained an extension signal sequence or a tomato signal sequence for transport of the constructs through the ER/Golgi for posttranslational modification, as well as Green Fluorescent Protein (GFP) as a reporter protein as described below. [0356]
  • A. Extensin Signal Sequence [0357]
  • Transformation vectors were derived from pBI121 (Clontech). These vectors contained an extensin signal sequence (SS) as well as Green Fluorescent Protein (GFP) as a reporter protein. 8, 20, 32, and 64 internal repeats of GAGP were inserted between the signal sequence and GFP to yield plasmids SS-GAGP[0358] 8-EGFP, SS-GAGP20-EGFP, SS-GAGP32-EGFP, and SS-GAGP64-EGFP, respectively. Because preliminary data showed that the gene encoding the 64 repeats of GAGP was unstable in pBI12, plasmids SS-GAGP8-EGFP, SS-GAGP20-EGFP, and SS-GAGP32-EGFP were used to transform Agrobacterium tumefacienes as described supra (Example 9).
  • B. Tomato LeAGP-1 Signal sequence [0359]
  • As an alternative to the extensin signal sequence, the tomato LeAGP-1 signal sequence was used. Cloning of the LeAGP-1 signal sequence was as follows using the [0360] sense primer 5′-CTC TTT TTC TCT G↓GA TCC GGT CTA TAT TTT CTT TTA GC-3′ (SEQ ID NO:227) (Tm: 68° C.) with the arrow showing the BamHI restriction site, and the antisense primer 5′-CGG GTG CTG C↓CC GGG TTG TCT GAC CCG TGA CAC TTG C-3′ (SEQ ID NO:228) (Tm: 80° C.) with the arrow showing the XmaI restriction site.
  • PCR was carried out using 52.8 pmol of sense primer and 47 pmol of antisense primer. The LeAGP-1 signal sequence template (0.01 μg) was added together with the PCR mixture. The reaction solution was covered with oil and the incubation was at 95° C. 5 min (circle one); 95° C. 45 sec, 58° C Imin, 74° C. 1 min (circle 2-30); 74° C. 5 min. 20 μl out of 50 μl total PCR solution was removed and purified using 2% agarose gel. The PCR product was 127-bp in size and was isolated by using QIAEXII kit. This fragment was digested as follows at 37° C. overnight.: [0361]
    Purified PCR fragment 100 ng pUC-SSTobGFP 200 ng
    BamH1 5 u BamH1 2 u
    Xmal 4 u Xmal 2 u
    Buffer B
    3 μl Buffer B 3 μl
    Add water to 30 μl Add water to 30 μl
  • The digested samples were run on an agarose gel. The vector and fragment were cut from the gel and were isolated with the QIAEXII kit. The ligation reaction [pUC-SS[0362] TobGFP(BX) 100 ng, PCR fragment(BX) 20 ng, Ligase Buffer (10×) 1 μl, Ligase 1 μl] was incubated at 10° C. overnight.
  • Transformation was carried out and 3 clones were cultured separately in LB media containing ampicillin overnight. Plasmids were isolated from the transformed cells and digested with BamH1 and Xmal to confirm that the fragments were 99 bp long. The plasmid containing the tomato signal sequence was named pUC-SS[0363] Tom-GFP.
  • Plasmids containing the tomato signal sequence in tandem with repeating. GAGP sequences and with EGFP as a reporter gene is used to transform [0364] Agrobacterium tumefacienes as described supra (Example 9).
  • The transformed Agrobacterium cells were used to transform tobacco cultured cells as described above (Example 10). Transformed cells were selected by detection of fluorescent cells which express GFP. [0365]
  • Transformed Agrobacterium cells will be used to transform tomato cultured cells and tobacco discs as described above (Examples 11 and 17, supra). Transformed cells will be selected by detection of fluorescent cells which express GFP. Successful expression of 8, 20, and 32, internal repeats of GAGP in tobacco cultured cells, tobacco leaf discs, and tomato cultured cells will be confirmed using the methods described in the above Examples. [0366]
    • EXAMPLE 20 Construction of Genes and Vectors Containing Contiguous and Noncontiguous Hydroxyproline glycomodules (SP)32, (GAGP)3, (SPP)24, (SPPP)16, and (SPPPP)18
  • This Example describes construction of three plasmids, each encoding a tobacco signal sequence and EGFP, as well as subcloning of (SP)[0367] 32, (GAGP)3, EGFP, (SPP)24, (SPPP)16, (SPPPP)18. In the three plasmids described here, the signal sequence was used to direct the products through the ER and Golgi, then out to the extracellular matrix [Goodenough et al. (1986) J. Cell Biol. 103 , 403; Gardiner & Chrispeels (1975) Plant Physiol. 55, 536-541]. Two of the plasmids also contained a synthetic gene (SEQ ID NOs:112, 113, 115, 116) encoding either six (Ser-Pro) internal repeat units (SEQ ID NO:117) or three (GAGP) internal repeat units (SEQ ID NO:122) (FIG. 11) sandwiched between the signal sequence and gene-enhanced green fluorescent protein (EGFP). In FIG. 11, internal repeat oligonucleotide sets encoding Ser-Pro repeats or the GAGP sequence were polymerized head-to-tail in the presence of the 5′-linker set [SEQ ID NOs:120 and 121 which encode SEQ ID NO:122]. Following ligation, the 3′-linker [SEQ ID NOs:123 and 124 which encode SEQ ID NO:125] was added and the genes then restricted with BamHI and EcoRI and inserted into pBluescript II SK. The signal sequence (SEQ ID NOs:118 and 119) was built by primer extension of the overlapping oligonucleotides featured here. The overlap is underlined.
  • The conserved (Ser-Hyp)[0368] n motif was chosen because it occurs both in green algae (Chlamydomonas) and in higher plant AGPs. This noncontiguous Hyp motif is of particular interest because it also occurs together with a contiguous Hyp motif in the consensus sequence of GAGP which contains both oligoarabinoside and polysaccharide addition sites.
  • The signal sequence (FIG. 11) was modeled after an extensin signal sequence from [0369] Nicotiana plumbaginifolia; mutually priming oligonucleotides were extended by T7 DNA Polymerase and the duplex placed in pUC18 as a Bam HI-Sst I fragment. Construction of a given synthetic gene involved the polymerization of three sets of partially overlapping, complementary oligonucleotide pairs as described earlier (FIG. 11). The following subclonings were required to create DNA fragments/restriction sites which allowed facile transfer of the Signal Sequence-synthetic gene-enhanced green fluorescent protein (EGFP) unit to the plant transformation vector pBI121 (Clontech): The synthetic genes were placed in pBluescript II SK (Stratagene) as BamHI-EcoRI fragments and then subcloned the genes into pEGFP (Clontech) as BamHI-AgeI fragments preceding the EGFP gene (Tsien, R. Y. (1998) Annu. Rev. Biochem. 67,509-544; Haseloff, J., Siemering, K. R., Prasher, D. C. & Hodge, S. (1997) Proc. Natl. Acad. Sci. 94, 2122-2127.22). The synthetic gene-EGFP fragments were then subcloned into pBluescript II KS (Stratagene) as XmaI/NotI fragments, removed as XmaI-SstI fragments and subcloned into pUC18 behind the signal sequence. DNA sequences were confirmed by sequence analysis before insertion into pBI121 as BamHI/SstI fragments, replacing the b-glucuronidase reporter gene. All constructs were under the control of the 35S cauliflower mosaic virus promoter. The oligonucleotides were synthesized by Lifesciences (Gibco/BRL). An Ala for Pro/Hyp substitution at residue 8 of the gum arabic glycoprotein (GAGP) internal repeat module (SEQ ID NO:208) (Ser-Pro-Ser-Pro-Thr-Pro-Thr-Pro-Pro-Pro-Gly-Pro-His-Ser-Pro-Pro-Pro-Thr-Leu) was inadvertently introduced during synthesis by a G for C base substitution in the sense strand.
  • The following is a more detailed description of the protocol used to subclone (SP)[0370] 32, (GAGP)3, EGFP, (SPP)24, (SPPP)16, (SPPPP)18. Briefly, Everything was first built and sequenced in pUC18, then transferred as a block (i.e., signal sequence-synthetic gene-EGFP) to pBI121. The constructs in pBI121 were not sequenced. The pBI121 plasmids were used to transform Agrobacterium and the transformed Agrobacterium was used to transform the plant cells, as described infra in Example 21.
  • 1. Synthesis of the Signal Sequence [0371]
  • The signal sequence was assembled by using mutually priming oligonucleotides [Current Protocols in Molecular Biology,” (1995) pages 8.2.8-8.2.10]. Oligonucleotides (0.2 nmol, 0.2 nmol) were annealed (5 min at 70° C. followed by 5 min at 40° C.) and extended by DNA polymerase I (Klenow) large fragment (Promega) (30 min at 37° C.). The reaction was stopped by heating 10 min at 75° C. The resulting DNA fragment was cut with BamHI and SstI enzymes and was placed in pUC18 plasmid. The plasmid was sequenced with pUC/M13 forward (17 mer) primer. [0372]
  • 2. Synthesis and Subcloning of Synthetic Genes [0373]
  • Oligonucleotides were synthesized and SDS-PAGE purified by Gibco-BRL or Integrated DNA Technologies Inc. They were dissolved in water at appropriate concentrations. [0374]
  • A. (SP)[0375] 32 and (GAGP)3 synthesis and subcloning
  • i. Annealing reaction [0376]
  • Oligonucleotide-pairs were combined in eppendorf tubes as follows: [0377]
  • a) 5.5 μl internal repeat sense oligonucleotide (0.5 nmol/μl) [0378]
  • 5.5 μl internal repeat antisense oligonucleotide (0.5 nmol/μl) [0379]
  • 11 μl T4 ligase 10× ligation buffer [0380]
  • b) 2 [0381] μl 5′-end sense linker (0.05 nmol/μl)
  • 2 [0382] μl 5′-end antisense linker (0.05 nmol/μl)
  • 1 μl water [0383]
  • 5 μl T4 ligase 10× ligation buffer [0384]
  • c) 2 [0385] μl 3′-end sense linker (1 nmol/μl)
  • 2 [0386] μl 3′-end antisense linker (1 nmol/μl)
  • 1 μl water [0387]
  • 5 μl T4 ligase 10× ligation buffer [0388]
  • All tubes were heated 5 min at 90-95° C. Then they were cooled to 45° C. over next 3 hours and kept at 45° C. for 2 more hours. [0389]
  • ii. Oligonucleotide polymerization [0390]
  • 10 μl of the internal repeat pair was combined with 10 μl of the 5′-end linker pair (15:1 molar ratio). This mixture was incubated 3 hour at 17° C. Then, 80 μl of water (to receive 1× concentration of ligation buffer) and 2 μl of T4 DNA ligase (4,000 U) were added. The ligation reaction was incubated 36 hours at 12-15° C. The extent of polymerization was checked on 2.2% agarose gel. [0391]
  • The 5′-end linker-internal repeat polymers were capped with the 3′-end linker. 5 μl of the 3′-end linker were added to 50 μl of ligation reaction from the step above. The mixture was heated to 30° C. (to destroy unspecific hybridization), and incubated at 17° C. for 3 hours. 20 μl of water and 2 μl T4 DNA ligase (4,000 U) were added and the ligation reaction was incubated at 12-15° C. for 36 hours. The reaction was stopped by heating at 65° C. for 10 min. [0392]
  • The constructs were ethanol precipitated, washed with 70% ethanol and air dried. The pellet was dissolved in 80 μl of water. 10 μl was used for restriction with EcoRI (10 Units) and BamHI (20 Units). The Sephacryl S-400 column (Pharmacia Microspin™) was used to remove salts and small oligonucleotide fragments. Qiaquick Nucleotide removal kit (Qiagen) was used to remove enzymes. The resultant fragments were inserted in pBluescript II SK plasmid (Stratagene) The selection of clones was done by white-blue assay. The structure of synthetic genes was checked by sequencing with pUC/M13 forward (17 mer) primer. [0393]
  • iii. Subcloning [0394]
  • The synthetic genes were first removed from pBluescript II SK (Strategene) as BamHI/AgeI fragments and subcloned in pEGFP (Clontech). (This step allowed directional cloning). The synthetic gene—EGFP fragments were removed from pEGFP as XmaI/NotI fragments and subcloned in KS (Stratagene) (This step was done to obtain SstI site at the end of EGFP). The synthetic gene—EGFP fragments were removed from KS as XmaI/SstI fragments and subcloned in pUC-signal sequence plasmid behind the signal sequence. The structure of the synthetic genes was checked by sequencing with pUC/M13 forward (17 mer) primer. The signal sequence-synthetic gene-EGFP fragments were removed from pUC18 plasmid as BamHI/SstI fragments and subcloned in pBI121 (Clontech). [0395]
  • iv. EGFP subcloning [0396]
  • The EGFP fragment was removed from pEGFP as XmaI/NotI fragments and subcloned in KS. (This step was done to obtain SstI site at the end of EGFP). The EGFP fragment was removed from KS as XmaI/SstI fragments and subcloned in pUC-signal sequence plasmid behind the signal sequence. The signal sequence-—EGFP fragment was removed from pUC18 plasmid as BamHI/SstI fragments and subcloned in pBI121. [0397]
  • B. (SPP)[0398] 24, (SPPP)16, (SPPPP)18, Palindromic repeat synthesis and subcloning
  • i. Annealing reaction [0399]
  • Oligonucleotide-pairs were combined in eppendorf tubes as follows: [0400]
  • a) 2 μl internal repeat sense oligonucleotide (0.25 nmol/μl) [0401]
  • 2 μl internal repeat antisense oligonucleotide (0.25 nmnol/μl) [0402]
  • 3 μl T4 ligase 10× ligation buffer [0403]
  • 23 μl water [0404]
  • b) 1 [0405] μl 5′-end sense linker (0.5 nmol/μl)
  • 1 [0406] μl 5′-end antisense linker (0.5 nmol/μl)
  • 4 μl T4 ligase 10× ligation buffer [0407]
  • 34 μl water [0408]
  • c) 2 [0409] μl 3′-end sense linker (0.25 nmol/μl)
  • 2 [0410] μl 3′-end antisense linker (0.25 nmol/μl)
  • 3 μl T4 ligase 10× ligation buffer [0411]
  • 23 μl water [0412]
  • All tubes were heated to 90-95° C. for 5 min. Then they were cooled to annealing temperature () over next 30 min and kept at that temperature for 1 more hour. [0413]
  • ii. Oligonucleotides polymerization [0414]
  • 25 μl of internal repeat pair was combined with 20 μl of 5′-end linker pair (1.5:1 ratio). The mixture was heated to 35° C. to destroy circular structures formed by internal repeat pair. After cooling to 20° C. 0.5 μl of T4 DNA ligase (1.5 U) was added. The ligation reaction was incubated 3 hours at 20° C. 3 μl of ligation mixture was used to check the extent of polymerization on 2% agarose gel. [0415]
  • The 5′-end linker-internal repeat polymers were capped with 3′-end linker. I added 15 μl of the 3′-end linker to 40 μl of ligation reaction from step above and 0.5 μl of T4 DNA ligase (1.5 U). The ligation reaction was incubated 3 hours at 20° C. The reaction was stopped by heating at 65° C. for 10 min. 3 μl of ligation mixture was used to check the extent of polymerization on 2% agarose gel. The Sephacryl S-200 column (Pharmacia Microspin)™ was used to remove salts. 4-6 μl of solution was used for restriction with EcoRI (10 Units) and BamHI (20 units). After restriction, 150-bp to 500-bp fragments were cut out of 2% agarose gel. QIAEX II gel extraction kit was used to isolate fragments from the gel. [0416]
  • The resultant fragments were inserted in pUC18 plasmid. The selection of clones was done by white-blue assay. The structure of synthetic genes was checked by sequencing with pUC/M13 forward (17 mer) primer. [0417]
  • iii. Subcloning [0418]
  • The synthetic genes were removed from pUC18 as XmaI/NcoI fragments and subcloned behind the signal sequence and in front of EGFP in pUC-signal sequence-EGFP plasmid. The signal sequence-synthetic gene-EGFP fragments were removed from pUC18 plasmid as BamHI/SstI fragments and subcloned in pBI121. [0419]
  • The above protocols yielded pBI121 expression constructs in which genes encoding each of (SP)[0420] 32, (GAGP)3, EGFP, (SPP)24, (SPPP)16, (SPPPP)18 palindromic repeats were ligated to sequences encoding the signal sequence and EGFP.
    • EXAMPLE 21 Transformation of Tobacco Cells And Selection of Transformed Cell Lines
  • This Example describes transformation of suspension cultured tobacco cells with the expression vectors of Example 20 and selection of transformants which express green fluorescent protein. [0421]
  • Suspension cultured tobacco cells ([0422] Nicotiana tabacum, BY2) were transformed with Agrobacterium tumifaciens strain LBA4404 containing the pBI121-derived plant transformation vector. Transformed cell lines were selected on solid Murashige-Skoog medium (Sigma # 5524) containing 100 mg/mL kanamycin. Timentin was initially included at 400 mg/mL to kill Agrobacterium. Cells were later grown in 1 L flasks containing 560 mL Shenck-Hildebrand medium (Sigma # 6765) and 100 mg/mL kanamycin, rotated at 100 rpm on a gyrotary shaker.
  • After transformation of tobacco cells with Agrobacterium harboring the plant transformation plasmid pBI121 outfitted with either Sig-(GAGP)[0423] 3-EGFP, Sig-(Ser-Pro)32-EGFP, or Sig-EGFP (described in Example 20), selection on solid medium and subsequent growth in liquid culture yielded cells bathed in a green fluorescent medium. The fluorescence in these highly vacuolated, cultured cells surrounds the nuclei, but is not within judging by optical sections (not shown). The microscope was a Molecular Dynamics Sarastro 2000 confocal laser scanning microscope using a 488 nm laser wave length filter, 510 nm primary beam splitter and a 510 nm barrier filter.
  • This Example demonstrates that inclusion of the EGFP reporter protein facilitated the selection of transformed cells and subsequent detection of the expression products during isolation (FIGS. 13 & 14). EGFP fluorescence in the growth medium was also a visual demonstration of Sig efficacy in directing secretion. The absence of any obvious cell lysis in the cultures and excellent product yields of the glycosylated expression products confirmed that the green fluorescence represented bona fide secretory products. Interestingly, EGFP without a glycomodule was secreted at very low levels, perhaps due to lower solubility. [0424]
    • EXAMPLE 22 Isolation of (Ser-Hyp)32-EGFP, (GAGP)3-EGFP, (SPP)24-EGFP, (SPPP)16-EGFP, and (SPPPP)18-EGFP From Transformed Cells
  • This Example describes the isolation of sequences containing contiguous and noncontiguous Hyp residues from the growth medium of tobacco cells transformed with expression vectors which express these polypeptides. [0425]
  • Culture medium of cells described in Example 21, supra, was harvested 7 to 21 days after subculture, and the gene products were purified by gel permeation and reverse-phase chromatography (FIGS. 13 and 14) as follows. Culture medium was concentrated ten fold via rotovapping, then injected onto a Superose-12 gel filtration column (Pharmacia) equilibrated in 200 mM sodium phosphate buffer, [0426] pH 7, and eluted at a flow rate of 1 mL/min. EGFP fluorescence was monitored by a Hewlett-Packard 1100 Series flow-through fluorometer (Excitation=488 nm; Emission=520 nm). The Superose-12 column was calibrated with molecular weight standards (BSA, insulin, catalase, and sodium azide). Fluorescent Superose-12 fractions were injected directly onto a Hamilton PRP-1 reverse phase column and gradient eluted at a flow rate of 0.5 mL/min. Start buffer consisted of 0.1% TFA (aq) and elution buffer was 0.1% TFA/80% acetonitrile (aq). The sample was repeatedly injected (0.5 mL/minute) onto the column over 35 min, then eluted with a gradient of elution buffer (0-70% /135 min). Native GAGP was isolated from gum arabic nodules as described by Qi et. al. Endogenous tobacco AGPs were isolated as by PRP-1 reverse-phase and the results are shown in FIG. 13. FIG. 13 shows PRP-1 reverse-phase fractionation of the Superose-12 peaks containing (A) (Ser-Hyp)32-EGFP, (B) (GAGP)3-EGFP, and (C) Glycoproteins in the medium of non-transformed tobacco cells. Endogenous tobacco AGPs eluted between 47 and 63 minutes; extensins eluted at 67 min. (C) Control medium collected from non-transformed tobacco cells was first fractionated on Superose-12 and the fractions eluting between 47 and 63 min collected for further separation on PRP-1 to determine if any endogenous AGPs/HRGPs co-chromatographed with (Ser-Hyp)32-EGFP or with (GAGP)3-EGFP, which they did not.
  • Six cell lines examined [three each of (Ser-Hyp)[0427] 32-EGFP and (GAGP)3-EGFP] synthesized fluorescent glycoproteins of comparable sizes, although product yields between lines differed as much as ten-fold. For product characterization high-yielding lines were chosen which typically produced 23 mg/L of (Ser-Hyp)32-EGFP and 8 mg/L of (GAGP)3-EGFP after isolation.
  • FIG. 12 shows Superose-12 gel permeation chromatography with fluorescence detection of (A) culture medium containing (Ser-Hyp)[0428] 32-EGFP, (B) (GAGP)3-EGFP medium concentrated four-fold, (C) Medium of EGFP targeted to the extracellular matrix (concentrated ten-fold), and (D) 10 mg standard EGFP from Clontech. Not shown is the fractionation of medium from non-transformed tobacco cells, which gave no fluorescent peaks consistent with the results discussed above. Superose-12 fractionation of the two fusion glycoproteins (FIG. 12) compared to molecular weight standards (not shown) indicated mass ranges of ˜95-115 kD for (Ser-Hyp)32-EGFP and ˜70-100 kD for (GAGP)3-EGFP. The above data demonstrates successful isolation of GAGP sequences from cells which had been transformed with vectors that are capable of expressing these sequences.
  • The recombinant (SPP)[0429] 24-EGFP, (SPPP)16-EGFP, and (SPPPP)18-EGFP were isolated from transformed cells as described supra in this Example with respect to (SP)32-EGFP and (GAGP)3-EGFP.
    • EXAMPLE 23 Characterization of Glycoproteins Isolated from Transformed Cells
  • The glycoproteins isolated from transformed tobacco cells as described in Example 22 were characterized as follows, and were shown to be new arabinogalactan-proteins (AGPs). [0430]
  • 1. Co-precipitation with Yariv Reagent [0431]
  • (Ser-Hyp)[0432] 32-EGFP, (GAGP)3-EGFP, tobacco AGPs, and native GAGP were co-precipitated with the Yariv reagent as described earlier. Both (Ser-Hyp)32-EGFP and (GAGP)3-EGFP precipitated with Yariv reagent (Table 10), which is a specific property of b-1,3-linked arabinogalactan-proteins.
    TABLE 10
    Yariv Assay of (Ser-Hyp)32 - EGFP and (GAGP)3 - EGFP
    Absorbencies at 420 nm
    Sample Standards
    Weight Tobacco
    (μg) (Ser-Hyp)32 - EGFP (GAGP)3 - EGFP GAGP AGP
    20 0.16 0.27 0.51 0.16
    50 0.45 0.56 1.22 0.38
    100 1.00 1.21 2.69 0.85
  • 2. Hydroxyproline Glycoside Profiles [0433]
  • Hyp-glycoside profiles were determined as described by Lamport and Miller. We hydrolyzed 5.8-12.2 mg (Ser-Hyp)[0434] 32-EGFP or (GAGP)3-EGFP in 0.44 N NaOH and neutralized the hydrolysate with 0.3 M HCl before injection onto a C2 cation exchange colurnn. Each Hyp residue in (Ser-Hyp)32-EGFP contained an arabinogalactan-polysaccharide substituent; (GAGP)3-EGFP Hyp residues contained arabinooligosaccharide substituents in addition to arabinogalactan-polysaccharide (Table 11).
    TABLE 11
    Hyp-Glycoside Profiles of (Ser-Hyp)32 - EGFP and (GAGP)3 - EGFP and
    Native Crude GAGP
    % of Total Hyp
    Native
    Hyp-Glycoside (Ser-Hyp)32 - EGFP GAGP3 - EGFP GAGP
    Hyp-polysaccharide 100 62 25
    Hyp-Ara 0 4 10
    Hyp-Ara 2 0 12 17
    Hyp-Ara 3 0 7 31
    Hyp-Ara 4 0 4 5
    Non-glycosylated Hyp 0 11 12
  • The Hyp-glycoside profile of (Ser-Hyp)[0435] 32-EGFP gave a single peak of Hyp corresponding to Hyp-polysaccharide. Significantly, peaks corresponding to Hyp-arabinosides and non-glycosylated Hyp were absent. Importantly, this indicates that all of the Hyp residues in the glycomodule were linked to a polysaccharide.
  • In contrast, (GAGP)[0436] 3-EGFP yielded peaks corresponding to Hyp-arabinosides, non-glycosylated Hyp, and Hyp-polysaccharide. However, (GAGP)3-EGFP (FIGS. 11 & 15) was designed with fewer contiguous Hyp residues than the consensus sequence of native GAGP and yielded fewer Hyp arabinosides consistent with fewer contiguous Hyp arabinosylation sites [Kieliszewski & Lamport (1994) Plant J. 5, 157-172; Kieliszewski et al. (1992) Plant Physiol. 98, 919-926.; Kieliszewski et al. (1995) J. Biol. Chem. 270, 2541-2549]. In addition, occasional incomplete hydroxylation of the middle proline residue in the Pro-Pro-Pro motif (FIG. 14B) converted a region of contiguous Hyp (putative arabinosylation site) to noncontiguous Hyp (polysaccharide addition sites). Control EGFP targeted to the extracellular matrix contained no Hyp, hence no glycosylated Hyp, judging by manual Hyp assays.
  • The following describes the sequences of the genes and the expressed proteins as well as the Hyp-glycoside glcoprotein profile which were obtained using the SPP, and SPPP modules described in Table 4, as well as the SPPPP module. [0437]
  • A. Ser-Pro-Pro gene [0438]
  • The [SPP][0439] n module described in Table 4, item 2.a. was expresed using the following sequence:
    GGA TCC GCA ATG GGA AAA ATG GCT TCT CTA TTT GCC ACA TTT TTA GTG GTT TTA (SEQ ID No: 229)
    G   S   A   M   G   K   M   A   S   L   F   A   T   F   L   V   V   L (SEQ ID No:230)
    GTG TCA CTT AGC TTA GCA CAA ACA ACC CGG GCC [CCA CCT TCA CCC CCA TCT CCA
    V   S   L   V   L   A   Q   T   T   R   A   [P   P   S   P   P   S   P
    CCG AGT CCA CCA TCC]6 CCA CCT TCA TCC ATG GCA TAA TAG AGC TCG
    P   S   P   P   S  ]6 P   S   S   M   A  Stop Stop.
  • The Ser-Pro-Pro gene expressed the protein sequence [Pro-Hyp-Ser-Hyp-Hyp-Ser-Hyp-Hyp-Ser-Hyp-Hyp-Ser][0440] 6 (SEQ ID NO:231) which had the following Hyp-glycoside profile: Hyp (51% of total Hyp), Hyp-Ara (0% of total Hyp), Hyp-Ara2 (0% of total Hyp), Hyp-Ara3 (49% of total Hyp), Hyp-Ara4 (0% of total Hyp), Hyp-Polysaccharide (0% of total Hyp).
  • B. Ser-Pro-Pro-Pro Gene [0441]
  • The [SPPP][0442] n module described in Table 4, item b. was expresed using the following sequence:
    GGA TCC TCA ACC CGG GCC TCA CCA [CCA CCA CCT TCT CCA CCT CCA TCA CCC CCA (SEQ ID NO:232)
    G   S   S   T   R   A   S   P   [P   P   P   S   P   P   P   S   P   P (SEQ ID NO:233)
    CCT TCG CCT CCA CCA TCC]4 CCT TCC ATG GCA TAA TAG AGC TCG AAT TCG
    P   S   P   P   P   S  ]4 P   S   M   A  STOP STOP
  • The expressed the protein sequence had the following Hyp-glycoside profile: Hyp (0% of total Hyp), Hyp-Ara (0% of total Hyp), Hyp-Ara[0443] 2 (21% of total Hyp), Hyp-Ara3 (39% of total Hyp), Hyp-Ara4 (3% of total Hyp), Hyp-Polysaccharide (37% of total Hyp).
  • C. The Ser-Pro-Pro-Pro-Pro gene [0444]
  • The [SPPPP][0445] n module was expresed using the following sequence:
    GGA TCC TCA ACC CGG GCC TCA CCA [CCA CCA CCT TCA CCT CCA CCC CCA TCT (SEQ ID NO:234)
    G   S   S   T   R   A   S   P   [P   P   P   S   P   P   P   P   S (SEQ ID NO:235)
    CCA]9 CCA CCA CCT TCC ATG GCA TTA TAG AGC TCG
    P  ]9 P   P   P   S   M   A  Stop Stop
  • The expressed the protein sequence had the following Hyp-glycoside profile: Hyp (7% of total Hyp), Hyp-Ara (2% of total Hyp), Hyp-Ara[0446] 2 (8% of total Hyp), Hyp-Ara3 (52% of total Hyp), Hyp-Ara4 (31% of total Hyp), Hyp-Polysacchride (0% of total Hyp).
  • 3. Monosaccharide and Glycosyl Linkage Analysis [0447]
  • Monosaccharide compositions and linkage analyses were determined at the Complex Carbohydrate Research Center, University of Georgia as described earlier. The results are shown in Table 12. [0448]
    TABLE 12
    Glycosyl Compositions of (Ser-Hyp)32 - EGFP (GAGP)3 - EGFP, Native
    GAGP and Crude Gum Arabic
    Mol %
    Glycosyl (Ser-Hyp)32 - (GAGP)3 - Native Crude
    Residue EGFP EGFPa GAGP Gum Arabic
    Ara 28 23 36 28
    Gal 45 49 46 37
    Rha 8 8 10 13
    Xyl 0 2 0 0
    GlcUA 19 16 9 17
    Mann 1 1 0 0
  • Gal and Ara accounted for the bulk of the saccharides in both fusion proteins, with lesser amounts of Rha and GlcUA (Table 12); saccharide accounted for 58% (dw) of (Ser-Hyp)[0449] 32-EGFP and 48% (dw) of (GAGP)3-EGFP. Methylation analyses indicated that 3- and 3,6-linked galactose species accounted for 50 mole % of the sugars in (Ser-Hyp)32-EGFP and 46 mole % of (GAGP)3-EGFP; 2-linked arabinofuranose (Ara (ƒ) accounted for 1.6 and 3.1 mole % respectively; terminal Ara(ƒ) accounted for 20 and 21 mole % respectively; 4-arabinopyranose or 5-Ara(ƒ) accounted for 6 and 8% respectively; all rhamnose was terminal; and all GlcUA was 4-linked.
  • The sugar analysis data in Table 12 shows that both fusion glycoproteins had sugar compositions typical of AGPs: a galactose: arabinose molar ratio of ˜2:1 with lesser amounts of glucuronic acid and rhamnose. The predominantly 3- and 3,6-linked galactose and terminal arabinofuranose determined by methylation analysis, was in keeping with a (−1,3-linked galactan backbone having sidechains of arabinose, glucuronic acid and rhamnose [Nothnagel, E. A. (1997) [0450] Int. Rev. Cytol. 174, 195-291]. The very low amount of 1,2-linked arabinose in (Ser-Hyp)32-EGFP agreed with the absence of Hyp arabinosides while the presence of 1,2-linked arabinose in (GAGP)3-EGFP agreed with the presence of Hyp arabinosides in its Hyp glycoside profile as they are known to be largely 1,2-linked [Sticher et al. (1993) Plant Physiol. 101, 1239-1247; Akiyama et al. (1980) Agric. Biol. Chem. 44, 2487-2489]. Thus, (GAGP)3-EGFP contained both types of Hyp glycosylation consistent with the presence of a polypeptide having contiguous and non-contiguous Hyp as putative arabinosylation and polysaccharide addition sites, respectively.
  • With respect to the size of attached polysaccharide, Hyp glycoside profiles showed the molar ratio of Hyp-polysaccharide in each fusion glycoprotein (Table 11). This gives the number of (polysaccharide)-Hyp residues in each glycoprotein molecule. (e.g. Hyp-polysaccharide accounted for 100% of the Hyp glycosides in (Ser-Hyp)[0451] 32 i.e. 31-32 Hyp-polysaccharide). Glycoprotein size before and after deglycosylation gave an approximate size for the attached polysaccharide. The size of each fusion protein before and after deglycosylation was ˜95-115 kDa and 34 kDa respectively for (Ser-Hyp)32-EGFP (˜71 kDa carbohydrate), and ˜70-100 kDa and 34 kDa respectively for (GAGP)3-EGFP (˜51 kDa carbohydrate). Judging by the gene sequence (not shown) and FIG. 14, (Ser-Hyp)32-EGFP contains ˜31-32 Hyp residues, all noncontiguous, hence with an average polysaccharide size of 71 kDa/31=2.2-2.3 kDa which corresponds to 14-15 sugar residues (average sugar residue weight of 155 calculated from the sugar composition in Table 12) and is consistent with the empirical formula Gal6 Ara3 GlcA2 Rha based on compositional data in Table 12. Similarly, (GAGP)3-EGFP contains ˜23-25 Hyp residues of which 62% (Table 11), or ˜15 occur with polysaccharide attached. Hence the polysaccharide approximates 51 kDa/15=3.4 kDa corresponding to about 22 sugar residues, a modest overestimate as it includes arabinose from the Hyp arabinooligosaccharides.
  • The similarity of these fusion glycoproteins to native GAGP (Table 12) suggests a model for the Hyp-polysaccharide based on the general arabinogalactan structure [Akiyama et al. (1980) [0452] Agric. Biol. Chem. 44, 2487-2489; Aspinall & Knebl (1986) Carbohyd. Res. 157, 257-260; Defaye & Wong (1986) Carbohydr. Res. 150, 221-231] of a galactan core with small sidechains containing rhamnose, arabinose and glucuronic acid. Possibly larger arabinogalactan polysaccharide can be built up by repeated addition [Clarke et al. (1979) Phytochem. 18, 521-540; Bacic et al. (1987) Carbohyd. Res. 162, 85-93] of small ˜12 residue motifs represented by the above empirical formula.
  • 4. Hydroxyproline Assay of Secreted EGFP [0453]
  • Secreted EGFP, the product of the Sig-EGFP gene, was isolated by the Superose-12 fractionation. We removed EGFP from the fusion glycoproteins by overnight pronase digestion (1% ammonium bicarbonate, 5 mM CaCl[0454] 2; 27° C. 1:100 enzyme:substrate ratio) followed by isolation of EGFP by gel permeation chromatography as described above. After dialysis and freeze-drying, we assayed Hyp on 0.5 mg EGFP as described earlier. There was no Hyp in secreted EGFP or in EGFP removed from the fusion glycoproteins by pronase.
  • 5. Anhydrous Hydrogen Fluoride (HF) Deglycosylation [0455]
  • We deglycosylated 4.5 mg each of (Ser-Hyp)[0456] 32-EGFP and (GAGP)3-EGFP in anhydrous HF containing 10% dry methanol for 1 hr at 0° C. then quenched the reactions in ddH2O. After deglycosylation of 4.5 mg of each fusion glycoprotein, we recovered 1 mg of deglycosylated (Ser-Hyp)32-EGFP (i.e. ˜23% weight recovery) and 2.2 mg deglycosylated (GAGP)3-EGFP (i.e. ˜50% recovery).
  • 6. Protein and DNA Sequence Analysis [0457]
  • Protein sequence analysis was performed at the Michigan State University Macromolecular Facility on a 477-A Applied Biosystems Inc. gas phase sequencer. DNA sequencing was performed at the Guelph Molecular Supercentre, University of Guelph, Ontario, Canada. Edman degradation confirmed the gene sequences and identified which Pro residues had been hydroxylated to Hyp. In particular, N-terminal sequencing of both (Ser-Hyp)[0458] 32-EGFP and (GAGP)3-EGFP (FIG. 14) verified the synthetic gene sequences and identified hydroxyproline residues. Occasional incomplete proline hydroxylation has been observed elsewhere [de Blanket al. (1993) Plant Mol. Biol. 22, 1167-1171] and may simply signify a prolyl hydroxylase with less than 100% fidelity.
  • The above data demonstrates that the repetitive Ser-Hyp motif directed the exclusive addition of arabinogalactan polysaccharide to Hyp in (Ser-Hyp)[0459] 32-EGFP while Hyp arabinosylation was correlated with the presence of contiguous Hyp motifs in (GAGP)3-EGFP. Thus the O-Hyp glycosyltransferases of plants seem to resemble the O-Ser and O-Thr glycosyltransferases of animals in their multiplicity and ability to discriminate based on primary sequence and site clustering [Bacic et al. (1987) supra; Gerken et al. (1997) J. Biol. Chem. 272, 9709-9719].
    • EXAMPLE 24 Assay of Emulsifying Activity and Emulsion Stabilizing Activity of GAGPs
  • This Example analyzes the emulsifying activity (EA) and emulsion stabilizing activity (ES) of recombinant (GAGP)[0460] 3-EGFP which was expressed in the medium of transformed tobacco cell cultures as described above (Example 23). These activities were compared with those for bovine serum albumin (BSA), crude gum arabic glycoprotein (crude GAGP) which was isolated from Acacia senegal, dialyzed gum arabic glycoprotein, and tobacco arabinogalactan-protein (AGP) which contains a mixture of at least four different arabinogalactan-proteins. In addition, this Example describes the emulsifying activity and emulsion stabilizing activity of (GAGP)3-EGFP protein fractions which were fractionated on Superose-6 and reverse-phase columns (Example 23), as well as the effect of size and glycosylation of (GAGP)3-EGFP on emulsifying activity and emulsion stabilizing activity. All GAGP emulsions used in Tables 14-17, infra, were prepared at a concentration of 0.5% (w/v).
  • The emulsifying activity and emulsion stabilizing activity were determined using orange oil (Sigma) following essentially the manufacturer's instructions. Freeze-dried glycoproteins were dissolved in 0.05 M phosphate buffer (pH 6.5) at a concentration of 0.5% (m/v). The aqueous solutions were combined with orange oil in a 60:40 (v/v) ratio. A 1 ml emulsion was prepared in a glass tube at 0° C. with a Sonic Dismembrator (Fisher Scientific) equipped with a Microtip probe. The amplitude value was set at 4 and mixing time was set to 1 min. [0461]
  • For the determination of emulsifying ability (EA), the emulsion was diluted serially with a solution containing 0.1 M NaCl and 0.1% SDS to give a final dilution of {fraction (1/1500)}. The optical density of the diluted emulsion was then determined in a 1-cm pathlength cuvette at a wavelength of 50 nm and defined as the emulsifying activity (EA). BSA was used as a positive control. Test samples which showed an emulsifying activity which was at least 10%, more preferably at least 50%, and most preferably at least 75% of the emulsifying activity of a BSA control are said to be “characterized by having emulsifying activity.”[0462]
  • For emulsifying stability, the emulsion was stored vertically in a glass tube for 3 h at room temperature, then the optical density of 1:1500 dilution of the low phase of the stored sample was measured. Emulsifying stability (ES) was defined as the percentage optical density remaining after 2 hour of storage. BSA was used as a positive control. Test samples which showed an emulsion stabilizing activity which was at least 10%, more preferably at least 50%, and most preferably at least 75% of the emulsion stabilizing activity of a BSA control are said to be “characterized by having emulsion stabilizing activity.”[0463]
  • To determine whether (GAGP)[0464] 3-EGFP had emulsifying activity and/or emulsion stabilizing activity, this glycoprotein was assayed as described above and its activities were compared with those for bovine serum albumin (BSA), crude gum arabic, dialyzed gum arabic, and tobacco AGP. The results are shown in Table 13, which demonstrates the emulsifying properties of native gum arabic when compared to BSA, the synthetic GAGP3-EGFP, and native tobacco AGPs.
    TABLE 13
    Emulsions properties of crude Gum Arabic and other Materialsa
    Crude Crude Dialyzed Synthetic Tobacco
    Materi- BSA GAGP GAGP GAGP GAGPb AGP
    als (0.5%) (0.5%) (1.0%) (0.5%) (0.5%) (0.5%)
    EA 0.801 0.102 0.472 0.146 0.007 0.035
    ES 90.6% 39.7% 83.0% 57.5% 20.2% 20.0%
  • In addition, different (GAGP)[0465] 3-EGFP fractions which were obtained from Superose-6 column fractionation were also assayed and the results are shown in Table 14 which demonstrates that fraction F-2, which contained native GAGP showed the highest emulsifying activity and emulsion stabilizing activity of all fractions tested. These results establish GAGP as the emulsifying component of gum arabic.
    TABLE 14
    Emulsion Properties of GAGP Protein Fractions separated by
    Superose-6 column
    Fractions F-1 F-2 F-3 F-4 F-5
    EA 0.442 0.558 0.299 0.081 0.019
    ES 74.1% 84.2% 48.5% 32.2% 22.4%
  • The F-2 fraction was further separated on Hydrophobic Interaction column (HIC). The F-2 fraction was dissolved in 4.2 M NaCl and injected onto the HIC column. The column was eluted, starting by 4.2 M NaCl, followed by 3.0 M NaCl, 2.0 M NaCl, 1.0 M NaCl, and distilled water. The resulting fractions were tested and the results are shown in Table 15, which demonstrates that F-2 contains GAGP which is characterized by having emulsifying activity and emulsion stabilizing activity. Table 15 also demonstrates that F-2 separates into four components which differ in hydrophobicity, with the 2.0M and 1.0M NaCl hydrolysates being good emulsifiers [0466]
    TABLE 15
    Emulsion Properties of F-2 Fractions Separated by Hydrophobic
    Interaction Column
    4.2 M NaCl 3.0 M 2.0 M 1.0 M Distilled
    Fractions
    1 2 NaCl NaCl NaCl water
    EA 0.076 0.284 0.475 0.710 0.670 0.04
    ES 28%   60.5% 78.5% 93.5% 94.6% 21.0%
  • In order to determine the effect of the size of GAGPs on their emulsion activity and emulsion stabilizing activity, the F-2 fraction containing native GAGP was incubated in 0.2 N NaOH at 50° C. for 0.5 hr, 1.0 hr, 2.0 hr, 4.0 hr, and 8.0 hr and the emulsifying properties of each sampl e were determined as shown in Table 16. [0467]
    TABLE 16
    Emulsion Properties of Partially-deglycosylated F-2
    Samples 0 hr 0.5 hr 1.0 hr 2.0 hr 4.0 hr 8.0 hr
    EA 0.558 0.354 0.245 0.097 0.036 0.011
    ES 84.2% 61.2% 41.5% 23.2% 0 0
  • The results in Table 16 demonstrate that both the emulsifying activity and emulsion stabilizing activity of GAGP decrease with decreasing GAGP size. [0468]
  • To determine whether the carbohydrate moiety of GAGPs affects their emulsion activity and emulsion stabilizing activity, the F-2 fraction was partially deglycosylated by anhydrous hydrogen fluoride (HF) as described above, and the emulsifying properties of the deglycosylated sample were determined. Deglycosylated F-2 fraction had an EA of 0.269, and an ES of 46.5%. These results demonstrate that the GAGP in the F-2 fraction lost most of its ability to emulsify, thus indicating the importance of the carbohydrate moiety of the GAGP for emulsification. [0469]
  • From the above, it should be clear that the present invention provides a new approach and solution to the problem of producing plant gums. The approach is not dependent on environmental factors and greatly simplifies production of a variety of naturally-occurring gums, as well as designer gums. [0470]

Claims (16)

I claim:
1. An isolated polynucleotide sequence encoding at least a portion of an amino acid sequence selected from (a) A-Hyp-B-C-D-E-F-Hyp-G-H-I-Hyp-J-Hyp-Hyp-K-L-Pro-M (SEQ ID NO:136), wherein A is selected from Ser, Thr, and Ala; B is selected from Hyp, Pro, Leu, and Ile; C is selected from Pro and Hyp; D is selected from Hyp, Pro, Ser, Thr, and Ala; E is selected from Leu and Ile; F is selected from Ser, Thr, and Ala; G is selected from Ser, Leu, Hyp, Thr, Ala, and Ile; H is selected from Hyp, Pro, Leu, and Ile; I is selected from Thr, Ala, and Ser; J is selected from Thr, Ser, and Ala; K is selected from Thr, Leu, Hyp, Ser, Ala, and Ile; L is selected from Gly, Leu, Ala, and Ile; and M is selected from His and Pro; and wherein said portion is greater than twelve contiguous amino acids of said amino acid sequence, (b) a polypeptide comprising a first motif selected from (Xaa-Hyp)x (SEQ ID NO:182) and Xaa-Hyp-Xaa-Xaa-Hyp-Xaa (SEQ ID NO: 183), wherein x is from 2 to 1000, (c) a polypeptide comprising a second motif selected from Xaa-Hyp-Hypn (SEQ ID NO:209) and Xaa-Pro-Hypn (SEQ ID NO:210), wherein n is from 1 to 500, and (d) a polypeptide comprising said first motif and said second motif, wherein Xaa is any amino acid other than hydroxyproline.
2. A recombinant expression vector comprising a polynucleotide sequence encoding a portion of an amino acid sequence selected from (a) A-Hyp-B-C-D-E-F-Hyp-G-H-I-Hyp-J-Hyp-Hyp-K-L-Pro-M (SEQ ID NO:136), wherein A is selected from Ser, Thr, and Ala; B is selected from Hyp, Pro, Leu, and Ile; C is selected from Pro and Hyp; D is selected from Hyp, Pro, Ser, Thr, and Ala; E is selected from Leu and Ile; F is selected from Ser, Thr, and Ala; G is selected from Ser, Leu, Hyp, Thr, Ala, and Ile; H is selected from Hyp, Pro, Leu, and Ile; I is selected from Thr, Ala, and Ser; J is selected from Thr, Ser, and Ala; K is selected from Thr, Leu, Hyp, Ser, Ala, and Ile; L is selected from Gly, Leu, Ala, and Ile; and M is selected from His and Pro; and wherein said portion is greater than twelve contiguous amino acids of said amino acid sequence, (b) a polypeptide comprising a first motif selected from (Xaa-Hyp)x (SEQ ID NO:182) and Xaa-Hyp-Xaa-Xaa-Hyp-Xaa (SEQ ID NO:183), wherein x is from 2 to 1000, (c) a polypeptide comprising a second motif selected from Xaa-Hyp-Hypn (SEQ ID NO:209) and Xaa-Pro-Hypn (SEQ ID NO:210), wherein n is from 1 to 500, and (d) a polypeptide comprising said first motif and said second motif, wherein Xaa is any amino acid other than hydroxyproline.
3. The expression vector of claim 2, further comprising a promoter operably linked to said polynucleotide sequence.
4. The expression vector of claim 3, wherein said promoter is a viral promoter.
5. The expression vector of claim 4, wherein said viral promoter is selected from the group consisting of the 35S and 19S RNA promoters of cauliflower mosaic virus.
6. The expression vector of claim 3, further comprising a signal sequence selected from extensin signal sequence (SEQ ID NO:14), and tomato arabinogalactan-protein signal sequence (SEQ ID NO:215).
7. The expression vector of claim 6, further comprising a reporter gene.
8. The expression vector of claim 7, wherein said reporter gene is the green fluorescence protein gene.
9. The expression vector of claim 2, wherein said vector is contained within a host cell.
10. The expression vector of claim 9, wherein said host cell is a plant cell.
11. The expression vector of claim 10, wherein said plant cell expresses a glycoprotein comprising said portion.
12. A method for producing at least a portion of a glycoprotein, comprising:
a) providing:
i) a recombinant expression vector comprising a polynucleotide sequence encoding at least a portion of an amino acid sequence selected from (a) A-Hyp-B-C-D-E-F-Hyp-G-H-I-Hyp-J-Hyp-Hyp-K-L-Pro-M (SEQ ID NO:136), wherein A is selected from Ser, Thr, and Ala; B is selected from Hyp, Pro, Leu, and Ile; C is selected from Pro and Hyp; D is selected from Hyp, Pro, Ser, Thr, and Ala; E is selected from Leu and Ile; F is selected from Ser, Thr, and Ala; G is selected from Ser, Leu, Hyp, Thr, Ala, and Ile; H is selected from Hyp, Pro, Leu, and Ile; I is selected from Thr, Ala, and Ser; J is selected from Thr, Ser, and Ala; K is selected from Thr, Leu, Hyp, Ser, Ala, and Ile; L is selected from Gly, Leu, Ala, and Ile; and M is selected from His and Pro; and wherein said portion is greater than twelve contiguous amino acids of said amino acid sequence, (b) a polypeptide comprising a first motif selected from (Xaa-Hyp)x (SEQ ID NO:182) and Xaa-Hyp-Xaa-Xaa-Hyp-Xaa (SEQ ID NO:183), wherein x is from 2 to 1000, (c) a polypeptide comprising a second motif selected from Xaa-Hyp-Hypn (SEQ ID NO:209) and Xaa-Pro-Hypn (SEQ ID NO:210), wherein n is from 1 to 500, and (d) a polypeptide comprising said first motif and said second motif, wherein Xaa is any amino acid other than hydroxyproline; and
ii) a host cell; and
b) introducing said vector into said host cell under conditions such that said portion is expressed.
13. The method of claim 12, wherein said host cell is growing in culture.
14. The method of claim 13, further comprising the step of c) recovering said portion from the host cell culture.
15. The method of claim 12, wherein said host cell is a plant cell.
16. The method of claim 15, wherein said plant cell is derived from a plant selected from the family Leguminoseae.
US10/437,708 1997-07-21 2003-05-14 Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins Abandoned US20040009555A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/437,708 US20040009555A1 (en) 1997-07-21 2003-05-14 Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US12/781,490 US20110003340A1 (en) 1997-07-21 2010-05-17 Synthetic genes for plant gums and other hydroxyproline-rich proteins
US13/149,016 US8871468B2 (en) 1997-07-21 2011-05-31 Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/897,556 US6570062B1 (en) 1997-07-21 1997-07-21 Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US09/119,507 US6548642B1 (en) 1997-07-21 1998-07-20 Synthetic genes for plant gums
US09/547,693 US6639050B1 (en) 1997-07-21 2000-04-12 Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US10/437,708 US20040009555A1 (en) 1997-07-21 2003-05-14 Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/547,693 Division US6639050B1 (en) 1997-07-21 2000-04-12 Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/781,490 Continuation US20110003340A1 (en) 1997-07-21 2010-05-17 Synthetic genes for plant gums and other hydroxyproline-rich proteins

Publications (1)

Publication Number Publication Date
US20040009555A1 true US20040009555A1 (en) 2004-01-15

Family

ID=24185737

Family Applications (5)

Application Number Title Priority Date Filing Date
US09/547,693 Expired - Fee Related US6639050B1 (en) 1997-07-21 2000-04-12 Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US10/257,199 Abandoned US20040230032A1 (en) 2000-04-12 2001-04-12 Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US10/437,708 Abandoned US20040009555A1 (en) 1997-07-21 2003-05-14 Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US12/781,490 Abandoned US20110003340A1 (en) 1997-07-21 2010-05-17 Synthetic genes for plant gums and other hydroxyproline-rich proteins
US13/149,016 Expired - Fee Related US8871468B2 (en) 1997-07-21 2011-05-31 Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/547,693 Expired - Fee Related US6639050B1 (en) 1997-07-21 2000-04-12 Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US10/257,199 Abandoned US20040230032A1 (en) 2000-04-12 2001-04-12 Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/781,490 Abandoned US20110003340A1 (en) 1997-07-21 2010-05-17 Synthetic genes for plant gums and other hydroxyproline-rich proteins
US13/149,016 Expired - Fee Related US8871468B2 (en) 1997-07-21 2011-05-31 Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins

Country Status (5)

Country Link
US (5) US6639050B1 (en)
EP (1) EP1387884A4 (en)
JP (1) JP2004516003A (en)
CA (1) CA2405753A1 (en)
WO (1) WO2001078503A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009557A1 (en) * 1997-07-21 2004-01-15 Ohio University, Technology Transfer Office, Technology And Enterprise Building Novel synthetic genes for plant gums
US20050074838A1 (en) * 1997-07-21 2005-04-07 Ohio University, Technology Transfer Office, Technology Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US20060026719A1 (en) * 2004-01-14 2006-02-02 Kieliszewski Marcia J Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
US20060252120A1 (en) * 2003-05-09 2006-11-09 Kieliszewski Marcia J Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
WO2007008708A2 (en) * 2005-07-08 2007-01-18 Ohio University Methods of predicting hyp-glycosylation sites for proteins expressed and secreted in plant cells, and related methods and products
US20070039073A1 (en) * 1997-07-21 2007-02-15 Kieliszewski Marcia J Novel synthetic genes for plant gums
US20080262198A1 (en) * 2004-04-19 2008-10-23 Ohio University Cross-Linkable Glycoproteins and Methods of Making the Same
US20100146668A1 (en) * 2007-03-02 2010-06-10 Kotaro Konno Insect-resistant protein and insect-resistance gene encoding the insect-resistant protein
US8871468B2 (en) 1997-07-21 2014-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8064850B2 (en) 2002-05-01 2011-11-22 Dali Systems Co., Ltd. High efficiency linearization power amplifier for wireless communication
US8380143B2 (en) 2002-05-01 2013-02-19 Dali Systems Co. Ltd Power amplifier time-delay invariant predistortion methods and apparatus
US6985704B2 (en) 2002-05-01 2006-01-10 Dali Yang System and method for digital memorized predistortion for wireless communication
US8811917B2 (en) 2002-05-01 2014-08-19 Dali Systems Co. Ltd. Digital hybrid mode power amplifier system
US8472897B1 (en) 2006-12-22 2013-06-25 Dali Systems Co. Ltd. Power amplifier predistortion methods and apparatus
BRPI0713153B8 (en) * 2006-06-13 2021-05-25 Helix Biomedix Inc tetrapeptide capable of inducing the production of extracellular matrix proteins and composition comprising
EP3790244A1 (en) 2006-12-26 2021-03-10 Dali Systems Co. Ltd. Method and system for baseband predistortion linearization in multi-channel wideband communication systems
US9026067B2 (en) * 2007-04-23 2015-05-05 Dali Systems Co. Ltd. Remotely reconfigurable power amplifier system and method
US8274332B2 (en) * 2007-04-23 2012-09-25 Dali Systems Co. Ltd. N-way Doherty distributed power amplifier with power tracking
US8224266B2 (en) * 2007-08-30 2012-07-17 Dali Systems Co., Ltd. Power amplifier predistortion methods and apparatus using envelope and phase detector
JP5250636B2 (en) * 2007-12-07 2013-07-31 ダリ システムズ カンパニー リミテッド Baseband derived RF digital predistortion
EP2361927A1 (en) * 2010-02-26 2011-08-31 BASF Plant Science Company GmbH Plants having enhanced yield-related traits and a method for making the same
LT2571510T (en) * 2010-05-21 2018-11-12 Xl-Protein Gmbh Biosynthetic proline/alanine random coil polypeptides and their uses
KR102136940B1 (en) 2010-09-14 2020-07-23 달리 시스템즈 씨오. 엘티디. Remotely Reconfigurable Distributed Antenna System and Methods
CN103641889B (en) * 2013-12-12 2016-02-10 中国药科大学 A kind of incretin peptide and pharmaceutical use thereof
US10206969B2 (en) * 2016-03-09 2019-02-19 Bio Pep Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
CN118147165B (en) * 2024-05-09 2024-07-02 中国热带农业科学院三亚研究院 Application of FTO gene in improving total solid content of latex

Citations (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3664925A (en) * 1970-02-20 1972-05-23 Martin Sonenberg Clinically active bovine growth hormone fraction
US4056520A (en) * 1972-03-31 1977-11-01 Research Corporation Clinically active bovine growth hormone fraction
US4374829A (en) * 1978-12-11 1983-02-22 Merck & Co., Inc. Aminoacid derivatives as antihypertensives
US4478827A (en) * 1983-05-09 1984-10-23 The General Hospital Corporation Renin inhibitors
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4940838A (en) * 1983-02-24 1990-07-10 Schilperoort Robbert A Process for the incorporation of foreign dna into the genome of dicotyledonous plants
US4956282A (en) * 1985-07-29 1990-09-11 Calgene, Inc. Mammalian peptide expression in plant cells
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US5034322A (en) * 1983-01-17 1991-07-23 Monsanto Company Chimeric genes suitable for expression in plant cells
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5352596A (en) * 1992-09-11 1994-10-04 The United States Of America As Represented By The Secretary Of Agriculture Pseudorabies virus deletion mutants involving the EPO and LLT genes
US5352605A (en) * 1983-01-17 1994-10-04 Monsanto Company Chimeric genes for transforming plant cells using viral promoters
US5474925A (en) * 1991-12-19 1995-12-12 Agracetus, Inc. Immobilized proteins in cotton fiber
US5501967A (en) * 1989-07-26 1996-03-26 Mogen International, N.V./Rijksuniversiteit Te Leiden Process for the site-directed integration of DNA into the genome of plants
US5506107A (en) * 1991-05-10 1996-04-09 Genentech, Inc. Selecting ligand agonists and antagonists
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5584807A (en) * 1994-01-21 1996-12-17 Agracetus, Inc. Gas driven gene delivery instrument
US5637686A (en) * 1993-01-28 1997-06-10 The Regents Of The University Of California Tata-binding protein associated factor, nucleic acids
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5646029A (en) * 1993-12-03 1997-07-08 Cooperative Research Centre For Industrial Plant Biopolymers Plant arabinogalactan protein (AGP) genes
US5650307A (en) * 1989-07-26 1997-07-22 Mogen International, N.V. Production of heterologous proteins in plants and plant cells
US5695971A (en) * 1995-04-07 1997-12-09 Amresco Phage-cosmid hybrid vector, open cos DNA fragments, their method of use, and process of production
US5723755A (en) * 1995-05-16 1998-03-03 Francis E. Lefaivre Large scale production of human or animal proteins using plant bioreactors
US5728810A (en) * 1990-04-20 1998-03-17 University Of Wyoming Spider silk protein
US5733771A (en) * 1994-03-14 1998-03-31 University Of Wyoming cDNAs encoding minor ampullate spider silk proteins
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5780279A (en) * 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
US5821089A (en) * 1996-06-03 1998-10-13 Gruskin; Elliott A. Amino acid modified polypeptides
US5849535A (en) * 1995-09-21 1998-12-15 Genentech, Inc. Human growth hormone variants
US5958879A (en) * 1989-10-12 1999-09-28 Ohio University/Edison Biotechnology Institute Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
US5994099A (en) * 1997-12-31 1999-11-30 The University Of Wyoming Extremely elastic spider silk protein and DNA coding therefor
US6020169A (en) * 1995-07-20 2000-02-01 Washington State University Research Foundation Production of secreted foreign polypeptides in plant cell culture
US6080560A (en) * 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US6210950B1 (en) * 1999-05-25 2001-04-03 University Of Medicine And Dentistry Of New Jersey Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
US6225080B1 (en) * 1992-03-23 2001-05-01 George R. Uhl Mu-subtype opioid receptor
US6355776B1 (en) * 1986-11-04 2002-03-12 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US20020127652A1 (en) * 2000-02-11 2002-09-12 Schambye Hans Thalsgard Follicle stimulating hormones
US20020160944A1 (en) * 2001-03-05 2002-10-31 Irving Boime Multifunctional single chain glycoprotein hormones
US20020162135A1 (en) * 2001-04-18 2002-10-31 Henry Daniell Expression of antimicrobial peptide via the plastid genome to control phytopathogenic bacteria
US20020174453A1 (en) * 2001-04-18 2002-11-21 Henry Daniell Production of antibodies in transgenic plastids
US6486382B1 (en) * 1996-05-01 2002-11-26 Pioneer Hi-Bred International, Inc. Use of the green fluorescent protein as a screenable marker for plant transformation
US20030009783A1 (en) * 1991-01-07 2003-01-09 Auburn University Genetic engineering of plant chloroplasts
US20030036181A1 (en) * 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
US20030041353A1 (en) * 2001-04-18 2003-02-27 Henry Daniell Mutiple gene expression for engineering novel pathways and hyperexpression of foreign proteins in plants
US6548642B1 (en) * 1997-07-21 2003-04-15 Ohio University Synthetic genes for plant gums
US6570062B1 (en) * 1997-07-21 2003-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6583115B1 (en) * 1989-10-12 2003-06-24 Ohio University/Edison Biotechnology Institute Methods for treating acromegaly and giantism with growth hormone antagonists
US20030167531A1 (en) * 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
US6639050B1 (en) * 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US20030204864A1 (en) * 2001-02-28 2003-10-30 Henry Daniell Pharmaceutical proteins, human therapeutics, human serum albumin, insulin, native cholera toxic b submitted on transgenic plastids
US6774283B1 (en) * 1985-07-29 2004-08-10 Calgene Llc Molecular farming
US6787336B1 (en) * 1989-10-12 2004-09-07 Ohio University/Edison Biotechnology Institute DNA encoding growth hormone antagonists
US20060026719A1 (en) * 2004-01-14 2006-02-02 Kieliszewski Marcia J Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
US20060252120A1 (en) * 2003-05-09 2006-11-09 Kieliszewski Marcia J Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US7378506B2 (en) * 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US7388081B2 (en) * 1998-12-09 2008-06-17 Dfb Biotech, Inc. Method for manufacturing glycoproteins having human-type glycosylation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
EP0397834B1 (en) 1988-10-28 2000-02-02 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
CA2087267A1 (en) 1990-08-17 1992-02-18 Steven H. Bass Metal ion mediated receptor binding of polypeptide hormones
WO1992020713A1 (en) 1991-05-15 1992-11-26 The University Of Melbourne Proline rich protein from nicotiana alata
WO1993000109A1 (en) 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
US6037456A (en) 1998-03-10 2000-03-14 Biosource Technologies, Inc. Process for isolating and purifying viruses, soluble proteins and peptides from plant sources
CN1325443A (en) 1998-10-30 2001-12-05 诺沃奇梅兹有限公司 Glycosylated proteins having reduced allergenicity
AU6678200A (en) 1999-08-27 2001-03-26 University Of Guelph Use of arabinogalactan protein fusion constructs in a method of expressing proteins and peptides in plants
AU2352201A (en) 1999-12-30 2001-07-16 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
AR027765A1 (en) 2000-04-03 2003-04-09 Monsanto Technology Llc EXPRESSION AND PURIFICATION OF AUTHENTIC BIOACTIVE POLYPEPTIDES FROM PLANTS
EP1156060B1 (en) 2000-05-12 2007-06-27 GPC Biotech AG Human peptides/proteins causing or leading to the killing of cells including lymphoid tumor cells
EP1334442A2 (en) 2000-11-06 2003-08-13 Thrasos, Inc. Computer method and apparatus for classifying objects
US7173113B2 (en) 2002-01-31 2007-02-06 The Trustees Of Columbia University In The City Of New York Long-acting hormone and growth factor compositions and uses thereof
JP2007523630A (en) 2003-05-09 2007-08-23 ネオス テクノロジーズ インコーポレイテッド Composition and formulation of human growth hormone glycosylation mutants
JP2005087172A (en) 2003-09-19 2005-04-07 Institute Of Physical & Chemical Research Arabinogalactan like o-bonded type sugar chain addition motif
WO2005110015A2 (en) 2004-04-19 2005-11-24 Ohio University Cross-linkable glycoproteins and methods of making the same
EP3088528B1 (en) 2004-09-29 2019-07-03 Collplant Ltd. Collagen producing plants and methods of generating and using same
WO2007008708A2 (en) 2005-07-08 2007-01-18 Ohio University Methods of predicting hyp-glycosylation sites for proteins expressed and secreted in plant cells, and related methods and products
EP2084285A4 (en) 2006-07-10 2010-01-13 Univ Ohio Co-expression of proline hydroxylases to facilitate hyp-glycosylation of proteins expressed and secreted in plant cells

Patent Citations (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3664925A (en) * 1970-02-20 1972-05-23 Martin Sonenberg Clinically active bovine growth hormone fraction
US4056520A (en) * 1972-03-31 1977-11-01 Research Corporation Clinically active bovine growth hormone fraction
US4374829A (en) * 1978-12-11 1983-02-22 Merck & Co., Inc. Aminoacid derivatives as antihypertensives
US5352605A (en) * 1983-01-17 1994-10-04 Monsanto Company Chimeric genes for transforming plant cells using viral promoters
US5034322A (en) * 1983-01-17 1991-07-23 Monsanto Company Chimeric genes suitable for expression in plant cells
US4940838A (en) * 1983-02-24 1990-07-10 Schilperoort Robbert A Process for the incorporation of foreign dna into the genome of dicotyledonous plants
US4478827A (en) * 1983-05-09 1984-10-23 The General Hospital Corporation Renin inhibitors
US4683202B1 (en) * 1985-03-28 1990-11-27 Cetus Corp
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4956282A (en) * 1985-07-29 1990-09-11 Calgene, Inc. Mammalian peptide expression in plant cells
US5629175A (en) * 1985-07-29 1997-05-13 Calgene, Inc. Molecular farming
US6774283B1 (en) * 1985-07-29 2004-08-10 Calgene Llc Molecular farming
US6096547A (en) * 1985-07-29 2000-08-01 Calgene, Llc Method and transgenic plant for producing mammalian peptides
US5550038A (en) * 1985-07-29 1996-08-27 Calgene, Inc. Molecular farming
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683195B1 (en) * 1986-01-30 1990-11-27 Cetus Corp
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US6355776B1 (en) * 1986-11-04 2002-03-12 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5650307A (en) * 1989-07-26 1997-07-22 Mogen International, N.V. Production of heterologous proteins in plants and plant cells
US5501967A (en) * 1989-07-26 1996-03-26 Mogen International, N.V./Rijksuniversiteit Te Leiden Process for the site-directed integration of DNA into the genome of plants
US5958879A (en) * 1989-10-12 1999-09-28 Ohio University/Edison Biotechnology Institute Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US6787336B1 (en) * 1989-10-12 2004-09-07 Ohio University/Edison Biotechnology Institute DNA encoding growth hormone antagonists
US5681809A (en) * 1989-10-12 1997-10-28 Ohio University Growth hormone antagonists
US6583115B1 (en) * 1989-10-12 2003-06-24 Ohio University/Edison Biotechnology Institute Methods for treating acromegaly and giantism with growth hormone antagonists
US5989894A (en) * 1990-04-20 1999-11-23 University Of Wyoming Isolated DNA coding for spider silk protein, a replicable vector and a transformed cell containing the DNA
US5728810A (en) * 1990-04-20 1998-03-17 University Of Wyoming Spider silk protein
US5780279A (en) * 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
US6680426B2 (en) * 1991-01-07 2004-01-20 Auburn University Genetic engineering of plant chloroplasts
US20030009783A1 (en) * 1991-01-07 2003-01-09 Auburn University Genetic engineering of plant chloroplasts
US5506107A (en) * 1991-05-10 1996-04-09 Genentech, Inc. Selecting ligand agonists and antagonists
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5474925A (en) * 1991-12-19 1995-12-12 Agracetus, Inc. Immobilized proteins in cotton fiber
US6225080B1 (en) * 1992-03-23 2001-05-01 George R. Uhl Mu-subtype opioid receptor
US5352596A (en) * 1992-09-11 1994-10-04 The United States Of America As Represented By The Secretary Of Agriculture Pseudorabies virus deletion mutants involving the EPO and LLT genes
US5637686A (en) * 1993-01-28 1997-06-10 The Regents Of The University Of California Tata-binding protein associated factor, nucleic acids
US5830747A (en) * 1993-12-03 1998-11-03 Cooperative Research Centre For Industrial Plant Biopolymers Plant arabinogalactan protein (AGP) genes
US5646029A (en) * 1993-12-03 1997-07-08 Cooperative Research Centre For Industrial Plant Biopolymers Plant arabinogalactan protein (AGP) genes
US5584807A (en) * 1994-01-21 1996-12-17 Agracetus, Inc. Gas driven gene delivery instrument
US5756677A (en) * 1994-03-14 1998-05-26 University Of Wyoming Minor ampullate spider silk proteins
US5733771A (en) * 1994-03-14 1998-03-31 University Of Wyoming cDNAs encoding minor ampullate spider silk proteins
US6080560A (en) * 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5695971A (en) * 1995-04-07 1997-12-09 Amresco Phage-cosmid hybrid vector, open cos DNA fragments, their method of use, and process of production
US5723755A (en) * 1995-05-16 1998-03-03 Francis E. Lefaivre Large scale production of human or animal proteins using plant bioreactors
US6020169A (en) * 1995-07-20 2000-02-01 Washington State University Research Foundation Production of secreted foreign polypeptides in plant cell culture
US5849535A (en) * 1995-09-21 1998-12-15 Genentech, Inc. Human growth hormone variants
US6486382B1 (en) * 1996-05-01 2002-11-26 Pioneer Hi-Bred International, Inc. Use of the green fluorescent protein as a screenable marker for plant transformation
US5821089A (en) * 1996-06-03 1998-10-13 Gruskin; Elliott A. Amino acid modified polypeptides
US6570062B1 (en) * 1997-07-21 2003-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US20040009557A1 (en) * 1997-07-21 2004-01-15 Ohio University, Technology Transfer Office, Technology And Enterprise Building Novel synthetic genes for plant gums
US20070039073A1 (en) * 1997-07-21 2007-02-15 Kieliszewski Marcia J Novel synthetic genes for plant gums
US6639050B1 (en) * 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6548642B1 (en) * 1997-07-21 2003-04-15 Ohio University Synthetic genes for plant gums
US7378506B2 (en) * 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US5994099A (en) * 1997-12-31 1999-11-30 The University Of Wyoming Extremely elastic spider silk protein and DNA coding therefor
US20030167531A1 (en) * 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
US7388081B2 (en) * 1998-12-09 2008-06-17 Dfb Biotech, Inc. Method for manufacturing glycoproteins having human-type glycosylation
US6210950B1 (en) * 1999-05-25 2001-04-03 University Of Medicine And Dentistry Of New Jersey Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
US20020127652A1 (en) * 2000-02-11 2002-09-12 Schambye Hans Thalsgard Follicle stimulating hormones
US20040230032A1 (en) * 2000-04-12 2004-11-18 Kieliszewski Marcia J. Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US20030036181A1 (en) * 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
US20030204864A1 (en) * 2001-02-28 2003-10-30 Henry Daniell Pharmaceutical proteins, human therapeutics, human serum albumin, insulin, native cholera toxic b submitted on transgenic plastids
US20020160944A1 (en) * 2001-03-05 2002-10-31 Irving Boime Multifunctional single chain glycoprotein hormones
US20020162135A1 (en) * 2001-04-18 2002-10-31 Henry Daniell Expression of antimicrobial peptide via the plastid genome to control phytopathogenic bacteria
US20020174453A1 (en) * 2001-04-18 2002-11-21 Henry Daniell Production of antibodies in transgenic plastids
US20030041353A1 (en) * 2001-04-18 2003-02-27 Henry Daniell Mutiple gene expression for engineering novel pathways and hyperexpression of foreign proteins in plants
US20060252120A1 (en) * 2003-05-09 2006-11-09 Kieliszewski Marcia J Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US20060148680A1 (en) * 2004-01-14 2006-07-06 Kieliszewski Marcia J Glycoproteins produced in plants and methods of their use
US20060026719A1 (en) * 2004-01-14 2006-02-02 Kieliszewski Marcia J Methods of producing peptides/proteins in plants and peptides/proteins produced thereby

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090030185A1 (en) * 1997-07-21 2009-01-29 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US20050074838A1 (en) * 1997-07-21 2005-04-07 Ohio University, Technology Transfer Office, Technology Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US8871468B2 (en) 1997-07-21 2014-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US8563687B2 (en) 1997-07-21 2013-10-22 Ohio University Synthetic genes for plant gums and other hydroxyproline rich glycoproteins
US20040009557A1 (en) * 1997-07-21 2004-01-15 Ohio University, Technology Transfer Office, Technology And Enterprise Building Novel synthetic genes for plant gums
US20070039073A1 (en) * 1997-07-21 2007-02-15 Kieliszewski Marcia J Novel synthetic genes for plant gums
US7378506B2 (en) 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US20100261874A1 (en) * 1997-07-21 2010-10-14 Ohio University Synthetic genes for plant gums and other hydroxyproline rich glycoproteins
US20060252120A1 (en) * 2003-05-09 2006-11-09 Kieliszewski Marcia J Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US20110230404A1 (en) * 2004-01-14 2011-09-22 Ohio University Glycoproteins Produced in Plants and Methods of Their Use
US20110217766A1 (en) * 2004-01-14 2011-09-08 Ohio University Methods of Producing Peptides in Plants and Peptides Produced Thereby
US20060148680A1 (en) * 2004-01-14 2006-07-06 Kieliszewski Marcia J Glycoproteins produced in plants and methods of their use
US20060026719A1 (en) * 2004-01-14 2006-02-02 Kieliszewski Marcia J Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
US9006410B2 (en) 2004-01-14 2015-04-14 Ohio University Nucleic acid for plant expression of a fusion protein comprising hydroxyproline O-glycosylation glycomodule
US20080262198A1 (en) * 2004-04-19 2008-10-23 Ohio University Cross-Linkable Glycoproteins and Methods of Making the Same
US8623812B2 (en) 2004-04-19 2014-01-07 Ohio University Cross-linkable glycoproteins and methods of making the same
WO2007008708A3 (en) * 2005-07-08 2009-04-23 Univ Ohio Methods of predicting hyp-glycosylation sites for proteins expressed and secreted in plant cells, and related methods and products
US20080242834A1 (en) * 2005-07-08 2008-10-02 Ohio University Methods of Predicting Hyp-Glycosylation Sites For Proteins Expressed and Secreted in Plant Cells, and Related Methods and Products
WO2007008708A2 (en) * 2005-07-08 2007-01-18 Ohio University Methods of predicting hyp-glycosylation sites for proteins expressed and secreted in plant cells, and related methods and products
US20100146668A1 (en) * 2007-03-02 2010-06-10 Kotaro Konno Insect-resistant protein and insect-resistance gene encoding the insect-resistant protein
US8624085B2 (en) * 2007-03-02 2014-01-07 National Institute Of Agrobiological Sciences Insect resistant protein and insect-resistance gene encoding the insect-resistant protein

Also Published As

Publication number Publication date
CA2405753A1 (en) 2001-10-25
US20040230032A1 (en) 2004-11-18
US20140287457A9 (en) 2014-09-25
US8871468B2 (en) 2014-10-28
WO2001078503A3 (en) 2003-11-06
JP2004516003A (en) 2004-06-03
US20110003340A1 (en) 2011-01-06
EP1387884A2 (en) 2004-02-11
US6639050B1 (en) 2003-10-28
EP1387884A4 (en) 2004-07-07
WO2001078503A2 (en) 2001-10-25
US20120077226A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
US8871468B2 (en) Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US8563687B2 (en) Synthetic genes for plant gums and other hydroxyproline rich glycoproteins
US7728191B2 (en) Nucleic acid for reducing protein content in rice seed
US20030167533A1 (en) Intein-mediated protein splicing
EP0861021A1 (en) Modified bacillus thuringiensis gene for lepidopteran control in plants
US6548642B1 (en) Synthetic genes for plant gums
KR101964658B1 (en) GmPAP2.1 gene from Glycine max controlling plant disease resistance against Soybean mosaic virus and uses thereof
US20060252120A1 (en) Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6570062B1 (en) Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US8623812B2 (en) Cross-linkable glycoproteins and methods of making the same
EP2518081B1 (en) Method of producing and purifying polymeric proteins in transgenic plants
AU2002301020B2 (en) Novel Synthetic Genes for Plant Gums
US20040117874A1 (en) Methods for accumulating translocated proteins
JPH07213185A (en) Plant improved in content of amino acid containing sulfur and method for improvement
CN112159465B (en) DRN protein and related biological material and application thereof in improving regeneration efficiency of plant somatic cells
CA2324520A1 (en) Plant promoter sequences and methods of use thereof
Shpak Synthetic genes for the elucidation of hydroxyproline-O-glycosylation codes

Legal Events

Date Code Title Description
AS Assignment

Owner name: OHIO UNIVERSITY, TECHNOLOGY TRANSFER OFFICE, TECHN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KIELISZEWSKI, MARCIA J.;REEL/FRAME:014401/0661

Effective date: 20030724

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION